index,src,mt,ref,pe,human_score,system,doc_id,sys_doc_id,dp_runs_scores
0,"Injizieren Sie nicht die doppelte Dosis, um eine vergessene Einzeldosis nachzuholen.",Do not inject a double dose to make up for a forgotten individual dose.,Do not inject a double dose to make up for a forgotten individual dose.,Do not inject a double dose to make up for a forgotten individual dose.,0.0,smt,1,1_smt,-0.016789354383945465|-0.016497725620865822|0.00959355104714632|0.019852546975016594|0.039093710482120514
1,Zwischen der 15- und 30-mg-Dosis Lansoprazol konnte kein klinisch bedeutsamer Unterschied hinsichtlich der Vorbeugung von Ulcera nachgewiesen werden.,"Between the 15 and 30 mg dose of lansoprazole, there was no clinically significant differences in prevention of gastric ulceration associated with the vaccine has not been established.",No clinically relevant difference in ulcer prevention between the 15 and 30 mg dose of lansoprazole could be demonstrated.,"Between the 15 and 30 mg dose of lansoprazole, there was no clinically significant differences in prevention of gastric ulceration has been established.",0.2,smt,1,1_smt,0.12921427190303802|0.20077086985111237|0.1963851898908615|0.24909836053848267|0.1893254965543747
2,Bei Schizophrenie beträgt die empfohlene Anfangsdosis zum Einnehmen 10 oder 15 mg pro Tag.,"In schizophrenia, the recommended starting dose is for oral use of 10 or 15 mg per day.","For schizophrenia, the recommended starting dose is 10 or 15 mg by mouth per day.","For schizophrenia, the recommended starting dose is 10 or 15 mg by mouth per day.",0.3529411764705882,smt,1,1_smt,-0.022380540147423744|-0.022979242727160454|0.014301628805696964|0.0052197701297700405|0.030325042083859444
3,Actos 30 mg Tabletten.,Actos 30 mg tablets.,Actos 30 mg tablets.,Actos 30 mg tablets.,0.0,smt,1,1_smt,-0.050436388701200485|-0.061015211045742035|0.009108250960707664|-0.03164370730519295|0.00022969208657741547
4,"Tritanrix HepB und einem Hib-haltigen Impfstoff untersucht: An zwei dieser Studien nahmen insgesamt 1 208 Säuglinge teil, die im Alter von zwei, vier und sechs Monaten geimpft wurden.","Tritanrix HepB and Hib-haltigen vaccine been studied: Two of these studies involved a total of 208 infants who were exposed to two, four, and six months of age.","au The effects of Quintanrix have been studied in five main studies involving over 2,000 infants.","Tritanrix HepB and Hib-haltigen vaccine been studied: Two of these studies involved a total of 208 infants who were vaccinated at two, four, and six months of age.",0.0625,smt,1,1_smt,0.1971965879201889|0.2884432077407837|0.19603540003299713|0.3151276111602783|0.25227129459381104
5,Diese Gebrauchsinformation wurde zuletzt genehmigt im [ist national auzufüllen].,This leaflet was last approved in [To be auzufüllen].,This leaflet was last approved in [To be completed nationally].,This leaflet was last approved in [To be filled out].,0.1538461538461538,smt,1,1_smt,0.037697821855545044|0.0691910833120346|0.09476012736558914|0.11349628865718842|0.09652923792600632
6,Der Name Ihres Arzneimittels ist EVRA transdermales Pflaster.,The name of your medicine is EVRA transdermal patch.,The name of your medicine is EVRA transdermal patch.,The name of your medicine is EVRA transdermal patch.,0.0,smt,1,1_smt,-0.03618713468313217|-0.036149993538856506|0.010032459162175655|-0.0057068015448749065|0.02044210024178028
7,"Es ist nicht bekannt, ob Telbivudin beim Menschen in die Muttermilch übergeht.",It is not known whether telbivudine in humans is excreted in human milk.,It is not known whether telbivudine is excreted in human milk.,It is not known whether telbivudine in humans is excreted in human milk.,0.0,smt,1,1_smt,-0.037018679082393646|-0.03776394575834274|0.017274560406804085|-0.001914112363010645|0.016573196277022362
8,Eine Filmtablette enthält 20 mg Rimonabant.,Each film-coated tablet contains 20 mg of rimonabant.,One film-coated tablet contains 20 mg rimonabant.,Each film-coated tablet contains 20 mg of rimonabant.,0.0,smt,1,1_smt,-0.03975290432572365|-0.0419917106628418|0.0095663545653224|-0.013773391023278236|0.014361314475536346
9,"Daher sollte der Kliniker daran denken, dass eine Überdosierung in vielen Fällen eher Blutkonzentrationen hervorrufen wird, die innerhalb des therapeutischen Bereichs für die antimikrobielle Behandlung liegen, für die durch umfangreiches Datenmaterial die Unbedenklichkeit der Anwendung bereits gesichert ist.","Therefore, clinicians should bear in mind that overdose more likely to occur in many cases, may cause the blood concentrations are within therapeutic range for the antimicrobial treatment, the safety of the administration umfangreiches data have already been established.","Therefore clinicians should bear in mind that in many cases overdose is likely to produce blood concentrations of doxycycline within the therapeutic range for antimicrobial treatment, for which there is a large quantity of data supporting the safety of the medicinal product.","Therefore, clinicians should bear in mind that overdose are more likely to occur in many cases where the blood concentrations are within therapeutic range for the antimicrobial treatment and the safety of the administration has already been established by extensive data.",0.2325581395348837,smt,1,1_smt,0.30577170848846436|0.4130226969718933|0.3732919692993164|0.44682303071022034|0.3879954218864441
10,Wie wird Firazyr angewendet?,How is Firazyr used?,How is Firazyr used?,How is Firazyr used?,0.0,smt,1,1_smt,-0.07555263489484787|-0.07998421788215637|0.008234567940235138|-0.05535425618290901|-0.014196610078215599
11,Der Anteil der betroffenen Patienten nimmt mit weiteren Infusionen ab.,The proportion of affected patients decreases with subsequent infusions.,The proportion of affected patients decreases with subsequent infusions.,The proportion of affected patients decreases with subsequent infusions.,0.0,smt,1,1_smt,-0.04187428206205368|-0.048153094947338104|0.009633907116949558|-0.009980615228414536|0.014979099854826927
12,"Wie EVRA aussieht und Inhalt der Packung EVRA ist ein dünnes, beiges, transdermales Pflaster aus Kunststoff.",What EVRA looks like and contents of the pack EVRA is a fucose unit transdermal patch.,"What EVRA looks like and contents of the pack EVRA is a thin, beige, plastic transdermal patch.",What EVRA looks like and contents of the pack: EVRA is a fucose unit transdermal patch.,0.0555555555555555,smt,1,1_smt,0.08329629898071289|0.12774401903152466|0.08013885468244553|0.18348079919815063|0.1433018147945404
13,Welches Risiko ist mit Ziagen verbunden?,What is the risk associated with Ziagen?,What is the risk associated with Ziagen?,What is the risk associated with Ziagen?,0.0,smt,1,1_smt,-0.06595216691493988|-0.06669887155294418|0.009197264909744263|-0.04209870845079422|-0.003368014469742775
14,- Kinder: Pharmakokinetische Daten bei Kindern liegen nicht vor.,- Children: No pharmacokinetic data in children have not been established.,Pharmacokinetic data in the paediatric population are not available. − Gender:,- Children: Pharmacokinetic data in children has not been established.,0.1666666666666666,smt,1,1_smt,0.09778594970703125|0.1534188687801361|0.11073556542396545|0.20670625567436218|0.1499764621257782
15,"In drei vergleichenden, kontrollierten Studien war die Immunantwort, die mit der flüssigen und der lyophilisierten Formulierung von Rotarix erreicht wurde, vergleichbar.","Three comparative, controlled studies of the immune response was achieved with the lyophilised formulation of Rotarix was comparable.","In three comparative controlled trials, the immune response elicited by Rotarix liquid formulation was comparable to the one elicited by Rotarix lyophilized formulation.","In three comparative, controlled studies the immune response with the lyophilised formulation of Rotarix was comparable.",0.2222222222222222,smt,1,1_smt,0.3596397936344147|0.4500693380832672|0.29975229501724243|0.5046729445457458|0.4351729154586792
16,Die Maximaldosis von 30 mg sollte jedoch bei Patienten mit schwerer Leberinsuffizienz mit Vorsicht angewendet werden (siehe Abschnitt 5.2).,The maximum dose of 30 mg should be used with caution in patients with severe hepatic insufficiency (see section 5.2).,13 maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).,"The maximum dose of 30 mg should, however, be used with caution in patients with severe hepatic insufficiency (see section 5.2).",0.1153846153846153,smt,1,1_smt,-0.04073629900813103|-0.042368195950984955|0.01159702893346548|-0.01882823370397091|0.013978864066302776
17,Sie haben Iscover zur Verhinderung von Blutgerinnseln und zur Verringerung des Risikos für das Auftreten dieser schweren Ereignisse aus folgenden Gründen verschrieben bekommen:,You have been prescribed Iscover to prevent blood clots and reduce the risk of these severe events because:,You have been prescribed Iscover to help prevent blood clots and reduce the risk of these severe events because:,You have been prescribed Iscover to help prevent blood clots and reduce the risk of these severe events because:,0.05,smt,1,1_smt,-0.03547760099172592|-0.03637204319238663|0.015078241005539894|-0.003327153157442808|0.02527710795402527
18,Was ist Spondylitis ankylosans (Morbus Bechterew)?,What is ankylosing spondylitis (ankylosing spondylitis)?,What is ankylosing spondylitis?,What is ankylosans spondylitis (ankylosing spondylitis)?,0.1111111111111111,smt,1,1_smt,0.0253929290920496|0.06390950083732605|0.21894396841526031|0.1138017550110817|0.0833403617143631
19,Wie wird Norvir angewendet?,How is Norvir used?,How is Norvir used?,How is Norvir used?,0.0,smt,1,1_smt,-0.06473446637392044|-0.06989368051290512|0.008214369416236877|-0.04768318682909012|-0.012419329956173897
20,Sexuell übertragbare Krankheiten EVRA schützt Sie nicht vor einer HIV-Infektion (AIDS) oder einer anderen sexuell übertragbaren Krankheit.,Sexuell transmissible diseases EVRA protects you are not infected with HIV (AIDS) or any other Si-rich zeolites having.,Sexually transmitted disease EVRA will not protect you against HIV infection (AIDS) or any other sexually transmitted disease.,Sexually transmissible diseases: EVRA does not protect you from infected with HIV (AIDS) or any other sexually transmissible diseases.,0.4347826086956521,smt,1,1_smt,0.19801613688468933|0.32242217659950256|0.31798896193504333|0.3515600264072418|0.31961601972579956
21,Es wird keine Dosisanpassung auf Grund des Geschlechts empfohlen.,It is recommended that no dose adjustment of gender.,No dose adjustment is recommended based on gender.,No dose adjustment ris recommended based on gender.,0.5555555555555556,smt,1,1_smt,0.10454931855201721|0.16817963123321533|0.2539184093475342|0.26286882162094116|0.19485612213611603
22,"Ziehen Sie das erforderliche Volumen Metalyse-Lösung in die Spritze auf, entsprechend dem Körpergewicht des Patienten.",Withdraw the necessary volume Metalyse-Lösung into the syringe body weight of the patient.,"Transfer the appropriate volume of reconstituted solution of Metalyse into the syringe, based on the patient’ s weight.",Withdraw the necessary volume metalyse solution into the syringe according to the body weight of the patient.,0.2777777777777778,smt,1,1_smt,0.3834657073020935|0.45272397994995117|0.1853959560394287|0.5314451456069946|0.4523754417896271
23,Daher ist der Vorteil des Stillens gegen die potentiellen Risiken für das Kind abzuwägen.,"Therefore, the advantage of breast-feeding should be weighed against the potential benefit justifies the potential risk to the child.","Therefore, the advantage of breast- feeding should be weighed against the potential risks for the child.","Therefore, the advantage of breast-feeding justifies the potential risk to the child.",0.5,smt,1,1_smt,0.059837281703948975|0.09257813543081284|0.1688520461320877|0.17510415613651276|0.14333385229110718
24,Die mittlere CL/F war bei Patienten mit einem Gewicht > 100 kg um ungefähr 55% höher als bei Patienten mit einem Gewicht ≤ 100 kg.,The mean CL / F was in patients with body weight 100 kg by approximately 55% higher than in patients with weight ≤ 100 kg.,The median CL/ F in patients with weight > 100 kg was approximately 55% higher compared to patients with weight ≤ 100 kg.,The mean CL/F in patients with body weight of more than 100 kg was approximately 55% higher than in patients weighing less that 100 kg.,0.2758620689655172,smt,1,1_smt,-0.018174882978200912|-0.01843501441180706|0.02121843583881855|0.012018704786896706|0.03432443365454674
25,9 von 11 Patienten wurden erfolgreich mit 800 mg/Tag Posaconazol in geteilten Dosen über einen medianen Zeitraum von 268 Tagen und bis zu 377 Tage behandelt.,9 of 11 patients were successfully treated with posaconazole 800 mg / day in divided doses for a median of 268 days and up to 377 days.,9 of 11 patients were successfully treated with posaconazole 800 mg/ day in divided doses for a median of 268 days and up to 377 days.,9 of 11 patients were successfully treated with posaconazole 800 mg / day in divided doses for a median of 268 days and up to 377 days.,0.0,smt,1,1_smt,-0.023099718615412712|-0.025454359129071236|0.012727675028145313|0.007336571346968412|0.026511186733841896
26,"Innerhalb kontrollierter Phasen von klinischen Studien wurden bei Patienten unter TNF-Antagonisten im Vergleich zu Kontrollpatienten mehr Fälle von malignen Erkrankungen, einschließlich Lymphome beobachtet.","In the controlled portions of clinical trials have been observed among patients receiving a TNF-antagonist compared with control patients, more cases of malignancies, including lymphoma.","In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including lymphoma have been observed among patients receiving a TNF-antagonist compared with control patients.","In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including lymphoma have been observed among patients receiving a TNF-antagonist compared with control patients.",0.2068965517241379,smt,1,1_smt,0.039184555411338806|0.05392695218324661|0.1693299114704132|0.10092417895793915|0.09364243596792221
27,"5 Im Falle einer Überdosierung, ist eine entsprechende Überwachung bzw. Unterstützung von Atmung und Herz-Kreislauf-System erforderlich.","5 In the event of overdose, appropriate monitoring and support of breathing and cardiovascular system is required.","Should overdosage occur, the respiratory and cardiovascular systems should be supported appropriately.","5 In the event of overdose, appropriate monitoring and support of breathing and cardiovascular system is required.",0.0,smt,1,1_smt,0.0743747279047966|0.10346535593271255|0.0556204617023468|0.17211349308490753|0.14094765484333038
28,"Zuckerarten leiden, fragen Sie ihn, bevor Sie dieses Arzneimittel einnehmen.",Women of child-bearing age must go before taking this medicinal product.,Read all of this leaflet carefully before you start taking this medicine. − Keep this leaflet.,"ask them, before taking this medicinal product.",0.6666666666666666,smt,1,1_smt,0.3127029836177826|0.4009946584701538|0.44402235746383667|0.46123847365379333|0.363174170255661
29,"Wenn Sie den Eindruck haben, dass die Wirkung von Zyrtec zu schwach oder zu stark ist, wenden Sie sich bitte an Ihren Arzt.","If you have the impression that the effect of Zyrtec is too weak or too strong, please ask your doctor.","If you feel that the effect of Zyrtec is too weak or too strong, please consult your doctor.","If you have the impression that the effect of Zyrtec is too weak or too strong, please ask your doctor.",0.0,smt,1,1_smt,-0.021288268268108368|-0.03135371953248978|0.012293124571442604|-0.0001716730184853077|0.02911520004272461
30,Bei anhaltend niedrigen Werten evtl. Dosisreduktion auf 400 mg einmal täglich erforderlich.,In case of low and high dose reduction to 400 mg once daily.,"If blood counts remain low, a dose reduction to 400 mg once daily may be required.","In case of sustained low levels, a dose reduction to 400 mg once daily may be necessary.",0.3684210526315789,smt,1,1_smt,0.0744016021490097|0.0972195640206337|0.25376442074775696|0.1699410378932953|0.12799175083637238
31,Amitraz ist ein Formamidinderivat und wirkt akarizid.,Amitraz Formamidinderivat and works flash-melt.,Amitraz is a formamidine acaricide.,Amitraz Formamidinderivat and effects acaricide.,0.3333333333333333,smt,1,1_smt,0.41433197259902954|0.5303487777709961|0.49794283509254456|0.5501462817192078|0.4855095446109772
32,"Patienten, bei denen während der Behandlung mit Somatropin ein Hinken einsetzt, sollten klinisch untersucht werden.","patients in whom during treatment with somatropin is a limp, should be examined clinically.","Patients limping during treatment with somatropin, should be examined clinically.",Patients who had a limp during treatment with somatropin should be examined clinically.,0.3571428571428571,smt,1,1_smt,0.05662641301751137|0.08027365058660507|0.16834262013435364|0.1536901891231537|0.11637098342180252
33,Es wird intrazellulär zum aktiven Metaboliten Lamivudin- 5'-Triphosphat metabolisiert.,"It is metabolised intracellularly to the active metabolite of lamivudine 5, lamivudine 5 '-triphosphate.","It is metabolised intracellularly to the active moiety, lamivudine 5’ - triphosphate.",It is metabolised intracellularly into the active metabolite of lamivudine 5' triphosphate.,0.3571428571428571,smt,1,1_smt,0.07385847717523575|0.11710479855537415|0.117474265396595|0.16574794054031372|0.1179276779294014
34,"Wenn Sie die Einnahme von ABILIFY vergessen haben Wenn Sie eine Dosis vergessen haben, nehmen Sie die vergessene Dosis ein, sobald Sie daran denken, nehmen Sie jedoch nicht an einem Tag die doppelte Dosis ein.","If you forget to take ABILIFY If you forget to take a dose, take the missed dose as soon as you remember, but not in one day to make up for a forgotten dose.","If you forget to take ABILIFY If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.","If you forget to take ABILIFY If you forget to take a dose, take the missed dose as soon as you remember, but do not take a double dose in one day to make up for a forgotten dose.",0.119047619047619,smt,1,1_smt,0.04051896184682846|0.05358137935400009|0.09531738609075546|0.08883976936340332|0.08130472153425217
35,Die Behandlung mit diesen Substanzen sollte während der Anwendung von Ketek unterbrochen werden.,Treatment with these agents should be interrupted during administration of Ketek.,Treatment with these agents should be interrupted during Ketek treatment.,Treatment with these agents should be interrupted during administration of Ketek.,0.0,smt,1,1_smt,0.006019159685820341|0.006613399833440781|0.015152836218476295|0.07580240815877914|0.06898915022611618
36,Weiterhin traten eine Verringerung der Blutzellen sowie der Blutplättchen auf.,"In addition, a reduction in blood cells and platelets.",Reductions in blood cell and platelet counts have also occurred.,"In addition, a reduction in blood cells and platelets occur.",0.0833333333333333,smt,1,1_smt,0.035012856125831604|0.06211359053850174|0.08500145375728607|0.11506492644548416|0.11304747313261032
37,rz Welche Risiken sind mit Forcaltonin verbunden?,er What is the risk associated with Forcaltonin?,tho What is the risk associated with Forcaltonin?,er What is the risk associated with Forcaltonin?,0.0,smt,1,1_smt,-0.03560834005475044|-0.04216429591178894|0.016174400225281715|-0.008292801678180695|0.013863862492144108
38,Für die ACUITY-Studie wurden Daten zu Blutungen getrennt von den unerwünschten Ereignissen erhoben.,For the ACUITY trial data were bleeding of adverse events.,"In ACUITY, bleeding data were collected separately from adverse events.",For the ACUITY trial data on bleeding were separated from the compiled adverse events.,0.4,smt,1,1_smt,0.24279969930648804|0.31619352102279663|0.3956540524959564|0.4015251696109772|0.32376572489738464
39,Die absolute Bioverfügbarkeit der Filmtabletten liegt aufgrund des First-Pass-Effekts im Darm und in der Leber bei ca. 40%.,The absolute bioavailability of the tablets is due to the First-Pass-Effekts in the gut and liver in approximately 40%.,"The absolute bioavailability of the film-coated tablets is around 40%, due to first-pass effect in the gut and liver.",The absolute bioavailability of the film tablets is about 40% due to the first-pass effect in the intestine and in the liver.,0.4583333333333333,smt,1,1_smt,0.06078792363405228|0.09321531653404236|0.14426301419734955|0.1505158245563507|0.12414298206567764
40,Nicht verwendeter Impfstoff oder Abfallmaterial ist gemäß den nationalen Anforderungen zu entsorgen.,Any unused vaccine or waste materials should be discarded according to local requirements.,11 Any unused product or waste material should be disposed of in accordance with local requirements.,Any unused vaccine or waste materials should be discarded according to local requirements.,0.0,smt,1,1_smt,-0.014212239533662796|-0.005170546472072601|0.016800597310066223|0.031141886487603188|0.045399777591228485
41,Die beobachteten hämodynamischen Reaktionen deuten auf einen sofortigen Wirkeintritt mit bevorzugter Wirkung der inhalativen Behandlung auf die pulmonalen Gefäße hin.,The observed haemodynamic reactions suggest a rapid onset of immediate inhaled side effect on pulmonary vessels.,The haemodynamics observed suggest an acute response with preferential effect of inhaled treatment on the pulmonary vessels.,The observed haemodynamic reactions suggest a rapid onset of immediate inhaled side effects on pulmonary vessels.,0.0588235294117647,smt,1,1_smt,0.039375919848680496|0.08015576750040054|0.05712311342358589|0.13235710561275482|0.10926419496536255
42,In einer klinischen Studie erhielten erwachsene Patienten übliche Sulfasalazin-Dosen und zusätzlich Enbrel. Im Vergleich zu den nur mit Enbrel bzw. Sulfasalazin behandelten Patientengruppen entwickelten die Patienten in der Kombinationsgruppe im Durchschnitt einen statistisch signifikanten Abfall der mittleren Anzahl weißer Blutkörperchen.,"In a clinical trial, adult patients usual Sulfasalazin-Dosen and Enbrel. when compared to the patients treated with Enbrel or sulfasalazine groups of patients developed, patients in the clinical study on average a statistically significant decrease in mean white blood cell count.","In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which Enbrel was added, patients in the combination group experienced a statistically significant decrease in mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone.","In a clinical trial, adult patients received usual doses of sulfasalazin and additionally Enbrel. When compared to the patient groups treated with only Enbrel or sulfasalazine, the patients in the combination group, on average, developed a statistically significant decrease in mean white blood cell count.",0.392156862745098,smt,1,1_smt,0.33488336205482483|0.42141762375831604|0.3242032527923584|0.44666150212287903|0.3658806383609772
43,Was ist Fevaxyn Pentofel?,What is Fevaxyn Pentofel?,What is Fevaxyn Pentofel?,What is Fevaxyn Pentofel?,0.0,smt,1,1_smt,-0.06539100408554077|-0.07305692136287689|0.008424585685133934|-0.0392780676484108|-0.01093202643096447
44,Eine Anwendung des Impfstoffs kann ab dem zweiten Schwangerschaftsdrittel erwogen werden.,Its use of the vaccine may be considered from the second trimester of pregnancy.,The use of this vaccine may be considered from the second trimester of pregnancy.,Use of the vaccine may be considered from the second trimester of pregnancy.,0.0714285714285714,smt,1,1_smt,-0.026496004313230515|-0.02139384113252163|0.06589368730783463|0.014787236228585243|0.03337467461824417
45,"Silapo 6000 I.E./0,6 ml Injektionslösung in Fertigspritze 1 Fertigspritze mit 0,6 ml Injektionslösung enthält 6000 Internationale Einheiten (I.E.) Epoetin zeta (rekombinantes humanes Erythropoetin).",Silapo 6000 IU / 0.6 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.6 ml solution for injection contains 6000 international units (IU) epoetin zeta (recombinant human erythropoietin).,Silapo 6000 IU/0.6ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.6 ml solution for injection contains 6000 international units (IU) epoetin zeta (recombinant human erythropoietin).,Silapo 6000 IU/0.6 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.6 ml solution for injection contains 6000 international units (IU) of epoetin zeta (recombinant human erythropoietin).,0.027027027027027,smt,1,1_smt,-0.004780556075274944|0.0041708629578351974|0.016709286719560623|0.03122822754085064|0.050949208438396454
46,5 mg einmal täglich.,5 mg once a day.,5 mg once daily.,5 mg once a day.,0.0,smt,1,1_smt,-0.007033802103251219|-0.004813250154256821|0.009718301706016064|0.031033052131533623|0.042329661548137665
47,"vorübergehendes verschwommenes Sehen, Xanthopsie Erkrankungen der Atemwege, des Brustraums und Mediastinums: Unbekannt:","transient blurred vision, xanthopsia Respiratory, thoracic and mediastinal disorders: Not known:",Not known:,"Transient blurred vision, blurry vision, xanthopsia, respiratory diseases, thoracic and mediastinal disorders: Not known:",0.25,smt,1,1_smt,0.1818387508392334|0.2786855399608612|0.10508926212787628|0.24318642914295197|0.21440793573856354
48,"Humalog Mix50 ist ein Ersatz für Ihr eigenes Insulin und wird dazu verwendet, eine langfristige Blutzuckerkontrolle zu erzielen.",Humalog Mix50 is a substitute for your own insulin and is used to control glucose to achieve long term glycaemic control.,Humalog Mix50 is a substitute for your own insulin and is used to control glucose in the long term.,Humalog Mix50 is a substitute for your own insulin and is used to achieve long term glycaemic control.,0.1578947368421052,smt,1,1_smt,-0.004333158954977989|0.004099646583199501|0.02463691495358944|0.03876558318734169|0.05286917835474014
49,"Wenn dies der Fall ist, müssen Sie dies sofort ohne Verzögerung Ihrem Arzt mitteilen.","If this is the case, you must immediately without delay your doctor straight away.","If this is the case, you should speak to your doctor without delay.","If this is the case, you must immediately contact your doctor straight away.",0.1333333333333333,smt,1,1_smt,0.0947767049074173|0.1308773010969162|0.10732398927211761|0.19084560871124268|0.1403544843196869
50,maternotoxischen Effekte von Amoxicillin nachgewiesen werden. die Verträglichkeit des Tierarzneimittels bei Rindern oder Sauen während der Trächtigkeit oder Laktation wurde nicht untersucht..,maternotoxic effects of amoxicillin impairment. has been demonstrated the safety of the product in cattle or sows during pregnancy and lactation has not been studied.,The safety of the product has not been assessed in pregnant and lactating targets species.,Maternotoxic effects of amoxicillin impairment has been demonstrated. The safety of the product in cattle or sows during pregnancy and lactation has not been studied.,0.074074074074074,smt,1,1_smt,0.15788397192955017|0.2748646140098572|0.22288744151592255|0.2966349124908447|0.23662430047988892
51,"Die Anwendung von Ultraschall-Kontrastmitteln zeigte in Studien am Tier biologische Nebenwirkungen (z.B. endothelialer Zellschaden, Kapillarruptur) durch Wechselwirkung mit dem Ultraschall.","The use of pre-epidermin (e. g., showed that the leaflets size Kapillarruptur) by interaction with the studies using biological effects.","In animal studies, the application of echo-contrast agents revealed biological side effects (e. g. endothelial cell injury, capillary rupture) by interaction with the ultrasound beam.","The use of ultrasound contrast agent showed biological side effects (e.g. endothelial cell damage, capilliary ruptures) in studies on animals through interaction with the ultrasound.",0.7586206896551724,smt,1,1_smt,0.4215874969959259|0.5025551915168762|0.5020715594291687|0.5421314835548401|0.49491190910339355
52,Nach 30- minütiger Perfusion mit Beromun allein wird Melphalan als Bolus in das Reservoir des Kreislaufs oder langsam in den arteriellen Zugang injiziert.,After 30- minütiger perfusion with Beromun melphalan alone is given as a bolus of the circuit in or slowly injected into the arterial line.,"After 30 minutes perfusion of Beromun alone, melphalan should be added as a bolus into the reservoir of the circuit, or slowly into the arterial line of the circuit.","After 30-minute perfusion with Beromun melphalan alone, melphalan is given as a bolus in the circuit or slowly injected into the arterial line.",0.24,smt,1,1_smt,0.11274877190589905|0.15576967597007751|0.20386801660060883|0.2313397228717804|0.18654276430606842
53,Für gewöhnlich handelte es sich um leichtgradige und vorübergehende Reaktionen.,"Usually, the majority of which leichtgradige and transient reactions.",Usually they were transient in nature and mild intensity.,They were usually mild and transient reactions.,0.875,smt,1,1_smt,0.23011986911296844|0.33144411444664|0.33509865403175354|0.4200941026210785|0.32637080550193787
54,"Die gewöhnliche Dosis beträgt zwischen 0,5 und 1,0 U/kg/Tag.",The usual dose is between 0.5 and 1.0 U / kg / day.,The usual dose is between 0.5 and 1.0 U/ kg/ day.,The usual dose is between 0.5 and 1.0 U / kg / day.,0.0,smt,1,1_smt,-0.030316326767206192|-0.03958090394735336|0.010165837593376637|-0.006045467685908079|0.016460783779621124
55,Zur Behandlung von bösartigen Weichteiltumoren des Verdauungstrakts (GIST).,For the treatment of malignant gastrointestinal stromal tumour (GIST) request.,Gastrointestinal stromal tumours (GIST).,For the treatment of malignant gastrointestinal stromal tumour (GIST) request.,0.0,smt,1,1_smt,0.10729171335697174|0.21373796463012695|0.15507772564888|0.19633445143699646|0.16275309026241302
56,"Die Anwendung von Comtess bei Patienten unter 18 Jahren wird nicht empfohlen, da für diese keine Daten zur Wirksamkeit und Sicherheit vorliegen.",The use of Comtess is not recommended for use in patients below 18 years of age due to a lack of data on efficacy and safety in this group.,Comtess is not recommended for use in children below age 18 due to lack of data of safety and efficacy.,The use of Comtess is not recommended for use in patients below 18 years of age due to a lack of data on efficacy and safety in this group.,0.0,smt,1,1_smt,-0.021528499200940132|-0.015936842188239098|0.017026560381054878|0.011432718485593796|0.03342632204294205
57,Topiramat änderte die Plasmakonzentrationen von Lamotrigin nicht.,topiramate did not alter the plasma concentrations of lamotrigine.,Topiramate resulted in no change in plasma concentrations of lamotrigine.,Topiramate did not alter the plasma concentrations of lamotrigine.,0.0,smt,1,1_smt,0.009374583140015602|0.01930977776646614|0.015344038605690002|0.07021456211805344|0.06658294796943665
58,"0,5 ml für die Injektionen am 7., 9. und 11. Therapietag.","0.5 ml for the injections at day 7, 9, 11 of therapy.","0.5 ml for the injections at day 7, 9 and 11 of therapy.","0.5 ml for the injections on day 7, 9, 11 of therapy.",0.0666666666666666,smt,1,1_smt,0.007976844906806946|0.0065931882709264755|0.024010974913835526|0.05560845881700516|0.06116598844528198
59,Die unerwünschten Arzneimittelreaktionen waren alle leicht bis mäßig schwer.,The adverse drug reactions are all of these were mild or moderate in intensity.,ADRs were all mild to moderate in severity.,The adverse drug reactions were all mild or moderate in intensity.,0.3333333333333333,smt,1,1_smt,0.10665079951286316|0.14258843660354614|0.1556074470281601|0.23260314762592316|0.16130705177783966
60,"Geeignete Vorsichtsmaßnahmen sollten getroffen werden, um die Übertragung der Krankheit durch sexuellen Kontakt (z.B.",Appropriate precautions should be taken to prevent passing the disease through sexual contact (e.g.,"If an erection lasts longer than 4 hours, you should get medical help immediately to avoid permanent damage to your penis.",Appropriate precautions should be taken to prevent passing the disease through sexual contact (e.g.,0.0,smt,1,1_smt,0.12060298025608063|0.1690523624420166|0.08370799571275711|0.2535969614982605|0.2039518505334854
61,"Wie bei allen parenteral zu verabreichenden Produkten, sollten die TAXOTERE-Basislösung und die Infusionslösung vor Gebrauch visuell überprüft werden. Lösungen, die einen Niederschlag enthalten, sollten verworfen werden.","As with all parenteral products, of the TAXOTERE premix solution and infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.","As with all parenteral products, TAXOTERE premix solution and infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.","As with all parenteral for administering products, TAXOTERE premix solution and infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.",0.1,smt,1,1_smt,0.010283470153808594|0.030606431886553764|0.0714176818728447|0.06209541857242584|0.07160113751888275
62,Das Verteilungsvolumen (Vss) beträgt 9 l.,The volume of distribution (Vss) is 9 l.,The volume of distribution (Vss) is 9 L.,The volume of distribution (Vss) is 9 l.,0.0,smt,1,1_smt,-0.03757112845778465|-0.046605490148067474|0.010520410723984241|-0.010881206020712852|0.018315821886062622
63,Der Impfstoff kann gleichzeitig mit Hepatitis B-Immunglobulin an unterschiedlichen Körperstellen verabreicht werden.,"This vaccine can be administered simultaneously with hepatitis B immunoglobulin, at a separate injection site.","This vaccine can be administered simultaneously with hepatitis B immunoglobulin, at a separate injection site.",This vaccine can be administered simultaneously with hepatitis B immunoglobulin at a separate injection site.,0.0625,smt,1,1_smt,-0.03314552456140518|-0.029541103169322014|0.013733663596212864|0.009079346433281898|0.034258872270584106
64,Wie wurde NEVANAC untersucht?,How has NEVANAC been studied?,How has NEVANAC been studied?,How has NEVANAC been studied?,0.0,smt,1,1_smt,-0.0703464075922966|-0.07161633670330048|0.008928194642066956|-0.045262448489665985|-0.009763730689883232
65,Warum wurde Privigen zugelassen?,Why has Privigen been approved?,Why has Privigen been approved?,Why has Privigen been approved?,0.0,smt,1,1_smt,-0.06556318700313568|-0.06456208229064941|0.009090877138078213|-0.0407772958278656|-0.006831023842096329
66,Bei Säuglingen mit akutem Durchfall oder Erbrechen sollte die Gabe von RotaTeq verschoben werden.,In infants with acute diarrhoea or vomiting of administration of RotaTeq.,The administration of RotaTeq should be postponed in subjects suffering from acute diarrhoea or vomiting.,In infants with acute diarrhoea or vomiting of administration of RotaTeq.,0.0,smt,1,1_smt,0.07569938153028488|0.12785758078098297|0.20787622034549713|0.18061189353466034|0.13401886820793152
67,Actraphane NovoLet darf nur von einer Person benutzt werden.,Actraphane NovoLet is for use by one person only.,84 Actraphane NovoLet is for single person use only.,Actraphane NovoLet is for use by one person only.,0.0,smt,1,1_smt,-0.00387700111605227|-0.0014113504439592361|0.0166885145008564|0.047946542501449585|0.0559643879532814
68,Hinweise für die Verabreichung des Impfstoffes:,Instructions for administration of the vaccine:,Instructions for administration of the vaccine:,Instructions for administration of the vaccine:,0.0,smt,1,1_smt,-0.0662749782204628|-0.07018882781267166|0.008455971255898476|-0.04441910609602928|-0.0016593411564826965
69,"Es wird empfohlen, das Injektionsvolumen auf maximal 4,0 ml zu beschränken.",It is recommended that the injection volume to a maximum of 4.0 ml.,It is recommended to limit injection volumes to a maximum of 4 ml.,It is recommended that the injection volume be limited to a maximum of 4.0 ml.,0.125,smt,1,1_smt,0.05601899325847626|0.07271454483270645|0.1424403190612793|0.14032885432243347|0.124215267598629
70,Bei Patienten mit Niereninsuffizienz ist keine Dosisanpassung erforderlich.,No dose adjustment is necessary in patients with renal insufficiency.,Patients with renal impairment should not require adjustment of dosage.,No dose adjustment is necessary in patients with renal insufficiency.,0.0,smt,1,1_smt,0.009282097220420837|0.015921548008918762|0.0132384542375803|0.07031002640724182|0.061277732253074646
71,In der Originalverpackung aufbewahren.,Store in the original package.,6 Store in the original package.,Store in the original package.,0.0,smt,1,1_smt,-0.03917510807514191|-0.042288511991500854|0.010004627518355846|-0.0007577077485620975|0.029763193801045418
72,Allerdings war die statistische Aussagekraft des Testes dieser Studie zur Entdeckung von Unterschieden zwischen den Behandlungsgruppen gering.,"However, the statistical lead to the testes of this study is to treat differences between treatment groups.","However, the power of this study to detect differences between treatment groups was low.","However, the statistical power of this study to detect differences between treatment groups was low.",0.4705882352941176,smt,1,1_smt,0.11330904066562653|0.1634368747472763|0.3966544270515442|0.25121697783470154|0.1760236769914627
73,Die Sicherheit und Wirksamkeit einer Indinavir/Ritonavir-Kombination wurden bei Patienten mit bestehenden relevanten Lebererkrankungen nicht untersucht. Die Kombination darf in dieser Patientenpopulation nicht angewendet werden.,The safety and efficacy of indinavir / Ritonavir-Kombination have not been studied in patients with significant underlying liver disorders and should not be used in this patient population.,The safety and efficacy of indinavir/ ritonavir has not been established in patients with significant underlying liver disorders and should not be used in this patient population.,The safety and efficacy of indinavir/Ritonavir-combination have not been studied in patients with significant underlying liver disorders and should not be used in this patient population.,0.0344827586206896,smt,1,1_smt,-0.011361129581928253|-0.0017016585916280746|0.03328462690114975|0.021840417757630348|0.04161295294761658
74,"Wird Erythropoetin zusammen mit Ciclosporin angewendet, sollten die Blutspiegel von Ciclosporin kontrolliert und die Ciclosporindosis dem steigenden Hämatokrit angepasst werden.","When erythropoietin is given concomitantly with cyclosporin, blood levels of cyclosporin should be monitored and the dose of cyclosporin adjusted as the haematocrit rises.","If erythropoietin is given concomitantly with ciclosporin, blood levels of ciclosporin should be monitored and the dose of ciclosporin adjusted as the haematocrit rises.","When erythropoietin is given concomitantly with cyclosporin, blood levels of cyclosporin should be monitored and the dose of cyclosporin adjusted as the haematocrit rises.",0.0,smt,1,1_smt,-0.013167252764105797|-0.0006763860583305359|0.01637873239815235|0.038828082382678986|0.04718031734228134
75,"Alle 24 Stunden, mindestens 1 Tag, bis die Heilung erfolgt ist.","Every 24 hours, at least 1 day, until healing is achieved.","Every 24 hours, at least 1 day, until healing is achieved.","Every 24 hours, at least 1 day, until healing is achieved.",0.0,smt,1,1_smt,-0.0336814783513546|-0.03910727798938751|0.011388810351490974|-0.0012642894871532917|0.018929438665509224
76,Bonviva 3 mg Injektionslösung in einer Fertigspritze ist eine Lösung zur intravenösen Injektion durch medizinisches Fachpersonal.,Bonviva 3 mg solution for injection in pre-filled syringes is a solution for intravenous injection by a healthcare provider.,Bonviva 3 mg solution for injection in pre-filled syringes is a solution for intravenous injection by a health care professional.,Bonviva 3 mg solution for injection in pre-filled syringes is a solution for intravenous injection by a healthcare provider.,0.0,smt,1,1_smt,-0.027419758960604668|-0.025791240856051445|0.01221003569662571|0.005374439526349306|0.03169276565313339
77,50 zehn Tage nach der Behandlung sein Maximum.,50 for ten days after treatment to exceed.,"Most often, OHSS occurs after hormonal treatment has been discontinued and reaches its maximum at about seven to ten days following treatment.",50 reaches it maximum 10 days after the treatment.,0.7,smt,1,1_smt,0.2693028450012207|0.39361780881881714|0.37827274203300476|0.44127872586250305|0.36232560873031616
78,"Die Behandlung mit Rebif sollte abgebrochen werden, wenn eine Gelbsucht oder andere klinische Symptome einer Leberfunktionsstörung auftreten (siehe Abschnitt 4.4).",Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear (see section 4.4).,Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear (see section 4.4).,Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear (see section 4.4).,0.0,smt,1,1_smt,-0.043094661086797714|-0.042267829179763794|0.009804320521652699|-0.01804148219525814|0.0164857916533947
79,Was Extavia enthält − Der Wirkstoff ist Interferon beta-1b.,What Extavia contains − The active substance is interferon beta-1b.,What Extavia conta ins − The active substance is interferon beta-1b.,What Extavia contains − The active substance is interferon beta-1b.,0.0,smt,1,1_smt,-0.024653390049934387|-0.021894073113799095|0.017163993790745735|0.015931112691760063|0.03182012960314751
80,"Veraliprid ist ein Benzamid-Neuroleptikum, das für die Behandlung vasomotorischer Symptome im Zusammenhang mit der Menopause indiziert ist.","veralipride is a Benzamid-Neuroleptikum, is indicated for the treatment of vasomotor symptoms associated with the menopause.",Veralipride is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause.,Veralipride is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause.,0.2222222222222222,smt,1,1_smt,0.055511120706796646|0.08352556079626083|0.12670400738716125|0.12487756460905075|0.10162270069122314
81,Welches Risiko ist mit Azarga verbunden?,What is the risk associated with Azarga?,What is the risk associated with Azarga?,What is the risk associated with Azarga?,0.0,smt,1,1_smt,-0.06189427524805069|-0.06568769365549088|0.00869548786431551|-0.04123975336551666|-0.0038192439824342728
82,"Deshalb ist es am besten, wenn Sie Xyrem zu einer festgelegten Zeit (2 bis 3 Stunden) nach einer Mahlzeit einnehmen.","Therefore, it is best to take Xyrem if you have a set time (2-3 hours) after meals.","Therefore, it is best to take Xyrem at set times well after a meal (two-three hours).","Therefore, it is best to take Xyrem at a set time (2-3 hours) after meals.",0.1578947368421052,smt,1,1_smt,0.03172340616583824|0.042674578726291656|0.11857238411903381|0.08899838477373123|0.0842600166797638
83,Pradaxa kann zu oder unabhängig von den Mahlzeiten eingenommen werden.,Pradaxa can be taken with or without food.,Pradaxa can be taken with or without food.,Pradaxa can be taken with or without food.,0.0,smt,1,1_smt,-0.05424090102314949|-0.053677499294281006|0.008840011432766914|-0.02732178382575512|0.0071413274854421616
84,beschleunigte Atmung sowie Kältegefühl oder Unwohlsein.,"mental status, rapid breathing, increased and feeling cold or uncomfortable.","Very rare side effects (likely to occur in less than 1 per 10,000).","Mental status, rapid breathing, increased and feeling cold or uncomfortable.",0.0,smt,1,1_smt,0.4777718782424927|0.5918393135070801|0.2868839502334595|0.582711398601532|0.5085688233375549
85,Revlimid sollte jeden Tag etwa um dieselbe Zeit eingenommen werden.,Revlimid should be taken every day at about the same time each.,Revlimid should be taken at around the same time each day.,Revlimid should be taken every day at about the same time each.,0.0,smt,1,1_smt,0.010757440701127052|0.009275272488594055|0.016529960557818413|0.058983854949474335|0.06041830778121948
86,"Mit einer abgeschirmten Spritze die erforderliche Radioaktivität von bis zu 1,8 GBq Natrium(99mTc)pertechnetat-Injektionslösung (mit Natriumchlorid-Injektionslösung, 0,9% m/V, auf ein Gesamtvolumen von 1 ml verdünnt) in die abgeschirmte Durchstechflasche geben.","With a abgeschirmten syringe until the required number of radioactivity of up to 1.8 GBq of sodium pertechnetate (99mTc) solution for injection (with sodium chloride, 0.9% w / v solution, to make a total volume of 1 ml) diluted into the vial inactivation.","Using a shielded syringe, inject the required radioactivity of up to 1.8 GBq of sodium pertechnetate (99mTc) solution for injection, (diluted as appropriate with sodium chloride 0.9% w/ v solution for injection to a total of 1 ml) into the shielded vial.","With a shielded syringe until the required number of radioactivity of up to 1.8 GBq of sodium pertechnetate (99mTc) solution for injection (with sodium chloride, 0.9% w / v solution, to make a total volume of 1 ml) diluted into the vial inactivation.",0.0196078431372549,smt,1,1_smt,0.15594619512557983|0.21185104548931122|0.15905135869979858|0.24864768981933594|0.21236485242843628
87,Eine Kapsel enthält 10 mg Zaleplon.,Each capsule contains 10 mg of zaleplon.,Each capsule contains 10 mg of zaleplon.,Each capsule contains 10 mg of zaleplon.,0.0,smt,1,1_smt,-0.07077062875032425|-0.07494141161441803|0.008773492649197578|-0.0518195815384388|-0.0134050864726305
88,Die separaten Hinweise zur Handhabung des Pens müssen gewissenhaft befolgt werden.,The separate instructions for using the pen must be followed carefully.,The separate instructions for using the pen must be followed carefully.,The separate instructions for using the pen must be followed carefully.,0.0,smt,1,1_smt,-0.043538372963666916|-0.055504366755485535|0.009246155619621277|-0.017701905220746994|0.01753617450594902
89,15 Vasodilatatoren ist bei Patienten mit Aorten- oder Mitralklappenstenose oder obstruktiver hypertropher Kardiomyopathie besondere Vorsicht angezeigt.,"15 other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, special caution should be exercised.","As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.",15 Special caution should be exercised in patients suffering from aortic or mitral stenosis who are taking Vasodilators,0.6111111111111112,smt,1,1_smt,0.12064068019390106|0.17956705391407013|0.4266657531261444|0.2483609914779663|0.19820860028266907
90,11 Pharmakogenomik Die Auswirkung bekannter Polymorphismen der Cytidin-Deaminase auf den Metabolismus von Azacitidin wurde nicht speziell untersucht.,11 Pharmakogenomik The effect of known cytidine deaminase infected with the metabolism of azacitidine has not been specifically studied.,Pharmacogenomics The effect of known cytidine deaminase polymorphisms on azacitidine metabolism has not been formally investigated.,11 Pharmacogenomics. The effect of known polymorphisms of the cytidine deaminase infected the metabolism of azacitidine has not been specifically studied.,0.2608695652173913,smt,1,1_smt,0.053258016705513|0.09641695022583008|0.13824306428432465|0.14129973948001862|0.11069441586732864
91,Schwangerschaft Es liegen keine hinreichenden Daten für die Anwendung von GANFORT bei Schwangeren vor.,Pregnancy There are no adequate data from the use of GANFORT in pregnant women.,Pregnancy There are no adequate data from the use of GANFORT in pregnant women.,Pregnancy. There are no adequate data from the use of GANFORT in pregnant women.,0.0625,smt,1,1_smt,-0.03452998772263527|-0.03857586532831192|0.011861244216561317|-0.006896450649946928|0.021856639534235
92,"Tetranoriloprost ist pharmakologisch inaktiv, wie in tierexperimentellen Untersuchungen gezeigt wurde.",Tetranoriloprost inactive in animal studies has been shown.,Tetranor-iloprost is pharmacologically inactive as shown in animal experiments.,Tetranor-iloprost is pharmacologically inactive as has been shown in animal studies.,0.5833333333333334,smt,1,1_smt,0.09894397109746933|0.1898086667060852|0.2916845977306366|0.22824853658676147|0.18585321307182312
93,"Erkrankungen der Atemwege, des Brustraums und Mediastinums: Häufig:","Respiratory, thoracic and mediastinal disorders Common:","Respiratory, thoracic and mediastinal disorders:","Respiratory, thoracic and mediastinal disorders Common:",0.0,smt,1,1_smt,-0.03521925210952759|-0.023355400189757347|0.020709937438368797|-6.119720637798309e-06|0.022658487781882286
94,Allgemeine Erkrankungen und Beschwerden am Verabreichungsort Orgalutran kann an der Injektionsstelle eine lokale Hautreaktion (vorwiegend Rötung mit oder ohne Schwellung) hervorrufen.,"General disorders and administration site conditions Orgalutran injection site can cause a local skin reaction (predominantly redness, with or without swelling).","General disorders and administration site conditions Orgalutran may cause a local skin reaction at the site of injection (predominantly redness, with or without swelling).","General sickness snd disorders and administration site. Orgalutran can cause a local skin reaction at the injection site (predominantly redness, with or without swelling).",0.3103448275862069,smt,1,1_smt,-0.0056639849208295345|0.013152606785297394|0.02484932541847229|0.04002441093325615|0.06032948940992355
95,"Es wurde eine Reduzierung des relativen Risikos von 61% nach 2 Jahren beobachtet (p = 0,0006).",There was a reduction of relative risk reduction of 61% was observed after 2 years of age (p = 0.0006]).,A relative risk reduction of 61% was observed after 2 years (p=0.0006).,A reduction of relative risk reduction of 61% was observed after 2 years of age (p = 0.0006]).,0.0869565217391304,smt,1,1_smt,0.12124098092317581|0.18653960525989532|0.1341259479522705|0.2451135218143463|0.19813956320285797
96,"Der arzneilich wirksame Bestandteil in Noxafil, Posaconazol, ist ein Antimykotikum aus der Gruppe der Triazole.","The active substance in Noxafil, posaconazole, is an antifungal that the triazoles.","The active substance in Noxafil, posaconazole, is an antifungal medicine that belongs to the triazoles group.","The active substance in Noxafil, posaconazole, is an antifungal from the triazole group.",0.1875,smt,1,1_smt,0.04754319787025452|0.06859226524829865|0.11800424009561539|0.11928503215312958|0.10404495149850845
97,Das Arzneimittel darf nicht im Abwasser oder Haushaltsabfall entsorgt werden.,This medicinal product should be disposed of in accordance with local requirements.,Insulatard should not be disposed of via wastewater or household waste.,This medicinal product should not be disposed of in sewage or with household waste.,0.3333333333333333,smt,1,1_smt,0.07960521429777145|0.10539761185646057|0.0822141170501709|0.1776418685913086|0.13946473598480225
98,Insulin Human Winthrop Rapid gibt es in Durchstechflaschen mit 5 ml Lösung (500 I.E.).,Insulin Human Winthrop Rapid is supplied in vials containing 5 ml solution (500 IU).,432 Insulin Human Winthrop Rapid is supplied in vials containing 5 ml solution (500 IU).,Insulin Human Winthrop Rapid is supplied in vials containing 5 ml solution (500 IU).,0.0,smt,1,1_smt,-0.02623846009373665|-0.03097083978354931|0.011613947339355946|0.004986416082829237|0.02562679722905159
99,"75% des Insulin lispro in Humalog Mix25 liegt als Suspension mit Protamin- sulfat vor, weshalb seine Wirkung verlängert ist.","75% of the insulin lispro in Humalog Mix25 is presented as a suspension with a soluble stent-graft, so that its action is prolonged.","75% of the insulin lispro in Humalog Mix25 Pen is available in a suspension together with protamine sulphate, so that its action is prolonged.",75% of the insulin lispro in Humalog Mix25 is available in a suspension together with protamine sulphate.,0.6842105263157895,smt,1,1_smt,0.031203683465719223|0.04980596899986267|0.07684686034917831|0.11371705681085587|0.08965945243835449
100,In dieser 26-wöchigen offenen Studie erhielten 33 MPS-1- Patienten eines von 4 Aldurazyme-Dosierungsschemata:,In this 26-week open-label study of 33 MPS-1- patients received a dose of 4 Aldurazyme-Dosierungsschemata:,"In this 26-week open label study, 33 MPS1 patients received 1 of 4 dose regimens of Aldurazyme:","In this 26-week open-label study, 33 MPS-1- patients received a dose of 4 aldurazyme dosage regimens:",0.2222222222222222,smt,1,1_smt,0.041285913437604904|0.07682386040687561|0.17910194396972656|0.13087834417819977|0.09751641750335693
101,107 Leberfunktionsstörungen Das pharmakokinetische Verhalten von Pegasys war bei gesunden Probanden und Patienten mit Hepatitis B oder C ähnlich.,107 or hepatic impairment The pharmacokinetics of Pegasys was similar to that seen in healthy subjects and in patients with hepatitis B or C).,Hepatic impairment The pharmacokinetics of Pegasys were similar between healthy subjects and patients with hepatitis B or C.,107 Hepatic impairment. The pharmacokinetic properties of Pegasys were similar to those seen in healthy subjects and in patients with hepatitis B or C.,0.2692307692307692,smt,1,1_smt,0.04274413362145424|0.09637001901865005|0.05821943283081055|0.1086263582110405|0.1045229434967041
102,"49 In den Studien 3, 4 und 5 hatten die mit Xolair behandelten Patienten jeweils Reduktionen der Exazerbationsraten von 37,5% (p = 0,027), 40,3% (p < 0,001) bzw. 57,6% (p < 0,001) im Vergleich zu Placebo.","In studies 3, 4 and 5 patients treated with Xolair had respective reductions in asthma exacerbation of 37.5% (p = 0.027), 40.3% (p 0.001) and 57.6% (p 0.001) compared to placebo.","In studies 3, 4 and 5 patients treated with Xolair had respective reductions in asthma exacerbation rates of 37.5% (p=0.027), 40.3% (p < 0.001) and 57.6% (p < 0.001) compared to placebo.","In studies 3, 4 and 5, patients treated with Xolair had respective reductions in asthma exacerbation of 37.5% (p = 0.027), 40.3% (p 0.001) and 57.6% (p 0.001) compared to placebo.",0.0227272727272727,smt,1,1_smt,0.0003324453718960285|-0.003484012559056282|0.03450845927000046|0.02588002197444439|0.04736332222819328
103,Cladribin-Konzentrationen zwischen 5 nM und 20 µM führen bei normalen und Leukämiezellen und -zelllinien zur Fragmentierung der DNA und zum Zelltod.,"Cladribin-Konzentrationen between 5 nM and 20 µM result in normal and leukaemia cells and -zelllinien propanol, and causes of death.",Exposure to cladribine induces DNA fragmentation and cell death in various normal and leukaemic cells and cell lines at concentrations of 5 nM to 20 µM.,"Cladribinn concentrations between 5 nM and 20 µM result in normal and leukaemia cells and cell lines the DNA fragmentation, and death of cells",0.4,smt,1,1_smt,0.46740826964378357|0.5791952013969421|0.38609644770622253|0.5854805111885071|0.5282899141311646
104,Der Inhaber der Genehmigung für das Inverkehrbringen ist das Unternehmen Pfizer Limited.,The holder of the marketing authorisation holder is Pfizer Limited.,The marketing authorisation holder is Pfizer Limited.,The holder of the marketing authorisation holder is Pfizer Limited.,0.0,smt,1,1_smt,-0.016737965866923332|-0.012907939031720161|0.05033724382519722|0.02580980770289898|0.04798135161399841
105,33 GEBRAUCHS INFORMATION:,33 PACKAGE LEAFLET:,31 PACKAGE LEAFLET:,33 PACKAGE LEAFLET:,0.0,smt,1,1_smt,-0.05381511524319649|-0.0602402463555336|0.011102049611508846|-0.02295965515077114|0.008470472879707813
106,Die Stelle für die intramuskuläre. Injektion ist jede Woche zu wechseln (siehe unter Abschnitt 5.3).,The site for intramuscular injection). a consequence of each week (see section 5.3).,The intramuscular injection site should be varied each week (see section 5.3).,The site for intramuscular injection should be changed every week (see section 5.3).,0.375,smt,1,1_smt,0.1079590767621994|0.153886616230011|0.22267530858516693|0.24163870513439178|0.18416357040405273
107,Synagis-Pulver in einer klaren und farblosen Durchstechflasche (4 ml) vom Glastyp I mit Brombutyl- Gummi-Stopfen und Hochklappversiegelung aus Aluminium. Eine Durchstechflasche enthält 50 mg Palivizumab.,"Synagis powder in a clear, colourless vial (4 ml, type I with bromobutyl rubber stopper and an aluminium Hochklappversiegelung. Each vial contains 50 mg of palivizumab when reconstituted as recommended.","Synagis powder in a clear, colourless, type I glass 4ml vial with bromobutyl rubber stopper and aluminium flip-off seal containing 50 mg palivizumab, providing 100 mg/ ml of palivizumab when reconstituted.","Synagis powder in a clear, colourless, glass type I vial (4 ml) with a bromobutyl rubber stopper and an aluminium flip-off cap. Each vial contains 50 mg of palivizumab.",0.2857142857142857,smt,1,1_smt,0.026070579886436462|0.0526636466383934|0.10962412506341934|0.08045832067728043|0.07976287603378296
108,Höhere Dosen als 70 mg/Tag wurden nicht ausreichend untersucht.,Doses greater than 70 mg / day have not been adequately studied.,Doses higher than 70 mg daily have not been adequately studied.,Doses greater than 70 mg / day have not been adequately studied.,0.0,smt,1,1_smt,-0.024939093738794327|-0.026746509596705437|0.010127232410013676|0.004178089555352926|0.01902727037668228
109,"Es wird angenommen, dass diese Symptome auf eine Verbesserung der körpereigenen Immunantwort zurückzuführen sind, die es dem Körper ermöglicht, Infektionen zu bekämpfen, die möglicherweise ohne erkennbare Symptome vorhanden waren.","It is believed that these symptoms are due to an improvement in the body's immune response, enabling, enabling the body to fight infections that may have been present with no obvious symptoms.","It is believed that these symptoms are due to improvement in the body’ s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.","It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms.",0.0588235294117647,smt,1,1_smt,0.05525221303105354|0.10016641765832901|0.07608344405889511|0.1378966122865677|0.12391234189271927
110,"Actos darf weder bei Patienten angewendet werden, die möglicherweise überempfindlich (allergisch) gegenüber Pioglitazon oder einen der anderen Bestandteile reagieren, noch bei Patienten mit Leberproblemen, Herzinsuffizienz oder diabetischer Ketoazidose (hohe Ketonspiegel – Säurespiegel – im Blut).","Actos must not be used in people who may be hypersensitive (allergic) to pioglitazone or any of the other ingredients, or in patients who have problems with their liver, heart failure or diabetic ketoacidosis (high levels of ketones [acids] in the blood).","Actos should not be used in people who may be hypersensitive (allergic) to pioglitazone or any of the other ingredients, or in patients with liver problems, heart failure or diabetic ketoacidosis (high levels of ketones [acids] in the blood).","Actos must not be used in people who may be hypersensitive (allergic) to pioglitazone or any of the other ingredients, or in patients who have problems with their liver, heart failure or diabetic ketoacidosis (high levels of ketones [acids] in the blood).",0.0,smt,1,1_smt,-0.030537104234099388|-0.026173679158091545|0.013708774000406265|-0.008210321888327599|0.02829776704311371
111,"Die glykämische Einstellung (HbA1c) mit Levemir ist mit NPH-Insulin vergleichbar, wobei das Risiko nächtlicher Hypoglykämien geringer und keine Gewichtszunahme damit verbunden ist.","The glycaemic control (HbA1c) with Levemir is comparable to that of human NPH insulin, where the risk of nocturnal hypoglycaemia mild and no weight gain.","Glycaemic control (HbA1c) with Levemir is comparable to NPH insulin, with a lower risk of nocturnal hypoglycaemia and no associated weight gain.","Glycaemic control (HbA1c) with Levemir is comparable to that of NPH insulin, where the risk of nocturnal hypoglycaemia milder is and not associated with weight gain.",0.2333333333333333,smt,1,1_smt,0.024171117693185806|0.05685270577669144|0.07683627307415009|0.10639107972383499|0.09172650426626205
112,Vidaza ist ein Pulver zur Herstellung einer Injektionssuspension.,Vidaza is a powder for suspension for injection.,Vidaza is a powder to be made up into a suspension for injection.,Vidaza is a powder for suspension for injection.,0.0,smt,1,1_smt,-0.013288265094161034|-0.017252231016755104|0.037627190351486206|0.03029400296509266|0.05032549798488617
113,"Ovale 2,5 ml Flasche mit Tropfer und Schraubverschluss aus Polypropylen in einer Folienverpackung.",2.5 ml of bilayer oval bottle with a screw cap and polypropylene presented in a foil pouch.,"2.5 ml oval bottle with dispensing plug and screw cap, all polypropylene, presented in an overwrap.",2.5 ml bottle with a dropper and polypropylene screw cap presented in a foil pouch.,0.3125,smt,1,1_smt,0.05124270170927048|0.07554949820041656|0.08091537654399872|0.13384200632572174|0.1169712096452713
114,"Es gibt keine gesicherten Erkenntnisse über die Langzeitsicherheit von Enbrel bei gleichzeitiger Gabe mit anderen antirheumatischen Basistherapeutika (disease modifying antirheumatic drugs, DMARD).","There is no confirmed data on the long-term safety of Enbrel when co-administered with antirheumatic therapies other than DMARDs (disease-modifying antirheumatic drugs, DMARD).",The long- term safety of Enbrel in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established.,"There is no confirmed data on the long-term safety of Enbrel when co-administered with other DMARDs (disease-modifying antirheumatic drugs, DMARD).",0.125,smt,1,1_smt,0.035996608436107635|0.08506627380847931|0.05323522910475731|0.09330062568187714|0.09864766150712967
115,Sie dürfen das Arzneimittel nach dem auf dem Karton und dem Behältnis angegebenen Verfalldatum (Verwendbar bis / EXP) nicht mehr anwenden.,Do not use after the expiry date (EXP) stated on the carton and the vial.,Do not use after the expiry date (EXP) stated on the carton and vial.,Do not use after the expiry date (EXP) stated on the carton and the vial.,0.0,smt,1,1_smt,-0.05078533664345741|-0.04897264391183853|0.009185479953885078|-0.030017687007784843|0.01102687418460846
116,Ketek darf deshalb von stillenden Müttern nicht eingenommen werden.,Ketek should therefore not be administered to breast- feeding mothers.,Ketek should not be used by breast- feeding women.,Ketek should therefore not be administered to breast- feeding mothers.,0.0,smt,1,1_smt,-0.004027467221021652|0.001164236105978489|0.016334740445017815|0.053015902638435364|0.054964810609817505
117,Ciprofloxacin Bayer kann Ihre Aufmerksamkeit beeinträchtigen.,Ciprofloxacin Bayer may impair your attention.,Ciprofloxacin Bayer may make you feel less alert.,Ciprofloxacin Bayer may impair your attention.,0.0,smt,1,1_smt,0.019280606880784035|0.0453750342130661|0.02929292619228363|0.09175490587949753|0.07459469139575958
118,die Spritze horizontal zwischen den Handflächen gehalten und schnell für mindestens 10 Sekunden hin und her gerollt wird.,the syringe is kept horizontal palms and rapidly for at least 10 seconds back and forth.,horizontally between the palms of the hands and rolling it quickly back and forth for no less than 10 seconds.,The syringe is kept horizontal between the palms and rolled rapidly back and forth for at least 10 seconds.,0.25,smt,1,1_smt,0.1209382489323616|0.17485536634922028|0.17585036158561707|0.24321164190769196|0.16537190973758698
119,Ändern Sie die Dosis nicht eigenmächtig.,Do not change the dose yourself.,Do not change the dose on your own.,Do not change the dose yourself.,0.0,smt,1,1_smt,0.010078022256493568|0.0012441407889127731|0.01287153735756874|0.05416104197502136|0.05850625038146973
120,29 Darunavir und Ritonavir sind beide Inhibitoren der CYP3A4-Isoform.,"29 darunavir and ritonavir, both of which are inhibitors of the CYP3A4 isoform.",Darunavir and ritonavir are both inhibitors of the CYP3A4 isoform.,29 Darunavir and ritonavir are both inhibitors of the CYP3A4 isoform.,0.3333333333333333,smt,1,1_smt,0.02443966642022133|0.028684506192803383|0.031171489506959915|0.07495685666799545|0.06652472913265228
121,"Binocrit wurde in Versuchsmodellen und an Menschen untersucht, um nachzuweisen, dass es mit dem Referenzarzneimittel Eprex/Erypo vergleichbar ist.","Binocrit was investigated in experimental models and in humans to show that it is comparable with the reference medicine, Eprex / Erypo.","Binocrit was studied to show that it is comparable with the reference medicine, Eprex/ Erypo, in experimental models and in humans.","Binocrit was investigated in experimental models and in humans to show that it is comparable with the reference medicine, Eprex / Erypo.",0.0,smt,1,1_smt,-0.005518970545381308|0.0015462152659893036|0.019534561783075333|0.03713546320796013|0.0503578744828701
122,Imiquimod-Creme ist bestimmt für die topische Behandlung von:,Imiquimod cream is intended for the treatment of:,Imiquimod cream is indicated for the topical treatment of:,Imiquimod cream is intended for the topical treatment of:,0.1,smt,1,1_smt,-0.03209025040268898|-0.03585828095674515|0.014527527615427971|-0.004675040487200022|0.023202460259199142
123,"Bitte sprechen Sie mit Ihrem Arzt, bevor Sie eines dieser cholesterinsenkenden Arzneimittel zusammen mit Norvir einnehmen (siehe auch „Norvir darf nicht eingenommen werden“).","Talk to your doctor before you are taking any of these cholesterol- lowering medicines, in combination with Norvir (see also under ""Do not take Norvir"").",Talk to your doctor before you take any cholesterol-reducing medicines with Norvir (see also ‘Do not take Norvir’ above).,"Talk to your doctor before you are taking any of these cholesterol- lowering medicines, in combination with Norvir (see also under ""Do not take Norvir"").",0.0,smt,1,1_smt,-0.0033274267334491014|-0.0057065729051828384|0.045895207673311234|0.02347826026380062|0.04352249950170517
124,Eine Verschlechterung eines schon bestehenden Ekzems wurde bei einer Patientin nach der ersten Orgalutran-Dosis beobachtet.,One exacerbation of already existing eczema has been observed in a patient after the first Orgalutran-Dosis.,17 Worsening of a pre-existing rash (eczema) has been reported in one subject after the first Orgalutran dose.,An exacerbation of already existing eczema has been observed in one patient after the first Orgalutran dose.,0.2222222222222222,smt,1,1_smt,0.038658808916807175|0.09614299982786179|0.11567564308643341|0.1372746378183365|0.11678458005189896
125,Den vollständigen Wortlaut des EPAR finden Sie hier.,The full EPAR for HBVAXPRO can be found here.,The full EPAR for IntronA is available here.,The full EPAR for HBVAXPRO can be found here.,0.0,smt,1,1_smt,0.025482844561338425|0.0300784669816494|0.04518173262476921|0.07123275846242905|0.08472318202257156
126,Elimination Parathyroidhormon wird in der Leber und – in geringerem Umfang – in den Nieren abgebaut.,Elimination Parathyroid hormone is broken down in the liver and to a lesser extent in the kidneys.,Elimination Parathyroid hormone is metabolised in the liver and to a lesser degree in the kidney.,Elimination Parathyroid hormone is broken down in the liver and to a lesser extent in the kidneys.,0.0,smt,1,1_smt,0.0018109683878719807|0.012210628017783165|0.016645383089780807|0.05533541738986969|0.061599984765052795
127,Die Anwendung von EVRA sollte am ersten Tag der Entzugsblutung beginnen.,The use of EVRA should be administered on the first day of the withdrawal bleeding.,Treatment with EVRA should begin on the first day of withdrawal bleeding.,The use of EVRA should be administered on the first day of the withdrawal bleeding.,0.0,smt,1,1_smt,0.0424872525036335|0.06631982326507568|0.023926524445414543|0.13021355867385864|0.11555540561676025
128,Nachfolgend werden Nebenwirkungen für jedes Behandlungsschema nach Systemorganklassen und absoluter Häufigkeit gegliedert aufgelistet.,Adverse reactions for each treatment regimen are presented below by system organ class and absolute frequency.,23 Adverse reactions for each treatment regimen are presented below by system organ class and absolute frequency.,Adverse reactions for each treatment regimen are presented below by system organ class and absolute frequency.,0.0,smt,1,1_smt,-0.03523131087422371|-0.03077009879052639|0.012701744213700294|0.010776666924357414|0.025697961449623108
129,"Sichtbare Schwellungen, die gelegentlich für einen Tag leicht schmerzhaft sind, können bei bis zu 45% der behandelten Tiere an der Injektionsstelle auftreten.","Obvious swelling, sometimes for one day to slightly painful, may occur in up to 45% of treated animals at the site of the injection.","Visible injection site swellings may develop in up to 45% of treated animals associated with occasional, slight pain evident for one day.","Obvious swelling, sometimes slightly painful for one day, may occur in up to 45% of treated animals at the site of the injection.",0.074074074074074,smt,1,1_smt,0.022715164348483086|0.0425383485853672|0.0875951424241066|0.09765001386404037|0.08555049449205399
130,Alle Anweisungen zur Handhabung von Druckbehältnissen müssen befolgt werden.,All the instructions for use of Druckbehältnissen must be followed.,All regulations concerning handling of pressurised gas cylinders must be followed.,All the instructions for use of pressure containers must be followed.,0.1666666666666666,smt,1,1_smt,0.11577696353197098|0.14438678324222565|0.1204189732670784|0.26319363713264465|0.1720937341451645
131,Mutagenität Lepirudin zeigte keine mutagenen oder clastogenen Eigenschaften in Standard-Versuchen zu solchen Wirkungen.,Mutagenicity lepirudin showed no mutagenic or clastogenen properties that such effects in Standard-Versuchen.,Mutagenicity Lepirudin was not mutagenic or clastogenic in standard assays for such effects.,Mutagenicity Lepirudin was not mutagenic or clastogenic in standard assays for such effects.,0.5714285714285714,smt,1,1_smt,0.12064502388238907|0.2330840826034546|0.17845399677753448|0.2553970515727997|0.20981791615486145
132,Das Tier sollte vor der Verabreichung nicht zuviel Wasser aufnehmen.,The animal should not be used to take too much water.,The animal should not be over-hydrated prior to administration.,The animal should not take too much water before administration.,0.3636363636363636,smt,1,1_smt,0.08343275636434555|0.13907063007354736|0.2607438266277313|0.1839197427034378|0.1549556404352188
133,Im Kühlschrank lagern (2°C – 8°C).,Store in a refrigerator (2 ° C - 8 ° C).,Store in a refrigerator (2 C – 8 C).,Store in a refrigerator (2 ° C - 8 ° C).,0.0,smt,1,1_smt,-0.016115516424179077|-0.025745270773768425|0.01177607849240303|0.01556122861802578|0.03245176374912262
134,Wie wurde ACOMPLIA untersucht?,How has ACOMPLIA been studied?,How has ACOMPLIA been studied?,How has ACOMPLIA been studied?,0.0,smt,1,1_smt,-0.0632130354642868|-0.06676451116800308|0.008777030743658543|-0.041929855942726135|-0.005164770409464836
135,Naxcel ist verfügbar in Flaschen mit 50 oder 100 ml Inhalt.,Naxcel is available in bottles of 50 or 100 ml.,Naxcel is available in 50 ml or 100 ml vials.,Naxcel is available in bottles of 50 or 100 ml.,0.0,smt,1,1_smt,-0.01550908200442791|-0.0257097240537405|0.01207400020211935|0.006693010684102774|0.02954801917076111
136,"Die Dosis von Acetylsalicylsäure, die vor Rapilysin zu verabreichen ist, soll mindestens 250 mg bis 350 mg betragen, gefolgt von 75 bis 150 mg/Tag, mindestens bis zur Entlassung aus dem Krankenhaus.","The dose of acetylsalicylic acid before Rapilysin, should be at least 250 mg to 350 mg, followed by 75 to 150 mg / day, at least up to, or until discharge from the hospital.","The dose of acetylsalicylic acid given before Rapilysin should be at least 250 mg – 350 mg and should be followed by 75 – 150 mg/ day, at least until discharge from hospital.","The dose of acetylsalicylic acid before Rapilysin, should be at least 250 mg to 350 mg, followed by 75 to 150 mg / day, at least up to, or until discharge from the hospital.",0.0,smt,1,1_smt,0.030545730143785477|0.042833782732486725|0.047741830348968506|0.07775154709815979|0.07354471832513809
137,34 Verteilung Die Serumproteinbindung beträgt für Ramipril etwa 73% und für Ramiprilat etwa 56%.,"34 Distribution The Serumproteinbindung is ramipril is about 73% and that of ramiprilat about 56%, respectively.",Distribution The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%.,34 Distribution. The serum protein binding for ramipril is about 73% and about 56% for ramprilrat.,0.45,smt,1,1_smt,0.14413826167583466|0.18989460170269012|0.171696737408638|0.2589200437068939|0.1890152543783188
138,Lassen Sie die Vorhänge zugezogen und nutzen Sie Glühbirnen von 60 W oder weniger.,Leave the skin and caught to you which includes a dose of 60 nanoseconds or less.,Keep the curtains drawn and use light bulbs of 60W or less.,Leave the curtains closed and use bulbs with 60 W or less.,0.8461538461538461,smt,1,1_smt,0.444987416267395|0.5356950759887695|0.5550692081451416|0.5715239644050598|0.5029606223106384
139,Für die Anwendung von Cisplatin in der Behandlung von fortgeschrittenem Ovarialkarzinom und nicht- kleinzelligem Bronchialkarzinom bitte die Fachinformation für Cisplatin heranziehen.,"The use of cisplatin in the treatment of advanced ovarian cancer and non-small cell lung cancer, see the SPC for cisplatin.","For use of cisplatin in treatment of advanced ovarian carcinoma and non-small cell lung carcinoma, please consult the Summary of Product Characteristics of Cisplatin for information.","The use of cisplatin in the treatment of advanced ovarian cancer and nonsmallcell lung cancer, please see the specialed information on cisplatin.",0.25,smt,1,1_smt,0.05827208608388901|0.08741533756256104|0.12015677988529205|0.11183283478021622|0.11944714933633804
140,"Die Hautreaktionen waren am häufigsten leicht bis mäßig ausgeprägt, traten meistens in der zweiten Therapiewoche auf und waren nach Woche 4 selten.","The skin reactions were most frequently mild to moderate in severity, mostly occurred in the first week of therapy and were infrequent after week 4.","Cutaneous reactions were most frequently mild to moderate, mostly occurred in the second week of therapy, and were infrequent after week 4.","The skin reactions were most frequently mild to moderate in severity, mostly occurred in the first week of therapy and were infrequent after week 4.",0.0,smt,1,1_smt,-0.019898850470781326|-0.017229488119482994|0.020825227722525597|0.022093839943408966|0.03447199612855911
141,"Ihr Arzt wird durch regelmäßig durchgeführte Bluttests sicherstellen, dass das Arzneimittel bei Ihnen anhaltend richtig wirkt.",Your doctor will 1513 due to carry out regular blood tests to ensure that your medicine is continuing to work properly persistent.,Your doctor will order regular blood tests to ensure that your medicine is continuing to work properly.,Your doctor will carry out regular blood tests to ensure that your medicine is continuing to work properly.,0.2105263157894736,smt,1,1_smt,0.182142972946167|0.2862987816333771|0.2652532458305359|0.33858707547187805|0.27809765934944153
142,"Die für Kinder vorgeschlagene Dosierung wurde in klinischen Studien erprobt, ist jedoch auch das Ergebnis von Dosisanpassungen nach Körpergewicht und Ausscheidung (Clearance), die je nach Entwicklungsstand des Nierensystems variiert.","Dosing in children have been proposed studies in clinical trials, but the result of body weight and clearance Dose adjustments, as dictated by the anniversary is omitted.","The posology proposed for children has been tested in clinical trials, but also results from dosing adaptations based on body weight and clearance that varies according to the maturation of the renal system.","The posology proposed for children has been tested in clinical trials, but also results from dosing adaptations based on body weight and clearance that varies according to the maturation of the renal system.",0.6571428571428571,smt,1,1_smt,0.22237616777420044|0.3372519910335541|0.3862113356590271|0.3737225830554962|0.31377410888671875
143,Weitere Informationen zur Anwendung von Gadograf finden sich in Abschnitt 3 der Packungsbeilage.,For further information on the use of Gadograf is provided in section 3 of the leaflet.,Further information regarding the use of Gadograf is given in section 3 of the leaflet.,Further information on the use of Gadograf is provided in section 3 of the leaflet.,0.0625,smt,1,1_smt,0.032293692231178284|0.03497758507728577|0.07713687419891357|0.0872240662574768|0.09596491605043411
144,96 Erkrankungen des Gastrointestinaltrakts:,96 disorders:,Gastrointestinal disorders:,96 Gastointestine disorders:,0.25,smt,1,1_smt,0.17848867177963257|0.2517726719379425|0.12456749379634857|0.31546589732170105|0.24176104366779327
145,Die Rebif-Starterpackung entspricht dem Bedarf eines Patienten für den ersten Behandlungsmonat.,The Rebif-Starterpackung corresponds to the patient needs for the first month of treatment.,The Rebif initiation package corresponds to the patient needs for the first month of treatment.,The Rebif starter pack corresponds to the patient needs for the first month of treatment.,0.1875,smt,1,1_smt,0.034266918897628784|0.055589720606803894|0.09988532960414886|0.10710442811250687|0.10036899149417877
146,Bei Macaca mulatta (Rhesus-Affen) konnte man für Interferon alfa-2b nach Gabe des 90- und 180fachen der empfohlenen intramuskulären oder subkutanen Dosis von 2 Millionen I.E./m² abortive Wirkungen nachweisen.,In copolymer rhesus interferon alfa-2b at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU / m2.,"ed or rabbits, nor did it adversely affect pregnancy, foetal development or reproductive capacity in offspring of treated rats. Interferon alfa-2b has been shown to have abortifacient effects in Macaca mulatta (rhesus monkeys) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU/ m2.",In the rhesus macaque one could prove abortive effects of interferon alfa-2b at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU / m2.,0.2666666666666666,smt,1,1_smt,0.2759639024734497|0.3708018362522125|0.19219250977039337|0.41436681151390076|0.3403817415237427
147,Leber- und Gallenerkrankungens:,Immune system disorders:,Hepatobiliary disorders:,Immune system disorders:,0.0,smt,1,1_smt,0.01941576600074768|0.04000642150640488|0.01914307102560997|0.09267526119947433|0.08084132522344589
148,"Gelegentlich: verminderter Appetit, Diabetes mellitus, Hyperamylasämie, Hypercholesterinämie Selten:","Uncommon: decreased appetite, diabetes mellitus, Hyperamylasämie, hypercholesterolaemia Rare:","Uncommon: decreased appetite, diabetes mellitus, hyperamylasaemia, hypercholesterolaemia.","Uncommon: decreased appetite, diabetes mellitus, hyperamylasaemia, hypercholesterolaemia Rare:",0.0769230769230769,smt,1,1_smt,0.025686874985694885|0.06858553737401962|0.030956100672483444|0.10540623962879181|0.07911738753318787
149,"Bei einer Dosierung von 0,5 - 3,0 ml beträgt der Zeitraum für eine ausreichende Kontrastgebung 2,5 - 4,5 Minuten.",At a dose of 0.5 - 3.0 ml The duration of the mean diameter range of 2.5 - 4.5 minutes.,2 the useful imaging time is 2.5 - 4.5 minutes for a dose of 0.5 - 3.0 ml.,"At a dose of 0.5 - 3.0 ml, the duration of the mean diameter range is 2.5 - 4.5 minutes.",0.0909090909090909,smt,1,1_smt,0.16063962876796722|0.23008109629154205|0.1267404556274414|0.31114429235458374|0.23881147801876068
150,"Da keine Ergebnisse aus Kompatibilitätsstudien vorliegen, sollte dieses Arzneimittel nicht mit anderen Arzneimitteln gemischt werden.","Because there are no results from Kompatibilitätsstudien, this medicinal product should not be mixed with other medicinal products.","In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.","Because there are no results from compatibility studies, this medicinal product should not be mixed with other medicinal products.",0.0952380952380952,smt,1,1_smt,0.002587478142231703|0.011869648471474648|0.05599799379706383|0.04577813670039177|0.05627106875181198
151,"Anhand der vorgelegten Daten stellte der CHMP fest, dass in den Studien mit fester Dosis eine flache Dosis-Wirkungs-Kurve beobachtet wurde, die keinen Anhaltspunkt dafür lieferte, dass die Verwendung höherer als die empfohlenen Dosen Vorteile bezüglich der Wirksamkeit bieten könnte.","Based on data, the CHMP noted that the studies with fixed dose also been seen, revealed no evidence that the use of Anagrelide higher than recommended doses of benefits regarding the efficacy of agomelatine.","From the data provided the CHMP noted that in the fixed dose studies there was a flat dose response curve, providing no suggestion of advantage in terms of efficacy for using higher than the recommended doses.","From the data provided the CHMP noted that in the fixed dose studies there was a flat dose response curve, providing no suggestion of advantage in terms of efficacy for using higher than the recommended doses.",0.7368421052631579,smt,1,1_smt,0.19565390050411224|0.28880035877227783|0.23311220109462738|0.3273410201072693|0.27553892135620117
152,Die niedrigste empfohlene Dosis beträgt 100 mg/m².,The lowest recommended dose is 100 mg / m2.,The lowest recommended dose is 100 mg/m2.,The lowest recommended dose is 100 mg / m2.,0.0,smt,1,1_smt,-0.058265116065740585|-0.06267008185386658|0.00883508287370205|-0.041495706886053085|-0.0063247401267290115
153,"Ihr Arzt wird Sie bitten, Schwangerschaftstests durchführen zu lassen, bevor Sie mit der Einnahme von Volibris beginnen, sowie regelmäßig während der Behandlung mit Volibris.","Your doctor will ask you to have regular follow-up ophthalmologic examinations for pregnancy tests before you start taking Volibris, and regularly during treatment with Volibris.","If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test before you start taking Volibris and regularly while you are taking Volibris.","Your doctor will ask you to have regular follow-up ophthalmologic examinations for pregnancy tests before you start taking Volibris, and regularly during treatment with Volibris.",0.0,smt,1,1_smt,0.03928935155272484|0.05688615143299103|0.12052728235721588|0.07806580513715744|0.08794142305850983
154,Wie ist CYSTAGON aufzubewahren? 6.,How to store CYSTAGON,How to store CYSTAGON 6.,How to store CYSTAGON,0.0,smt,1,1_smt,-0.02263057790696621|-0.023227954283356667|0.016554472967982292|0.010512035340070724|0.03139359503984451
155,Nach oraler Anwendung von Irbesartan Hydrochlorothiazide Winthrop beträgt die absolute Bioverfügbarkeit von Irbesartan nach oraler Anwendung 60-80% bzw. von Hydrochlorothiazid 50-80%.,"Following oral administration of Irbesartan Hydrochlorothiazide Winthrop, the absolute bioavailability of irbesartan after oral administration is 60-80% and 50-80% for hydrochlorothiazide.","Following oral administration of Irbesartan Hydrochlorothiazide Winthrop, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.","Following oral administration of Irbesartan Hydrochlorothiazide Winthrop, the absolute bioavailability of irbesartan is 60-80% and 50-80% for hydrochlorothiazide.",0.1363636363636363,smt,1,1_smt,-0.007273521274328232|0.0008233729749917984|0.04345211759209633|0.039468914270401|0.045460350811481476
156,"las Nebenwirkungen bemerken, die nicht in dieser Gebrauchsinformation angegeben sind, informieren Sie bitte Ihren Arzt oder Apotheker.","ori you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist.",ori please tell your doctor or pharmacist.,"if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist.",0.0526315789473684,smt,1,1_smt,0.015677738934755325|0.030018923804163933|0.024074645712971687|0.0382671058177948|0.06455188989639282
157,Vor der Anwendung ist die Lösung visuell auf Ausfällungen und Verfärbung zu überprüfen.,"Prior to administration, the solution should be inspected visually for evidence of precipitation and discoloration prior to administration.",It should be inspected visually for particulate matter and discoloration before administration.,"Prior to administration, the solution should be inspected visually for evidence of precipitation and discoloration.",0.1764705882352941,smt,1,1_smt,0.07462415844202042|0.139860600233078|0.20486682653427124|0.18233847618103027|0.1512642353773117
158,"Dazu wird die Patrone in den Spezial-Injektionsstift eingesetzt und dieser zusammengeschraubt, so dass sich Pulver und Lösung zu einer fertigen Injektionslösung verbinden.","These will be used in the cartridge in the Spezial-Injektionsstift and this silylating reagents comprise organosilicon compounds, powder and solution with a solution for injection.","When the cartridge is inserted in the special injection pen and the pen screwed together, the powder and solvent mix to make up the solution for injection.","These will be used in the cartridge in the special injection pen and this is srewed together, so that the powder and solution with a solution for injection.",0.3333333333333333,smt,1,1_smt,0.34210383892059326|0.43454664945602417|0.4458383023738861|0.45971816778182983|0.41519978642463684
159,Humalog Mix50 Pen dient zur Behandlung des Diabetes mellitus.,Humalog Mix50 Pen is used to treat diabetes.,Humalog Mix50 Pen is used to treat diabetes.,Humalog Mix50 Pen is used to treat diabetes.,0.0,smt,1,1_smt,-0.04044085741043091|-0.03144751489162445|0.009813888929784298|-0.008071929216384888|0.015583094209432602
160,Wofür wird RotaTeq angewendet?,What is RotaTeq used for?,What is RotaTeq used for?,What is RotaTeq used for?,0.0,smt,1,1_smt,-0.06653659045696259|-0.07067430764436722|0.008457863703370094|-0.04400527849793434|-0.008276458829641342
161,"Es ist leichter, Protaphane zu resuspendieren, wenn es Raumtemperatur erreicht hat.","It is easier, Protaphane is to be stressed when the insulin has reached room temperature.",Resuspending is easier when the insulin has reached room temperature.,It is easier to resuspend Protaphane if it has reached room temperature.,0.6153846153846154,smt,1,1_smt,0.12874364852905273|0.17933864891529083|0.46700483560562134|0.2595890760421753|0.20405219495296478
162,Es liegen keine Erkenntnisse zu möglichen Wechselwirkungen zwischen Infliximab und anderen wirksamen Substanzen vor.,There is no evidence to potential interactions between infliximab and other active substances.,Nothing is known regarding possible interactions between infliximab and other active substances.,There is no evidence of potential interactions between infliximab and other active substances.,0.0714285714285714,smt,1,1_smt,-0.01345597393810749|-0.002555614337325096|0.07442928850650787|0.03259100764989853|0.04415584355592728
163,"Nehmen Sie die erste Dosis ein, wenn Sie zu Bett gehen und die zweite Dosis 2,5 bis 4 Stunden später.",Do not take the first dose if you are going to bed and the second dose of 2.5 to 4 hours later.,Take the first dose upon getting into bed and the second dose 2.5 to 4 hours later.,Take the first dose if you are going to bed and the second dose of 2.5 to 4 hours later.,0.0952380952380952,smt,1,1_smt,0.0314873531460762|0.04952148348093033|0.145664244890213|0.09612170606851578|0.08391870558261871
164,Es liegen keine spezifischen Erfahrungswerte im Hinblick auf die Behandlung einer Thelin- Überdosierung vor.,There is no specific experience in the treatment of reintroduction of overdosage is limited.,There is no specific experience with the management of Thelin overdose.,There is no specific experience in the treatment of a Thelin overdosage.,0.3076923076923077,smt,1,1_smt,0.17314952611923218|0.25291234254837036|0.23795859515666962|0.31719210743904114|0.26448413729667664
165,"Die optimale Wirkung wird erreicht, wenn die Dosis abends angewendet wird.",The optimal effect is reached when the dose is administered in the evening.,Optimal effect is obtained if the dose is administered in the evening.,The optimal effect is reached when the dose is administered in the evening.,0.0,smt,1,1_smt,-0.030055632814764977|-0.03412030637264252|0.011791631579399109|0.0011860551312565804|0.028138041496276855
166,"Nehmen Sie nicht die doppelte Dosis ein, um eine ausgelassene Dosis auszugleichen.",Do not take a double dose to make up for a missed dose.,Do not take a double dose to make up for a forgotten tablet.,Do not take a double dose to make up for a missed dose.,0.0,smt,1,1_smt,0.003329864237457514|0.006501062773168087|0.01169348880648613|0.056338921189308167|0.05411326885223389
167,"Patienten, die bekanntermaßen ein CYP 2C9-Enzymsystem mit verminderter Aktivität haben, sollen mit Vorsicht behandelt werden.",Patients who have known to be CYP2C9 poor metabolisers should be treated with caution.,Patients known to be CYP2C9 poor metabolisers should be treated with caution.,Patients known to be CYP2C9 poor metabolisers should be treated with caution.,0.1538461538461538,smt,1,1_smt,0.015295488759875298|0.03950238227844238|0.041403185576200485|0.09087616205215454|0.07237356901168823
168,"Doribax ist ein Arzneimittel, das den Wirkstoff Doripenem enthält.",Doribax is a medicine containing the active substance doripenem.,Doribax is a medicine containing the active substance doripenem.,Doribax is a medicine containing the active substance doripenem.,0.0,smt,1,1_smt,-0.05929392948746681|-0.06847924739122391|0.008954006247222424|-0.038599781692028046|-0.0004649478942155838
169,"188 Wenn Sie Ihre Blutung mit KOGENATE Bayer 1000 I.E. nicht beherrschen können, konsultieren Sie sofort Ihren Arzt.","188 If your bleeding is not controlled with KOGENATE Bayer 1000 IU, consult your doctor immediately.","If your bleeding is not being controlled with KOGENATE Bayer 1000 IU, consult your doctor immediately.","188 If your bleeding is not controlled with KOGENATE Bayer 1000 IU, consult your doctor immediately.",0.0,smt,1,1_smt,-0.030429769307374954|-0.029073258861899376|0.012360391207039356|-0.004249170888215303|0.028722817078232765
170,"95 Um von der Insulininfusion zu profitieren und um eine mögliche Fehlfunktion der Insulinpumpe feststellen zu können, sollten Sie regelmäßig Ihren Blutzuckerspiegel messen.","95 To get the benefit of insulin infusion, and to detect possible malfunction of the insulin pump, you should measure your blood sugar level regularly.","To get the benefit of insulin infusion, and to detect possible malfunction of the insulin pump, it is recommended that you measure your blood sugar level regularly.","95 To get the benefit of insulin infusion, and to detect possible malfunction of the insulin pump, you should measure your blood sugar level regularly.",0.0,smt,1,1_smt,-0.019038505852222443|-0.02086910419166088|0.01805337332189083|0.015040447935461998|0.03776202350854874
171,Füllen Sie den Becher nicht bis zu einer anderen Dosismarkierung.,Add the inside of the cup is not up to another next to the dosage indicator.,Do not fill the cup to any other dosing line.,Do not fill the cup up to another dosage indicator.,0.8181818181818182,smt,1,1_smt,0.3935049772262573|0.45203733444213867|0.553244411945343|0.5311416983604431|0.4527518153190613
172,Wie viel Sebivo müssen Sie einnehmen? Die übliche Dosis Sebivo ist einmal täglich 30 ml Lösung zum Einnehmen (600 mg Telbivudin).,How much Sebivo to take The usual dose of Sebivo is 30 ml once daily oral solution (600 mg telbivudine).,How much Sebivo to take The usual dose of Sebivo is 30 ml of oral solution (600 mg telbivudine) once a day.,How much Sebivo to take The usual dose of Sebivo is 30 ml once daily oral solution (600 mg telbivudine).,0.0,smt,1,1_smt,0.003605491016060114|0.006686944514513016|0.01773633249104023|0.02904687263071537|0.04592083394527435
173,Packung mit 1 Flasche.,Each pack contains one bottle.,Pack size of 1 bottle.,Each pack contains one bottle.,0.0,smt,1,1_smt,-0.02509108930826187|-0.02636507712304592|0.017730800434947014|0.00809234008193016|0.039346978068351746
174,Zur subkutanen Injektion nach Rekonstitution mit Lösungsmittel.,For subcutaneous injection after reconstitution with solvent.,For subcutaneous injection after reconstitution with solvent.,For subcutaneous injection after reconstitution with solvent.,0.0,smt,1,1_smt,-0.060894954949617386|-0.05864166468381882|0.009144559502601624|-0.02062969282269478|0.00947765726596117
175,"1,74 ± 1,28 Std., Eliminationshalbwertszeit:","1.74 ± 1.28 h., elimination half-life:","1.74 ± 1.28 h, elimination half-life:","1.74 ± 1.28 h., elimination half-life:",0.0,smt,1,1_smt,-0.016658226028084755|-0.012127811089158058|0.019318414852023125|0.03406909108161926|0.04373522847890854
176,Die Anwesenheit von Stickstoffdioxid und Feuchtigkeit verursacht jedoch eine aggressive Atmosphäre.,"The presence of nitrogen dioxide and moisture, however, that causes aggressive.","However, the presence of nitrogen dioxide and moisture creates an aggressive atmosphere.","The presence of nitrogen dioxide and moisture, however, causes an aggressive atmosphere.",0.2,smt,1,1_smt,0.08860457688570023|0.12291834503412247|0.18173564970493317|0.18803149461746216|0.15356148779392242
177,Etoricoxib 60 mg einmal täglich führte bei Arthrose-Patienten zu signifikanten Verbesserungen hinsichtlich Schmerz und in der Patientenbewertung des Krankheitsstatus.,Etoricoxib 60 mg once a day in Arthrose-Patienten provided significant improvements in terms of pain and pain and patient assessments of disease status.,"22 In patients with osteoarthritis (OA), etoricoxib 60 mg once daily provided significant improvements in pain and patient assessments of disease status.",Etoricoxib 60 mg once a day in osteoarthritis patients provided significant improvements in terms of pain and patient assessments of disease status.,0.1739130434782608,smt,1,1_smt,0.055677659809589386|0.09985729306936264|0.14364421367645264|0.14652344584465027|0.1130015105009079
178,"Die Anwendung von Nukleosid-Analoga, allein oder in Kombination mit anderen Nukleosiden, führte zu Laktatazidose.","The use of nucleoside analogues, alone or in combination with other nucleoside-experienced, were associated with lactic acidosis.","Use of nucleoside analogs, alone or in combination with other nucleosides, has resulted in lactic acidosis.","The use of nucleoside analogues, alone or in combination with other nucleosides were associated with lactic acidosis.",0.1052631578947368,smt,1,1_smt,0.05787999555468559|0.07127729058265686|0.10077333450317383|0.13925760984420776|0.11034932732582092
179,- können Sie schwere Migräne bekommen.,- You may get severe migraine.,- you may develop a severe migraine.,- You may get severe migraine.,0.0,smt,1,1_smt,0.007883569225668907|0.014777597971260548|0.012351778335869312|0.048871058970689774|0.048014238476753235
180,"Verwenden Sie eine Cetrotide 3 mg-Lösung nicht, wenn sie Schwebstoffe enthält oder nicht klar ist.",Use a Cetrotide 3 mg-Lösung not be administered if it contains particles or is not clear.,Do not use a Cetrotide 3 mg solution if it contains particles or if it is not clear.,Do not use a Cetrotide 3 mg solution if it contains particles or is not clear.,0.2352941176470588,smt,1,1_smt,0.13232125341892242|0.23357152938842773|0.2243221551179886|0.2645259201526642|0.1950853168964386
181,"Orales Topotecan in Kombination mit BSC zeigte eine statistisch signifikante Verbesserung bezüglich des Gesamtüberlebens im Vergleich zu BSC allein (p=0,0104 [Log-Rank]).",Oral topotecan plus BSC group had a statistically significant improvement in overall survival compared with the BSC alone group (p = 0.0104).,Oral topotecan plus BSC group had a statistically significant improvement in overall survival compared with the BSC alone group (Log- rank p=0.0104).,Oral topotecan plus BSC had a statistically significant improvement in overall survival compared with the BSC alone group (p = 0.0104 [log-rank]).,0.1481481481481481,smt,1,1_smt,0.009491890668869019|0.016585860401391983|0.03430930897593498|0.05174131691455841|0.06343433260917664
182,"as Jeder 0,5 ml vorgefüllte Injektor enthält 20 Mikrogramm Darbepoetin alfa (40 Mikrogramm/ml).",Each 0.5 ml pre-filled pen contains 20 micrograms darbepoetin alfa (40 micrograms / ml).,Each 0.5 ml pre-filled pen contains 20 micrograms darbepoetin alfa (40 micrograms/ ml).,Each 0.5 ml pre-filled pen contains 20 micrograms darbepoetin alfa (40 micrograms / ml).,0.0,smt,1,1_smt,-0.044736675918102264|-0.04691530019044876|0.01062232069671154|-0.020242875441908836|0.008904446847736835
183,"Ferriprox ist zur Therapie der Eisenüberlast bei Patienten mit Thalassaemia major indiziert, wenn eine Therapie mit Deferoxamin kontraindiziert oder ungeeignet ist.","Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major, if treatment with deferoxamine is contraindicated or inadequate.",Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.,"Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major, if treatment with deferoxamine is contraindicated or inadequate.",0.0,smt,1,1_smt,-0.027021124958992004|-0.029042331501841545|0.016305139288306236|0.0022802609018981457|0.027543263509869576
184,Unmittelbar vor Entnahme von DepoCyte die Durchstechflasche zur gleichmäßigen Durchmischung der Partikel vorsichtig umdrehen.,Immediately before withdrawal of DepoCyte vial MW-cutoff in gently umdrehen particles.,"Just before withdrawing DepoCyte, gently invert the vial to mix the particles evenly.","Immediately before withdrawal of DepoCyte, gently turn the vial to evenly blend the particles.",0.5,smt,1,1_smt,0.30946552753448486|0.43686437606811523|0.4363197684288025|0.46685200929641724|0.38677385449409485
185,Jet Generici S.R.L.,Jet Generici S. R. L.,Jet Generici S. R. L.,Jet Generici S. R. L.,0.0,smt,1,1_smt,-0.02820437029004097|-0.03823088854551315|0.01312723197042942|-0.00530848978087306|0.028658971190452576
186,"Simulect darf nicht gegeben werden, bevor absolut sichergestellt ist, dass der Patient das Transplantat und eine begleitende Immunsuppression erhalten wird.",Simulect must not be administered before pathway procedure that the patient and concomitant immunosuppression.,Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression.,Simulect must not be administered before it is ensured that the patient will receive the transplant and concomitant immunosuppression.,0.35,smt,1,1_smt,0.20432789623737335|0.3371857702732086|0.2987495958805084|0.371534526348114|0.2943066656589508
187,Jede Packung ALIMTA enthält eine Durchstechflasche ALIMTA.,Each pack of ALIMTA contains a vial of ALIMTA.,Each pack of ALIMTA consists of one ALIMTA vial.,Each pack of ALIMTA contains a vial of ALIMTA.,0.0,smt,1,1_smt,-0.02508782409131527|-0.03619632124900818|0.019423136487603188|0.004853252787142992|0.027130387723445892
188,"Sie brauchen nicht täglich Ihren Blutzuckerspiegel zu messen, um die BYETTA-Dosis zu bestimmen.",You will not be daily test your blood sugar level to measure the INR.,You will not need to test your sugar levels on a day-by-day basis to set the dose of BYETTA.,You do not need to test your blood sugar level daily to determine the BYETTA dose.,0.4117647058823529,smt,1,1_smt,0.18823249638080597|0.27727675437927246|0.3565693497657776|0.3110601305961609|0.25957435369491577
189,Toxikologische Prüfungen mit intramuskulärer Verabreichung von Einzeldosen wurden an Cynomolgus-Affen durchgeführt.,Toxicological trials with intramuscular administration of single doses have been carried out in cynomolgus monkeys.,Single dose intramuscular toxicology studies have been performed in cynomolgus monkeys.,Toxicological trials with intramuscular administration of single doses have been carried out in cynomolgus monkeys.,0.0,smt,1,1_smt,0.04448506608605385|0.10174471139907837|0.04066159948706627|0.1513129323720932|0.11009906977415085
190,Die klinische Relevanz dieser Befunde ist nicht belegt.,The clinical relevance of these findings has not been established.,The clinical relevance of these findings has not been established.,The clinical relevance of these findings has not been established.,0.0,smt,1,1_smt,-0.04937434569001198|-0.055283643305301666|0.008759272284805775|-0.014681141823530197|0.009420378133654594
191,Die vollständige Liste der im Zusammenhang mit Levitra berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen.,"For the full list of related to Levitra reported adverse drug reactions, see the Package Leaflet.","For the full list of all side effects reported with Levitra, see the Package Leaflet.","For the full list of related to Levitra reported adverse drug reactions, see the Package Leaflet.",0.0,smt,1,1_smt,0.00840814784169197|0.028211001306772232|0.03506843000650406|0.059877634048461914|0.07315536588430405
192,Leitungswasser darf zu jeder Zeit während der laufenden Behandlung mit Bondronat getrunken werden.,plain water must be drunk at any time during therapy with Bondronat.,Plain water may be taken at any time during the course of Bondronat treatment.,Water must be drunk at any time during therapy with Bondronat.,0.0833333333333333,smt,1,1_smt,0.03881414607167244|0.06514249742031097|0.021052347496151924|0.10741035640239716|0.10324999690055847
193,- Die sonstigen Bestandteile von [Neurontin und zugehörige Namen] Hartkapseln sind:,- The other ingredients of [Neurontin and associated names] hard capsules:,− The other ingredients in [Neurontin and associated names] capsules are:,- The other ingredients of [Neurontin and associated names] hard capsules are:,0.0666666666666666,smt,1,1_smt,-0.016625816002488136|-0.015620661899447441|0.03778323158621788|0.01626509800553322|0.03818713501095772
194,Montelukast wirkte weder in In-vitro- und In– vivo-Tests mutagen noch induzierte es bei Nagetieren Tumoren.,"Montelukast was not mutagenic in bacterial vivo-Tests in vitro and injections, nor did it in rodents.",Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent species.,Montelukast was not effective in either in vitro and in vivo tests nor did it in rodent tumours.,0.4210526315789473,smt,1,1_smt,0.11984951049089432|0.20536525547504425|0.18300414085388184|0.24999308586120605|0.18480153381824493
195,"Bei Patienten mit ischämischer Herzkrankheit ist Vorsicht geboten, da allergieähnliche und/oder gefäßerweiternde Reaktionen bei solchen Patienten zu lebensbedrohlichen Zuständen führen können.","Caution should be exercised in patients with ischaemic cardiopathy, as an allergic reaction and / or in which reactions in such patients can lead to life-threatening conditions.",3 Care should be taken in patients with ischaemic cardiac disease because in these patients allergy-like and/ or vasodilatory reactions may lead to life-threatening conditions.,"Caution should be exercised in patients with ischaemic cardiopathy, as an allergic reaction and/or in which reactions in such patients can lead to life-threatening conditions.",0.0,smt,1,1_smt,0.032118216156959534|0.054836712777614594|0.1562192291021347|0.09757974743843079|0.09207595139741898
196,51 TEIL III:,51 Medicine III:,48 PART III:,51 PART III:,0.25,smt,1,1_smt,0.049110446125268936|0.05020608752965927|0.05248555913567543|0.10201315581798553|0.08869311213493347
197,Bei Patienten mit dem CYP2D6-Status „EM“ sind Vorsichtsmaßnahmen in geringerem Maße erforderlich.,In patients with CYP2D6 EM status precautions are needed to a lesser extent.,There is a lower need for precautions in patients with CYP2D6 EM status.,There is a lower need for precautions in patients with CYP2D6 EM status.,0.5714285714285714,smt,1,1_smt,0.0382172167301178|0.07184530794620514|0.0439859963953495|0.13876879215240479|0.10652514547109604
198,Allerdings wurde die Studie aufgrund von Nebenwirkungen (Nieren- und Lungenproblemen) vorzeitig abgebrochen.,"However, the study because of side effects (renal or heart and lung problems in the baby discontinued).","However, the study had to be stopped early because of side effects (kidney and lungs problems).","However, the study was discontinued early because of side effects (renal and lung problems).",0.5,smt,1,1_smt,0.0980694517493248|0.1621728241443634|0.08508659154176712|0.226279616355896|0.1737557053565979
199,"Eine einzelne Spritze enthält 0,5 ml Injektionssuspension.",A single syringe contains 0.5 ml suspension for injection.,A single syringe contains 0.5 ml of suspension for injection.,A single syringe contains 0.5 ml suspension for injection.,0.0,smt,1,1_smt,-0.049275800585746765|-0.06135086715221405|0.008843249641358852|-0.016985245048999786|0.01071163546293974
200,Patienten mit Risikofaktoren für eine QTc- Verlängerung oder Risikofaktoren für Torsade de Pointes sollten überwacht und einer kontinuierlichen Herzüberwachung (EKG) unterzogen werden.,Patients with risk factors for QTc prolongation or risk factors for torsade de pointes should be monitored and continuous AN (priapism).,Patients with risk factors of QTc prolongation or risk factors of torsade de pointes should be monitored with continuous cardiac monitoring (ECG).,Patients with risk factors for QTc prolongation or risk factors for torsade de pointes should be monitored and their heat shoud be continuously monitored (EKG).,0.25,smt,2,2_smt,0.07529395818710327|0.11794351041316986|0.11295411735773087|0.1893826127052307|0.13513581454753876
201,Der Schweregrad war im Allgemeinen schwach bis mäßig ausgeprägt.,Severity was generally mild to moderate.,Severity was generally mild to moderate.,Severity was generally mild to moderate.,0.0,smt,2,2_smt,-0.03988498076796532|-0.04386843740940094|0.009281092323362827|-0.0019714455120265484|0.01737358048558235
202,Die gleichzeitige Anwendung von Invirase/Ritonavir und Digoxin muss mit Vorsicht erfolgen.,Co-administration of Invirase / ritonavir and digoxin should be considered with caution.,Caution should be exercised when Invirase/ritonavir and digoxin are co- administered.,Co-administration of Invirase / ritonavir and digoxin should be performed with caution.,0.0769230769230769,smt,2,2_smt,0.016900893300771713|0.023447774350643158|0.030370471999049187|0.06235484778881073|0.06218353658914566
203,Wie ist Corlentor einzunehmen?,How to take Corlentor 4.,How to take Corlentor 4.,How to take Corlentor.,0.2,smt,2,2_smt,-0.04607715457677841|-0.05572657287120819|0.010892346501350403|-0.02238185703754425|0.007967405021190643
204,"Vereinzelt traten lebensbedrohliche Überempfindlichkeitsreaktionen bei Patienten auf, die Abacavir wieder einnahmen, nachdem bei Ihnen nur eines der auf der Warnhinweiskarte aufgeführten Symptome vor der Therapieunterbrechung aufgetreten war.",tonoclonic life-threatening hypersensitivity reactions have occurred in patients receiving abacavir in only on the Alert Card symptoms of hypersensitivity before stopping.,Occasionally life-threatening hypersensitivity reactions have occurred when abacavir was restarted in patients who reported only one of the symptoms on the Alert Card before stopping.,Occasionally life-threatening hypersensitivity reactions have occurred when abacavir was restarted in patients who reported only one of the symptoms on the Alert Card before treatment was stopped.,0.6071428571428571,smt,2,2_smt,0.22263330221176147|0.357266902923584|0.2820923924446106|0.3941335380077362|0.3144112825393677
205,Solche Veränderungen der Leberfunktion wurden bisher in klinischen Studien am Menschen nicht beobachtet.,Such changes in liver function have not been observed in human clinical studies.,Such alterations in liver function have not been seen to date in human clinical studies.,Such changes in liver function have not been observed in human clinical studies.,0.0,smt,2,2_smt,-0.036044422537088394|-0.03692876547574997|0.01244226936250925|-0.009727582335472107|0.01852652058005333
206, Sie dürfen immer nur jeweils ein Pflaster tragen.,Do not use only every patch at a time., Only one patch is to be worn at a time.,Only use one patch at a time.,0.5,smt,2,2_smt,0.10130152106285095|0.1532229632139206|0.09619320183992386|0.20228055119514465|0.15299609303474426
207,Wie wurde Jalra untersucht?,How has Jalra been studied?,How has Jalra been studied?,How has Jalra been studied?,0.0,smt,2,2_smt,-0.06961869448423386|-0.06797204166650772|0.009317818097770214|-0.04260930418968201|-0.007955839857459068
208,"Die Hypertonie war in der Regel leicht bis mäßig, trat in einer frühen Phase der Behandlung auf und sprach auf antihypertensive (blutdrucksenkende) Standardtherapien an.","Hypertension was usually mild to moderate, was more frequent in the early phase of treatment and addressed impaired on antihypertensive (antihypertensive) standard therapy.","Hypertension was usually mild to moderate, occurred early in the course of treatment, and was amenable to management with standard antihypertensive therapy.","Hypertension was usually mild to moderate, occurred in the early phase of treatment and responded to standard antihypetensive therapy.",0.5238095238095238,smt,2,2_smt,0.07701129466295242|0.13964921236038208|0.2808252274990082|0.1836489737033844|0.141609787940979
209,"Bei versehentlicher Selbstinjektion des Impfstoffes wird angeraten, einen Arzt aufzusuchen und ihm die Gebrauchsinformation oder das Etikett zu zeigen.","In case of accidental self injection of the vaccine, it is advised to seek medical advice and show the package leaflet or the label to the physician.","In case of accidental self-administration, seek medical advice immediately and show the package leaflet or the label to the physician.","In case of accidental self injection of the vaccine, it is advised to seek medical advice and show the package leaflet or the label to the physician.",0.0,smt,2,2_smt,0.03770468011498451|0.0711030587553978|0.031187614426016808|0.10679452866315842|0.10656646639108658
210,"Falls wiederholte oder schwere niedrige Blutzuckerspiegel auftreten, informieren Sie bitte Ihren Arzt oder Ihr Krankenhaus und ziehen Sie die Notwendigkeit einer Reduktion oder einer Unterbrechung der Insulininfusion in Betracht.","If repeated or severe low blood glucose levels occur, please tell your doctor or clinic and consider the need to reduce or pump malfunction should be considered.","If repeated or severe low blood glucose levels occur, notify your health care professional and consider the need to reduce or stop your insulin infusion.","If repeated or severely low blood glucose levels occur, please tell your doctor or clinic and consider the need for a resuction or an interruption in the insulin infusion.",0.3225806451612903,smt,2,2_smt,0.11462397128343582|0.18426725268363953|0.27867773175239563|0.224473237991333|0.17666879296302795
211,Eine Anpassung der Dosierung von Ritonavir kann notwendig sein.,The dose of ritonavir may be necessary.,The dose of ritonavir may need adjusting.,An adjustment of the dose of Ritonavir may be necessary.,0.2727272727272727,smt,2,2_smt,0.04400807246565819|0.0429082065820694|0.0571366623044014|0.11851833760738373|0.08310957998037338
212,kann dies auf Leberschäden hinweisen.,this can be suggestive of hepatic impairment.,Other possible side effects with PRODUCT NAME:,this can be suggestive of hepatic impairment.,0.0,smt,2,2_smt,0.09693959355354309|0.14337247610092163|0.10646911710500717|0.2165365070104599|0.16765430569648743
213,"Die Behandlung sollte so lange fortgeführt werden, wie ein klinischer Nutzen zu beobachten ist.",Treatment should be continued as long clinical benefits are observed.,"There is limited information on the use of Lysodren in children, but a daily starting dose of 1.5 to 3.5 g per square metre body surface area (calculated using the child ’ s height and weight) is recommended. Lysodren is not recommended for use in patients with severe liver or kidney problems, and it should be used with caution in those with mild or moderate liver or kidney problems.",Treatment should be continued as long clinical benefits are observed.,0.0,smt,2,2_smt,0.16914302110671997|0.2387688010931015|0.15295696258544922|0.30369576811790466|0.235760897397995
214,Nicht gebrauchte Spritzen oder Abfall sollten entsprechend den örtlich gültigen Vorschriften entsorgt werden.,Any unused product or waste material should be applied according to the current veterinary medicinal product must be discarded.,e prevent needle stick injuries following injection. ng Any unused product or waste material should be disposed of in accordance with local requirements.,Any unused product or waste material should be disposed of according to the current local ordinances.,0.4705882352941176,smt,2,2_smt,0.11676212400197983|0.18847915530204773|0.4369824230670929|0.2490563988685608|0.18589183688163757
215,Bei Patienten mit Schlafwandeln sollte an das Risiko einer Verletzung gedacht werden.,In patients with somnambulism should be experienced on the risk of needlestick injury.,The risk of injury or self-harm should be borne in mind in any patient with sleepwalking.,In patients with somnambulism the risk of injury should be considered.,0.4166666666666667,smt,2,2_smt,0.25529080629348755|0.3581051230430603|0.426076203584671|0.42198771238327026|0.34262561798095703
216,Inverkehrbringen Sanofi-Synthelabo S.A.,Union for Sanofi-Synthelabo S. A.,Sanofi-Synthelabo S. A.,Marketing Authorisation Holder Sanofi-Synthelabo S. A.,0.375,smt,2,2_smt,0.005733700934797525|0.013820525258779526|0.12305334955453873|0.04785331338644028|0.054998211562633514
217,"Der primäre Wirksamkeitsendpunkt war das Auftreten bewiesener/wahrscheinlicher IFIs zur Woche 16 nach Randomisierung, das durch ein unabhängiges, verblindetes externes Expertengremium bestimmt wurde.","The primary efficacy endpoint was the incidence of proven / probable IFIs at week 16 after randomisation, determined by a blinded, the first Expertengremium.","The primary efficacy endpoint was the incidence of proven/ probable IFIs at 16 weeks post-randomization as determined by an independent, blinded external expert panel.","The primary efficacy endpoint was the incidence of proven/probable IFIs at week 16 after randomisation, determined by a blinded, independent external panel of experts.",0.1724137931034483,smt,2,2_smt,0.08319078385829926|0.14882324635982513|0.16318455338478088|0.22133426368236542|0.17709073424339294
218,62 ähnlich ist. Die begrenzten Daten zu AVANDAMET entsprechen ebenfalls diesem kombinierten Nebenwirkungsprofil.,62. The limited data on AVANDAMET also correspond to this combined adverse reaction profile.,Data with AVANDAMET is also consistent with this combined adverse reaction profile.,62. The limited data on AVANDAMET also corresponds to these combined adverse reaction profile.,0.125,smt,2,2_smt,0.01290440745651722|0.02987910807132721|0.053846437484025955|0.0768771842122078|0.07550400495529175
219,Wofür wird Micardis angewendet?,What is Micardis used for?,What is Micardis used for?,What is Micardis used for?,0.0,smt,2,2_smt,-0.05998880788683891|-0.06081116199493408|0.008440281264483929|-0.03946955129504204|-0.0032616499811410904
220,"Um eine unerwünschte Akkumulation im Tagesverlauf zu vermeiden, ist bei diesen Patienten während der anfänglichen Dosistitration besonders vorsichtig vorzugehen.","In order to avoid the unwanted accumulation in the Tagesverlauf, in these patients during the initial titration.","To avoid undesired accumulation over the day, special caution has to be exercised with these patients during initial dose titration.","In order to avoid unwanted accumulation in the course of the day, special care should be taken when dealing with these patients during the initial titration.",0.4285714285714285,smt,2,2_smt,0.26745134592056274|0.3783029317855835|0.34217941761016846|0.4393446445465088|0.3852905333042145
221,"Die skalierte Dosierpipette fasst bis zu 1.000 mg Levetiracetam (entsprechend 10 ml), die Skalierungsschritte betragen 25 mg (entsprechend 0,25 ml).","The 6-8 which is packaged with an oral dosing syringe summarises up to 1,000 mg levetiracetam (corresponding to 10 ml), titrating the Skalierungsschritte 25 mg (equivalent to 0.25 ml).","The graduated oral syringe contains up to 1,000 mg levetiracetam (corresponding to 10 ml) with a graduation every 25 mg (corresponding to 0.25 ml).","The scaled dosage pipette holds up to 1,000 mg levetiracetam (corresponding to 10 ml), the scaling measure is 25 mg (equivalent to 0.25 ml).",0.4666666666666667,smt,2,2_smt,0.054480500519275665|0.07369456440210342|0.16494569182395935|0.11502779275178909|0.09541697055101395
222,"Für den Fall einer allergischen Reaktion während einer Verabreichung von MabThera sollen Arzneimittel zur Behandlung von Überempfindlichkeitsreaktionen wie z.B. Epinephrin (Adrenalin), Antihistaminika und Glukokortikoide für den sofortigen Einsatz zur Verfügung stehen.","In the event of an allergic reaction during administration of MabThera medicines for the treatment of hypersensitivity reactions, e. g. epinephrine (adrenaline), antihistamines and corticosteroids for immediate use should be available.","Medicinal products for the treatment of hypersensitivity reactions, e. g., epinephrine (adrenaline), antihistamines and glucocorticooids, should be available for immediate use in the event of an allergic reaction during administration of MabThera.","In the event of an allergic reaction during administration of MabThera, medicines for the treatment of hypersensitivity reactions, e. g. epinephrine (adrenaline), antihistamines and corticosteroids for immediate use should be available.",0.027027027027027,smt,2,2_smt,0.017004113644361496|0.03682710975408554|0.060312896966934204|0.060782648622989655|0.0737026259303093
223,"In der Original Flasche aufbewahren, um den Inhalt vor Feuchtigkeit zu schützen.","Store in the original bottle in order to protect from light, in the product.",Store in the original bottle in order to protect from moisture.,"Store in the original bottle in order to protect from light, in the product.",0.0,smt,2,2_smt,0.09108931571245193|0.11915075033903122|0.1798333376646042|0.2009832262992859|0.1609540432691574
224,"4 (siehe Abschnitt 4.5). Falls der Einsatz von Antazida während der Behandlung mit Tarceva als notwendig erachtet wird, sollte die Einnahme wenigstens 4 Stunden vor oder 2 Stunden nach der täglichen Tarceva Dosis erfolgen.","4 (see section 4.5). If the use of antacids is considered necessary, they should be taken at least 4 hours before or 2 hours after the daily dose of Tarceva during treatment with Tarceva.","If the use of antacids is considered necessary during treatment with Tarceva, they should be taken at least 4 hours before or 2 hours after the daily dose of Tarceva.","4 (see section 4.5). If the use of antacids is considered necessary, they should be taken at least 4 hours before or 2 hours after the daily dose of Tarceva during treatment with Tarceva.",0.0,smt,2,2_smt,-0.003286603605374694|-0.005500288680195808|0.046662937849760056|0.02795294113457203|0.044383347034454346
225,"Die präklinischen Studien, einschließlich konventioneller Studien zur allgemeinen Pharmakologie, zur Genotoxizität und zum kanzerogenem Potential lassen keine besonderen Gefahren für den Menschen erkennen.","The preclinical studies, including special hazard for humans based on conventional studies of global pharmacology, genotoxicity, carcinogenic potential kanzerogenem Non-clinical data reveal no special hazard to humans.","Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, genotoxicity and carcinogenic potential.","The preclinical studies of conventional studies of general pharmacology, genotoxicity and carcinogenic potential revealed no special hazard to humans.",0.6666666666666666,smt,2,2_smt,0.12390870600938797|0.2071007639169693|0.26758018136024475|0.20893654227256775|0.18771271407604218
226,Nicht über 25ºC lagern.,Do not store above 25 ° C.,195 Do not store above 25°C.,Do not store above 25 ° C.,0.0,smt,2,2_smt,-0.01598665863275528|-0.026636434718966484|0.009909088723361492|0.019978206604719162|0.028900757431983948
227,Das in diesen klinischen Studien beobachtete Sicherheitsprofil von Biograstim war dem des in diesen Studien verwendeten Referenzpräparats vergleichbar.,The observed in these clinical studies safety profile of Biograstim was comparable to the reference product used in these reference product used in these studies.,The safety profile of Biograstim observed in these clinical studies was consistent with that reported with the reference product used in these studies.,The observations of these clinical studies on the safety profile of Biograstim was comparable to the reference product used in these studies.,0.3478260869565217,smt,2,2_smt,0.06014878302812576|0.09687560796737671|0.2443539947271347|0.15671135485172272|0.12756109237670898
228,"Der Wirkstoff in Myfenax, Mycophenolatmofetil, ist ein Immunsuppressivum. Im Körper wird es zu Mycophenolsäure umgewandelt, die ein Enzym mit der Bezeichnung „Inosinmonophosphat- dehydrogenase“ blockiert.","The active substance in Myfenax, mycophenolate mofetil, is an immunosuppressant in transplants, in one study with a total of 1,493 adults following kidney enzyme.","This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected.","The active substance in Myfenax, mycophenolate mofetil, is an immunosuppressant. In the body it is metabolised to mycophenolic acid, which blocks an enzyme with the identification IMP dehydrogenase.",0.5757575757575758,smt,2,2_smt,0.40026894211769104|0.4925991892814636|0.36525577306747437|0.5284045338630676|0.45892956852912903
229,zu Den vollständigen Wortlaut des EPAR für Quintanrix finden Sie hier.,The full EPAR for up for Quintanrix can be found here.,This summary was last updated in 04-2008.,The full EPAR for up for Quintanrix can be found here.,0.0,smt,2,2_smt,0.28527581691741943|0.34921297430992126|0.29934024810791016|0.4199255704879761|0.36637330055236816
230,"8/38 Zur Weiterbehandlung können Flexicam 1,5 mg/ml Suspension zum Eingeben für Hunde in einer Dosierung von 0,1 mg Meloxicam/kg Körpergewicht 24 Stunden nach der Injektion eingesetzt werden.","8 / 34 may be used for continuation of Flexicam 1.5 mg / ml oral suspension for dogs of treatment at a dosage of 0.1 mg meloxicam / kg body weight, 24 hours after administration of the injection.","Flexicam 1.5 mg/ ml oral suspension may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/ kg body weight, 24 hours after administration of the injection.","8/34 may be used for continuation of Flexicam 1.5 mg/ml oral suspension for dogs at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.",0.0526315789473684,smt,2,2_smt,0.03546926751732826|0.06111033260822296|0.08431309461593628|0.10410340875387192|0.09228891134262085
231,"Xiliarx 50 mg Tabletten sind in Packungen mit 7, 14, 28, 30, 56, 60, 90, 112, 180 oder 336 Tabletten und in Bündelpackungen mit 336 (3x112) Tabletten erhältlich.","Xiliarx 50 mg tablets are available in packs containing 7, 14, 28, 30, 56, 60, 90, 112, 180 or 336 tablets and in multipacks containing 336 (3x112) tablets.","Xiliarx 50 mg tablets are available in packs containing 7, 14, 28, 30, 56, 60, 90, 112, 180 or 336 tablets and in multipacks containing 336 (3x112) tablets.","Xiliarx 50 mg tablets are available in packs containing 7, 14, 28, 30, 56, 60, 90, 112, 180 or 336 tablets and in multipacks containing 336 (3x112) tablets.",0.0,smt,2,2_smt,-0.041568391025066376|-0.049930207431316376|0.011204922571778297|-0.03419021517038345|0.006449257023632526
232,Führen Sie die Injektion entsprechend der Anweisung Ihres Arztes durch.,Inject as instructed by your health care professional.,Follow the injection procedure as instructed by your health care professional.,Inject as instructed by your health care professional.,0.0,smt,2,2_smt,0.03626614809036255|0.039509810507297516|0.015624526888132095|0.09759468585252762|0.095729298889637
233,Bitte lesen und befolgen Sie diese Bedienungsanleitung genau.,Please read and follow these instructions exactly.,Read and follow all of these instructions carefully.,Please read and follow these instructions exactly.,0.0,smt,2,2_smt,0.005411023739725351|0.0012790132313966751|0.015457885339856148|0.04313879460096359|0.051043346524238586
234,"Entfernen Sie NICHT den grauen Stopfen oder den Aluminiumring, der sich rund um den oberen Teil der Durchstechflasche befindet (siehe Abb. 1).",Do NOT remove the grey stopper or aluminium ring around the top of the vial (see Diagram 1).,DO NOT remove the grey stopper or aluminium ring around the top of the vial (see Diagram 1).,Do NOT remove the grey stopper or aluminium ring around the top of the vial (see Diagram 1).,0.0,smt,2,2_smt,-0.031098945066332817|-0.03516890108585358|0.010429213754832745|-0.0030572526156902313|0.025609800592064857
235,Bei Untersuchungen mit anderen Interferonen konnte eine Speziesspezifität nachgewiesen werden.,In Studies with other interferons have demonstrated species specificity.,Studies with other interferons have demonstrated species specificity.,"In studies with other interferons, a species specificity could be demonstrated.",0.3846153846153846,smt,2,2_smt,0.015289541333913803|0.03519773110747337|0.17898526787757874|0.08783316612243652|0.07944143563508987
236,"Vedaprofen ist ein nichtsteroidales Antiphlogistikum (NSAID), welches zur Gruppe der Arylpropionsäurederivate gehört.","Vedaprofen is a non-steroidal anti-inflammatory drug (NSAID), belongs to the group of Arylpropionsäurederivate.",Vedaprofen is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivate group.,Vedaprofen is a non-steroidal anti-inflammatory drug (NSAID) which belongs to the group of propionic acid derivate group.,0.25,smt,2,2_smt,0.024979785084724426|0.041180048137903214|0.08364236354827881|0.08344072848558426|0.08301357179880142
237,"Salzsäure, Natriumhydroxid (zur pH-Einstellung).","hydrochloric acid, sodium hydroxide (to adjust pH).","Hydrochloric acid, sodium hydroxide (for pH adjustment).","Hydrochloric acid, sodium hydroxide (to adjust pH).",0.0,smt,2,2_smt,-0.030894845724105835|-0.02419624663889408|0.010923872701823711|0.005461063701659441|0.026999905705451965
238,"Die wichtigsten zu harmonisierenden Abschnitte waren: Abschnitt 4.1, 4.2, 4.3, 4.4 und 4.6 der Zusammenfassung der Merkmale des Arzneimittels.","The main cause harmonisierenden sections were: section 4.1, 4.2, 4.3, 4.4 and 4.6 of the SPC.","The main areas for harmonisation were: the sections 4.1, 4.2, 4.3, 4.4 and 4.6 of the summary of product information (SPC).","The main cause harmonising sections were: section 4.1, 4.2, 4.3, 4.4 and 4.6 of the SPC.",0.0476190476190476,smt,2,2_smt,0.1756039559841156|0.23764905333518982|0.1085355132818222|0.2980633080005646|0.25428757071495056
239,Ethnische Unterschiede ACE-Hemmer verursachen bei Patienten mit schwarzer Hautfarbe häufiger angioneurotische Ödeme als bei Patienten mit nicht schwarzer Hautfarbe.,Ethnic differences of ACE inhibitors cause a higher in patients with Black angioedema than in non-black patients.,Ethnic differences ACE inhibitors cause higher rate of angioedema in black patients than in non black patients.,Ethnic differences: ACE inhibitors cause angioedema more frequently in patients with black skin colour than in patients with non-black skin colour.,0.4347826086956521,smt,2,2_smt,0.04376409947872162|0.06398290395736694|0.19879721105098724|0.12617208063602448|0.09568814933300018
240,Nach Markteinführung gab es Berichte schwerwiegender Fälle einschließlich eines tödlich verlaufenden Falles von Herpesenzephalitis.,"There have also been post-marketing reports of serious cases of rash, including fatal Falles of Herpesenzephalitis.","In post marketing experience, there have been reports of serious cases, including one fatal case of herpes encephalitis.","There have also been post-marketing reports of serious cases, including one fatal case of herpesviral encephalitis.",0.3333333333333333,smt,2,2_smt,0.041575752198696136|0.06488150358200073|0.06807513535022736|0.1196487694978714|0.09916592389345169
241,"Außerdem erhalten Ärzte einen „Dosierungsrechner“, mit dessen Hilfe sie die zu injizierende Menge Nplate berechnen können.","will also receive a ""Dosierungsrechner to help them calculate the volumes of Nplate.",Doctors will also receive a ‘ dosing calculator’ to help them calculate the volumes of Nplate that need to be injected.,"Doctors also receive a ""dosage calcculator"" to help them calculate the volumes of Nplate to in inject.",0.35,smt,2,2_smt,0.12338409572839737|0.20718352496623993|0.18563386797904968|0.26468297839164734|0.21068958938121796
242,Forsteo kann zu einem Anstieg der Kalziummenge in Ihrem Urin führen.,Forsteo may result in an increase in Kalziummenge in your urine.,FORSTEO may cause an increase in the amount of calcium in your urine.,Forsteo may result in an increase in calcium concentration in your urine.,0.1538461538461538,smt,2,2_smt,0.0800730362534523|0.13065941631793976|0.06432097405195236|0.16152971982955933|0.1446072906255722
243,"Wenn eine Erhöhung der FSH-Dosis 103 angezeigt ist, sollte die Anpassung der Dosis vorzugsweise in 7-14tägigen Intervallen und in Schritten von 37,5-75 I.E. erfolgen.","If an FSH dose increase is deemed appropriate, dose adaptation should preferably be at 7-14 day intervals and preferably with 37.5-75 IU increments.","If an FSH dose increase is deemed appropriate, dose adaptation should preferably be at 7-14 day intervals and preferably with 37.5-75 IU increments.","If an FSH dose increase is deemed appropriate, dose adaptation should preferably be carried out at 7-14 day intervals and preferably with 37.5-75 IU increments.",0.074074074074074,smt,2,2_smt,-0.019074616953730583|-0.021655598655343056|0.02088845707476139|0.013739565387368202|0.03747761994600296
244,"Die Patienten waren bei Beginn der Behandlung zwischen 6 Monate und 3,5 Jahre alt.",Patients had after initiation of therapy between 6 months and 3.5 years of age.,Subjects ranged in age from 6 months to 3.5 years at initiation of treatment.,Patients were between 6 months and 3.5 years of age after initiation of therapy.,0.1333333333333333,smt,2,2_smt,0.10801613330841064|0.16173231601715088|0.1555979996919632|0.20778679847717285|0.17841888964176178
245,"Sicherstellen, dass alle Verbindungen fest sind.",gastropathy that all the container.,Ensure all connections are tight.,Ensure that all connections are secure.,0.5714285714285714,smt,2,2_smt,0.5258112549781799|0.5978029370307922|0.6300680637359619|0.6132993698120117|0.5800815224647522
246,"Irbesartan Hydrochlorothiazide Winthrop 150 mg/12,5 mg Tabletten.",Irbesartan Hydrochlorothiazide Winthrop 150 mg / 12.5 mg tablets.,Irbesartan Hydrochlorothiazide Winthrop 150 mg/ 12.5 mg tablets.,Irbesartan Hydrochlorothiazide Winthrop 150 mg / 12.5 mg tablets.,0.0,smt,2,2_smt,-0.028844382613897324|-0.03044125996530056|0.011665038764476776|0.0037372582592070103|0.01918693631887436
247,"Jede Fertigspritze enthält 0,20 mg Phenylalanin.",Each pre-filled syringe contains 0.20 mg phenylalanine.,Each pre-filled syringe contains 0.20 mg phenylalanine.,Each pre-filled syringe contains 0.20 mg phenylalanine.,0.0,smt,2,2_smt,-0.05510687828063965|-0.058026693761348724|0.008869150653481483|-0.027337199077010155|0.004601760767400265
248,Diese Aktualisierung könnte freilich durch eine Typ-II-Änderung auf nationaler Ebene erfolgen.,This update may be freilich by • The national level.,This could indeed be done through a type II variation at national level.,This update may be voluntarily carried out on a national level.,0.4166666666666667,smt,2,2_smt,0.31752878427505493|0.4526824951171875|0.4489695429801941|0.5070421695709229|0.41075217723846436
249,TMZ wurde als Salvage-Therapie in der Folgephase an 161 von 282 Patienten (57%) des RT (allein) Arms und an 62 von 277 (22%) des TMZ + RT Arms verabreicht.,"41 TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.","86 TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm.",41 TMZ was administered as salvage therapy in the follow-up phase in 161 of 282 patients (57%) in the RT (alone) arm and 62 of 277 patients (22%) in the TMZ + RT arm.,0.2093023255813953,smt,2,2_smt,-0.008839445188641548|-0.01782778836786747|0.01714668609201908|0.022306840866804123|0.04337785392999649
250,"Welche Konsequenzen hat die Rücknahme für Patienten, die derzeit an klinischen Studien bzw. „Compassionate-Use“ -Programmen mit Advexin teilnehmen?",What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Advexin?,What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Advexin?,What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Advexin?,0.0,smt,2,2_smt,-0.04132353141903877|-0.04296787828207016|0.01224338635802269|-0.0015448685735464096|0.02258290722966194
251,"Die Daten zeigen, dass Abacavir und Lamivudin in das zentrale Nervensystem (ZNS) eindringen und in der Zerebrospinalflüssigkeit nachweisbar sind.",Data show that abacavir and lamivudine penetrate the central nervous system (CNS) and dabigatran in the cerebrospinal fluid.,Data show that abacavir and lamivudine penetrate the central nervous system (CNS) and reach the cerebrospinal fluid (CSF).,Data show that abacavir and lamivudine penetrate the central nervous system (CNS) and are traceable in the cerebrospinal fluid.,0.0909090909090909,smt,2,2_smt,0.04862097650766373|0.06639958918094635|0.05220891162753105|0.11020790040493011|0.09684335440397263
252,CEPROTIN gehört zu einer Klasse von Arzneimitteln die Antithrombotika genannt werden.,CEPROTIN belongs to a class of medicines called the antithrombotic agents.,CEPROTIN belongs to a class of medicines called antithrombotics.,CEPROTIN belongs to a class of medicines called the antithrombotic agents.,0.0,smt,2,2_smt,-0.032263293862342834|-0.041037075221538544|0.011161688715219498|-0.008144086226820946|0.024545790627598763
253,"11 Diabetiker Die Bioverfügbarkeit (AUC) von Tadalafil war bei Diabetikern etwa 19% niedriger, als der AUC- Wert von gesunden Probanden.",11 Patients with diabetes Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value for healthy subjects.,10 Patients with diabetes Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value for healthy subjects.,11 Patients with diabetes Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value for healthy subjects.,0.0,smt,2,2_smt,-0.02153165638446808|-0.018648391589522362|0.023355435580015182|0.010312406346201897|0.03094855509698391
254,Erkrankungen des Nervensystems:,Nervous system disorders:,Nervous system disorders Common:,Nervous system disorders:,0.0,smt,2,2_smt,-0.07132498919963837|-0.06874625384807587|0.010317781940102577|-0.04516575485467911|-0.008330361917614937
255,"Agenerase Lösung zum Einnehmen ist bei Patienten, die mit Metronidazol behandelt werden, kontraindiziert (siehe Abschnitt 4.3).","Agenerase oral solution is preferable in patients who are being treated with metronidazole, is contraindicated (see section 4.3).",Agenerase oral solution is contraindicated in patients treated with metronidazole (see section 4.3).,Agenerase oral solution is contraindicated in patients who are being treated with metronidazole (see section 4.3).,0.2105263157894736,smt,2,2_smt,0.033801157027482986|0.05537808686494827|0.20198222994804382|0.09183245152235031|0.08211293071508408
256,Ivabradin hat eine geringe Affinität zu CYP3A4 und zeigt keine klinisch relevante CYP3A4 Induktion oder Hemmung. Daher ist eine Veränderung des CYP3A4-Substrat-Metabolismus oder der Plasmakonzentrationen unwahrscheinlich.,"Ivabradine has a low affinity for CYP3A4 and shows no clinically relevant CYP3A4 inhibition or induction and, therefore, no change in CYP3A4-Substrat-Metabolismus or plasma concentrations is unlikely.","Ivabradine has low affinity for CYP3A4, shows no clinically relevant CYP3A4 induction or inhibition and is therefore unlikely to modify CYP3A4 substrate metabolism or plasma concentrations.","Ivabradine has a low affinity for CYP3A4 and shows no clinically relevant CYP3A4 inhibition or induction and, therefore, change to the CYP3A4 substrate metabolism or plasma concentrations is unlikely.",0.1875,smt,2,2_smt,0.028793226927518845|0.06317059695720673|0.06787653267383575|0.09439738094806671|0.08938479423522949
257,* Die Häufigkeit für das Auftreten dieser Ereignisse wurde in den Placebogruppen der klinischen Studien als „häufig“ klassifiziert.,"* The frequency for the background incidence of these events, as taken from placebo group data from clinical trials category'common '.","24 *The frequency category for the background incidence of this event, as taken from placebo group data from clinical trials, is'common '.",* The frequency for the incidence of these events was classified in the placecbo group in clinical studies as common.,0.5714285714285714,smt,2,2_smt,0.04997961223125458|0.07065276056528091|0.13705560564994812|0.14468927681446075|0.1105421781539917
258,Jede 300 mg Hartkapsel enthält 300 mg Gabapentin.,Each 300 mg hard capsule contains 300 mg of gabapentin.,Each 300 mg hard capsule contains 300 mg of gabapentin.,Each 300 mg hard capsule contains 300 mg of gabapentin.,0.0,smt,2,2_smt,-0.04052184522151947|-0.04903368651866913|0.008781159296631813|-0.015133047476410866|0.008046312257647514
259,Cetrotide erwies sich bei der Vermeidung eines plötzlichen Anstiegs bei der Bildung des luteinisierenden Hormons als ebenso wirksam wie die Vergleichsbehandlungen.,Cetrotide was more effective to prevent sudden increase in the formation of human α-fetoprotein as effective as the comparator treatments.,Cetrotide was as effective as the comparator treatments in preventing a surge (sudden increase) in the production of luteinising hormone.,Cetrotide was more effective to prevent sudden increase in the formation of human α-fetoprotein as the comparator treatments.,0.1052631578947368,smt,2,2_smt,0.14432096481323242|0.22314918041229248|0.14916418492794037|0.28060007095336914|0.22270651161670685
260,"Kinzalkomb 80 mg/12,5 mg Tabletten sind rot-weiße, ovale, aus zwei Schichten bestehende Tabletten, in die die Code-Nummer ""H8"" eingeprägt ist.","Kinzalkomb 80 mg / 12.5 mg tablets are red and white, oval-shaped two-layer tablets engraved with the Code-Nummer ""H8.""","Kinzalkomb 80 mg/ 12.5 mg tablets are red and white, oval-shaped, two-layer tablets engraved with the code number'H8 '.","Kinzalkomb 80 mg / 12.5 mg tablets are red and white, oval-shaped two-layer tablets engraved with the Code-Nummer ""H8.""",0.0,smt,2,2_smt,-0.006628869101405144|-0.008168807253241539|0.020156903192400932|0.023834766820073128|0.04029083997011185
261,"ge von Quintanrix sind am Anfang der vorliegenden Packungsbeilage aufgezählt. Eine allergische Reaktion kann sich durch juckende Hautausschläge, Atemnot oder Anschwellen des Gesichts oder der Zunge äußern.","au Before your child receives Quintanrix are listed at the beginning of the leaflet. Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.","Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. • if your child has previously had an allergic reaction to any vaccine against diphtheria, tetanus, pertussis (whooping cough), hepatitis B or Haemophilus influenzae type b diseases.","of Quintanrix are listed at the beginning of the leaflet. Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.",0.1515151515151515,smt,2,2_smt,0.08047361671924591|0.13467174768447876|0.13079194724559784|0.16518408060073853|0.1469988226890564
262,Nach Anbruch können Sie Ihren Humalog BASAL Pen bis zu 21 Tage bei Raumtemperatur (unter 30°C) aufbewahren.,Keep your Humalog BASAL Pen in use at room temperature (below 30 ° C) for up to 21 days.,Keep your Humalog BASAL Pen in use at room temperature (below 30°C) for up to 21 days.,Keep your Humalog BASAL Pen in use at room temperature (below 30 ° C) for up to 21 days after opening.,0.0833333333333333,smt,2,2_smt,-0.03732984885573387|-0.039502277970314026|0.011249026283621788|-0.010906385257840157|0.018648585304617882
263,"In den Studien II, III und V wurde eine signifikante Verbesserung des DAS28 im Vergleich zu Placebo beobachtet.","In Studies II, III and V, a significant improvement in DAS28 was observed compared to those treated with placebo.","There was a significant improvement of DAS in Studies II, III, and V as compared to placebo.","In Studies II, III and V, a significant improvement in DAS28 was observed compared to those treated with placebo.",0.0,smt,2,2_smt,0.008139418438076973|0.005727606825530529|0.04228883236646652|0.04113587364554405|0.057300008833408356
264,"Pathologisches Spielen, gesteigerte Libido und Hypersexualität wurde bei Patienten berichtet, die mit Dopaminagonisten aufgrund ihres Morbus Parkinson behandelt wurden.","compulsive behaviours Pathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson's disease.","Pathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson’ s disease, including pramipexole.","Compulsive behaviours Pathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson's disease.",0.0,smt,2,2_smt,0.03535836935043335|0.0718822181224823|0.04387278109788895|0.11113438010215759|0.08749764412641525
265,Der Inhaber der Zulassung wird weiterhin jährlich PSURs einreichen.,The MAH will continue to submit yearly PSURs.,The Marketing Authorisation Holder will continue to submit annual PSURs.,The MAH will continue to submit yearly PSURs.,0.0,smt,2,2_smt,0.04202309623360634|0.08357187360525131|0.049181513488292694|0.12690573930740356|0.11197402328252792
266,28 Die folgenden Informationen sind nur für Ärzte bzw. medizinisches Fachpersonal bestimmt:,28 The following information is intended for intended for medical or healthcare professionals only:,The following information is intended for medical or healthcare professionals only:,28 The following information is intended for intended for medical or healthcare professionals only:,0.0,smt,2,2_smt,0.005119121167808771|0.002761445939540863|0.11793143302202225|0.04114796221256256|0.05045335739850998
267,"Ist die Lösung kalt, wärmen Sie die Spritze zwischen Ihren Handflächen auf.","If the solution is cold, warm the syringe between your palms.","If the solution is cold, warm the syringe between your palms.","If the solution is cold, warm the syringe between your palms.",0.0,smt,2,2_smt,-0.04660739377140999|-0.058861419558525085|0.010517695918679237|-0.022756638005375862|0.01112626027315855
268,Macugen wird während der Stillzeit nicht empfohlen.,Macugen is not recommended during lactation.,Macugen is not recommended during breast-feeding.,Macugen is not recommended during lactation.,0.0,smt,2,2_smt,-0.0003114752471446991|0.009281902574002743|0.014654645696282387|0.05240451544523239|0.05240987241268158
269,"Der Metabolismus von Fulvestrant ist nicht vollständig geklärt, beinhaltet aber Kombinationen einer Anzahl verschiedener Biotransformationswege, die denen von endogenen Steroiden entsprechen.","The metabolism of fulvestrant is not fully understood, but in a number of various Biotransformationswege, those in the endogenous steroids.","Metabolism The metabolism of fulvestrant has not been fully evaluated, but involves combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids.","The metabolism of fulvestrant is not fully understood, but it contains a combination of various biotransformation paths, which correspond to those of endogenous steroids.",0.3703703703703703,smt,2,2_smt,0.2927839756011963|0.3834005296230316|0.311536580324173|0.4209861755371094|0.35950717329978943
270,Telbivudin muss im Anschluss an die Hämodialyse gegeben werden.,Telbivudine should be given after the haemodialysis session.,Telbivudine should be administered after haemodialysis.,Telbivudine should be given after the haemodialysis session.,0.0,smt,2,2_smt,0.01483195275068283|0.019381307065486908|0.018879028037190437|0.06727360188961029|0.06807799637317657
271,Bei Rhesus-Affen ergab eine Ganzkörperszintigraphie nach der Verabreichung von radiomarkiertem Tasonermin kein spezifisches Verteilungsmuster.,In rhesus monkeys revealed a diagnostic imaging after administration of tasonermin is inputted not identified distribution pattern.,In the Rhesus monkey whole body radiography following administration of radiolabelled tasonermin indicated no specific distribution pattern.,In the Rhesus monkey whole body radiography following administration of radiolabelled tasonermin indicated no specific distribution pattern.,0.6666666666666666,smt,2,2_smt,0.3732336163520813|0.5064622759819031|0.38437220454216003|0.5343841910362244|0.4504655599594116
272,"3-ml-Fläschchen des Glastyps I, verschlossen mit einem Halogenobutylgummistopfen und versiegelt mit einer codierten Aluminiumkappe.","3-ml-Fläschchen Type I, closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap by qnr-genes.",3-ml vials of glass Type I closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.,"3-ml vials Type I glass, closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.",0.25,smt,2,2_smt,0.09264573454856873|0.14026343822479248|0.15715356171131134|0.204856738448143|0.1495606005191803
273,"Falls die Lösung trübe ist oder Partikel enthält, darf sie nicht benutzt werden.","If the solution is cloudy or contains particles, it should not be used.","If the solution is cloudy or contains particulate matter, it should not be used.","If the solution is cloudy or contains particles, it should not be used.",0.0,smt,2,2_smt,-0.040767595171928406|-0.04682637006044388|0.010252278298139572|-0.01495634950697422|0.014721278101205826
274,Bei den dosisabhängigen unerwünschten Reaktionen ist die Häufigkeit bei der höheren Volibris-Dosis angegeben.,"In the dose-related adverse reactions, the frequency can be presented in the higher Volibris-Dosis.",For dose-related adverse reactions the frequency category reflects the higher dose of Volibris.,"In the dose-dependant adverse reactions, the frequency is stated in the higher Volibris-Dosis.",0.2666666666666666,smt,2,2_smt,0.14638200402259827|0.21269607543945312|0.20169223845005035|0.2965964078903198|0.22306782007217407
275,Bei Verdacht auf latente Tuberkulose sollte ein in der Tuberkulosebehandlung erfahrener Arzt aufgesucht werden.,In cases of suspected latent tuberculosis is a physician with expertise in the treatment should be consulted.,"86 If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.",In cases of suspected latent tuberculosis is a physician with expertise in the treatment should be consulted.,0.0,smt,2,2_smt,0.058041516691446304|0.08574680238962173|0.060506999492645264|0.16507771611213684|0.12880222499370575
276,"97 In klinischen Studien mit 73 vorbehandelten Hämophilie-Patienten (PTP, Patienten mit mehr als 100 Expositionstagen) die über 4 Jahre duchgeführt wurde, wurde kein de-novo Hemmkörper beobachtet.","In clinical studies with 73 previously treated patients (PTP, defined as having more than 100 exposure days), followed over four years, no de-novo inhibitors were observed.","In clinical studies with 73 previously treated patients (PTP, defined as having more than 100 exposure days), followed over four years, no de-novo inhibitors were observed.","In clinical studies with 73 previously treated patients (PTP, defined as having more than 100 exposure days), followed over four years, no de-novo inhibitors were observed.",0.0,smt,2,2_smt,-0.003886115737259388|-0.0023487452417612076|0.02639479748904705|0.041033919900655746|0.049099817872047424
277,Procoralan sollte während der Mahlzeiten eingenommen werden.,Procoralan should not be used during meals.,Procoralan should be taken during meals.,Procoralan should not be used during meals.,0.0,smt,2,2_smt,-0.026148220524191856|-0.02808534912765026|0.014482288621366024|0.005341632757335901|0.024278488010168076
278,- Sonstige Bestandteile:,- Other ingredients:,- Other ingredients:,- Other ingredients:,0.0,smt,2,2_smt,-0.07812816649675369|-0.07975316047668457|0.008342375978827477|-0.060546137392520905|-0.015486111864447594
279,Der Impfstoff verringert die klinischen Anzeichen einer Pferdegrippe und der Ausscheidung (Shedding) des Virus nach der Infektion.,The vaccine reduces the clinical signs of flu and the excretion (CO) of the virus after infection.,The vaccine reduces the clinical signs of equine influenza and the excretion (shedding) of the virus after infection.,The vaccine reduces the clinical signs of flu and the excretion (shedding) of the virus after infection.,0.05,smt,2,2_smt,0.004452607128769159|0.015692759305238724|0.023003118112683296|0.06121426075696945|0.06604424118995667
280,Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.,Activated factor VIII acts as a Cofactor of factor IX and for activated factor X to activated factor X.,"Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X.","Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X.",0.3043478260869565,smt,2,2_smt,0.057671576738357544|0.0968652069568634|0.1550164371728897|0.17616227269172668|0.1252831220626831
281,Nach einem vierwöchigen behandlungsfreien Zeitraum soll dann die Abheilung der AKs beurteilt werden.,After a four-week treatment-free period should then a beneficial effect on the healing of AKs on a regular basis.,"After a 4-week treatment-free period, clearance of AKs should be assessed.","After a four-week treatment-free period, healing of AKs should then be evaluated.",0.7857142857142857,smt,2,2_smt,0.20994062721729279|0.33612215518951416|0.3608894944190979|0.37258338928222656|0.3229442238807678
282,"Bei Patienten, die mehrere Infusionen von Remicade erhielten, hielt zudem das Ansprechen auf die Behandlung länger an (40 Wochen) als bei den Patienten, die ein Placebo erhielten (14 Wochen).",In patients receiving several infusions of Remicade were also considered response to adequate treatment (40 weeks) than in those receiving placebo (14 weeks).,Patients receiving a series of infusions of Remicade also maintained a response to treatment for longer (40 weeks) than those receiving placebo (14 weeks).,"In patients receiving several infusions of Remicade, the response to adequate treatment (40 weeks) than in those receiving placebo (14 weeks).",0.1111111111111111,smt,2,2_smt,0.09557788819074631|0.1429705172777176|0.24875295162200928|0.22668978571891785|0.15697160363197327
283,Die gleichzeitige Anwendung von Ribavirin und Zidovudin wird wegen des erhöhten Anämierisikos nicht empfohlen (siehe Abschnitt 4.4).,The concomitant use of ribavirin with zidovudine is not recommended due to an increased Anämierisikos (see section 4.4).,The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).,The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).,0.1304347826086956,smt,2,2_smt,-0.008715840056538582|0.00691316369920969|0.0825338289141655|0.03612888604402542|0.048412613570690155
284,"Beim Auftreten schwerer Nebenwirkungen, die das Gehirn oder Nervensystem des Patienten betreffen, muss die Behandlung gestoppt werden.","In case of severe side effects affecting the brain or nervous system of the patient, treatment must be stopped.",Treatment should be stopped if the patient develops serious side effects affecting the brain or nervous system.,"In case of severe side effects affecting the brain or nervous system of the patient, treatment must be stopped.",0.0,smt,2,2_smt,-0.012502443045377731|-0.009276527911424637|0.01949625462293625|0.03424840420484543|0.04470766335725784
285,"INOmax sollte für Säuglinge verwendet werden, die erwartungsgemäß > 24 Stunden künstlich beatmet werden müssen.",INOmax should be used for infants expected to mechanical ventilation 24 hours.,INOmax should be used in ventilated infants expected to require support > 24 hours.,INOmax should be used for infants expected to undergo mechanical ventilation for more than 24 hours.,0.2352941176470588,smt,2,2_smt,0.14164257049560547|0.18375560641288757|0.18432646989822388|0.300922691822052|0.1925807148218155
286,"Wenn Sie versehentlich vergessen haben, die tägliche Dosis einzunehmen, sollten Sie die Behandlung wie verordnet fortsetzen.","If you accidentally miss a daily dose, just take the next dose as normal.","If you forget to take Irbesartan Winthrop If you accidentally miss a daily dose, just take the next dose as normal.","If you accidentally miss a daily dose, just take the next dose as normal.",0.0,smt,2,2_smt,0.00013360055163502693|0.009073492139577866|0.044784869998693466|0.05753413215279579|0.05375795066356659
287,Die Patienten wurden mit Posaconazol oder Fluconazol Suspension zum Einnehmen behandelt (Posaconazol und Fluconazol wurden beide wie folgt verabreicht:,Patients were treated with posaconazole or fluconazole oral suspension (posaconazole and fluconazole were given to both groups were as follows:,Patients were treated with posaconazole or fluconazole oral suspension (both posaconazole and fluconazole were given as follows:,Patients were treated with posaconazole or fluconazole oral suspension (posaconazole and fluconazole were given to both groups:,0.1578947368421052,smt,2,2_smt,-0.008847136050462723|-0.006129041314125061|0.06205800548195839|0.01995561085641384|0.03891373425722122
288,- Mobilisierung peripherer Blutstammzellen (PBPC).,- the mobilisation of peripheral blood progenitor cell (PBPC).,- Mobilisation of peripheral blood progenitor cells (PBPC).,- the mobilisation of peripheral blood progenitor cells (PBPC).,0.0833333333333333,smt,2,2_smt,-0.033741895109415054|-0.023666461929678917|0.019254568964242935|0.004054929595440626|0.030351653695106506
289,"Hypotonie kann zu Behandlungsbeginn auftreten, besonders dann, wenn die Dosistitration von Pramipexol zu schnell erfolgt.","Hypotension may occur at the beginning of treatment, especially if pramipexole is titrated too fast.","Hypotension may occur at the beginning of treatment, especially if pramipexole is titrated too fast.","Hypotension may occur at the beginning of treatment, especially if pramipexole is titrated too fast.",0.0,smt,2,2_smt,-0.049860719591379166|-0.04863008111715317|0.011274936608970165|-0.020864291116595268|0.013443486765027046
290,Wie wird Zomarist angewendet?,How is Zomarist used?,How is Zomarist used?,How is Zomarist used?,0.0,smt,2,2_smt,-0.06387153267860413|-0.06594114750623703|0.008303629234433174|-0.04517573118209839|-0.005329752340912819
291,"Die klinischen Erfahrungen bei schwangeren Frauen sind begrenzt, jedoch wurden kongenitale Anomalien und Aborte berichtet.","Clinical experience in pregnant women is limited, but congenital anomalies and abortions have been reported.","Clinical experience in pregnant women is limited, but congenital anomalies and abortions have been reported.","Clinical experience in pregnant women is limited, but congenital anomalies and abortions have been reported.",0.0,smt,2,2_smt,-0.0537232868373394|-0.04779178649187088|0.011697694659233093|-0.02597728930413723|0.010497316718101501
292,"Die Serumspiegel von Ritonavir können durch bestimmte gleichzeitig angewendete Arzneimittel beeinflusst werden (z.B. Delavirdin, Efavirenz, Phenytoin und Rifampicin).","Serum levels of ritonavir can be affected by certain concomitantly administered medicinal products (e. g. delavirdine, efavirenz, phenytoin and rifampicin).","Serum levels of ritonavir may be affected by select co-administered medicinal products (eg delavirdine, efavirenz, phenytoin and rifampicin).","Serum levels of ritonavir can be affected by certain concomitantly administered medicinal products (e. g. delavirdine, efavirenz, phenytoin and rifampicin).",0.0,smt,2,2_smt,-0.028387557715177536|-0.017395349219441414|0.012889452278614044|-0.0029980302788317204|0.024689044803380966
293,"Falls Patienten von einem anderen Arzneimittel gegen Diabetes auf Prandin umgestellt werden, beträgt die empfohlene Anfangsdosis 1 mg.",If patients in another medicine for Prandin may be switched to the initial recommended dose is 1 mg.,"If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.","If patients are switched from another medicine for diabetes to Prandin, the initial recommended dose is 1 mg.",0.35,smt,2,2_smt,0.18737953901290894|0.2544059753417969|0.3608522415161133|0.3099704086780548|0.2598687410354614
294,Die Plasmamelatoninspiegel bei Patienten mit Leberzirrhose waren während des Tages signifikant erhöht.,The Plasmamelatoninspiegel in patients with cirrhosis of the liver were significantly increased during the day.,7 Plasma melatonin levels in patients with cirrhosis were significantly increased during daylight hours.,The plasma melatonin level in patients with cirrhosis of the liver was significantly increased during the day.,0.2222222222222222,smt,2,2_smt,0.09229132533073425|0.1300666779279709|0.1707432121038437|0.20023423433303833|0.14006377756595612
295,Wie wirkt Ketek?,How does Ketek work?,How has Ketek been studied?,How does Ketek work?,0.0,smt,2,2_smt,-0.018209578469395638|-0.013448353856801987|0.02485208585858345|0.017319489270448685|0.032580725848674774
296,I.E. (5 µg)/kg/Tag subkutan als Einzeldosis oder in mehreren Dosen.,0.5 MIU (5 μ g) / kg / day subcutaneously as a single dose or in divided doses.,Idiopathic or cyclic neutropenia The recommended starting dose is 0.5 MIU (5 μ g)/ kg/ day subcutaneously as a single dose or in divided doses.,0.5 MIU (5 μ g)/kg/day subcutaneously as a single dose or in divided doses.,0.0,smt,2,2_smt,-0.004860304296016693|0.01179279014468193|0.03378821164369583|0.04130680114030838|0.051993146538734436
297,Nach Untersuchungen bei Ratten beläuft sich die maximale Konzentration im zentralen Nervensystem auf ein Mehrfaches der entsprechenden Konzentration im Plasma.,"After studies have been conducted in rats, the maximum concentration in the central nervous system and 15 of the corresponding plasma concentration.","According to studies in rats, the maximum concentration in the central nervous system is several times that of the corresponding concentration in plasma.","According to studies in rats, the maximum concentration in the central nervous system is several times that of the corresponding concentration in plasma.",0.4,smt,2,2_smt,0.28139108419418335|0.37054458260536194|0.2504844069480896|0.4403877258300781|0.34519538283348083
298,Valsartan kann zusammen mit anderen Arzneimitteln zur Behandlung der Herzinsuffizienz gegeben werden.,Valsartan may be administered with other medicinal products for the treatment of heart failure.,Valsartan may be administered with other heart failure therapies.,Valsartan may be administered with other medicinal products for the treatment of heart failure.,0.0,smt,2,2_smt,-0.008501119911670685|-0.014334268867969513|0.014392674900591373|0.020630663260817528|0.03976776450872421
299,"E. coli J5, inaktiviert; S. aureus CP8, Stamm SP140, inaktiviert; flüssiges Paraffin; Benzylalkohol.","E. coli J5 inactivated, S. aureus CP8 strain SP140 inactivated, cows that were given Startvac); benzyl alcohol.",E. coli J5 inactivated; S. aureus CP8 strain SP140 inactivated; Liquid paraffin; Benzyl alcohol.,"E. coli J5 inactivated, S. aureus CP8 strain SP140 inactivated, liquid parrafin; benzyl alcohol.",0.3333333333333333,smt,2,2_smt,0.13474486768245697|0.23015648126602173|0.19512753188610077|0.2587583065032959|0.21825718879699707
300,"Leichte bis mittlere Rötung des Ohres (bei 2,4% der behandelten Hunde).",Mild to moderate unstable redness (in 2.4% of treated dogs).,Mild to moderate redness of the ear was common (2.4% of treated dogs).,Mild to moderate unstable redness (in 2.4% of treated dogs).,0.0,smt,2,2_smt,0.025959640741348267|0.06169108301401138|0.023861054331064224|0.10116200894117355|0.07787125557661057
301,"Der Wirkstoff in Implanon, Etonogestrel, ist ein synthetisches weibliches Hormon, das dem Progesteron ähnelt.","The active substance in Implanon, etonogestrel, and estradiol (a naturally occurring hormone, which is similar to the progesterone.","The active substance in Implanon, etonogestrel, is a synthetic female hormone resembling progesterone.","The active substance in Implanon, etonogestrel, and estradiol is a naturally occurring hormone, which is similar to the progesterone.",0.0434782608695652,smt,2,2_smt,0.11019683629274368|0.15088067948818207|0.08164796978235245|0.21516567468643188|0.15570726990699768
302,Wie ist Intrinsa anzuwenden?,How to use Intrinsa 4.,How to use Intrinsa 4.,How to use Intrinsa?,0.4,smt,2,2_smt,-0.036500513553619385|-0.03887646645307541|0.013568191789090633|-0.001838709693402052|0.021845024079084396
303,"Zubereitung von Humalog BASAL • Humalog BASAL Patronen sollen unmittelbar vor Verwendung zwischen den Handflächen 10x gerollt und 10x um 180° gedreht werden, um das Insulin bis zu einem einheitlich milchigen oder wolkigen Aussehen zu durchmischen.",Preparing Humalog BASAL • Humalog BASAL cartridges should be rotated in the palms of the hands ten times and inverted 180 ° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.,233 Preparing Humalog BASAL • Cartridges containing Humalog BASAL should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend insulin until it appears uniformly cloudy or milky.,Preparing Humalog BASAL • Humalog BASAL cartridges should be rotated in the palms of the hands ten times and inverted 180 ° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.,0.0,smt,2,2_smt,-0.006131158210337162|0.005443420261144638|0.02718335948884487|0.04127521812915802|0.05317544937133789
304,"In Abhängigkeit von der Studiendauer waren alle muskulären Effekte, einschließlich der mikroskopischen Veränderungen, innerhalb von 1-3 Monaten nach Beendigung der Dosierung vollständig reversibel.","In view of the above, throughout the study, all Thermus aquaticus effects, including microscopic changes in fully reversible, within the recovery period of 1-3 months after completion of dosing.","Depending on the study duration, all muscle effects, including microscopic changes, were fully reversible within 1-3 months following cessation of dosing.","In view of thelenght of the study, all  muscular effects, including microscopic changes, were fully reversible within the recovery period of 1-3 months after completion of dosing.",0.2903225806451613,smt,2,2_smt,0.1380026936531067|0.20836882293224335|0.18123723566532135|0.292407363653183|0.21771517395973206
305,"Wenn Sie die Behandlung beenden bzw. beenden möchten, besprechen Sie dies zunächst mit Ihrem Arzt.","If you stop treatment and want to stop, discuss this with your doctor.","If you stop or wish to stop treatment, you should discuss this with your doctor first.","If you want to stop treatment, discuss this with your doctor.",0.2307692307692307,smt,2,2_smt,0.004632672760635614|0.007617161609232426|0.12028728425502777|0.039642516523599625|0.05074826627969742
306,"Eine wahrscheinliche toxische Reaktion auf AMMONAPS (450 mg/kg/Tag) wurde von einer 18 Jahre alten anorektischen Patientin gemeldet, die eine metabolische Enzephalopathie in Verbindung mit Laktatazidose, schwerer Hypokalämie, Panzytopenie, peripherer Neuropathie und Pankreatitis entwickelte.","One probable case of toxic reaction to AMMONAPS (450 mg / kg / day) were reported in an 18-year old anorectic female patient who developed a metabolic encephalopathy associated with lactic acidosis, severe hypokalaemia, pancytopenia, peripheral neuropathy, and pancreatitis.","A probable case of toxic reaction to AMMONAPS (450 mg/ kg/ d) was reported in an 18-year old anorectic female patient who developed a metabolic encephalopathy associated with lactic acidosis, severe hypokalaemia, pancytopaenia, peripheral neuropathy, and pancreatitis.","One probable case of toxic reaction to AMMONAPS (450 mg / kg / day) were reported in an 18-year old anorectic female patient who developed a metabolic encephalopathy associated with lactic acidosis, severe hypokalaemia, pancytopenia, peripheral neuropathy, and pancreatitis.",0.0,smt,2,2_smt,-0.012944737449288368|-0.007005898281931877|0.021531611680984497|0.010492518544197083|0.04356420040130615
307,"2,5 ml und 5 ml.",2.5 ml and 5 ml.,2.5 ml and 5 ml.,2.5 ml and 5 ml.,0.0,smt,2,2_smt,-0.042631085962057114|-0.05384788662195206|0.009631268680095673|-0.02697513997554779|0.01280661765486002
308,"Im systemischen Kreislauf wird Micafungin in hohem Maße an das Plasmaprotein gebunden (> 99%), hauptsächlich an Albumin.","In the systemic circulation, micafungin is highly bound to plasma protein ( 99%) to plasma proteins, primarily to albumin.","10 In systemic circulation, micafungin is highly bound to plasma protein (> 99%), primarily to albumin.","In the systemic circulation, micafungin is highly bound to plasma protein (> 99%), primarily to albumin.",0.1818181818181818,smt,2,2_smt,0.041122764348983765|0.0650918036699295|0.08029768615961075|0.11086220294237137|0.09617695957422256
309,"Eine langfristige Überdosierung kann möglicherweise Zeichen und Symptome einer Akromegalie nach sich ziehen, die den bekannten Wirkungen eines Überschusses an menschlichem Wachstumshormon entsprechen.","One long-term overdose may potentially signs and symptoms of acromegaly, staphylococcal scalded the known effects of human growth hormone.",Long-term overdose could result in signs and symptoms of acromegaly consistent with the known effects of excess human growth hormone.,A long-term overdose may imply potential signs and symptoms of acromegaly that correspond with the known effects of a surplus of human growth hormone.,0.36,smt,2,2_smt,0.2816227078437805|0.39059415459632874|0.2658612132072449|0.4593387544155121|0.3553999662399292
310,"ABILIFY Injektionslösung wird angewendet, wenn die Behandlung mit Darreichungsformen zum Einnehmen nicht angebracht ist.",ABILIFY solution for injection is used when treatment with oral formulations is not appropriate.,ABILIFY solution for injection is given when treatment with oral formulations of ABILIFY is not appropriate.,ABILIFY solution for injection is used when treatment with oral formulations is not appropriate.,0.0,smt,2,2_smt,-0.0010523255914449692|-0.006746208295226097|0.01716565154492855|0.041269466280937195|0.05241328477859497
311,"Daten von älteren Patienten, die mit Einzeldosen an PegIntron behandelt wurden, geben k einen Hinweis darauf, dass eine Anpassung der PegIntron-Dosis aufgrund des Alters notwendig ist (siehe Abschnitt 5.2).","Data from elderly patients treated with PegIntron, suggest no alteration in PegIntron dose is necessary based on age (see section 5.2).",Data from elderly patients treated with a single dose of PegIntron suggest no alteration in PegIntron dose is necessary based on age (see section 5.2).,Data from elderly patients treated with PegIntron suggest that no alteration in PegIntron dose is necessary based on age (see section 5.2).,0.08,smt,2,2_smt,-0.021695325151085854|-0.019686562940478325|0.028269367292523384|0.012367835268378258|0.03256075829267502
312,Als Analgetikum ist Fentanyl etwa 100-mal stärker wirksam als Morphin.,The analgesic fentanyl is about 100-mal a more active than morphine.,Fentanyl is approximately 100-fold more potent than morphine as an analgesic.,The analgesic fentanyl is about 100 times stronger acting than morphine.,0.3333333333333333,smt,2,2_smt,0.05057435482740402|0.06432010233402252|0.1256188601255417|0.1237664595246315|0.10973311215639114
313,4 Basierend auf in vitro Daten scheint Repaglinid ein Substrat für die aktive hepatische Aufnahme zu sein (Transportprotein für organische Anionen OATP1B1).,"2 Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1).","Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1).","4 Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1).",0.04,smt,2,2_smt,-0.006126069463789463|0.020724110305309296|0.016143932938575745|0.050029207020998|0.061116889119148254
314,"Nebenwirkungen, nicht bekannter Häufigkeit können umfassen:",Side effects of unknown frequency may include:,Side effects of unknown frequency may include:,Side effects of unknown frequency may include:,0.0,smt,2,2_smt,-0.06890866160392761|-0.06556769460439682|0.008812109008431435|-0.035237960517406464|-0.0042421817779541016
315,"as Informieren Sie Ihren Arzt, wenn Sie stillen, da Ihre Insulindosis und Ihre Ernährung dann möglicherweise angepasst werden müssen.","ed Tell your doctor if you are breast feeding, as your dose of insulin and your diet may need to be adjusted.",If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.,"ed Tell your doctor if you are breast feeding, as your dose of insulin and your diet may need to be adjusted.",0.0,smt,2,2_smt,0.027403295040130615|0.04210123047232628|0.04693502560257912|0.08684428036212921|0.08596903830766678
316,"Einige Patienten hatten derartige Symptome, wenn sie VIAGRA zusammen mit Alphablockern verwendeten.",Some patients have had these symptoms when VIAGRA is coadministered with Alphablockern used.,Certain patients have experienced these symptoms when taking VIAGRA with alpha-blockers.,Some patients have had these symptoms when VIAGRA is coadministered with Alphablockern.,0.0769230769230769,smt,2,2_smt,0.10517678409814835|0.16276761889457703|0.16299621760845184|0.19758081436157227|0.17005006968975067
317,Dompé Biotec S.p.A.,Dompé Biotec S. p. A.,au Dompé Biotec S. p. A.,Dompé Biotec S. p. A.,0.0,smt,2,2_smt,-0.0004322696477174759|0.000491434708237648|0.054467953741550446|0.04127602279186249|0.059096112847328186
318,"Je nachdem, wie Ihre Blutarmut (Anämie) auf die Behandlung anspricht, kann die Dosis etwa alle vier Wochen angepasst werden, bis Ihr Zustand unter Kontrolle ist.","Depending on how your anaemia responds, the dose may be adjusted approximately every four weeks until your condition is controlled.","Depending on how your anaemia responds to treatment, the dose may be adjusted approximately every four weeks until your condition is controlled.","Depending on how your anaemia responds, the dose may be adjusted approximately every four weeks until your condition is controlled.",0.0,smt,2,2_smt,-0.03769984096288681|-0.04361880570650101|0.013514058664441109|-0.011601921170949936|0.016357021406292915
319,Pulver in einem Fläschchen (Glasart I) mit einem Stopfen (Butyl-Gummi) und Flip-off-Verschluss (Aluminium) und Lösungsmittel in einem Fläschchen (Glasart I) mit Stopfen (Chlorobutyl-Gummi) und Flip-off-Verschluss (Aluminium) in Packungsgrößen zu 1x1 und 10x1 Impfdosis.,Powder in a vial (Type 1 glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (Type 1 glass) with stopper (chlorobutyl rubber) and flip off cap (aluminium) in a pack size of 1 and 10.,Powder in a vial (Type I glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (Type I glass) with a stopper (chlorobutyl rubber) and flip off cap (aluminium) in a pack size of 1 or 10.,Powder in a vial (Type 1 glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (Type 1 glass) with stopper (chlorobutyl rubber) and flip off cap (aluminium) in pack sizes of 1x1 and 10x1 vaccine doses.,0.1071428571428571,smt,2,2_smt,-0.021834904327988625|-0.02806292288005352|0.028592796996235847|-0.0038285856135189533|0.03200482577085495
320,"Pradofloxacin, der in Veraflox enthaltene Wirkstoff, gehört zu einer Klasse von Antibiotika, die als Fluorchinolone der dritten Generation bezeichnet werden.","pradofloxacin, the active ingredient in Veraflox), which belongs to a class of antibiotics called third generation fluoroquinolones.","The active substance in Veraflox, pradofloxacin, belongs to a class of antibiotics called third generation fluoroquinolones.","The active substance in Veraflox, pradofloxacin, belongs to a class of antibiotics called third generation fluoroquinolones.",0.2631578947368421,smt,2,2_smt,-0.008489605039358139|-0.012302083894610405|0.02510257437825203|0.03026166372001171|0.041502051055431366
321,"Imiquimod, der Wirkstoff in Aldara Creme, moduliert die Immunantwort.","imiquimod, the active ingredient in Aldara cream, is an immune response modifier.","The active substance in Aldara cream, imiquimod, is an immune response modifier.","The active substance in Aldara cream, imiquimod, is an immune response modifier.",0.1333333333333333,smt,2,2_smt,-0.015341803431510925|-0.01554134301841259|0.010320678353309631|0.02446136623620987|0.04588775336742401
322,Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht.,Not all pack sizes may be marketed.,18 Not all pack sizes may be marketed.,Not all pack sizes may be marketed.,0.0,smt,2,2_smt,-0.02291758358478546|-0.01844494603574276|0.010911824181675911|0.01764795184135437|0.0313909649848938
323,Stoffwechsel- und Ernährungsstörungen:,Metabolism and nutrition disorders:,56 Metabolism and nutrition disorders:,Metabolism and nutrition disorders:,0.0,smt,2,2_smt,-0.06860712170600891|-0.061558328568935394|0.009250813163816929|-0.035711534321308136|0.0009574759751558304
324,"Da viele Nebenwirkungen den Symptomen der Erkrankung ähneln, ist nicht immer klar, ob eine in den klinischen Prüfungen beobachtete Reaktion auf Zevalin zurückzuführen ist oder nicht.","Because many side effects are similar to the symptoms of the disease, it is not clear whether always used in the clinical trials that seen due to Zevalin or not.","Because many side effects resemble the effects of the illness, it is not always clear if a reaction seen in clinical trials was due to Zevalin or not.","As many side effects are similar to the symptoms of the disease, it is not always clear if a reaction seen in clinical trials was due to Zevalin or not.",0.25,smt,2,2_smt,0.09954462945461273|0.1599581390619278|0.1952151507139206|0.2027597427368164|0.1633192002773285
325,"Ein multiples Myelom ist eine Art von Blutkrebs, der die weißen Blutkörperchen schädigt, die die Antikörper produzieren.",A multiple myeloma is a cancer of the white blood cells that produce damages to produce the monoclonal antibody.,Multiple myeloma is a type of blood cancer that affects the white blood cells that produce antibodies.,"A multiple myeloma is a type of blood cancer, which damages the white blood cells that produce antibodies.",0.4,smt,2,2_smt,0.06350067257881165|0.11067228019237518|0.1344781070947647|0.1620742827653885|0.13675014674663544
326,Die gesamte Menge des rekonstituierten Impfstoffs wird dann aus dem Fläschchen in die Injektionsspritze aufgezogen.,The entire content of the reconstituted vaccine is then the reconstituted vaccine vial into a syringe for injection.,Withdraw the entire contents into a syringe for injection.,The entire content of the reconstituted vaccine is then drawn from the vial into a syringe for injection.,0.1578947368421052,smt,2,2_smt,0.2445370852947235|0.3561539053916931|0.19018052518367767|0.4127446413040161|0.33536913990974426
327,"Besondere Vorsichtsmaßnahmen für die Anwendung bei Tieren Wegen der anzunehmenden (zeitlich, geografisch) unterschiedlichen Resistenzsituation gegen Trimethoprim/Sulfamethoxazol wird die Durchführung von bakteriologischen Probenahmen und Empfindlichkeitstests empfohlen.","Special precautions for use in animals Due to the anzunehmenden (time, geografisch) different local prevalence of resistance of bacteria for trimethoprim / sulfamethoxazole bacteriological sampling and susceptibility testing are recommended.","Special precautions for use in animals Due to the likely variability (time, geographical) in the occurrence of resistance of bacteria for trimethoprim/ sulfamethoxazole bacteriological sampling and susceptibility testing are recommended.","Special precautions for use in animals: Due to the proposed (time, geografisch) different local prevalence of resistance of bacteria for trimethoprim/sulfamethoxazole, bacteriological sampling and susceptibility testing are recommended.",0.0833333333333333,smt,2,2_smt,0.10299526900053024|0.17087121307849884|0.13763964176177979|0.21129392087459564|0.16473668813705444
328,"Das Myopathie-Risiko einschließlich Rhabdomyolyse kann auch erhöht sein in Kombination mit Atorvastatin, das ebenfalls durch CYP3A4 metabolisiert wird.","The risk of myopathy including rhabdomyolysis may also be increased in combination with atorvastatin, will also be due to an induction of CYP3A4.","The risk of myopathy including rhabdomyolysis may also be increased with atorvastatin, which is also metabolised by CYP3A4.","The risk of myopathy including rhabdomyolysis may also be increased in combination with atorvastatin, will also be due to an induction of CYP3A4.",0.0,smt,2,2_smt,0.06287408620119095|0.10159766674041748|0.1391071081161499|0.15089593827724457|0.1262991577386856
329,24 Stunden nach Verabreichung) um durchschnittlich 8-13/5-8 mmHg (systolisch/diastolisch) mehr als Placebo.,"24 hours after dosing, an average of 0.5-6.0 / 5 - 8 mm Hg (systolic / diastolic) more than placebo.",24 hours after dosing) by an average of 8-13/ 5-8 mm Hg (systolic/ diastolic) greater than those associated with placebo.,24 hours after dosing) by an average of 8 - 13 / 5 - 8 mm Hg (systolic / diastolic) more than placebo.,0.1851851851851851,smt,2,2_smt,0.035702869296073914|0.04998821020126343|0.14570407569408417|0.08565653860569|0.07821851223707199
330,"In klinischen Studien mit Patienten und Probanden, die Rapinyl einnahmen, wurden folgende Nebenwirkungen mit einem möglichen Zusammenhang zur Therapie, aufgelistet nach Organsystem und Häufigkeit, berichtet (sehr häufig ≥ 1/10; häufig ≥ 1/100 bis < 1/10).","In clinical trials with patients and subjects who took Rapinyl, the following adverse drug reactions were reported with possibly related to treatment are listed below, by system organ class and frequency, have been reported (very common ≥ 1 / 10; common ≥ 1 / 100 to 1 / 10).","Adverse reactions from clinical studies with Rapinyl in patients and volunteers, with a suspected relationship to treatment, are listed below by system organ class and frequency (very common ≥ 1/ 10; common ≥ 1/ 100 to < 1/ 10).","In clinical trials with patients and subjects who took Rapinyl, the following adverse drug reactions were reported and are possibly related to treatment listed below by system organ class and frequency (very common ≥ 1 / 10; common ≥ 1 / 100 to 1 / 10).",0.1372549019607843,smt,2,2_smt,0.10655763000249863|0.15978407859802246|0.12589819729328156|0.20045410096645355|0.1572982519865036
331,"Insuman Infusat ist eine klare, farblose, wässrige Injektionslösung ohne sichtbare Teilchen.","Insuman Infusat is a clear, colourless solution for injection, with no solid particles visible.","What Insuman Infusat looks like and contents of the pack Insuman Infusat is a clear, colourless solution for injection, with no solid particles visible, and of water-like consistency.","Insuman Infusat is a clear, colourless solution for injection, with no solid particles visible.",0.0,smt,2,2_smt,-0.0023679998703300953|0.009448087774217129|0.032352279871702194|0.04282919317483902|0.06085564196109772
332,"Flush betrifft vor allem Kopf, Hals und Oberkörper.","Flushing, particularly, neck and upper body.","Flushing is most prominent in the head, neck, and upper torso.","Flushing particularly affects head, neck and upper body.",0.3,smt,2,2_smt,0.11692214757204056|0.13876985013484955|0.13480964303016663|0.23391978442668915|0.1733357012271881
333,"Die systemische Aufnahme findet hauptsächlich durch die Lungen statt, und zwar anfangs schnell, dann verzögert.",The systemic bioconversion primarily by the lungs and is initially rapid then.,Systemic absorption occurs mainly through the lungs and is initially rapid then prolonged.,The systemic bioconversion primarily by the lungs and is initially quick and then slows.,0.2,smt,2,2_smt,0.2569725811481476|0.4038369655609131|0.21054542064666748|0.4544276297092438|0.3717438876628876
334,"(Phantasiebezeichnung) darf nicht zur Behandlung von Kindern angewendet werden, die jünger als 8 Jahre sind.",(Invented name) ® should not be used for the treatment of children less than 8 years old.,(Invented name)® should not be used in the treatment of children under the age of 8 years.,(Invented name) ® should not be used for the treatment of children less than 8 years old.,0.0,smt,2,2_smt,-0.008551239036023617|-0.007376000285148621|0.012501319870352745|0.02134193666279316|0.042599305510520935
335,"Die pharmakologische Behandlung sollte ein integraler Bestandteil eines umfassenderen Behandlungsprogramms sein, das psychosoziale und edukative Interventionen einschließt.","Pharmacological treatment should be an programme has been assessed, the psychosoziale and edukative interventions.","Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention.","Pharmacological treatment should be an integral component of a comprehensive treatment programme, that includes psychosociological and educational interventions.",0.55,smt,2,2_smt,0.34431949257850647|0.4507790803909302|0.6159547567367554|0.5065222978591919|0.43782931566238403
336,Diese werden wie folgt weiterverdünnt:,These are hydrogen as follows:,This should then be further diluted as follows:,These are diluted as follows:,0.1666666666666666,smt,2,2_smt,0.1607987880706787|0.22550661861896515|0.20359264314174652|0.3119678497314453|0.22851966321468353
337,Es liegen keine Erfahrungen zur Anwendung von MicardisPlus bei Patienten mit einer kurz zurückliegenden Nierentransplantation vor.,There is no experience regarding the administration of MicardisPlus in patients with recent kidney transplantation.,There is no experience regarding the administration of MicardisPlus in patients with recent kidney transplantation.,There is no experience regarding the administration of MicardisPlus in patients with recent kidney transplantation.,0.0,smt,2,2_smt,-0.04550895094871521|-0.0443338006734848|0.009550202637910843|-0.012856842949986458|0.016132084652781487
338,"Sie sollten die Tabletten mit oder kurz nach dem Essen einnehmen, um die Möglichkeit von Magenproblemen zu verringern.","You should take the tablets with or just after a meal, to reduce the possibility of stomach problems.",You should take the tablets with or just after food to reduce the chance of an upset stomach.,"You should take the tablets with or just after a meal, to reduce the possibility of stomach problems.",0.0,smt,2,2_smt,-0.014820531010627747|-0.01529776118695736|0.013062980957329273|0.015565332025289536|0.037820711731910706
339,Bei weiteren Fragen zur Anwendung dieses Arzneimittels wenden Sie sich an Ihren Arzt.,A further questions about this medicine please ask your doctor.,"If you have any further questions on the use of this medicine, ask your doctor.",If you have further questions about this medicine please ask your doctor.,0.2307692307692307,smt,2,2_smt,0.04497238248586655|0.039039090275764465|0.12267936766147614|0.0804636999964714|0.0789494588971138
340,Die chemische und physikalische Stabilität nach Anbruch wurde für 30 Tage bei 2°C bis 8°C nachgewiesen.,Chemical and physical in-use stability after first opening the bottle has been demonstrated for 30 days at 2 ° C - 8 ° C).,Chemical and physical in-use stability has been demonstrated for 30 days at 2°C to 8°C.,Chemical and physical stability after first opening the bottle has been demonstrated for 30 days at 2 ° C - 8 ° C.,0.0833333333333333,smt,2,2_smt,0.06539778411388397|0.1387232393026352|0.03674101084470749|0.18378731608390808|0.15152396261692047
341,Beim Auftreten dieser Nebenwirkung sollte sofort der Arzt verständigt werden.,"Should this happen to you, your doctor verständigt should be used immediately.","Should this happen to you, seek immediate advice from your doctor.","Should this happen to you, your doctor should be informed immediately.",0.1538461538461538,smt,2,2_smt,0.1135673075914383|0.15777699649333954|0.3747628629207611|0.24002006649971008|0.17425356805324554
342,Das in den Beuteln befindliche Granulat wird in einem Glas Wasser als Suspension eingenommen.,The granules in the sachets will be taken in a glass of water to form a suspension.,The granules in the sachets must be taken as a suspension in a glass of water.,The granules in the sachets are taken in a glass of water as a suspension.,0.25,smt,2,2_smt,-0.015039699152112007|-0.021529050543904305|0.05394236743450165|0.024962661787867546|0.04654037207365036
343,"Dennoch wird die Kombination von DULOXETINE BOEHRINGER INGELHEIM mit einem selektiven, reversiblen MAO-Hemmer nicht empfohlen (siehe Abschnitt 4.4).","However, the concomitant use of DULOXETINE BOEHRINGER INGELHEIM with selective, reversible MAOI is not recommended (see section 4.4).","However, the concomitant use of DULOXETINE BOEHRINGER INGELHEIM with selective, reversible MAOIs is not recommended (see section 4.4).","However, the concomitant use of DULOXETINE BOEHRINGER INGELHEIM with selective, reversible MAOIs is not recommended (see section 4.4).",0.0434782608695652,smt,2,2_smt,-0.022309115156531334|-0.017880549654364586|0.013461410067975521|0.011164374649524689|0.03478742763400078
344,In mehreren kontrollierten Studien zeigten Epoetine keine Verbesserung des Gesamtüberlebens oder eine Verminderung des Risikos der Tumorprogression bei Tumorpatienten mit symptomatischer Anämie nachgewiesen.,"In several controlled studies, epoetins have not been shown to improve overall survival or decrease the risk of tumour progression in patients with anaemia associated with cancer.","In several controlled studies, epoetins have not been shown to improve overall survival or decrease the risk of tumour progression in patients with anaemia associated with cancer.","In several controlled studies, epoetins have not been shown to improve overall survival or decrease the risk of tumour progression in patients with anaemia associated with cancer.",0.0,smt,2,2_smt,-0.04142244532704353|-0.04074351489543915|0.013105916790664196|-0.008443871513009071|0.018871258944272995
345,"Die Spiegel der freien Schilddrüsenhormone bleiben allerdings unverändert, und es gibt keine klinischen Hinweise auf eine Störung der Schilddrüsenfunktion.","The levels of thyroid hormones; however, remain unchanged and there is no clinical evidence of impaired thyroid function.","Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.","The levels of thyroid hormones; however, remain unchanged and there is no clinical evidence of impaired thyroid function.",0.0,smt,2,2_smt,-0.01188720390200615|-0.00046982988715171814|0.015416495501995087|0.03722234070301056|0.04543277621269226
346,Injektionsnadel in die unmittelbar unter der Haut gelegene Fettschicht injiziert wird.,injection needle into the fatty tissue just under the skin.,"If you are injecting this medicine yourself, you will be instructed how to prepare and give the injection.",Injection needle is injected into the fatty tissue just under the skin.,0.1538461538461538,smt,2,2_smt,0.28525039553642273|0.3465370833873749|0.2547449767589569|0.40978682041168213|0.334511935710907
347,- Erhöhung des Blutdrucks.,- increase in blood pressure.,- increase in blood pressure.,- increase in blood pressure.,0.0,smt,2,2_smt,-0.061504464596509933|-0.06710527092218399|0.008933697827160358|-0.03542805835604668|0.00041015446186065674
348,Zur intramuskulären oder subkutanen Injektion. Lesen Sie vor der Anwendung die Packungsbeilage.,Intramuscular or subcutaneous injection Read the package leaflet before use.,Intramuscular or Subcutaneous injection Read the package leaflet before use.,Intramuscular or subcutaneous injection. Read the package leaflet before use.,0.0833333333333333,smt,2,2_smt,-0.040775496512651443|-0.04130328446626663|0.009565211832523346|-0.004223658703267574|0.02490072511136532
349,"Es ist nicht bekannt, ob Etoricoxib beim Menschen in der Muttermilch ausgeschieden wird.",It is not known whether etoricoxib in humans is excreted in breast milk.,It is not known whether etoricoxib is excreted in human milk.,It is not known whether etoricoxib in humans is excreted in breast milk.,0.0,smt,2,2_smt,-0.04599159210920334|-0.042518965899944305|0.010589676909148693|-0.011833352968096733|0.013715331442654133
350,Anschließend wurde das Arzneimittel zwölf Wochen lang in einer stabilen Dosis verabreicht.,"Then, the medicine was given over 12 weeks at a stable dose.",The main measure of effectiveness was the change in pain levels between the start of the study and the last four weeks on the stable dose.,"Then, the medicine was given over 12 weeks at a stable dose.",0.0,smt,2,2_smt,0.09289737045764923|0.12994158267974854|0.09703053534030914|0.20731747150421143|0.159307599067688
351,Genotoxizität und kanzerogenes Potential werden nicht erwartet.,genotoxicity and carcinogenic potential are not expected.,Genotoxic and carcinogenic potential are not expected.,Genotoxicity and carcinogenic potential are not expected.,0.0,smt,2,2_smt,-0.02289508655667305|-0.02449811063706875|0.009973126463592052|0.011094247922301292|0.02917534112930298
352,"Zu einer Durchstechflasche mit Rasburicase wird der Inhalt einer Lösungsmittel-Ampulle gegeben, dann wird durch sehr vorsichtiges Schwenken gemischt.","When a vial containing Rasburicase is the contents of a given volume, then is mixed with the very Gently.",Add the content of one ampoule of solvent to one vial containing rasburicase and mix by swirling very gently under controlled and validated aseptic conditions.,Add the content of one ampoule of solvent to one vial containing rasburicase and mix by swirling very gently under controlled and validated aseptic conditions.,0.8461538461538461,smt,2,2_smt,0.3647814691066742|0.4799080491065979|0.5185739994049072|0.5132725238800049|0.4294426143169403
353,59 Filgrastim ratiopharm und eine Knochenmarktransplantation Die übliche Anfangsdosis beträgt 1 Million internationale Einheiten (Mio. I.E.) pro Kilogramm Körpergewicht pro Tag.,59 Filgrastim ratiopharm and bone marrow transplantation The usual starting dose is 1 million international units (MIU) per kilogram of bodyweight each day.,Filgrastim ratiopharm and bone marrow transplantation The usual starting dose is 1 million international units (MIU) per kilogram of bodyweight each day.,59 Filgrastim ratiopharm and bone marrow transplantation The usual starting dose is 1 million international units (MIU) per kilogram of bodyweight each day.,0.0,smt,2,2_smt,-0.026676349341869354|-0.020415766164660454|0.015442254021763802|0.0016856491565704346|0.026473643258213997
354,"Die Steady-State-Pharmakokinetik von Gabapentin ist bei gesunden Probanden und Patienten mit Epilepsie, die andere Antiepileptika einnehmen, ähnlich.","The pharmacokinetics of gabapentin in healthy subjects and patients with epilepsy who are taking other antiepileptics, similar.",Gabapentin steady-state pharmacokinetics are similar for healthy subjects and patients with epilepsy receiving these antiepileptic agents.,The pharmacokinetics of gabapentin is similar in healthy subjects and patients with epilepsy who are taking other antiepileptics.,0.1052631578947368,smt,2,2_smt,0.04583241418004036|0.08250615000724792|0.07091285288333893|0.1199503093957901|0.11064788699150085
355,2. Was müssen Sie vor der Anwendung von Humalog Mix25 Pen beachten? 3.,Before you use Humalog Mix25 Pen 3.,Before you use Humalog Mix25 Pen 3.,Before you use Humalog Mix25 Pen 3.,0.0,smt,2,2_smt,-0.0261026993393898|-0.007814865559339523|0.02653866447508335|0.02095675840973854|0.029178060591220856
356,Bei den Patientinnen unter Anastrozol waren es 126 Tage. Die 250 mg-Dosis Faslodex war wirksamer als die 125 mg-Dosis.,In those patients taking anastrozole did not receive 126 days. The 250 mg dose of Faslodex was more effective than the 125-mg dose.,The 250-mg dose of Faslodex was more effective than the 125-mg dose.,It was 126 days in patients taking Anastrozol. The 250 mg dose of Faslodex was more effective than the 125-mg dose.,0.3478260869565217,smt,2,2_smt,0.19065432250499725|0.25719451904296875|0.2211771309375763|0.3279646337032318|0.2479155957698822
357,"Falls PRCA, eine sehr seltene Erkrankung bei Ihnen auftritt, wird Ihr Arzt die Behandlung mit Silapo abbrechen und bestimmen, wie Ihre Anämie am besten zu behandeln ist.","If PRCA, a very rare condition occurs, your doctor will stop treatment with Silapo and determine how your anaemia is the best course of action to treat.","If PRCA, a very rare condition, occurs, the Silapo therapy will be stopped and your doctor will determine the best course of action to treat the anaemia.","If PRCA, a very rare condition occurs, your doctor will stop treatment with Silapo and determine how best to treat your anaemia.",0.36,smt,2,2_smt,0.028058286756277084|0.038279153406620026|0.14442628622055054|0.0789007842540741|0.08329244703054428
358,Die Behandlung mit TRISENOX muss dann unverzüglich abgebrochen werden. Ihr Arzt wird Sie auf eine Arsenüberdosis behandeln.,Treatment with TRISENOX must be discontinued immediately. Your doctor will advise you on the arsenic overdose.,"If this happens, treatment with TRISENOX must be stopped immediately and your doctor will treat the arsenic overdose.",Treatment with TRISENOX must be discontinued immediately. Your doctor will advise you on the arsenic overdose.,0.0,smt,2,2_smt,0.020882798358798027|0.03989366441965103|0.0650676041841507|0.06716079264879227|0.07550383359193802
359,Patienten mit Myasthenia gravis Nicht-epileptische (myo)klonische Reaktionen können auftreten.,Patients with myasthenia gravis Nicht-epileptische (binding) klonische reactions may occur.,Patients with myasthenia gravis Non-epileptic (myo)clonic reactions can occur.,Non-epileptic myoclonic reactions may occur in patients with myasthenia gravis.,0.7272727272727273,smt,2,2_smt,0.08286641538143158|0.1575644463300705|0.1390245109796524|0.21492262184619904|0.14366500079631805
360,"Die Strahlendosis, der der Patient aufgrund der therapeutischen Exposition ausgesetzt wird, kann sekundäre Malignome und die Entwicklung vererbbarer genetischer Defekte zur Folge haben.","The dose of radiation exposed to the patient due to the therapeutic exposures, none, secondary malignancies, and development of radioactive defects (10).",The radiation dose resulting from therapeutic exposure may result in secondary malignancies and in development of hereditary defects.,The dose of radiation that the patient is exposed to due to the therapeutic exposure may cause secondary malignancies and development of hereditary genetic defects.,0.5384615384615384,smt,2,2_smt,0.18267491459846497|0.25132983922958374|0.2859954833984375|0.30804285407066345|0.2673680782318115
361,Die vollständige Auflistung der im Zusammenhang mit Thymanax berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen.,For a full list of the side-effects reported with Thymanax hypersensitive (allergic) to ribavirin or any of the other ingredients.,"For the full list of all side effects reported with Thymanax, see the Package Leaflet.","For a full list of the side-effects reported with Thymanax hypersensitive (allergic) to ribavirin or any of the other ingredients, see the package insert.",0.1785714285714285,smt,2,2_smt,0.22705473005771637|0.3272915184497833|0.5823479890823364|0.36576157808303833|0.283658504486084
362,Bei der Untersuchung auf Infektionen sollte das Risiko für Patienten hinsichtlich relevanter opportunistischer Infektionen (z.B. Exposition gegenüber endemischen Mykosen) in Betracht gezogen werden.,"In evaluating the risk of infections in patients should be evaluated for relevant opportunistic infections (e. g., exposure to endemic mycoses) should be considered.","In evaluating patients for infections, the patient ’ s risk for relevant opportunistic infections (e. g., exposure to endemic mycoses) should be considered.","In evaluating the risk of infections in patients, the risk for patients should be evaluated for relevant opportunistic infections (e. g. exposure to endemic mycoses).",0.3448275862068966,smt,2,2_smt,0.09808044135570526|0.16129812598228455|0.19520600140094757|0.22244015336036682|0.17178048193454742
363,"Die Ergebnisse schließen einen Patienten, bei dem das Auftreten eines Inhibitors nach 9 Monaten beobachtet wurde, aus.","The results include a patient, the possibility of pacemaker has been observed after 9 months.",Data exclude those collected from one patient after evidence of inhibitor development was observed at 9 months.,Data exclude those collected from one patient after evidence of inhibitor development was observed at 9 months.,0.7222222222222222,smt,2,2_smt,0.13825877010822296|0.19637420773506165|0.33774757385253906|0.28868240118026733|0.215605691075325
364,"Wieviele Pflaster müssen angewendet werden? • Woche 1, 2 & 3:","Wieviele patches must be expected to be used for? • Week 1, 2 & 3.","How many patches to use • Weeks 1, 2 & 3:","How many patches must be used for? • Week 1, 2 & 3.",0.3125,smt,2,2_smt,0.07861920446157455|0.11698012799024582|0.1619577705860138|0.19351410865783691|0.12960544228553772
365,"45 Eigeninjektion sollte jedoch nur von Patienten durchgeführt werden, die entsprechend motiviert und hinreichend geschult sind sowie die Möglichkeit haben, fachlichen Rat einzuholen.","45 should only be performed by patients who are well-motivated, adequately trained and with access Self with access to expert advice.","Self administration of Puregon should only be performed by patients who are well-motivated, adequately trained and with access to expert advice.","45 Self injection should only be performed by patients who are well-motivated, adequately trained and with access with access to expert advice.",0.0833333333333333,smt,2,2_smt,0.15099145472049713|0.23186662793159485|0.1606745421886444|0.27078691124916077|0.2206457555294037
366,Cefuroxim wird nicht metabolisiert.,cefuroxime is not metabolized.,Cefuroxime is not metabolised.,cefuroxime is not metabolized.,0.0,smt,2,2_smt,-0.022728800773620605|-0.03424849361181259|0.009088064543902874|0.01417168416082859|0.02594497986137867
367,"Es ist nicht möglich zu beurteilen, ob diese Ereignisse direkt mit den kardiovaskulären Risikofaktoren oder mit anderen Faktoren in Zusammenhang stehen.","It is not possible to determine whether these events are related directly to the cardiovascular risk factors, or other factors.",It is not possible to determine whether these events are related directly to these factors or to other factors.,"It is not possible to determine whether these events are related directly to the cardiovascular risk factors, or other factors.",0.0,smt,2,2_smt,-0.010417657904326916|-0.010727506130933762|0.022210493683815002|0.020178254693746567|0.039669767022132874
368,"In den Wechseljahren produzieren die Eierstöcke keine weiblichen Hormone, Östrogen, mehr, die helfen, das Skelett von Frauen gesund zu erhalten.","At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps's skeleton a woman.","At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps to keep a woman ’ s skeleton healthy.","At the menopause, the ovaries stop producing the female hormone, oestrogen, which helps's skeleton a woman.",0.0,smt,2,2_smt,0.0627799853682518|0.10144557803869247|0.10117373615503311|0.16639061272144318|0.1398102343082428
369,"Sonstige Bestandteile: Jede 4 mg Retardtablette enthält 0,525 mg entölte Phospholipide aus Sojabohnen und 91,125 mg Lactose-Monohydrat.",Excipients Each 8 mg prolonged-release tablet contains 0.525 mg of soya lecithin and 91.125 mg lactose monohydrate.,Excipients Each 4 mg prolonged-release tablet contains 0.525 mg of soya lecithin and 91.125 mg lactose monohydrate.,Excipients Each 8 mg prolonged-release tablet contains 0.525 mg of soya lecithin and 91.125 mg lactose monohydrate.,0.0,smt,2,2_smt,-0.02950778789818287|-0.027506297454237938|0.014214103110134602|0.0039076185785233974|0.026790179312229156
370,Bei Patienten mit kompensierter Lebererkrankung geht dieser Anstieg des ALT-Serumspiegels im Allgemeinen nicht mit erhöhten Bilirubin-Serumspiegeln oder anderen Anzeichen einer Leberdekompensation einher.,"In patients with compensated liver disease, these elevation of serum ALT are generally not associated with an increased Bilirubin-Serumspiegeln or other signs of hepatic decompensation.","In patients with compensated liver disease, this elevation of serum ALT is generally not accompanied by elevated levels of serum bilirubin or by other signs of hepatic decompensation.","In patients with compensated liver disease, these elevation of serum ALT are generally not associated with an increased bilirubin serum level or other signs of hepatic decompensation.",0.1034482758620689,smt,2,2_smt,0.04068306088447571|0.07464799284934998|0.11857030540704727|0.11543893069028854|0.09200117737054825
371,"Succinylaceton hemmt den Porphyrinsynthese-Pathway, wodurch es zur Ansammlung von 5-Aminolaevulinat kommt.","succinylacetone inhibits the Porphyrinsynthese-Pathway, resulting in accumulation of 5-Aminolaevulinat.",Succinylacetone inhibits the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate.,"Succinylacetone inhibits the porphyrinsynthese pathway, resulting in accumulation of 5-aminolevulinic acid.",0.3076923076923077,smt,2,2_smt,0.08809899538755417|0.14447811245918274|0.13316790759563446|0.1858573853969574|0.13700218498706818
372,"Der mittlere Ausgangswert der HIV- 1-RNA betrug 4,98 log10 Kopien/ml und 5,01 log10 Kopien/ml in der Nelfinavir- bzw. Lopinavir/Ritonavir-Behandlungsgruppe.","The mean baseline plasma HIV 1-RNA was 4,98 log10 copies / ml; and / or is a log10 copies / ml in the nelfinavir and lopinavir / ritonavir and lopinavir / Ritonavir-Behandlungsgruppe.",Median baseline HIV-1 RNA was 4.98 log10 copies/ml and 5.01 log10 copies/ml in the nelfinavir and lopinavir/ritonavir treatment groups respectively.,"The mean baseline plasma HIV 1-RNA was 4.98 log10 copies/ml; and 5,01 log10 copies/ml in the nelfinavir and lopinavir/ritonavir and lopinavir/Ritonavir treatment groups.",0.2121212121212121,smt,2,2_smt,0.25272849202156067|0.34445223212242126|0.2563835382461548|0.38693684339523315|0.29384031891822815
373,11 Belastung. Die größte Verbesserung wurde im Bereich der gewohnten Aufgaben und der durch die Symptome eingeschränkten alltäglichen Tätigkeiten festgestellt.,11. The improvement was observed in the usual tasks and symptoms of impaired everyday activities.,The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.,"11. The greatest improvement was observed in the realm of usual tasks and in that of everyday activities, which had been imparied by the symptoms.",0.5,smt,2,2_smt,0.056770823895931244|0.10864879190921783|0.16407160460948944|0.1679830402135849|0.12486711144447327
374,Arzneimittel außer Reich- und Sichtweite von Kindern aufbewahren.,Keep out of the reach and sight of children.,Keep out of reach and sight of children.,Keep out of the reach and sight of children.,0.0,smt,2,2_smt,-0.03813908249139786|-0.03895849734544754|0.009943190030753613|0.000971553847193718|0.022596409544348717
375,"Infizierte Verletzungen, die eine Länge von 10 cm oder eine Gesamtfläche von > 100 cm2 überschreiten.","subjects, 31 cm or birefringent 100 cm2.",• Infected lesions that exceed 10 cm in length or a total surface area > 100 cm2.,"Infected wounds, that are longer than 10 cm or have a total area of more than 100 cm2.",0.7,smt,2,2_smt,0.37007415294647217|0.5036361217498779|0.3851965069770813|0.5416427254676819|0.4798200726509094
376,"Epidemiologische Studien haben gezeigt, dass eine Langzeitbehandlung mit Hydrochlorothiazid das Risiko der kardiovaskulären Mortalität und Morbidität senkt.","Epidemiological studies have shown that long-term treatment with hydrochlorothiazide, the risk of cardiovascular mortality and morbidity.",Epidemiological studies have shown that long term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.,Epidemiological studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.,0.0555555555555555,smt,2,2_smt,0.005105810705572367|0.01931098848581314|0.0864655002951622|0.05477823689579964|0.06119021773338318
377,"Analytische Hilfsmittel können zwar als Konsistenzkriterien eingesetzt werden, nicht jedoch als Korrelate für die Sicherheit und Wirksamkeit (Immunogenität) der von SPMSD hergestellten Hepatitis B-Chargen.","recombinantly expressing the flavonglycosides may be used as a treatment Konsistenzkriterien, but is not Korrelate the safety and efficacy (immunogenicity) of the hepatitis B component from SPMSD predict islands.","Analytical tools can be used as consistency criteria, but not as correlates for safety and efficacy (immunogenicity) of Hepatitis B batches produced at SPMSD.","Analytic aids may be used as criteria of consistency, but not as a correlation for the safety and efficacy (immunogenicity) of the hepatitis B batches produced by SPMSD.",0.5,smt,2,2_smt,0.41586023569107056|0.5402873754501343|0.3994664251804352|0.5480536222457886|0.4832628667354584
378,"Fortpflanzungsstudien mit Ratten und Kaninchen zeigten, dass die Kombination etwas toxischer ist als die beiden Wirkstoffe alleine, eine teratogene Wirkung der Kombination wurde jedoch in keiner Studie nachgewiesen.","Animal reproduction studies have not been conducted in rats and rabbits showed that the combination of somewhat toxic than the two active substances alone, a teratogenic effect of the combination, however, was not demonstrated in the study.",Reproduction studies in rats and rabbits revealed that the combination is somewhat more toxic than either of the single components but none of the studies revealed a teratogenic effect of the combination.,Animal reproduction studies have not been conducted in rats and rabbits showed that the combination is somewhat more toxic than either of the single components but none of the studies revealed a teratogenic effect of the combination.,0.4736842105263157,smt,2,2_smt,0.1388024240732193|0.20790302753448486|0.210852712392807|0.28564247488975525|0.22201579809188843
379,Dieses Ereignis steht im Zusammenhang mit der Stimulationsbehandlung mit Gonadotropinen (Hormone zur Förderung der Eireifung).,This event is associated with the stimulation with gonadotropins (hormones promoting egg maturation).,This event is related to the stimulation procedure with gonadotropins (hormones promoting egg maturation).,This event is associated with the stimulation treatment with gonadotropins (hormones promoting egg maturation).,0.0588235294117647,smt,2,2_smt,-0.03679003193974495|-0.029788995161652565|0.01769031025469303|0.00949682667851448|0.02919994294643402
380,Äußerlich kann Insulatard NovoLet durch Abwischen mit einem medizinischen Tupfer gereinigt werden.,You can clean the exterior of your Insulatard NovoLet by wiping it with a medicinal swab.,You can clean the exterior of your Insulatard NovoLet by wiping it with a medicinal swab.,You can clean the exterior of your Insulatard NovoLet by wiping it with a medicinal swab.,0.0,smt,2,2_smt,-0.022088242694735527|-0.019191613420844078|0.011272874660789967|0.02179688774049282|0.04409119486808777
381,"Hypromellose Titandioxid (E171) Macrogol Eisenoxid, rot (E172).","Hypromellose Titanium dioxide (E171) Macrogol iron oxide, red (E172).",Hypromellose (E464) Titanium dioxide (E171) Macrogol Iron oxide red (E172).,"Hypromellose, Titanium dioxide (E171), Macrogol iron oxide, red (E172).",0.1176470588235294,smt,2,2_smt,0.031345024704933167|0.05927615612745285|0.0423208512365818|0.09052682667970657|0.07569931447505951
382,"Der Impfstoff wird rekonstituiert, indem man dem Fläschchen mit dem darin enthaltenen Hib-Pulver den gesamten Inhalt der Spritze zusetzt.",The vaccine is reconstituted by rolling the vial by mixing the door the entire contents of the syringe.,The vaccine is reconstituted by adding the contents of the syringe to the vial containing the Hib powder.,The vaccine is reconstituted by adding the contents of the syringe to the vial containing the Hib powder.,0.4736842105263157,smt,2,2_smt,0.11304016411304474|0.20256364345550537|0.18847247958183289|0.2637392580509186|0.21173804998397827
383,"Ziehen Sie so viel Luft in die Spritze auf wie die Dosis an schnell wirkendem Insulin, die Sie benötigen.",Draw as much air into the syringe as the dose of fast-acting insulin you need.,Draw as much air into the syringe as the dose of fast-acting insulin you need.,Draw as much air into the syringe as the dose of fast-acting insulin needs.,0.1333333333333333,smt,2,2_smt,-0.032800108194351196|-0.03848254680633545|0.00970262847840786|-0.000347101129591465|0.025570357218384743
384,"Die Wirkungen von EXULETT wurden zunächst in Versuchsmodellen getestet, bevor sie an Menschen untersucht wurden.",The effects of EXULETT were first tested in experimental models before being studied in three main studies involving.,The effects of EXULETT were first tested in experimental models before being studied in humans.,The effects of EXULETT were first tested in experimental models before being studied in three main studies.,0.0555555555555555,smt,2,2_smt,0.002245888579636812|0.010364081710577011|0.0832907035946846|0.060371316969394684|0.059017524123191833
385,Der arzneilich wirksame Bestandteil ist:,The active substance is:,The active substance is temozolomide.,The active substance is:,0.0,smt,2,2_smt,0.05570823699235916|0.0530194491147995|0.036487285047769547|0.13863685727119446|0.10885012894868851
386,"Die mediane Nachbeobachtungsdauer betrug zum Zeitpunkt der Analyse 6,9 Jahre.",The median duration of follow-up was 6.9 years of age at the time of analysis.,The median follow up at the time of the analysis was 6.9 years.,The median duration of follow-up was 6.9 years of age at the time of analysis.,0.0,smt,2,2_smt,0.03666921332478523|0.053727343678474426|0.059662386775016785|0.12530231475830078|0.09512969106435776
387,"Ferner zeigte sich der CHMP besorgt darüber, dass bei Patienten unter MULTAQ eine höhere Rate von Nebenwirkungen auftrat als bei Patienten unter Placebo.","In addition, there are concerned, the CHMP considered that a higher rate of adverse reactions occurred in patients receiving MULTAQ than in those taking placebo.",The CHMP also had concerns over a higher rate of side effects in patients taking MULTAQ than those taking placebo.,The CHMP considered that a higher rate of adverse reactions occurred in patients receiving MULTAQ than in those taking placebo.,0.3333333333333333,smt,2,2_smt,0.11499909311532974|0.16953416168689728|0.21530066430568695|0.2156665027141571|0.1849268525838852
388,In der zweiten Studie wurde die Anwendung von Flebogammadif zur Immunmodulation bei 20 Patienten mit ITP untersucht.,The second study looked at the use of Flebogammadif for immunomodulation in 20 patients with ITP.,The second study looked at using Flebogammadif for immunomodulation in 20 patients with ITP.,The second study looked at the use of Flebogammadif for immunomodulation in 20 patients with ITP.,0.0,smt,2,2_smt,-0.030165040865540504|-0.02896432764828205|0.013038855977356434|0.005243597086519003|0.028823083266615868
389,Aufgrund dieses kurzen Wirkprofils sollte NovoRapid in der Regel in Kombination mit mittellang oder lang wirkenden Insulinpräparaten verabreicht werden.,Because this short Wirkprofils NovoRapid should usually be given in combination with mittellang or long-acting insulin preparations.,Due to this short action NovoRapid should normally be taken in combination with intermediate-acting or long-acting insulin preparations.,"Because of this, short Wirkprofils NovoRapid should usually be given in combination with medium or long-acting insulin preparations.",0.15,smt,2,2_smt,0.28702402114868164|0.3889506161212921|0.23733754456043243|0.44520303606987|0.3535308539867401
390,Es hat gegenüber den zu bekämpfenden Bakterien eine ähnliche antibakterielle Aktivität wie Ceftiofur.,"It has been shown to cause the antibodies to bacteria a similar antibacterial activity, such as ceftiofur.",It has an antimicrobial activity similar to that of ceftiofur against the target pathogens.,"It has been shown to cause the antibodies to bacteria a similar antibacterial activity, such as ceftiofur.",0.0,smt,2,2_smt,0.16397541761398315|0.25343331694602966|0.2386835515499115|0.28715503215789795|0.23266702890396118
391,"Die klinische Bedeutung dieser Erkenntnis ist unbekannt, da keine Korrelation zwischen IgG-Antikörperspiegeln und der klinischen Wirksamkeit nachgewiesen wurde.",The clinical significance of this finding is unknown because of a lack of correlation between IgG-Antikörperspiegeln and clinical efficacy has been demonstrated.,The clinical significance of this finding is unknown since there were no consistent relationships between IgG antibody level and clinical efficacy endpoints.,The clinical significance of this finding is unknown because of a lack of correlation between IgG antibody levels and clinical efficacy has been demonstrated.,0.12,smt,2,2_smt,0.06956798583269119|0.1264849603176117|0.16523762047290802|0.17865926027297974|0.13084286451339722
392,Die bakterielle und die mykotische Otitis treten häufig als Sekundärerkrankungen auf.,Bacterial and fungal otitis is Sekundärerkrankungen.,Bacterial and fungal otitis is often secondary in nature.,Bacterial and fungal otitis occur more often as secondary complications.,0.5454545454545454,smt,2,2_smt,0.1257466822862625|0.21119308471679688|0.15156815946102142|0.24188770353794098|0.18258774280548096
393,"Stoffwechsel- und Ernährungsstörungen Gelegentlich: Anorexie, verminderter Appetit, Dehydratation.","Metabolism and nutrition disorders Uncommon: anorexia, decreased appetite, dehydration.","Metabolism and nutrition disorders Uncommon: anorexia, decreased appetite, dehydration.","Metabolism and nutrition disorders Uncommon: anorexia, decreased appetite, dehydration.",0.0,smt,2,2_smt,-0.05024707689881325|-0.044500209391117096|0.009411754086613655|-0.015786316245794296|0.013384141027927399
394,"15) Achten Sie beim Abziehen darauf, dass Sie die Schutzhülle nicht verbiegen oder drehen, um zu vermeiden, dass die Kanüle beschädigt wird.","15) Be careful, not to bend or twist the cover during removal to avoid damage to the needle.",Be careful not to bend or twist the cover during removal to avoid damage to the needle.,15) Be careful not to bend or twist the cover during removal to avoid damage to the needle.,0.05,smt,2,2_smt,-0.008055253885686398|0.0005498304963111877|0.019807416945695877|0.044430918991565704|0.05246981978416443
395,"Dieser Plan soll Maßnahmen enthalten, um die Nebenwirkungen im Zusammenhang mit dem Verfahren der intravitrealen Injektion (z.B.",This plan shall consist of measures to reduce adverse reactions associated with the production of an intravitreal injection (e. g.,This pl an shall consist of measures aiming to minimise adverse events associated with the intravitreal injection procedure (e.g. endophthalmitis) through adequate education about:,This plan shall consist of measures to reduce adverse reactions associated with the procedure of an intravitreal injection (e. g.,0.0454545454545454,smt,2,2_smt,0.038790419697761536|0.07289507240056992|0.04601830244064331|0.11611631512641907|0.10915177315473557
396,"InductOs darf bei dieser Indikation nicht alleine, sondern muss mit dem „LT-CAGE Kegelförmige Instrumentation für Fusionen des lumbalen Rückgrats“ angewendet werden.","InductOs should not be used in this indication on its own, but must be used with the LT-CAGE Lumbar Tapered Fusion Device size antisense-oligonucleotides for DBP of 2 lumbar vertebrae "").","InductOs should not be used alone for this indication, but must be used with the LT-CAGE Lumbar Tapered Fusion Device.","InductOs should not be used in this indication on its own, but must be used with the LT-CAGE conical instruments for fusion of the Lumbar Tapered Fusion Device.",0.3,smt,2,2_smt,0.27944326400756836|0.3710496425628662|0.2074633538722992|0.3934346139431|0.3554106056690216
397,"Dabei handelt es sich um Enzyme, die Bestandteil bestimmter Rezeptoren auf der Zelloberfläche (z.",This is the enzymes of certain receptors on the cell surface (e. g.,This means that it blocks some specific enzymes known as tyrosine kinases.,This is the enzymes of certain receptors on the cell surface (e. g.,0.0,smt,2,2_smt,0.1896529346704483|0.22128403186798096|0.12853483855724335|0.2918470799922943|0.238739013671875
398,Welches Risiko ist mit Norvir verbunden?,What is the risk associated with Norvir?,What is the risk associated with Norvir?,What is the risk associated with Norvir?,0.0,smt,2,2_smt,-0.062104906886816025|-0.06697842478752136|0.008824911899864674|-0.04116933047771454|-0.00651128776371479
399,"Ihr Arzt wird gewissenhaft abwägen, ob Sie mit Tenofovirdisoproxilfumarat und Didanosin in Kombination behandelt werden sollen.",Your doctor will consider whether followed carefully for loading with tenofovir disoproxil fumarate and didanosine in combination should be treated.,Your doctor will carefully consider whether to treat you with combinations of tenofovir and didanosine.,Your doctor will consider whether you should take tenofovir disoproxil fumarate and didanosine in combination.,0.5,smt,2,2_smt,0.1930665820837021|0.23982414603233337|0.40190237760543823|0.28662109375|0.23035693168640137
400,"Wird eine Frau während der Behandlung mit dem Arzneimittel schwanger, sollte sie ihren Arzt konsultieren.","If a woman while pregnant while taking the medicine, she should consult her doctor.","If a woman becomes pregnant while taking the medicine, she should consult her doctor.","If a woman becomes pregnant while taking the medicine, she should consult her doctor.",0.0625,smt,3,3_smt,0.036336567252874374|0.046764813363552094|0.1179274246096611|0.088039331138134|0.08903238922357559
401,"Bei Patienten mit eingeschränkter Nierenfunktion und einer GFR von ≥ 30 ml/min/1,73 m2 ist keine Dosisanpassung erforderlich.",No dose adjustment is necessary in patients with reduced renal function (GFR ≥ 30 ml / min / 1.73 m2.,No dosage adjustment is necessary in patients with renal impairment whose GFR is ≥ 30 ml/ min/ 1.73 m2.,No dose adjustment is necessary in patients with reduced renal function (GFR ≥ 30 ml / min / 1.73 m2.,0.0,smt,3,3_smt,-0.004250821657478809|0.0006272066384553909|0.01574951782822609|0.045749884098768234|0.04916522651910782
402,Eine Überwachung der INR (International Normalised Ratio) wird empfohlen.,Monitoring of INR (International Normalised Ratio) is recommended.,It is recommended that INR (international normalised ratio) be monitored.,Monitoring of INR (International Normalised Ratio) is recommended.,0.0,smt,3,3_smt,0.02281847782433033|0.03443799167871475|0.030259324237704277|0.07384326308965683|0.06604447960853577
403,"- wenn bei Ihnen Eierstock-, Gebärmutter- oder Brustkrebs diagnostiziert wurde.","- if you have ovarian, uterine or breast cancer has been diagnosed in the flock.",This treatment increases your risk of developing a condition called ovarian hyperstimulation syndrome (OHSS) (see also section headed ‘ Possible side effects’).,"- if you have been diagnosed with ovarian, uterine or breast cancer.",0.4285714285714285,smt,3,3_smt,0.2620881497859955|0.34727466106414795|0.33053892850875854|0.4365771412849426|0.35188591480255127
404,• Patienten mit schubförmiger Multipler Sklerose (MS).,• patients with relapsing multiple sclerosis (MS).,• Patients diagnosed with relapsing multiple sclerosis (MS).,• patients with relapsing multiple sclerosis (MS).,0.0,smt,3,3_smt,-0.03053371235728264|-0.03486281633377075|0.011073753237724304|0.007911860942840576|0.020527798682451248
405,Kühl lagern und transportieren (2°C – 8°C).,Store and transport refrigerated (2 ° C - 8 ° C).,Store and transport refrigerated (2 °C - 8 °C).,Store and transport refrigerated (2 ° C - 8 ° C).,0.0,smt,3,3_smt,-0.036869727075099945|-0.04459904879331589|0.009415671229362488|-0.005814000498503447|0.018352709710597992
406,"Auch wenn Sie sich besser fühlen, dürfen Sie die Einnahme von Norvir nicht ohne vorherige Rücksprache mit Ihrem Arzt unterbrechen.","Even if you feel better, you should not stop taking Norvir without talking to your doctor first.","Even if you feel better, do not stop taking Norvir without talking to your doctor.","Even if you feel better, you should not stop taking Norvir without talking to your doctor first.",0.0,smt,3,3_smt,-0.010130081325769424|-0.013655487447977066|0.011629479937255383|0.014866458252072334|0.03572617471218109
407,las Zenapax ist während der Stillzeit kontraindiziert (siehe Abschnitt 4.6).,uth Zenapax is contraindicated during breast-feeding (see section 4.6).,ed Zenapax is contraindicated during lactation (see section 4.6).,uth Zenapax is contraindicated during breast-feeding (see section 4.6).,0.0,smt,3,3_smt,-0.0021192445419728756|0.005331147462129593|0.037819258868694305|0.03635729104280472|0.05039180815219879
408,Nach dem Wechsel von einem anderen Insulin zu Insulinglulisin muss Ihre Dosierung möglicherweise von Ihrem Arzt angepasst werden.,"121 If you switch from another insulin to insulin glulisine, your dosage may have to be adjusted by your doctor.","If you switch from another insulin to insulin glulisine, your dosage may have to be adjusted by your doctor.","If you switch from another insulin to insulin glulisine, your dosage may have to be adjusted by your doctor.",0.0476190476190476,smt,3,3_smt,-0.01601976901292801|-0.01560528390109539|0.016738589853048325|0.01669333688914776|0.03924030810594559
409,"Das Pflaster ist 39 cm² groß und gibt pro 24 Stunden nominal 3,9 mg Oxybutynin ab.",The patch is 39 cm2 per 24 hours is a nominal 3.9 mg of oxybutynin.,"The area of the patch is 39 cm2, releasing a nominal 3.9 mg of oxybutynin per 24 hours.",The patch is 39 cm2 and releases a nominal 3.9 mg of oxybutynin per 24 hours.,0.2941176470588235,smt,3,3_smt,0.13304275274276733|0.195020854473114|0.18564251065254211|0.2684192955493927|0.19233696162700653
410,"Insuman Rapid ist eine klare, farblose, wässrige Injektionslösung ohne sichtbare Teilchen.","Insuman Rapid is a clear, colourless solution for injection, with no solid particles visible.","475 What Insuman Rapid looks like and contents of the pack Insuman Rapid is a clear, colourless solution for injection, with no solid particles visible, and of a water- like consistency.","Insuman Rapid is a clear, colourless solution for injection, with no solid particles visible.",0.0,smt,3,3_smt,0.002032829914242029|0.01371526625007391|0.03417965769767761|0.049958761781454086|0.06533408164978027
411,"Es ist wichtig, dass Sie dieser Aufforderung nachkommen.",It is important that you take this FGF-2 obligations.,It is important that you follow this advice.,It is important that you follow this advice.,0.3333333333333333,smt,3,3_smt,0.23314905166625977|0.2993999123573303|0.25231584906578064|0.3626624643802643|0.3350468575954437
412,Nach Anbruch können Sie Ihren Humalog Mix50 Pen bis zu 28 Tage bei Raumtemperatur (unter 30°C) aufbewahren.,Keep your Humalog Mix50 Pen in use at room temperature (below 30 ° C) for up to 28 days.,Keep your Humalog Mix50 Pen in use at room temperature (below 30°C) for up to 28 days.,Keep your Humalog Mix50 Pen at room temperature (below 30 ° C) for up to 28 days.,0.1,smt,3,3_smt,-0.04298756271600723|-0.04544399678707123|0.010470129549503326|-0.017858928069472313|0.011624371632933617
413,"Die Behandlung mit TORISEL sollte so lange fortgeführt werden, bis der Patient keinen klinischen Nutzen mehr von der Therapie hat oder inakzeptable Toxizität auftritt.",Treatment with TORISEL should continue until continued until the patient does not feel the clinical benefit of therapy or experience unacceptable toxicity occurs.,Treatment with TORISEL should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.,Treatment with TORISEL should continue until the patient does not feel the clinical benefit of therapy or experience unacceptable toxicity occurs.,0.0909090909090909,smt,3,3_smt,0.05541561543941498|0.07537529617547989|0.13022176921367645|0.14168398082256317|0.11051654815673828
414,Focetria enthält geringe Mengen von Bestandteilen eines Influenzavirus vom Typ H5N1.,Focetria contains small amounts of influenza virus type H5N1.,Focetria contains small amounts of parts of a virus called H5N1.,Focetria contains small amounts of influenza virus type H5N1.,0.0,smt,3,3_smt,-0.00775393471121788|-0.004096677526831627|0.014243312180042267|0.03299234062433243|0.04456660896539688
415,"Bondenza ist weniger wirksam, wenn es zusammen mit Nahrung eingenommen wird.",Bondenza is less effective when given with food.,Bondenza is less effective if it’s taken with food.,Bondenza is less effective when given with food.,0.0,smt,3,3_smt,-0.008105440065264702|0.0013829777017235756|0.021131504327058792|0.03378129377961159|0.053452931344509125
416,"Es wird empfohlen, ein begleitendes Beckenbodentraining in Betracht zu ziehen.",It is recommended that the monomer Pelvic Floor Muscle Training (PFMT) should be considered.,It is recommended that consideration be given to concomitant PFMT.,It is recommended that the accompanying Pelvic Floor Muscle Training (PFMT) should be considered.,0.0588235294117647,smt,3,3_smt,0.19033321738243103|0.2883324921131134|0.2094329446554184|0.3575376570224762|0.31034865975379944
417,Es wurden keine Interaktionsstudien mit Kepivance durchgeführt.,No interaction studies have been performed with Kepivance.,No interaction studies have been conducted with Kepivance.,No interaction studies have been performed with Kepivance.,0.0,smt,3,3_smt,-0.043818891048431396|-0.04190412908792496|0.009438919834792614|-0.012617303058505058|0.0167517252266407
418,"36 HDL-C um 2,9% (Pravastatin: +5,6%, p = NS).","36 HDL-C by 2.9% (pravastatin: + 5.6%, p = NS).","Atorvastatin increased mean HDL-C by 2.9% (pravastatin: +5.6%, p=NS).","36 HDL-C by 2.9% (pravastatin: + 5.6%, p = NS).",0.0,smt,3,3_smt,0.10582425445318222|0.16803492605686188|0.07167267799377441|0.1984444409608841|0.1531885266304016
419,"Auch das Aussehen des Insulins muss geprüft werden: Die Insulinlösung muss klar, farblos und wässrig sein und darf keine sichtbaren Parti- kel enthalten.","Even if the appearance of the insulin should be checked: the insulin solution must be clear, colourless, with no solid particles and colourless, with no solid particles visible must have a water-like consistency.","The appearance of insulin should also be checked: the insulin solution must be clear, colourless, with no solid particles visible, and must have a water-like consistency.","Even if the appearance of the insulin should be checked: the insulin solution must be clear, colourless, with no solid particles visible.",0.4615384615384615,smt,3,3_smt,0.09077911823987961|0.16189205646514893|0.3932145833969116|0.2212783396244049|0.17682558298110962
420,"Die Häufigkeit von Nebenwirkungen, die in kontrollierten klinischen Studien mit der Behandlung mit Aranesp in Zusammenhang gebracht wurden, ist folgende:",Incidence of undesirable effects considered related to treatment with Aranesp from controlled clinical studies are:,177 Incidence of undesirable effects considered related to treatment with Aranesp from controlled clinical studies are:,The incidence of undesirable effects considered related to treatment with Aranesp from controlled clinical studies are:,0.0588235294117647,smt,3,3_smt,-0.026206860318779945|-0.020345067605376244|0.033679306507110596|0.02097276970744133|0.03485758230090141
421,"Die Überdosierung führte zu Symptomen wie Nystagmus, Ataxie, Bewusstseinsstörungen und Koma.","The overdose resulted in symptoms such as ataxia, nystagmus, reduced consciousness and coma.","Overdose has resulted in symptoms including nystagmus, ataxia, impaired consciousness and coma.","The overdose resulted in symptoms such as ataxia, nystagmus, reduced consciousness and coma.",0.0,smt,3,3_smt,-0.025709085166454315|-0.02538907341659069|0.012253290973603725|0.016098620370030403|0.032622773200273514
422,Nach kontinuierlicher oraler Verabreichung von 10 mg/kg/Tag Dicural orale Lösung an fünf aufeinanderfolgenden Tagen beträgt die durchschnittliche Plasmakonzentration von Difloxacin ca. 60 ng/ml.,"Following continuous oral administration of 10 mg / kg / day of Dicural oral solution for five consecutive days, the mean plasma concentration of difloxacin is approximately 60 ng / ml.",Following continuous oral dosing of Dicural oral solution at 10 mg/ kg/ day for five consecutive days the mean difloxacin steady state plasma concentrations are approximately 60 ng/ ml.,"Following continuous oral administration of 10 mg/kg/day of Dicural oral solution for five consecutive days, the mean plasma concentration of difloxacin is approximately 60 ng/ml.",0.0,smt,3,3_smt,-0.015891635790467262|-0.015061983838677406|0.0194319449365139|0.01828078366816044|0.03241332620382309
423,"Wie alle Arzneimittel kann OLANZAPIN MYLAN Nebenwirkungen haben, die aber nicht bei jedem auftreten müssen.","Like all medicines, Olanzapine Mylan may cause side effects, although not every body gets them.","Like all medicines, Olanzapine Mylan can cause side effects, although not everybody gets them.","Like all medicines, Olanzapine Mylan may cause side effects, although not every body gets them.",0.0,smt,3,3_smt,-0.030160071328282356|-0.033119261264801025|0.010649521835148335|-0.0025406857021152973|0.024713121354579926
424,"Veröffentlichte Ergebnisse der Basisimmunsuppression nach anderen Organtransplantationen < Phantasiebezeichnung > hat sich zu einem anerkannten Basisimmunsuppressivum nach Pankreas-, Lungen- und Darmtransplantationen entwickelt.","Results from published data, treatment should begin after other organ transplantation Invented name has evolved into an accepted treatment as prospective immunosuppressive medicinal product, lung and intestinal transplantation.","Results from published data in other primary organ transplantation< Invented name > has evolved into an accepted treatment as primary immunosuppressive medicinal product following pancreas, lung and intestinal transplantation.","Results from published data in other primary organ transplantation< Invented name > has evolved into an accepted treatment as primary immunosuppressive medicinal product following pancreas, lung and intestinal transplantation.",0.34375,smt,3,3_smt,0.13493163883686066|0.23516537249088287|0.24890398979187012|0.2973043918609619|0.23854146897792816
425,"Nehmen Sie Starlix so, wie es Ihnen Ihr Arzt verschrieben hat.",Always take Starlix as prescribed by your doctor.,How much to take Take Starlix as your doctor told you to.,Always take Starlix as prescribed by your doctor.,0.0,smt,3,3_smt,0.05133097991347313|0.07290545105934143|0.04642809182405472|0.09395571798086166|0.09809241443872452
426,- Die Patienten dürfen sich nach der Einnahme von Bondronat 60 Minuten lang nicht hinlegen.,- Patients should not lie down until after taking Bondronat over 60 minutes.,- Patients should not lie down for 60 minutes after taking Bondronat.,- Patients may not lie down for 60 minutes after taking Bondronat.,0.3076923076923077,smt,3,3_smt,-0.004438420757651329|0.005534166470170021|0.044165339320898056|0.04747598618268967|0.04902327060699463
427,Weitere Informationen über Velmetia:,2 / 3 Other information about Velmetia:,Other information about Velmetia:,2/3 Other information about Velmetia:,0.0,smt,3,3_smt,0.025150800123810768|0.0318349227309227|0.0654037818312645|0.06026504188776016|0.07424835860729218
428,"Nehmen Sie danach die nächste Dosis zur gewohnten Zeit ein. Wenn es jedoch schon fast Zeit für Ihre nächste Dosis ist, nehmen sie einfach die nächste Tablette zur gewohnten Zeit ein.","Always take then take your next dose at the usual time. However, if it is almost time for your next dose, simply take the next tablet at the usual time.","However, if it is almost time for your next dose you should simply take the next tablet at the usual time.","Always take then take your next dose at the usual time. However, if it is almost time for your next dose, simply take the next tablet at the usual time.",0.0,smt,3,3_smt,0.06254551559686661|0.09144219011068344|0.11536626517772675|0.13352984189987183|0.10432423651218414
429,Der Grund hierfür ist nicht bekannt.,This is unknown.,The cause of this finding is unknown.,The reason for this is unknown.,0.4285714285714285,smt,3,3_smt,0.032524071633815765|0.04725424945354462|0.13972008228302002|0.1228661760687828|0.0927032083272934
430,Es wurden keine Wirkungen auf die Fortpflanzungsfähigkeit bei männlichen und weiblichen Ratten festgestellt.,There were no effects on reproductive function was observed in male and female rats.,No effect on the reproductive capacity in male and female rats was noted.,No effect on reproductive function was observed in male and female rats.,0.2307692307692307,smt,3,3_smt,0.027485813945531845|0.05261969566345215|0.046153850853443146|0.11386041343212128|0.0969134196639061
431,Die für Sie geeignete Dosis richtet sich nach Ihrem Körpergewicht und nach der zu untersuchenden Körperregion:,The dose will depend on your body weight and on the same shaft:,The actual dosage of Gadograf that is right for you will depend on your body weight and on the region of examination:,The dose will depend on your body weight and on the region of examination:,0.2,smt,3,3_smt,0.08060118556022644|0.11957912147045135|0.17398998141288757|0.17321205139160156|0.14851787686347961
432,"NovoRapid ist ein Ersatzinsulin, das dem von der Bauchspeicheldrüse gebildeten Insulin sehr ähnlich ist.",NovoRapid is a replacement insulin which identical to the insulin made by the pancreas.,NovoRapid is a replacement insulin which is very similar to the insulin made by the pancreas.,NovoRapid is a replacement insulin which identical to the insulin made by the pancreas.,0.0,smt,3,3_smt,-0.008181383833289146|-0.0025904644280672073|0.014844788238406181|0.04222717881202698|0.05724742263555527
433,Die meisten Fälle traten in den Behandlungsmonaten auf.,Most of the cases occurred in the months of treatment.,Most of them occurred during the first months of treatment.,Most of the cases occurred in the months of treatment.,0.0,smt,3,3_smt,-0.013500817120075226|-0.016108332201838493|0.020539382472634315|0.028241438791155815|0.04302588105201721
434,"Der rekombinante Blutgerinnungsfaktor IX ist ein rekombinantes Proteintherapeutikum, dessen strukturellen und funktionellen Eigenschaften mit denen des endogenen Faktor IX vergleichbar sind.",Recombinant coagulation factor IX is a DNA-based protein therapeutic which has structural modifiable characteristics comparable to endogenous factor IX.,Recombinant coagulation factor IX is a recombinant DNA-based protein therapeutic which has structural and functional characteristics comparable to endogenous factor IX.,Recombinant coagulation factor IX is a recominant therapeutic protein which has structural modifiable characteristics comparable to endogenous factor IX.,0.1,smt,3,3_smt,-0.008154048584401608|0.015586929395794868|0.015269414521753788|0.05521587282419205|0.057435616850852966
435,Nr. L 272 vom 25.10.96 6 ABL.,L 272 of 25.10.96 5 OJ No.,L 272 of 25.10.96 6 OJ No.,L 272 of 25.10.96 5 OJ No.,0.0,smt,3,3_smt,0.014538148418068886|0.022854197770357132|0.03158772736787796|0.06649171561002731|0.06193409860134125
436,"Wenn Sie SUSTIVA einnehmen, dürfen Sie Ihr Kind nicht stillen.",If you are taking SUSTIVA you should not breast-feed your baby.,You should not breast feed your baby if you are taking SUSTIVA.,If you are taking SUSTIVA you should not breast-feed your baby.,0.0,smt,3,3_smt,-0.01807394251227379|-0.028542963787913322|0.013579551130533218|0.005000547971576452|0.029257096350193024
437,"Personen, bei denen schon einmal Hautreaktionen beim Umgang mit Aivlosin oder ähnlichen Produkten aufgetreten sind, sollten jeden Kontakt mit Aivlosin vermeiden.",People who have ever had skin reactions have occurred in handling Aivlosin or similar products should avoid any contact with Aivlosin.,"People who had in the past skin reactions when handling Aivlosin or similar products, should avoid any contact with Aivlosin.",People who have ever had skin reactions when handling Aivlosin or similar products should avoid any contact with Aivlosin.,0.15,smt,3,3_smt,0.07311663031578064|0.12719041109085083|0.08643736690282822|0.18558195233345032|0.1371202915906906
438,"Die Studien mit Zarzio dienten der Erbringung des Nachweises, dass es mit dem Referenzarzneimittel Neupogen vergleichbar ist.","The studies with Zarzio was infection, similar to that seen with the reference medicine, Neupogen.","Zarzio was studied to show that it is comparable to the reference medicine, Neupogen.",The studies with Zarzio proved that it is similar to the reference medicine Neupogen.,0.4666666666666667,smt,3,3_smt,0.21499003469944|0.2846989333629608|0.2431669980287552|0.33580151200294495|0.2788203954696655
439,Der Umsatz von Tipranavir in Gegenwart von niedrig dosiertem Ritonavir ist minimal.,The intraneuronal tipranavir and in the presence of low dose ritonavir to be minimal.,The metabolism of tipranavir in the presence of low dose ritonavir is minimal.,The metabolism of tipranavir in the presence of low dose ritonavir is minimal.,0.3571428571428571,smt,3,3_smt,0.186947762966156|0.23741649091243744|0.38149896264076233|0.3272629976272583|0.22075720131397247
440,2/3 Weitere Informationen über Efient:,2 / 3 Other information about Efient:,Other information about Efient:,2 / 3 Other information about Efient:,0.0,smt,3,3_smt,0.009555015712976456|0.020836787298321724|0.049102816730737686|0.037881072610616684|0.06034325063228607
441,Insulin Human Winthrop Comb 15 gibt es in Durchstechflaschen mit 10 ml Suspension (400 I.E.).,Insulin Human Winthrop Comb 15 is supplied in vials containing 10 ml suspension (400 IU).,Insulin Human Winthrop Comb 15 is supplied in vials containing 10 ml suspension (400 IU).,Insulin Human Winthrop Comb 15 is supplied in vials containing 10 ml suspension (400 IU).,0.0,smt,3,3_smt,-0.0448206327855587|-0.049215830862522125|0.010144536383450031|-0.017862293869256973|0.011267904192209244
442,"Die Stickstoffmonoxiddosis muss reduziert werden, wenn die Konzentration von NO2 0.5 ppm übersteigt.",The dose should be reduced if the concentration of NO2 0.5 ppm.,The dose of nitric oxide should be reduced if the concentration of nitrogen dioxide exceeds 0.5 ppm.,The dose should be reduced if the concentration exceeds NO2 0.5 ppm.,0.0769230769230769,smt,3,3_smt,0.11813816428184509|0.1482478529214859|0.1171952337026596|0.261380672454834|0.17950107157230377
443,"OPTISON wird durch intravenöse Injektion verabreicht, woraufhin die Mikrosphären in die Herzkammern gelangen und die linke Herzkammer gefüllt wird.","OPTISON is administered as an intravenous injection, which quenches the chambers of the heart and / or lifetimes.",OPTISON is administered via an intravenous injection to allow the microspheres to enter the heart chamber and fill the left heart chamber.,"OPTISON is administered as an intravenous injection, whereupon it reaches the chambers of the heart and the left heart chamber is filled.",0.375,smt,3,3_smt,0.1023501604795456|0.14129500091075897|0.12045019119977951|0.1952897310256958|0.17341046035289764
444,"Im Falle einer Überdosierung wird empfohlen, eine geeignete unterstützende Therapie, dem klinischen Zustand des Patienten entsprechend, einzuleiten.","In the event of an overdose, it is recommended that appropriate supportive treatment, the clinical status of the patient is to be initiated accordingly.","In the event of an overdose, it is recommended that appropriate supportive treatment should be initiated as dictated by the patient’ s clinical status.","In the event of an overdose, it is recommended that appropriate supportive treatment should be initiated as dictated by the clinical status of the patient.",0.2222222222222222,smt,3,3_smt,0.06421870738267899|0.09644512832164764|0.2721593379974365|0.15632297098636627|0.13670776784420013
445,Jedoch waren die GMTs bei Frauen über 25 Jahren niedriger.,"However, GMTs in females over 25 years of age.","The GMTs were, however, lower in women above 25 years.","However, GMTs in females over 25 years of age were lower.",0.1538461538461538,smt,3,3_smt,0.12669827044010162|0.18765446543693542|0.23021377623081207|0.27156707644462585|0.18247555196285248
446,"Fertilitätsstudien wurden mit Trabectedin nicht durchgeführt, aber in Toxizitätsstudien mit wiederholter Gabe wurden in begrenztem Ausmaß histopathologische Veränderungen in den Gonaden festgestellt.","fertility studies have not been conducted with trabectedin, but in toxicity studies were Histopathological changes in the extent of disturbed gonadal function.",Fertility studies with trabectedin were not performed but limited histopathological changes were observed in the gonads in the repeat dose toxicity studies.,"Fertility studies have not been conducted with trabectedin, but in toxicity studies with repeated doses histopathological changes in the gonads were detected to a limited extent.",0.3571428571428571,smt,3,3_smt,0.09499812871217728|0.16555701196193695|0.2087980955839157|0.22075824439525604|0.1628645360469818
447,"In klinischen Prüfungen mit Tocilizumab wurde eine rasche Abnahme des CRPs, der Blutsenkungsgeschwindigkeit (BSG) und des Serum-Amyloid-Proteins A (SAA) beobachtet.","In clinical trials with tocilizumab was rapid decrease in CRPs, ESR increased erythrocyte sedimentation rate (ESR) and Serum-Amyloid-Proteins (0.05%) were seen.","In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed.","In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed.",0.4074074074074074,smt,3,3_smt,0.10876081138849258|0.2075272500514984|0.1913117915391922|0.2109207808971405|0.17869558930397034
448,"Die folgenden Nebenwirkungen wurden ebenfalls berichtet: Taubheitsgefühl, Sehstörungen, Akne, Schleimhautentzündungen in Magen und Dünndarm (Gastroenteritis) und Schmerzen.","The following side effects have also been reported: numbness, blurred vision, acne, Schleimhautentzündungen in the stomach and small intestine (gastroenteritis) and pain.","The following adverse reactions have also been reported: numbness, blurred vision, acne, gastroenteritis, and pain.","The following side effects have also been reported: numbness, blurred vision, acne, mucosal inflammation in the stomach and small intestine (gastroenteritis) and pain.",0.0666666666666666,smt,3,3_smt,0.0446760393679142|0.08468100428581238|0.0770050510764122|0.12042160332202911|0.10833468288183212
449,Außerdem kam es unter der Behandlung mit Mirapexin bei mehr Patienten zu einer Linderung der Symptome.,More symptoms during treatment with Mirapexin More patients.,More patients taking Mirapexin also had an improvement in symptoms.,Furthermore during treatment with Mirapexin more patients had alleviation of the symptoms.,0.4615384615384615,smt,3,3_smt,0.11765790730714798|0.1694108545780182|0.223398819565773|0.23428377509117126|0.1805044412612915
450,"Gadovist ist eine klare, farblose bis schwach gelbliche Lösung.","Gadovist is a clear, colourless to pale yellow solution.","Gadovist is a clear, colourless to pale yellow solution.","Gadovist is a clear, colourless to pale yellow solution.",0.0,smt,3,3_smt,-0.0414816178381443|-0.04741900414228439|0.0101358937099576|-0.01524796150624752|0.021009458228945732
451,Thrombozytopenie und Anämie treten weniger häufig auf und werden selten ohne eine vorausgegangene Neutropenie beobachtet.,thrombocytopenia and anaemia are less common and are rarely observed without prior neutropenia.,"Thrombocytopenia and anaemia occur less frequently, and are rarely seen without a preceding neutropenia.",Thrombocytopenia and anaemia are less common and are rarely observed without prior neutropenia.,0.0,smt,3,3_smt,-0.024281874299049377|-0.008391765877604485|0.018069863319396973|0.021402711048722267|0.03615891933441162
452,"Kivexa darf bei Patienten mit schwerer Einschränkung der Leberfunktion oder bei Patienten, die möglicherweise überempfindlich (allergisch) auf Lamivudin, Abacavir oder einen der anderen Bestandteile reagieren, nicht angewendet werden.","Kivexa should not be used in patients with severe hepatic impairment, or in patients who may be hypersensitive (allergic) to lamivudine, abacavir or any of the other ingredients.","Kivexa should not be used in patients with severe liver disease or in patients who may be hypersensitive (allergic) to lamivudine, abacavir or any of the other ingredients.","Kivexa should not be used in patients with severe hepatic impairment, or in patients who may be hypersensitive (allergic) to lamivudine, abacavir or any of the other ingredients.",0.0,smt,3,3_smt,-0.02725606970489025|-0.022696545347571373|0.011361885815858841|-0.00650830427184701|0.024784322828054428
453,Wie ist Insulin Human Winthrop Basal anzuwenden? 4.,How to use Insulin Human Winthrop Basal 4.,How to use Insulin Human Winthrop Basal 4.,How to use Insulin Human Winthrop Basal 4.,0.0,smt,3,3_smt,-0.02438957244157791|-0.019802184775471687|0.01256963424384594|0.018893808126449585|0.028892146423459053
454,Die gleichzeitige Anwendung von Vectibix mit IFL oder Bevacizumab und Chemotherapie- Kombinationen wird nicht empfohlen (siehe Abschnitte 4.4 und 4.8).,Concomitant use of Vectibix with IFL or bevacizumab and an aroma is not recommended (see sections 4.4 and 4.8).,Concomitant use of Vectibix and IFL or bevacizumab and chemotherapy combinations is not recommended (see sections 4.4 and 4.8).,Concomitant use of Vectibix with IFL or bevacizumab and a chemotherapy combination is not recommended (see sections 4.4 and 4.8).,0.1304347826086956,smt,3,3_smt,0.007846426218748093|0.026062246412038803|0.0721311941742897|0.0503939688205719|0.05928667634725571
455,"Das Befassungsverfahren gemäß Artikel 29 Absatz 4 der Richtlinie 2001/83/EG wurde am 3. März 2008 beim CHMP beantragt, weil Deutschland und Frankreich den Antrag als nicht akzeptabel betrachteten.","The referral procedure under Article 29 (4) of Directive 2001 / 83 / EC, as amended, was renewed on 3 March 2008, the CHMP requested in Germany and France, the application for not.","The referral under article 29(4) of directive 2001/ 83/ EC was notified to the CHMP on March 3rd, 2008 as Germany and France did not consider the application acceptable.","The referral procedure under Article 29 Paragraph 4 of the Directive 2001/83/EC was amended on 3 March 2008, the CHMP because Germany and France considered the request unacceptable.",0.4117647058823529,smt,3,3_smt,0.10629256814718246|0.17487655580043793|0.2274787873029709|0.19114501774311066|0.17315411567687988
456,"Doxorubicin kann seine antitumorigenen und toxischen Wirkungen über eine Reihe von Mechanismen ausüben, einschließlich Hemmung der Topoisomerase II, Interkalation zwischen DNS Basenpaaren, Bildung freier Radikale und Membranbindung.","Doxorubicin may perform its antitumorigenen and toxic effects over a number of mechanisms, including inhibition of both type II, implantable cardiac defibrillator (between the formation of a patient and Membranbindung.","Doxorubicin may exert its antitumour and toxic effects by a number of mechanisms including inhibition of topoisomerase II, intercalation with DNA and RNA polymerases, free radical formation and membrane binding.","Doxorubicin may perform its antitumorigenen and toxic effects over a number of mechanisms, including inhibition of both type II, including intercalation between DNA basepairs, the formation of free radical and membrane binding.",0.2777777777777778,smt,3,3_smt,0.3665630519390106|0.45669493079185486|0.27002739906311035|0.48460736870765686|0.43368247151374817
457,"In klinischen Untersuchungen kam es in seltenen Fällen (0,8%) zu Lymphadenopathie.",In clinical trials there was rarely (0.8%) lymphadenopathy.,Lymphadenopathy was uncommonly (0.8%) reported in clinical trials.,In clinical trials there was rarely (0.8%) lymphadenopathy.,0.0,smt,3,3_smt,0.04105154797434807|0.07114484161138535|0.060668155550956726|0.1264028549194336|0.09244217723608017
458,"Allerdings ist bei aktiver Teilnahme am Straßenverkehr oder Bedienen von Maschinen zu berücksichtigen, dass unter antihypertensiver Therapie gelegentlich Schwindel oder Müdigkeit auftreten können, insbesondere bei Behandlungsbeginn oder Dosiserhöhung.","However, should be taken into account in active driving or using machines that combines therapy occasionally dizziness or weariness may occur, especially at the beginning of treatment with the increase in dose.","However, when driving vehicles or operating machinery it must be borne in mind that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy, in particular during initiation of treatment or when the dose is increased.","However, it should be taken into account that occasionally dizziness or weariness may occur while driving or using machines under antihypertensive therapy, especially at the beginning of treatment or with an increase in dosage.",0.2702702702702703,smt,3,3_smt,0.17024222016334534|0.24383796751499176|0.22285732626914978|0.3100229501724243|0.27375322580337524
459,Enviage sollte nicht zusammen mit Grapefruitsaft eingenommen werden.,Enviage should not be taken with grapefruit juice.,Grapefruit juice should not be taken together with Enviage.,Enviage should not be taken with grapefruit juice.,0.0,smt,3,3_smt,-0.013794634491205215|-0.008978543803095818|0.014450853690505028|0.024175245314836502|0.041200682520866394
460,3 Blisterstreifen mit 10 Filmtabletten in PVC/PVDC/Aluminium Blisterpackungen.,3 blister cards of 10 film-coated tablets in PVC / PVDC / Aluminium blisters.,3 blister cards of 10 film-coated tablets in PVC/ PVDC/ Aluminium blisters.,3 blister cards of 10 film-coated tablets in PVC / PVDC / aluminium blisters.,0.0,smt,3,3_smt,-0.03455816209316254|-0.03297538310289383|0.013280701823532581|6.523355841636658e-05|0.021109020337462425
461,"Auf Grund seiner pharmakodynamischen Eigenschaften ist es 22 jedoch unwahrscheinlich, dass Irbesartan Hydrochlorothiazide BMS diese Fähigkeit beeinflusst.","Based on its pharmacodynamic properties, Irbesartan Hydrochlorothiazide BMS is unlikely to affect this ability.","Based on its pharmacodynamic properties, Irbesartan Hydrochlorothiazide BMS is unlikely to affect this ability.","Based on its pharmacodynamic properties, Irbesartan Hydrochlorothiazide BMS is unlikely to affect this ability.",0.0,smt,3,3_smt,-0.026114143431186676|-0.011329485103487968|0.013549243099987507|0.020731167867779732|0.0370103195309639
462,Ein Rückgang ihrer hypernormalen eGFR (geschätzte glomeruläre Filtrationsrate) wurde innerhalb von 6 Monaten nach Einleitung der Replagal- Therapie beobachtet.,A reduced their hypernormalen of extensive renal damage (eGFR (estimated glomerular filtration rate) was observed within 6 months after initiating Replagal therapy.,Reduction in their hypernormal eGFRs was observed within 6 months of initiating Replagal therapy.,A reduced hypernormalen eGFR (estimated glomerular filtration rate) was observed within 6 months after initiating Replagal therapy.,0.3,smt,3,3_smt,0.16116414964199066|0.2723252475261688|0.23661261796951294|0.3165327310562134|0.24281281232833862
463,Was ist Advagraf?,What is Advagraf?,What is Advagraf?,What is Advagraf?,0.0,smt,3,3_smt,-0.07681221514940262|-0.08083611726760864|0.008508414961397648|-0.05798017233610153|-0.02066769264638424
464,Eine gleichzeitige Gabe von 10 mg Ketamin/kg mit 40 Mikrogramm Dexmedetomidin/kg kann zu Tachykardie führen.,Concomitant administration of 10 mg ketamine / kg with 40 micrograms dexmedetomidine / kg may lead to tachycardia.,A dose of 10 mg ketamine/ kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.,Concomitant administration of 10 mg ketamine / kg with 40 micrograms dexmedetomidine / kg may lead to tachycardia.,0.0,smt,3,3_smt,-0.004156084731221199|0.007071328349411488|0.013928400352597237|0.03395918011665344|0.04691062867641449
465,Beim Myelom beeinflusst Bortezomib die Fähigkeit der Myelomzellen mit dem Knochenmarksmikromilieu in Wechselwirkung zu treten.,When myeloma bortezomib does not affect the ability of the individual with the Knochenmarksmikromilieu.,"In myeloma, bortezomib affects the ability of myeloma cells to interact with the bone marrow microenvironment.","In myeloma, bortezomib affects the ability of myeloma cells to interact with the bone marrow microenvironment.",0.6666666666666666,smt,3,3_smt,0.34366536140441895|0.44327402114868164|0.45741745829582214|0.4781218469142914|0.3941706418991089
466,In diesen Fällen sollte die Anwendung des Pflasters beendet werden.,"In these cases, the use of the patch should be discontinued.",Use of the patch should be discontinued if this occurs.,"In these cases, the use of the patch should be discontinued.",0.0,smt,3,3_smt,-0.0047720642760396|-0.0071752239018678665|0.014229131862521172|0.047369424253702164|0.04661133140325546
467,Welche Informationen werden für ATryn noch erwartet?,is still awaited for ATryn expected to work?,What information is still awaited for ATryn?,What information is still awaited for ATryn?,0.5,smt,3,3_smt,0.21119187772274017|0.3215833008289337|0.5603036284446716|0.43230533599853516|0.2977156937122345
468,"Sollte ein Extravasat auftreten, muss der betroffene Bereich mindestens 3 Monate lang vor Licht geschützt werden.","If extravasation occur, the area must be discontinued for at least 3 months to protect from light.","If extravasation occurs, protect the area from light for at least 3 months.","If extravasation occur, the area must be discontinued for at least 3 months to protect from light.",0.0,smt,3,3_smt,0.012364430353045464|0.03689000383019447|0.056925948709249496|0.07380589097738266|0.07439891993999481
469,Warum wurde Wilzin zugelassen?,Why has Wilzin been approved?,Why has Wilzin been approved?,Why has Wilzin been approved?,0.0,smt,3,3_smt,-0.0666176825761795|-0.06694623082876205|0.008496238850057125|-0.045485638082027435|-0.009677918627858162
470,Numerisch zeigten die Einzelkomponenten des primären Endpunktes bereits einen Trend zugunsten der primären PCI allein:,Numerisch the individual components of the primary endpoint already taking a trend in favour of primary PCI alone:,Numerically all of the components of the clinical composite endpoint were in favour of the PCI only regimen: death:,Numerically the components of the clinical composite endpoint were in favour of the PCI only regimen:,0.6470588235294118,smt,3,3_smt,0.21174119412899017|0.3070792257785797|0.24390463531017303|0.373371958732605|0.31188124418258667
471,"Der Ausschuss empfahl, bei Solacyl 100% Pulver zur Herstellung einer Lösung zum Einnehmen für Kälber und Schweine dem Ergebnis des gemeinschaftlichen Verfahrens gemäß Artikel 35 Absatz 2 für Natriumsalicylat-haltige Pulver zur Herstellung einer Lösung zum Einnehmen zu folgen.",The Committee recommended that in Solacyl 100% powder for oral solution for calves and pigs outcome of the Community referral under Article 35 (2) for Natriumsalicylat-haltige powder for oral solution.,It was recommended that Solacyl 100% powder for oral solution for calves and pigs should follow the outcome of the Community Referral according to Article 35(2) for sodium salicylate-containing oral soluble powders.,It was recommended that Solacyl 100% powder for oral solution for calves and pigs should follow the outcome of the Community Referral according to Article 35(2) for sodium salicylate-containing oral soluble powders.,0.3513513513513513,smt,3,3_smt,0.11786166578531265|0.18565651774406433|0.2238185852766037|0.22669605910778046|0.18244187533855438
472,41 Irbesartan: Bei klinisch relevanten Dosen gibt es keine Hinweise auf eine anomale systemische Toxizität oder Toxizität am Zielorgan.,"41 Irbesartan: clinically relevant doses, there was no evidence of abnormal systemic or target organ toxicity at.",Irbesartan: there was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses.,"41 Irbesartan: clinically relevant doses, there was no evidence of anomalous systemic toxicity or toxicity to the target organ.",0.2727272727272727,smt,3,3_smt,0.021165715530514717|0.05502723902463913|0.11853727698326111|0.0887693390250206|0.07997272908687592
473,- Dieses Arzneimittel wurde Ihnen persönlich verschrieben und darf nicht an Dritte weiter.,- This medicine has been prescribed for you personally and you should not pass it on to others.,- This medicine has been prescribed for you. Do not pass it on to others.,- This medicine has been prescribed for you personally and you should not pass it on to others.,0.0,smt,3,3_smt,-0.014850795269012451|-0.019302068278193474|0.017051726579666138|0.00860731303691864|0.03216301649808884
474,Wichtige Informationen über bestimmte sonstige Bestandteile von Lansoprazol-CT 15 mg Dieses Arzneimittel enthält Sucrose.,Important information about some of the ingredients of Lansoprazol-CT This medicine contains sucrose.,Important information about some of the ingredients of Lansoprazol-CT This medicine contains sucrose.,Important information about some of the ingredients of Lansoprazol-CT: This medicine contains sucrose.,0.0666666666666666,smt,3,3_smt,-0.02698340453207493|-0.02957955189049244|0.012033694423735142|0.00021286914125084877|0.025990068912506104
475,Beim Einsatz als pharmakokinetischer Verstärker hängen die Nebenwirkungen von Norvir von den anderen verabreichten antiviralen Arzneimitteln ab.,When as a pharmacokinetic enhancer will be dependent on the side effects of Norvir are administered in the other antiviral medicines.,"When it is used as a pharmacokinetic enhancer, the side effects of Norvir depend on the other antiviral medicine being taken.","When it is used as a pharmacokinetic enhancer, the side effects of Norvir depend on the other antiviral medicine being taken.",0.4782608695652174,smt,3,3_smt,0.14822286367416382|0.21020092070102692|0.3238663077354431|0.26325327157974243|0.22749371826648712
476,"98-100%) bei Patienten, die pegyliertes Interferon alfa-2b (mit oder ohne Rebetol) erhielten.",98-100%) for patients receiving pegylated interferon alfa-2b (with or without Rebetol).,98-100%) for patients receiving pegylated interferon alfa-2b (with or without Rebetol).,98-100%) for patients receiving pegylated interferon alfa-2b (with or without Rebetol).,0.0,smt,3,3_smt,-0.0413263738155365|-0.043113432824611664|0.010515696369111538|-0.017812056466937065|0.01452333852648735
477,"Zerit ist ein Arzneimittel, das den Wirkstoff Stavudin enthält.",Zerit is a medicine that contains the active substance stavudine.,Zerit is a medicine containing the active substance stavudine.,Zerit is a medicine that contains the active substance stavudine.,0.0,smt,3,3_smt,-0.058085255324840546|-0.06470176577568054|0.00917687825858593|-0.0330987386405468|0.0054361168295145035
478,Die benannten Berichterstatter und Mitberichterstatter waren: Dr. P. Neels bzw. Dr.,"The Rapporteur and Co-Rapporteur appointed were Dr P. Neels, respectively, and Dr.",The Rapporteur and Co-Rapporteur appointed were:,The Rapporteur and Co-Rapporteur appointed were Dr P. Neels and Dr.,0.2307692307692307,smt,3,3_smt,0.0738697201013565|0.08931787312030792|0.09814092516899109|0.1441870480775833|0.11693692952394485
479,Ziehen Sie bei der Aufdosierungspackung die Löung nur bis zur Markierung auf der Spritze auf:,"Withdraw the titration pack for administration by injection, and only up to a mark on the syringe:","With the titration pack, withdraw solution only up to the mark on the syringe:",Withdraw the solution from the titration pack up to the mark on the syringe:,0.6,smt,3,3_smt,0.049661993980407715|0.0807461217045784|0.17969532310962677|0.14430464804172516|0.11700993776321411
480,"Dies kann bedeuten, dass eine Infektion vorliegt.",This may mean that an infection.,This may mean there is an infecti on.,This may mean that there is an infection.,0.2222222222222222,smt,3,3_smt,0.12555883824825287|0.13547495007514954|0.1417471170425415|0.21270747482776642|0.18103648722171783
481,Eine Attacke dauert üblicherweise 2 bis 5 Tage.,One attack usually lasts between 2 to 5 days.,An attack usually lasts between 2 to 5 days.,One attack usually lasts between 2 to 5 days.,0.0,smt,3,3_smt,-0.05276838317513466|-0.05870968848466873|0.00997669156640768|-0.029138019308447838|0.0018627773970365524
482,"Bei der Gaucher-Krankheit des Typs 1 wird eine Substanz, Glukosylzeramid, nicht aus Ihrem Körper entfernt.","In type 1 Gaucher disease is a Glukosylzeramid, not be removed from your body.","In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body.","In type 1 Gaucher disease, the substance glucosylceramide is not removed from your body.",0.375,smt,3,3_smt,0.23542708158493042|0.30540210008621216|0.32645609974861145|0.39506131410598755|0.2977018654346466
483,Besondere Vorsicht bei der Einnahme von Revlimid ist erforderlich Bitte sprechen Sie in den folgenden Situationen mit Ihrem Arzt:,Take special care with Revlimid Please speak in the following situations with your doctor.,82 Take special care with Revlimid Please talk to your doctor in the following situations:,Take special care with Revlimid. Please speak in the following situations with your doctor.,0.0625,smt,3,3_smt,0.02436021715402603|0.021096251904964447|0.12056002765893936|0.07924535125494003|0.07481106370687485
484,APTIVUS sollte nicht bei Patienten unter 18 Jahren angewendet werden.,APTIVUS is not recommended for use in patients below 18 years of age.,APTIVUS should not be used by patients under 18 years of age.,APTIVUS should not be used in patients below 18 years of age.,0.3076923076923077,smt,3,3_smt,-0.024208005517721176|-0.022951459512114525|0.012524091638624668|0.0016946429386734962|0.030120808631181717
485,Bitte befolgen Sie alle Anweisungen Ihres Arztes sorgfältig.,Please follow the advice carefully.,94 Follow your doctor’ s instructions carefully.,Please follow the advice carefully.,0.0,smt,3,3_smt,0.06366832554340363|0.07324452698230743|0.04233786091208458|0.14623382687568665|0.13449443876743317
486,Keine klinisch relevante pharmakokinetische Änderung.,No clinically significant pharmacokinetic variation.,No clinically significant pharmacokinetic change.,No clinically significant pharmacokinetic variation.,0.0,smt,3,3_smt,-0.05826259404420853|-0.05158240348100662|0.009937615133821964|-0.019281430169939995|0.013370935805141926
487,Örtlich begrenzte Infektionen mit Carbapenem-resistenten Erregern wurden in der Europäischen Gemeinschaft berichtet.,local infections with Carbapenem-resistenten pathogens have been reported in the European Community.,Localized clusters of infections due to carbapenem-resistant organisms have been reported in the European Union.,Local infections with Carbapenem-resistant pathogens have been reported in the European Community.,0.0769230769230769,smt,3,3_smt,0.12073457986116409|0.23491625487804413|0.09949351847171783|0.2582406997680664|0.19057157635688782
488,"ge Störung hatte, um das potenzielle Risiko bei einer Rimonabant-Behandlung abzuschätzen.","au suicidal thoughts, outweighs the potential risk for suicide.",or order to evaluate the potential risks with rimonabant treatment.,"suicidal thoughts, in order to estimate the potential wih a rimonabant treatment.",0.6428571428571429,smt,3,3_smt,0.31833165884017944|0.35934266448020935|0.37680643796920776|0.43030574917793274|0.38742929697036743
489,"Einhaltung der empfohlenen Dosierung für Ovitrelle, Anwendung des empfohlenen Behandlungsschemas und sorgfältige Überwachung der Therapie minimieren die Inzidenz für ein ovarielles Überstimulationssyndrom oder eine Mehrlingsschwangerschaft.","9 Adherence to recommended Ovitrelle dosage, regimen of administration and careful monitoring of therapy will minimise the incidence of ovarian hyperstimulation syndrome, the ovarian hyperstimulation syndrome and multiple pregnancy.","Adherence to recommended Ovitrelle dosage, regimen of administration and careful monitoring of therapy will minimise the incidence of ovarian hyperstimulation and multiple pregnancy.","9 Adherence to recommended Ovitrelle dosage, regimen of administration and careful monitoring of therapy will minimise the incidence of ovarian hyperstimulation syndrome or a multiple pregnancy.",0.2142857142857142,smt,3,3_smt,0.039598193019628525|0.07970792055130005|0.10408782213926315|0.118734210729599|0.09360432624816895
490,Blutzuckerwert stark absinken (Hypoglykämie).,Blutzuckerwert severely may become too low (hypoglycaemia).,sugar may become too low (hypoglycaemia).,Blood sugar level may severely decrease (hypoglycaemia).,0.6,smt,3,3_smt,0.020545165985822678|0.04135732352733612|0.1760970801115036|0.0821673572063446|0.06423082947731018
491,Von den 42 Patienten der historischen Vergleichsgruppe war hingegen nur ein Patient mit 18 Monaten noch am Leben.,"Of the 42 patients in the historical comparison group However, this was only one patient with 18 months is still alive.","In contrast, only one of the 42 patients in the historical comparison group was alive at 18 months of age.","Of the 42 patients in the historical comparison group, however, only one patient wsa still alive after 18 months.",0.3181818181818182,smt,3,3_smt,0.15749764442443848|0.22831077873706818|0.21380621194839478|0.2955239713191986|0.23248369991779327
492,"Der wirksame Bestandteil, der in 1 Dosis (0,5 ml) Fendrix enthalten ist, ist:","The active ingredient, contained in 1 dose (0.5 ml) of Fendrix is:",The active substance contained in 1 dose (0.5 ml) of Fendrix is:,"The active ingredient, contained in 1 dose (0.5 ml) of Fendrix is:",0.0,smt,3,3_smt,-0.05341542512178421|-0.06008554995059967|0.009904191829264164|-0.032793182879686356|0.005020006559789181
493,Wie wird Duloxetine Boehringer Ingelheim angewendet?,What Duloxetine Boehringer Ingelheim used for?,How is Duloxetine Boehringer Ingelheim used?,What is Duloxetine Boehringer Ingelheim used for?,0.125,smt,3,3_smt,0.00426503038033843|0.00863055419176817|0.03652462735772133|0.05968558043241501|0.05175158381462097
494,"Wenn Sie schwanger sind, eine Schwangerschaft planen oder ein Kind stillen: Bitte fragen Sie Ihren Arzt um Rat.","If you are pregnant, planning a pregnancy or breast-feeding: please contact your doctor for advice before taking any medicine.","If you are pregnant, planning a pregnancy or breast-feeding: please contact your doctor for advice.","If you are pregnant, planning a pregnancy or breast-feeding: please contact your doctor for advice.",0.2222222222222222,smt,3,3_smt,-0.015346504747867584|-0.015589671209454536|0.021716805174946785|0.008243050426244736|0.0375872477889061
495,en (absolute Bioverfügbarkeit 100%).,ris and rapidly absorbed (absolute bioavailability of 100%).,"ho Absorption After subcutaneous dosing, fondaparinux is completely and rapidly absorbed (absolute bioavailability 100%).",(absolute bioavailability of 100%).,0.5,smt,3,3_smt,0.051712341606616974|0.09899324178695679|0.1508963257074356|0.13837930560112|0.11108382791280746
496,"Wie alle Arzneimittel kann STAMARIL Nebenwirkungen haben, die aber nicht bei jedem auftreten müssen.","Like all medicines, STAMARIL can have side effects, although not everybody gets them.","Like all medicines, STAMARIL can cause side effects, although not everybody gets them.","Like all medicines, STAMARIL can have side effects, although not everybody gets them.",0.0,smt,3,3_smt,-0.03977232798933983|-0.047277405858039856|0.009998607449233532|-0.022129207849502563|0.013053120113909245
497,"38/46 Selten (mehr als 1 von 10.000 Patienten, aber weniger als 1 von 1.000 Patienten):","38 / 44 Rare (more than 1 in every 10,000 patients, but less than 1 in every 1,000 patients):","Rare (more than 1 out of 10.000, but less than 1 out of 1.000 patients):","38 / 44 Rare (more than 1 in every 10,000 patients, but less than 1 in every 1,000 patients):",0.0,smt,3,3_smt,0.009676694869995117|0.0026481160894036293|0.01600351370871067|0.03608940169215202|0.04920481890439987
498,"Lesen Sie die gesamte Packungsbeilage, einschließlich der Hinweise zur Handhabung von Insulin Human Winthrop Rapid, Fertigpen, SoloStar, sorgfältig durch, bevor Sie mit der Anwendung dieses Arzneimittels beginnen.","Read all of this leaflet carefully, including the Instructions for Use of Insulin Human Winthrop Rapid, pre-filled pen, SoloStar, before you start using this medicine.","Read all of this leaflet carefully, including the Instructions for Use of Insulin Winthrop Rapid, pre-filled pen, SoloStar, before you start using this medicine.","Read all of this leaflet carefully, including the Instructions for Use of Insulin Human Winthrop Rapid, pre-filled pen, SoloStar, before you start using this medicine.",0.0,smt,3,3_smt,-0.006595072336494923|-0.005231047049164772|0.020500922575592995|0.02185300923883915|0.04230058193206787
499,Es besteht keine lineare Beziehung zwischen Dosis und Plasmaspiegel.,There is no a linear relationship between dose and plasma levels.,There is no linear relationship between doses and plasma levels.,There is no a linear relationship between dose and plasma levels.,0.0,smt,3,3_smt,-0.04401769861578941|-0.052266351878643036|0.011260720901191235|-0.013383574783802032|0.012286737561225891
500,Eine ähnliche Wechselwirkung mit Astemizol ist wahrscheinlich.,A similar interaction with astemizole is likely.,- Interaction with saquinavir/ ritonavir not evaluated.,A similar interaction with astemizole is likely.,0.0,smt,3,3_smt,0.1439874768257141|0.19809840619564056|0.06399530172348022|0.24495933949947357|0.1936488151550293
501,Aufgrund der hohen interindividuellen Variabilität waren diese Unterschiede nicht statistisch signifikant.,Due to the high inter-subject variability in these differences were not statistically significant.,"However, due to high inter-subject variability, these differences were not statistically significant.",Due to the high inter-subject variability in these differences were not statistically significant.,0.0,smt,3,3_smt,0.019886640831828117|0.04031703621149063|0.07675034552812576|0.09565132111310959|0.0778685063123703
502,Kinder und Jugendliche (im Alter von 2 bis 18 Jahren): Die empfohlene Dosis Mycophenolatmofetil beträgt 600 mg/m2 zweimal täglich oral verabreicht (bis zu einer maximalen Tagesdosis von 2 g).,Children and adolescents (aged 2 to 18 years): the recommended dose of mycophenolate mofetil is 600 mg / m2 administered orally twice daily (up to a maximum of 2 g daily).,Children and adolescents (aged 2 to 18 years): the recommended dose of mycophenolate mofetil is 600 mg/ m2 administered orally twice daily (up to a maximum of 2 g daily).,Children and adolescents (aged 2 to 18 years): the recommended dose of mycophenolate mofetil is 600 mg / m2 administered orally twice daily (up to a maximum of 2 g daily).,0.0,smt,3,3_smt,-0.041579149663448334|-0.04639261215925217|0.010491075925529003|-0.027071306481957436|0.009215408004820347
503,199 Bei Patienten mit eingeschränkter Nierenfunktion kann der Insulinbedarf infolge des verminderten Insulinabbaus verringert sein.,"199 In patients with renal impairment, insulin requirements may be diminished due to reduced.","In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.","199 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin degradation.",0.1111111111111111,smt,3,3_smt,-0.018124835565686226|-0.010445451363921165|0.08206355571746826|0.03166325390338898|0.03911890089511871
504,Wenn die Behandlung abgebrochen wird:,If the treatment is stopped:,If treatment is discontinued:,If the treatment is stopped:,0.0,smt,3,3_smt,-0.013710912317037582|-0.013782637193799019|0.015111406333744526|0.02915947698056698|0.04540316015481949
505,"Derartige Untersuchungen deuten darauf hin, dass das Geschlecht die Pharmakokinetik von Rufinamid nicht in klinisch signifikantem Ausmaß beeinflusst.",Such studies suggest that that gender on the pharmacokinetics of rufinamide is not a clinically significant extent.,Such evaluations indicate that sex does not affect the pharmacokinetics of rufinamide to a clinically relevant extent.,Such studies suggest that gender has no clinically relevant effect on the pharmacokinetics of rufinamide.,0.5625,smt,3,3_smt,0.07178977876901627|0.11354098469018936|0.25015395879745483|0.15356262028217316|0.13890340924263
506,Die Nebenwirkungen sollten im Hinblick auf den chirurgischen Eingriff interpretiert werden.,The adverse reactions should be interpreted with regard to the surgery.,The adverse reactions should be interpreted within the surgical setting.,The adverse reactions should be interpreted with regard to the surgery.,0.0,smt,3,3_smt,0.06466397643089294|0.0671265497803688|0.11867354065179825|0.16600975394248962|0.13973745703697205
507,Bei richtiger Anwendung ist nach der Beendigung des Auftragens noch etwas Gel auf der Oberfläche der Läsion sichtbar.,"In 20, use of disengaging a gel on the lesion seen.",Proper application will leave some gel visible on the surface of the lesion when you are finished.,"If used correctly, there is a gel on the lesion after the application.",0.6,smt,3,3_smt,0.29297199845314026|0.43408632278442383|0.5764005184173584|0.4723763167858124|0.397357314825058
508,Die Injektionsdauer liegt zwischen 2 und 4 Minuten.,The Injektionsdauer between 2 and 4 minutes.,The duration of injection is between 2 and 4 minutes.,The duration of injection is between 2 and 4 minutes.,0.3636363636363636,smt,3,3_smt,0.04548335820436478|0.058082498610019684|0.10169089585542679|0.09879186749458313|0.0907415822148323
509,"Es wurde ein Fall einer allergischen Reaktion beobachtet, die wahrscheinlich in einem Zusammenhang mit der Atosiban-Behandlung stand.",One case of allergic reaction likely to have been observed in association with the Atosiban-Behandlung.,"One case of allergic reaction was reported, which was considered to be probably related to atosiban.","One case of allergic reaction has been observed, which was probably in connection with the atosiban treatment.",0.4736842105263157,smt,3,3_smt,0.13847778737545013|0.22641529142856598|0.16883571445941925|0.2838638722896576|0.2029866874217987
510,"Weichkapseln • Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, Vereinigtes Königreich.","soft capsules • Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, United Kingdom.","Soft capsules • Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, United Kingdom Manufacturing authorisation issued on 30 June 1995 by the Medicine Control Agency, Market Towers, 1 Nine Elms Lane, Vauxhall, London SW8 5NQ, United Kingdom.","soft capsules • Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, United Kingdom.",0.0,smt,3,3_smt,0.056501418352127075|0.07909651100635529|0.0334487184882164|0.10220801830291748|0.10495015978813171
511,- wenn Sie bestimmte seltene erbliche Augenerkrankungen haben (wie Retinitis pigmentosa).,- if you are taking certain rare hereditary disorders (such as retinitis pigmentosa).,− If you have certain rare inherited eye diseases (such as retinitis pigmentosa).,- if you have certain rare hereditary disorders (such as retinitis pigmentosa).,0.1333333333333333,smt,3,3_smt,-0.02703619934618473|-0.02395722083747387|0.040571168065071106|0.0075261858291924|0.030358433723449707
512,"Rosa kapselförmige, bikonvexe Filmtabletten, die auf einer Seite mit der Prägung GXLL7 versehen sind.","Pink, capsule-shaped yellow, hexagonal, biconvex, film-coated tablets, engraved on one side with GXLL7.","Pink film coated, capsule shaped, biconvex tablets, marked with GXLL7 on one side.","Pink, capsule-shaped yellow, hexagonal, biconvex, film-coated tablets, engraved on one side with GXLL7.",0.0,smt,3,3_smt,0.030133217573165894|0.05354701727628708|0.03208785131573677|0.10256260633468628|0.08136496692895889
513,(Siehe Fachinformation zu Ribavirin Kapseln zur Dosierung von Ribavirin Kapseln und zu den Richtlinien für die Dosierungsanpassung bei der Kombinationstherapie.,"(See ribavirin capsule SPC for dose of ribavirin capsules and guidelines for the management of patients, no combination therapy.", 45 (See ribavirin capsule SPC for dose of ribavirin capsules and dosage modification guidelines for combination therapy.,"(See ribavirin capsule SPC for dose of ribavirin capsules and guidelines for the management of patients, no combination therapy.",0.0,smt,3,3_smt,0.07416900247335434|0.0942620187997818|0.1416490375995636|0.14512741565704346|0.1168079748749733
514,Während und kurz nach der ILP werden Ihr Blutdruck und Ihr Kreislauf sorgfältig überwacht.,during and shortly after the ILP your blood pressure and your circulation should be monitored carefully.,Careful monitoring of your blood pressure and circulation will be performed during the ILP and for a short time afterwards.,During and shortly after the ILP your blood pressure and your circulation should be monitored carefully.,0.0,smt,3,3_smt,0.03529231250286102|0.0492718443274498|0.0352327860891819|0.11410551518201828|0.10699548572301865
515,intrakranielle Läsionen inaktiv sein und eine Tumorbehandlung muss abgeschlossen sein.,intracranial lesions may be inactive and must be matched.,therapy complete prior to the institution of growth hormone therapy.,intracranial lesions may be inactive and treatment for tumours must be completed.,0.3076923076923077,smt,3,3_smt,0.3132511079311371|0.44613006711006165|0.3432792127132416|0.4609720706939697|0.40706899762153625
516,Alle Hauptmetaboliten haben sich als pharmakologisch inaktiv erwiesen.,All metabolite have been shown to be pharmacologically inactive.,All major metabolites have been shown to be pharmacologically inactive.,All metabolites have been shown to be pharmacologically inactive.,0.1,smt,3,3_smt,-0.020986154675483704|-0.015154266729950905|0.021122785285115242|0.018636340275406837|0.04000582545995712
517,Zur Therapie einer Überdosierung von Bondenza stehen keine speziellen Informationen zur Verfügung.,Treatment of overdose with Bondenza No specific information is available.,No specific information is available on the treatment of overdosage with Bondenza.,No specific information is available on the treatment of overdose with Bondenza .,0.2307692307692307,smt,3,3_smt,0.01554676704108715|0.04126419126987457|0.04453514143824577|0.08083607256412506|0.07620873302221298
518,"Anfangsdosis Die empfohlene Anfangsdosis beträgt 2,5 mg TRITACE einmal täglich.",The recommended initial dose is 2.5 mg of TRITACE once daily.,Starting dose: The recommended initial dose is 2.5 mg of TRITACE once daily.,The recommended initial dose is 2.5 mg of TRITACE once daily.,0.0,smt,3,3_smt,-0.022561177611351013|-0.02632901258766651|0.014340264722704887|0.0025745052844285965|0.03285352885723114
519,"Wird in dieser Gebrauchsinformation eine Nebenwirkung als „sehr häufig“ beschrieben, bedeutet dies, dass sie von mindestens 1 von 10 Patienten berichtet wurde.","When a side effect is listed as ""very common"" described, this means that it has been reported in at least 1 in 10 patients.",When a side effect is described as “common” this means that it has been reported in at least 1 in every 100 patients but less than 1 in every 10 patients.,"When a side effect is listed as ""very common"", this means that it has been reported in at least 1 in 10 patients.",0.074074074074074,smt,3,3_smt,0.019703369587659836|0.04403774440288544|0.05889129638671875|0.07532410323619843|0.06250335276126862
520,"Eine phänotypische Resistenz gegen Abacavir erfordert neben einer M184V- noch mindestens eine weitere Abacavir-bedingte Mutation, oder M184V mit mehreren TAMs.","One phenotypic resistance to abacavir requires neutralization of M184V for at least another Abacavir-bedingte, or M184V with TAMs.","Phenotypic resistance to abacavir requires M184V with at least one other abacavir-selected mutation, or M184V with multiple TAMs.","One phenotypic resistance to abacavir requires neutralization of M184V for at least another mutation conditional on Abacavir, or M184V with several TAMs.",0.2083333333333333,smt,3,3_smt,0.18596839904785156|0.29235804080963135|0.2615879476070404|0.3327152729034424|0.2600516974925995
521,"B. Methadon), Hormone wie Östrogene und Gestagene (z.","(e. g. methadone), hormones such as oestrogens and progestogens (e. g.",You should continue to use appropriate precautions to prevent this.,"(e. g. methadone), hormones such as oestrogens and progestogens (e. g.",0.0,smt,3,3_smt,0.2618568241596222|0.38694116473197937|0.14174006879329681|0.39250490069389343|0.3584045171737671
522,Der wichtigste sekundäre Endpunkt war eine MCyR im Verhältnis zur Tagesgesamtdosis bei den Imatinib-resistenten Patienten.,The primary secondary endpoint was MCyR at some of the total daily dose in imatinib-resistant patients.,The main secondary endpoint was MCyR by total daily dose level in the imatinib-resistant patients.,The primary secondary endpoint was an MCyR in proportion to the total daily dose in imatinib-resistant patients.,0.2222222222222222,smt,3,3_smt,0.03428112715482712|0.08477355539798737|0.07979613542556763|0.13260352611541748|0.09593507647514343
523,Was STOCRIN enthält • Jede STOCRIN-Filmtablette enthält als Wirkstoff 600 mg Efavirenz. • Die sonstigen Bestandteile des Tablettenkerns sind:,• Each STOCRIN-Filmtablette hard capsule contains 600 mg of the active substance efavirenz. • The other ingredients are the following:,"• Each STOCRIN film-coated tablet contains 600 mg of the active substance efavirenz. • The other ingredients of the tablet core are: croscarmellose sodium, microcrystalline cellulose, sodium laurilsulfate, hydroxypropylcellulose, lactose monohydrate and magnesium stearate. • The film coating contains: hypromellose (E464), titanium dioxide (E171), macrogol 400, yellow iron oxide (E172), and carnauba wax.",What STOCRIN contains • Each STOCRIN film-coated tablet contains 600 mg of the active substance efavirenz. • The other ingredients of the tablet core are:,0.3703703703703703,smt,3,3_smt,0.14097703993320465|0.1742672324180603|0.09797041863203049|0.21742691099643707|0.16948886215686798
524,"Tragen Sie (Name (Phantasiebezeichnung) nicht auf die Brüste auf, wenn Sie stillen.","Apply a thin layer of Invented Name is not on the breast, or if you are breast-feeding.",Do not apply < Invented Name > to the breasts if breast-feeding.,Do not apply Invented Name on the breast if you are breast-feeding.,0.6923076923076923,smt,3,3_smt,0.20386816561222076|0.275780588388443|0.37002432346343994|0.36117857694625854|0.2711886167526245
525,Keine Glukoselösung verwenden (siehe 6.2).,Do not use with glucose-containing solutions (see section 6.2).,Do not use with glucose-containing solutions (see 6.2).,Do not use with glucose-containing solutions (see section 6.2).,0.0,smt,3,3_smt,-0.04571753740310669|-0.0474376454949379|0.0104041937738657|-0.02028323896229267|0.009712530300021172
526,Hypertonie (siehe unter Abschnitt 4.4):,Hypertension (see section 4.4):,Hypertension (see section 4.4):,Hypertension (see section 4.4):,0.0,smt,3,3_smt,-0.06808449327945709|-0.06855508685112|0.009204015135765076|-0.04781884700059891|-0.007533468306064606
527,Ribavirin Teva darf nicht von stillenden Müttern eingenommen werden.,Ribavirin Teva should not be administered to breast- feeding mothers.,Ribavirin Teva must not be taken by women who are breast-feeding.,Ribavirin Teva should not be administered to breast- feeding mothers.,0.0,smt,3,3_smt,-0.011900698766112328|-0.01019497774541378|0.023653794080018997|0.03305346891283989|0.04001743346452713
528,Diese Veränderung ist möglicherweise dauerhaft.,This change may be permanently.,This change may be permanent.,This change may be permanent.,0.1666666666666666,smt,3,3_smt,-0.022550491616129875|-0.024114688858389854|0.10749907791614532|0.012407628819346428|0.02932725101709366
529,"Falls Hinweise auf ein Tumorwachstum vorliegen, ist Valtropin abzusetzen.","If evidence of neoplasia develops, Valtropin should be discontinued.",Valtropin should be discontinued if there is evidence of tumour growth.,"If there is evidence of neoplasia, Valtropin should be discontinued.",0.25,smt,3,3_smt,0.01193699985742569|0.022625111043453217|0.023940738290548325|0.0743463933467865|0.06389691680669785
530,Die übliche Dosis ist eine Tablette zweimal täglich.,The usual dose is one tablet taken twice a day.,The usual dose is one tablet taken twice daily.,The usual dose is one tablet taken twice a day.,0.0,smt,3,3_smt,-0.022903677076101303|-0.035577304661273956|0.00928697269409895|0.004291676450520754|0.02533463016152382
531,Die Impfung der Hühner erfolgt in Form einer intramuskulären Injektion in den Brustmuskel.,Vaccination of chickens aiming to a single intramuscular injection given by injection.,Vaccinate chickens by the intramuscular route into the breast.,Vaccination of chickens is carried out in the forom of a single intramuscular injection in the breast muscle.,0.5789473684210527,smt,3,3_smt,0.24141304194927216|0.3791954815387726|0.4772286117076874|0.4054402709007263|0.33769387006759644
532,"Dies entspricht einem Wert von 0,1 ml/kg Körpergewicht der 1,0-M-Lösung“.","This corresponds to a value of 0.1 ml / kg body weight of the 1,0-M-Lösung. """,This is equivalent to 0.1 ml/ kg BW of the 1.0 M solution”.,"This corresponds to a value of 0.1 ml / kg body weight of the 1.0 m solution. """,0.1578947368421052,smt,3,3_smt,0.20617182552814484|0.2512066066265106|0.15065352618694305|0.3602931797504425|0.2746405303478241
533,"Der Inhaber der Genehmigung für das Inverkehrbringen muss gewährleisten, dass das Pharmakovigilanz-System, wie beschrieben in der Version 4.0, vorgelegt in Modul 1.8.1 des Zulassungsantrags, besteht und funktioniert, sowohl bevor als auch während sich das Arzneimittel im Markt befindet.","The MAH must ensure that the system of pharmacovigilance, as described in version 4.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and both before and during the medicinal product is on the market.","The MAH must ensure that the system of pharmacovigilance, as described in version 4.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.","The MAH must ensure that the system of pharmacovigilance, as described in version 4.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functions both before and during the medicinal product is on the market.",0.0238095238095238,smt,3,3_smt,0.025527920573949814|0.04488072544336319|0.05467035621404648|0.07688354700803757|0.08880757540464401
534,"CANCIDAS kann zur Behandlung einer schwerwiegenden Pilzinfektion, der sog. invasiven Candidiasis verordnet werden.",CANCIDAS can be prescribed for the treatment of serious fungal infection called invasive candidiasis.,CANCIDAS may have been prescribed to treat a serious fungal infection called invasive candidiasis.,CANCIDAS can be prescribed for the treatment of serious fungal infection called invasive candidiasis.,0.0,smt,3,3_smt,-0.012107586488127708|-0.009919675067067146|0.016386153176426888|0.009529566392302513|0.042826712131500244
535,Während des Absetz-Zeitraums kehrten die Symptome der Psoriasis allmählich zurück; bis zum Rezidiv der Erkrankung vergingen median 3 Monate.,"During the Absetz-Zeitraums levels of psoriasis symptoms over time, time to relapse of the disease On a median of 3 months.","During the withdrawal period, symptoms of psoriasis gradually returned with a median time to disease relapse of 3 months.","During the weaning period, psoriasis symptoms returned gradually; until the Rezidiv of the disease went a median of 3 months.",0.4347826086956521,smt,3,3_smt,0.4123353064060211|0.5284320712089539|0.41989967226982117|0.574247419834137|0.47209614515304565
536,"Eine Durchstechflasche enthält 150 I.E. (entsprechend 11 Mikrogramm) Follitropin alfa (r-hFSH) und 75 I.E. (entsprechend 3,0 Mikrogramm) Lutropin alfa (r-hLH).",One vial contains 150 IU (equivalent to 11 micrograms) of follitropin alfa (r-hFSH) and 75 IU (equivalent to 3.0 micrograms) of lutropin alfa (r-hLH).,One vial contains 150 IU (equivalent to 11 micrograms) of follitropin alfa (r-hFSH) and 75 IU (equivalent to 3.0 micrograms) of lutropin alfa (r-hLH).,One vial contains 150 IU (equivalent to 11 micrograms) of follitropin alfa (r-hFSH) and 75 IU (equivalent to 3.0 micrograms) of lutropin alfa (r-hLH).,0.0,smt,3,3_smt,-0.03314635530114174|-0.03824494779109955|0.011834219098091125|-0.01714959926903248|0.02012874186038971
537,Weibliche Patienten im gebärfähigen Alter und ihre Partner müssen beide während der Behandlung und für weitere 4 Monate nach Abschluss der Behandlung eine wirksame Methode zur Empfängnisverhütung anwenden.,Females of childbearing potential and their partners must each use an effective contraceptive during treatment and for 4 months after treatment has been concluded. 4 months after treatment has been concluded.,125 childbearing potential and their partners must each use an effective contraceptive during treatment and for 4 months after treatment has been concluded.,Females of childbearing age and their partners must each use an effective contraceptive during treatment and for 4 months after treatment has been concluded.,0.36,smt,3,3_smt,0.030508480966091156|0.07106336951255798|0.18221914768218994|0.10465896129608154|0.09495054185390472
538,las FORCALTONIN ist nur auf ärztliche Verschreibung erhältlich.,tho FORCALTONIN can only be obtained with a prescription.,FORCALTONIN is only available from your doctor.,tho FORCALTONIN can only be obtained with a prescription.,0.0,smt,3,3_smt,0.07811447232961655|0.08927401900291443|0.12359294295310974|0.1282423436641693|0.12184139341115952
539,"In diesen Fällen ist möglicherweise eine Unterbrechung der Therapie erforderlich. 20 Treten während oder nach der Behandlung mit Cefuroximaxetil schwere Durchfälle auf, ist die Möglichkeit einer pseudomembranösen Kolitis in Betracht zu ziehen, die lebensbedrohlich sein kann.","In these cases, may be given to interrupting treatment is required. In patients who develop during or after treatment with Cefuroximaxetil who develop severe diarrhoea, the possibility of pseudomembranous colitis should be taken into account that can be life-threatening.","In patients who develop severe diarrhoea during or after use of cefuroxime axetil, the risk of life threatening pseudomembranous colitis should be taken into account.","In these cases, an interruption of the treatment may be required. Severe diarrhoea occurred during or after the treatment with Cefuroximaxetil, the possibility of pseudomembranous colitis should be taken into account, which can be life-threatening.",0.4,smt,3,3_smt,0.14387159049510956|0.19945111870765686|0.24278363585472107|0.2608442008495331|0.1981474757194519
540,"Zum Dosieren wird ein oraler Dispenser mit 30-mg, 45-mg und 60-mg-Einteilungen in der Packung mitgeliefert.","For antiadherent is an oral dispenser with 30-, 45-mg and 60-mg-Einteilungen is included in the pack.","For dosing, an oral dispenser with 30 mg, 45 mg and 60 mg graduations is provided in the box.","For dosing, an oral dispenser with 30, 45 and 60 mg grades is included in the pack.",0.35,smt,3,3_smt,0.30522310733795166|0.4008767008781433|0.2943146526813507|0.4127058684825897|0.36405879259109497
541,"Eine Studie an asymptomatischen Patienten zeigte, dass - im Vergleich zu Nüchterngabe - die Verfügbarkeit der Substanz ähnlich ist, wenn Stavudin zusammen mit einer standardisierten Mahlzeit mit hohem Fettanteil verabreicht wird. Dabei wird jedoch die Cmax gesenkt und Tmax verlängert.","A study of asymptomatic patients showed that compared to the fasted state - the availability of aseptic techniques are similar when stavudine is used together with a standardized meal with high fat meal. They will, however, reduced Cmax and Tmax.","A study in asymptomatic patients demonstrated that systemic exposure is similar while Cmax is lower and Tmax is prolonged when stavudine is administered with a standardised, high-fat meal compared with fasting conditions.","A study of asymptomatic patients showed that compared to the fasted state - the availability of aseptic techniques are similar when stavudine is used together with a standardized meal with high fat meal. They will, however, reduced Cmax and Tmax.",0.0,smt,3,3_smt,0.24883584678173065|0.3510958254337311|0.2361908257007599|0.3973933458328247|0.3256070017814636
542,"Der Filmüberzug besteht aus Opadry 00F44042 [Hypromellose, Macrogol 8000, Titandioxid (E171), Talkum und Eisen(III)-oxid (E172)].","The film-coating consists of Opadry 00F44042 [consists of [hypromellose, macrogol 8000, titanium dioxide (E171), talc and iron oxide (E172), yellow iron oxide (E172).","The film-coating consists of Opadry 00F44042 [hypromellose, macrogols (8000), titanium dioxide (E171), talc and ferric oxide red (E172)].","The film-coating consists of Opadry 00F44042 [hypromellose, macrogol 8000, titanium dioxide (E171), talc and iron oxide (E172)].",0.3703703703703703,smt,3,3_smt,0.02290845662355423|0.03739148750901222|0.08626741915941238|0.06609899550676346|0.06933410465717316
543,Die verfügbaren Daten deuten auf ein möglicherweise erhöhtes Risiko für Spontanaborte hin.,Available data indicate that there may be an increased risk of spontaneous abortion.,Available data indicates that there may be an increased risk of spontaneous abortion.,Available data indicate that there may be an increased risk of spontaneous abortion.,0.0,smt,3,3_smt,-0.03922940418124199|-0.040806375443935394|0.010939654894173145|-0.006077780853956938|0.018717946484684944
544,"Wie lange dauert es, bevor das Tier geschlachtet werden und das Fleisch für den menschlichen Verzehr verwendet werden kann (Wartezeit)?",What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?,Page 2/ 3 ©EMEA 2008 What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?,How long does it take before the animal can be slaughtered and the meat used for human consumption (withdrawal period)?,0.2608695652173913,smt,3,3_smt,0.005330837797373533|0.025176402181386948|0.061493515968322754|0.064490906894207|0.0705261379480362
545,Weitere Informationen über Xarelto:,2 / 3 Other information about Xarelto:,Other information about Xarelto:,2 / 3 Other information about Xarelto:,0.0,smt,3,3_smt,0.017830435186624527|0.028688127174973488|0.05101579427719116|0.052551914006471634|0.06783904880285263
546,Was ist Replagal?,What is Replagal?,What is Replagal?,What is Replagal?,0.0,smt,3,3_smt,-0.07011985778808594|-0.07760588079690933|0.008496025577187538|-0.054285258054733276|-0.013323673978447914
547,"Wenn Sie nach dieser Zeit nicht auf die Behandlung angesprochen haben, kann Ihre Behandlung für mindestens 18 Monate weitergeführt werden.","If you are not after this period who have responded to treatment, your treatment should continue for at least 18 months.","If you have not responded after this period, your treatment may carry on for at least 18 months.","If you have not responded to treatment after this period, your treatment should continue for at least 18 months.",0.1904761904761904,smt,3,3_smt,0.030559860169887543|0.04958237707614899|0.15384376049041748|0.09821534901857376|0.08177735656499863
548,"Es wurde überprüft, ob die Ergebnisse der beiden Tests übereinstimmten.",The results of the two tests up to a storage period.,The results obtained were compared to see if they agreed.,The results of the two tests were compared to see if they were in agreement.,0.5,smt,3,3_smt,0.26050180196762085|0.31945493817329407|0.47549551725387573|0.4202631711959839|0.3533864915370941
549,"21 In der ersten Phase nach der Transplantation sind folgende Parameter routinemäßig zu überwachen: Blutdruck, EKG, neurologischer Status, Sehvermögen, Blutzuckerspiegel (Nüchternwerte), Elektrolyte (insbesondere Kalium), Leber- und Nierenfunktion, hämatologische Parameter, Blutgerinnung und Plasmaproteine.","21 In the initial post-transplant period, the following parameters are: blood pressure, ECG, neurological and visual status, fasting blood glucose values, electrolytes (particularly potassium), liver and renal function, haematology parameters, coagulation values, and plasma protein determinations.","During the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations.","21 In the initial post-transplant period, the following parameters should be routinely monitored: blood pressure, ECG, neurological and visual status, fasting blood glucose values, electrolytes (particularly potassium), liver and renal function, haematology parameters, coagulation values, and plasma protein.",0.0980392156862745,smt,3,3_smt,0.0047212024219334126|0.0184338241815567|0.02622583881020546|0.03953807055950165|0.0657738521695137
550,Der Efavirenz-Plasmaspiegel kann bei Patienten mit der homozygot vererbten Variante G516T des CYP2B6 Isoenzyms erhöht sein.,Efavirenz plasma exposure may be increased in patients with the second chemotherapeutic agent is guanylhydrazone G516T of the CYP2B6 isoenzyme.,Efavirenz plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isoenzyme.,Efavirenz plasma exposure may be increased in patients with the homozygous inherited variant G516T of the CYP2B6 isoenzyme.,0.2631578947368421,smt,3,3_smt,0.1300458014011383|0.2286708503961563|0.0977967157959938|0.2774401903152466|0.2147151231765747
551,Entfernen Sie nach jeder Injektion die Nadel und bewahren Sie SoloStar ohne Nadel auf.,Remove the needle after each injection and store SoloStar without the needle attached.,Always remove the needle after each injection and store SoloStar without a needle attached.,Remove the needle after each injection and store SoloStar without the needle attached.,0.0,smt,3,3_smt,-0.016682280227541924|-0.017281947657465935|0.01762535609304905|0.03143516182899475|0.04390732944011688
552,"Wird dieses Enzym blockiert, kann sich das Virus nicht mehr normal vermehren, wodurch die Ausbreitung der Infektion verlangsamt wird.","Reyataz, taken in combination, reduces the amount of HIV infection.","When the enzyme is blocked, the virus does not reproduce normally, slowing down the spread of infection.","If this enzyme is blocked, the virus can no longer multiply, which slows the spread of the infection.",0.7142857142857143,smt,3,3_smt,0.3204379379749298|0.40932658314704895|0.2139676809310913|0.47309839725494385|0.40099382400512695
553,"Patienten, die das Therapieregime nach einem Ansprechen nach 48 Wochen beendet hatten, wurden zensiert.",35%). Patients completing treatment while in response after 48 weeks were censored.,97 lopinavir + ritonavir were 46% (35%). Patients completing treatment while in response after 48 weeks were censored.,Patients completing treatment after a response after 48 weeks were graded.,0.5833333333333334,smt,3,3_smt,0.09002991765737534|0.144596129655838|0.2520862817764282|0.21958455443382263|0.1397305279970169
554,"Die Plasma-Konzentrationen von Wirkstoffen, die in erster Linie durch CYP2C9 metabolisiert werden, können bei gleichzeitiger Gabe von Sitaxentan-Natrium erhöht sein.","Plasma concentrations of non-response are excluded, and the patient is primarily metabolised by CYP2C9, may be increased when co-administered with sitaxentan sodium.",Plasma concentrations of drugs principally metabolized by CYP2C9 may be increased during sitaxentan sodium co-administration.,"Plasma concentrations of active substances that is primarily metabolised by CYP2C9, may be increased when co-administered with sitaxentan sodium.",0.3333333333333333,smt,3,3_smt,0.1489080786705017|0.23392221331596375|0.4144872725009918|0.2912890911102295|0.2150493562221527
555,"1,5 mg/ml) vor. Meloxivet ist ein Generikum. Das heißt, Meloxivet entspricht einem in der EU bereits zugelassenen „Referenztierarzneimittel“ (Metacam 1,5 mg/ml Suspension zum Eingeben).","1.5 mg / ml). Meloxivet is a ""generic medicine '. This means that Meloxivet is a medicine' already authorised in the EU"" generic 'which means that Loxicom is equivalent to Metacam 1.5 mg / ml oral suspension).",Meloxivet is a ‘ generic’: this means that Meloxivet is similar to a ‘ reference veterinary medicine ’ already authorised in the EU (Metacam 1.5 mg/ ml oral suspension).,"1.5 mg/ml). Meloxivet is a ""generic medicine '. This means that Meloxivet is a medicine already authorised in the EU (Metacam 1.5 mg/ml).",0.3823529411764705,smt,3,3_smt,0.08315905183553696|0.1313713937997818|0.21029670536518097|0.16773509979248047|0.1378922462463379
556,Bei Einnahme von Competact mit anderen Arzneimitteln:,Taking Competact with other medicinal products:,Taking other medicines:,Taking Competact with other medicinal products:,0.0,smt,3,3_smt,0.10296114534139633|0.16014547646045685|0.11629454046487808|0.20692235231399536|0.2042226493358612
557,"Sicherheitsmaßnahmen, um dies zu verhindern, beinhalten Bluttests und sorgfältige Überwachung durch das Pflegepersonal, das sich um Sie kümmert.","handled in order to avoid this may include blood tests and monitor for nurse, your caregiver that.",Safety measures to prevent this from happening include blood tests and careful checking by the healthcare professionals taking care of you.,Safety measures to avoid this may include blood tests and monitoring by your caregivers.,0.6,smt,3,3_smt,0.5624815821647644|0.6044754385948181|0.5468069911003113|0.6370810866355896|0.5885167121887207
558,"Methyl-4-hydroxybenzoat (E 218) / Propyl-4-hydroxybenzoat (E 216), Natriumacetat, Essigsäure, gereinigtes Wasser.","methyl (4-hydroxybenzoate) / propyl (4-hydroxybenzoate) = E 216, flavouring agent, sodium acetate, acetic acid, purified water.","stearate, hypromellose, colloidal silicon dioxide, titanium dioxide (E 171).","methyl (4-hydroxybenzoate) / propyl (4-hydroxybenzoate) = E 216, flavouring agent, sodium acetate, acetic acid, purified water.",0.0,smt,3,3_smt,0.1612386703491211|0.2329956293106079|0.13396523892879486|0.28070375323295593|0.20291009545326233
559,"Bei Patienten mit Anämie [z.B. Hämoglobinkonzentration ≤10 g/dl (6,2 mmol/l)] sollte die Behandlung mit Silapo mittels subkutaner Applikation erfolgen.","In patients with anaemia (e.g. haemoglobin concentration ≤ 10 g / dl (6.2 mmol / l)), treatment with Silapo should be administered by the subcutaneous route.",Silapo should be administered by the subcutaneous route to patients with anaemia (e. g. haemoglobin concentration ≤ 10 g/ dl (6.2 mmol/ l).,"Treatment with Silapo should be administered by the subcutaneous route in patients with anaemia (e.g. haemoglobin concentration ≤ 10 g / dl (6.2 mmol / l)), .",0.03125,smt,3,3_smt,-0.013783229514956474|-0.0176831241697073|0.014153171330690384|0.017351621761918068|0.041329577565193176
560,"Falls Sie eine Mischkanüle verwenden, entfernen Sie die Schutzhülle und stechen Sie 106 die Mischkanüle durch den Gummistopfen der Durchstechflasche mit dem Lösungsmittel.","If using a transfer needle, remove the tip of the needle, and the protective cap and the transfer needle into the rubber stopper of the solvent vial.","If using a transfer needle, remove the protective cap and insert the transfer needle into the rubber stopper of the solvent vial.","If using a transfer needle, remove the tip the protective cap and pierce the transfer needle into the rubber stopper of the solvent vial with the solution.",0.2413793103448276,smt,3,3_smt,0.03624296188354492|0.06342763453722|0.0652625635266304|0.11099860072135925|0.09530860930681229
561,In Bezug auf das Nutzen-Risiko-Verhältnis des Arzneimittels wurden erhebliche Unterschiede festgestellt.,With regards to the benefit / risk balance of the product had been identified.,Significant differences have been identified with regard to the benefit/ risk ratio of the product.,"With regards to the benefit / risk ratio of the product, significant differences had been identified.",0.2222222222222222,smt,3,3_smt,0.06954117119312286|0.10705608129501343|0.25823307037353516|0.19576837122440338|0.1439530998468399
562,Im Fall einer Überdosierung von LUMIGAN sollte symptomatisch und durch unterstützende Maßnahmen behandelt werden.,"In the event of an overdose, LUMIGAN should be symptomatic and supportive.","If overdosage occurs, treatment should be symptomatic and supportive.","In the event of an overdose of LUMIGAN, treatment should be symptomatic and supportive.",0.1875,smt,3,3_smt,0.06601632386445999|0.08315528929233551|0.11099392175674438|0.15633226931095123|0.13255688548088074
563,Berechnen Sie die Gesamtdosis und die Anzahl der benötigten Durchstechflaschen Elaprase.,Calculate the dose and the number of ORENCIA vials needed in vials of Elaprase.,Calculate the total dose to be administered and number of Elaprase vials needed.,Calculate the dose and the number of vials of Elaprase needed.,0.3333333333333333,smt,3,3_smt,0.1464006006717682|0.18998734652996063|0.17147302627563477|0.24802342057228088|0.18697457015514374
564,"3-ml-Ampullen, farblos, Glas Typ I, enthalten 2 ml Lösung für einen Vernebler und sind mit zwei farbigen Ringen (weiß – pink) gekennzeichnet.","3-ml-Ampullen, colourless, glass type I, containing 2 ml nebuliser solution and show two coloured rings (white - pink).","3-ml ampoules, colourless, glass type I, containing 2 ml nebuliser solution, ring coded with two coloured rings (white – pink).","3-ml-Ampullen, colourless, glass type I, containing 2 ml nebuliser solution and show two coloured rings (white - pink).",0.0,smt,3,3_smt,0.05366860330104828|0.08188716322183609|0.11907314509153366|0.11665107309818268|0.11274217069149017
565,Am 19. Januar 2007 erteilte die Europäische Kommission dem Unternehmen Sanofi Pharma Bristol- Myers Squibb SNC eine Genehmigung für das Inverkehrbringen von Irbesartan Hydrochlorothiazide Winthrop in der gesamten Europäischen Union.,The European Commission granted to Sanofi Pharma Bristol-Myers Squibb SNC Marketing Authorisation for Irbesartan Hydrochlorothiazide Winthrop throughout the European Union on 19 January 2007.,The European Commission granted a marketing authorisation valid throughout the EU for Irbesartan Hydrochlorothiazide Winthrop to Sanofi Pharma Bristol-Myers Squibb SNC on 19 January 2007.,The European Commission granted to Sanofi Pharma Bristol-Myers Squibb SNC the Marketing Authorisation for Irbesartan Hydrochlorothiazide Winthrop throughout the European Union on 19 January 2007.,0.0384615384615384,smt,3,3_smt,0.032367147505283356|0.057284578680992126|0.055447936058044434|0.09912154823541641|0.08850368857383728
566,Patienten mit schweren Leberfunktionsstörungen sollten nicht mit Paclitaxel behandelt werden.,Patients with severe hepatic impairment should not be treated with paclitaxel.,Patients with severe hepatic impairment should not be treated with paclitaxel.,Patients with severe hepatic impairment should not be treated with paclitaxel.,0.0,smt,3,3_smt,-0.062398966401815414|-0.06215795874595642|0.00847155787050724|-0.03669257462024689|-0.0008048545569181442
567,Invasive Eingriffe/Chirurgie Eine Initialdosis von 90 µg pro kg Körpergewicht sollte unmittelbar vor Beginn der Intervention als intravenöse Injektion erfolgen.,Invasive procedures / sevoflurane The starting dose of 90 µg per kg body weight should be used immediately before the start of intervention as an intravenous injection.,Invasive procedure/ surgery An initial dose of 90 µg per kg body weight should be given immediately before the intervention.,Invasive procedures / surgery The starting dose of 90 µg per kg body weight should be used immediately before the start of intervention as an intravenous injection.,0.0357142857142857,smt,3,3_smt,0.017995383590459824|0.03357166796922684|0.048231519758701324|0.0746249407529831|0.0801258236169815
568,Ärzte müssen die Patienten auf Drogenmissbrauch in der Vorgeschichte untersuchen und solche Patienten genau überwachen.,Physicians should advise patients on a history of drug abuse and such patients more closely.,Physicians should evaluate patients for a history of drug abuse and follow such patients closely.,Physicians should examine patients on a history of drug abuse monitor such patients more closely.,0.125,smt,3,3_smt,0.043895818293094635|0.0646437406539917|0.18637436628341675|0.11113764345645905|0.10036889463663101
569,"Trotz der geringeren Wirksamkeit ließ sich aufgrund der Daten aus der Hauptstudie und aus den Veröffentlichungen in der Fachliteratur die Anwendung von Opgenra bei Patienten rechtfertigen, bei denen die autologe Knochentransplantation keinen Erfolg gebracht hatte oder nicht durchgeführt werden konnte.","Despite efficacy was managed due to the data from the main study and from the scientific literature publications, the use of Opgenra may justify in patients in whom the autogenous had no success or has not been performed.","Despite the lower effectiveness, there was sufficient evidence from the study and from the published literature to support the use of Opgenra in patients in whom autograft has failed or who must not undergo the procedure.","Despite the low efficacy, the data from the main study and from the scientific literature publications justified the use of Opgenra patients in whom the autologous bone marrow transplant had no success or could not be performed.",0.3846153846153846,smt,3,3_smt,0.17012108862400055|0.2646788954734802|0.21692590415477753|0.3013145327568054|0.2473074048757553
570,Bei Lagerung kann sich ein weißlicher Bodensatz mit einem klaren Überstand bilden.,The following information is off-white Upon storage of the vial.,"Upon storage, a white deposit and clear supernatant can be observed.","After storage, a whiteish deposit with a clear overlap can form.",0.9230769230769232,smt,3,3_smt,0.31956717371940613|0.4344214200973511|0.5523692965507507|0.4561214745044708|0.41088342666625977
571,"Es gab weniger Aspergillus-Durchbruchs- infektionen bei Patienten, die eine Posaconazol-Prophylaxe erhielten im Vergleich zu Patienten der Kontrollgruppen.",There were fewer Aspergillus-Durchbruchs-. in patients who received Posaconazol-Prophylaxe compared to patients in the control arms.,There were fewer breakthrough Aspergillus infections in patients receiving posaconazole prophylaxis when compared to control patients.,There were fewer Aspergillus breakthroughs. in patients who received posaconazole prophylaxis compared to patients in the control arms.,0.2105263157894736,smt,3,3_smt,0.17926670610904694|0.28320109844207764|0.2726731300354004|0.3222731947898865|0.23607371747493744
572,"20,2% versus 6,6%, p < 0,001).","20.2% versus 6.6%, p 0.001).","6.6%, p < 0.001, respectively).","20.2% versus 6.6%, p 0.001).",0.0,smt,3,3_smt,0.07011035829782486|0.09121123701334|0.04961789771914482|0.12802952527999878|0.10967469215393066
573,"Dosierung Die empfohlene Dosis beträgt 0,5 ml - 3,0 ml pro Patient.",Posology The recommended dose is 0.5 ml - 3.0 ml per patient.,Dosage The recommended dose is 0.5 ml - 3.0 ml per patient.,Posology The recommended dose is 0.5 ml - 3.0 ml per patient.,0.0,smt,3,3_smt,-0.001455893274396658|-0.009182311594486237|0.013638349249958992|0.03318675234913826|0.043749235570430756
574,Packungen mit 1 oder 10 Durchstechflaschen.,Pack sizes of 1 or 10 vial (s).,Supplied in packs of 1 vial or 10 vials.,Pack sizes of 1 or 10 vial (s).,0.0,smt,3,3_smt,0.019241904839873314|0.030561238527297974|0.023019708693027496|0.08114489167928696|0.06658882647752762
575,"Patientinnen, die eine Schwangerschaft planen, sollten auf alternative blutdrucksenkende Therapien mit einem bewährten Sicherheitsprofil zur Anwendung in der Schwangerschaft umgestellt werden, es sei denn, dass die Fortführung einer Losartan/HCT-Therapie als unbedingt erforderlich erachtet wird.","patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy, unless Unless continued losartan / HCT-Therapie is considered essential.","Unless continued Losartan/ HTCZ therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.","patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy, unless Unless continued losartan / HCT-Therapie is considered absolutely essential.",0.03125,smt,3,3_smt,0.06171010434627533|0.10944162309169769|0.13261090219020844|0.14926466345787048|0.1289079636335373
576,Nicht verwendeter Impfstoff oder Abfallmaterial ist entsprechend den nationalen Anforderungen zu entsorgen.,Any unused vaccine or waste material is to be disposed of in accordance with local requirements.,Any unused product or waste material should be disposed of in accordance with local requirements.,Any unused vaccine or waste material is to be disposed of in accordance with local requirements.,0.0,smt,3,3_smt,-0.028247497975826263|-0.02272171713411808|0.012072719633579254|0.0005597122944891453|0.032753266394138336
577,Timolol wird nicht vollständig dialysiert.,Timolol is not fully dialysed.,Timolol does not dialyse readily.,Timolol is not fully dialysed.,0.0,smt,3,3_smt,0.05875431001186371|0.09200803190469742|0.02853686735033989|0.1540544331073761|0.10621580481529236
578,Nach Einbau in die DNS scheint Gemcitabin den programmierten Zelltod (Apoptose) zu induzieren.,"After incorporation into DNA, gemcitabine seems to the frame (11).","After incorporation into DNA, gemcitabine appears to induce the programmed cell death process known as apoptosis.","After incorporation into DNA, gemcitabine seems to induce the programmed cell death (apoptosis).",0.2941176470588235,smt,3,3_smt,0.2153247445821762|0.30297860503196716|0.36249998211860657|0.41932913661003113|0.35620611906051636
579,"Pharmakotherapeutische Gruppe: Antiepileptika, Carboxamid-Derivate; ATC-Code:","Pharmacotherapeutic group: anti-epileptics, carboxamide derivatives; ATC-code:","Pharmacotherapeutic group: anti-epileptics, carboxamide derivatives; ATC-code:","Pharmacotherapeutic group: anti-epileptics, carboxamide derivatives; ATC-code:",0.0,smt,3,3_smt,-0.044892583042383194|-0.04814014583826065|0.010664407163858414|-0.020675718784332275|0.013310564681887627
580,Wofür wird Oxyglobin angewendet?,What is Oxyglobin used for?,What is Oxyglobin used for?,What is Oxyglobin used for?,0.0,smt,3,3_smt,-0.05453655496239662|-0.06078564375638962|0.008411808870732784|-0.030375884845852852|0.0013670604676008224
581,2. Was müssen Sie vor der Einnahme von Levitra beachten? 3.,What you should know before you take Levitra 3.,Before you take Levitra 3.,What you should know before you take Levitra 3.,0.0,smt,3,3_smt,-0.003425182541832328|0.002189844846725464|0.02674938179552555|0.03427503630518913|0.046658679842948914
582,Hämorrhagien wurden selten bei mit SUTENT behandelten Patienten beobachtet (siehe Abschnitt 4.4).,Haemorrhage has been rarely reported in patients treated with SUTENT (see section 4.4).,Haemorrhage has been observed rarely in patients treated with SUTENT (see section 4.4).,Haemorrhage has been rarely reported in patients treated with SUTENT (see section 4.4).,0.0,smt,3,3_smt,-0.05067532882094383|-0.04802645742893219|0.01019060704857111|-0.0277075357735157|0.0071392906829714775
583,"Falls der Tubenverschluss versehentlich in die Tube gedrückt wurde, verwerfen Sie bitte den Impfstoff.","If the tip seal could be accidentally gets into the tube, please discard the vaccine.","In the event that the tip seal is accidentally pushed into the tube, discard the vaccine.","If the tip seal was accidentally pressed into the tube, please discard the vaccine.",0.1875,smt,3,3_smt,0.0664748102426529|0.12687286734580994|0.10152990370988846|0.2000012993812561|0.15197883546352386
584,"Nespo-Anwendung wurde bei wenigen Patienten über eine Kaliumerhöhung berichtet, ein kausaler Zusammenhang konnte jedoch nicht hergestellt werden.","Clinical studies have demonstrated that adult patients have been reported in a few patients receiving Nespo Kaliumerhöhung been established, but has not been established.","Potassium elevation has been reported in a few patients receiving Nespo, though causality has not been established.","Potassium elevation has been reported in a few patients receiving Nespo, though causality has not been established.",0.6842105263157895,smt,3,3_smt,0.29153773188591003|0.42997872829437256|0.5474918484687805|0.4616435170173645|0.3629169464111328
585,"Jede Tablette enthält 13,2 mg Lactose.",Each tablet contains 13.2 mg lactose.,Each tablet contains 13.2 mg lactose.,Each tablet contains 13.2 mg lactose.,0.0,smt,3,3_smt,-0.049938127398490906|-0.05712802708148956|0.008566020987927914|-0.025421645492315292|0.002058671787381172
586,"Falls Sie davon betroffen sind, besprechen Sie dies bitte mit Ihrem Arzt.","If you are affected, discuss this with your doctor.",You should discuss this with your doctor if you are concerned.,"If you are affected, discuss this with your doctor.",0.0,smt,3,3_smt,0.003172127064317465|-0.0035508032888174057|0.01807313598692417|0.02570394240319729|0.045371122658252716
587,Dieses Behandlungsschema wird üblicherweise alle drei Wochen wiederholt.,This treatment schedule is usually repeated every three weeks.,This pattern of treatment will normally be repeated every three weeks.,This treatment schedule is usually repeated every three weeks.,0.0,smt,3,3_smt,-0.020526975393295288|-0.02226020209491253|0.012990913353860378|0.023556919768452644|0.030433539301156998
588,"Gegeben Sie die Injektion jedoch nicht, wenn Sie/Ihr Kind kurz vor oder nach der Injektion nichts essen können.","Gegeben you not, however, if you / your child shortly before or after injection, No.",Do not give the injection if you/your child is unable to eat shortly before or after the injection.,Do not give the injection if you/your child is unable to eat shortly before or after the injection.,0.5714285714285714,smt,3,3_smt,0.4056328237056732|0.5104449391365051|0.4273225665092468|0.5340290069580078|0.4667813777923584
589,Eine Atemdepression in Folge einer Überdosierung kann die Wirkungsdauer des Opioid-Antagonisten überdauern.,One respiratory depression as a result of overdose may reduce the time of the opioid überdauern.,Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist.,A respiratory depression as a result of overdose may reduce the length of efficacy of the opioid antagonists.,0.2631578947368421,smt,3,3_smt,0.19903694093227386|0.30324557423591614|0.17211823165416718|0.39048781991004944|0.2845715284347534
590,"Es wird empfohlen, in Abschnitt 4.5 der relevanten Zusammenfassungen der Merkmale des Arzneimittels den Standardsatz „Die Anwendung des Tierarzneimittels sollte unter Berücksichtigung einer Empfindlichkeitsprüfung (Antibiogramm) und entsprechend den offiziellen und örtlichen Regelungen zum Einsatz von Antibiotika erfolgen“ aufzunehmen.","It is recommended in section 4.5 of the relevant Summaries of Product Characteristics to implement the standard sentence ""Use of the product should be based on culture should be based on susceptibility testing and take into official and local antimicrobial policies"" antibiotics.",It is recommended to implement the standard sentence “Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies ” in section 4.5 of the relevant SPCs.,"It is recommended in section 4.5 of the relevant Summaries of Product Characteristics to implement the standard sentence ""Use of the product should be based on culture should be based on susceptibility testing and take into account official and local antimicrobial policies"" antibiotics.",0.0217391304347826,smt,3,3_smt,0.1273859590291977|0.2256273329257965|0.20282331109046936|0.24787652492523193|0.22220809757709503
591,psychotischen Störungen die psychotischen Symptome verschlechtern; paranoide Wahnvorstellungen können sich verstärken.,psychotic disorders that may worsen psychotic symptoms; paranoid delusions may feel worse.,"Bone marrow depression Bone marrow depression, usually presenting as granulocytopenia or agranulocytosis, has been reported during treatment with Remeron.",psychotic disorders that may worsen psychotic symptoms; paranoid delusions may feel increase.,0.0714285714285714,smt,3,3_smt,0.3093733489513397|0.3955444395542145|0.2737542390823364|0.4496050179004669|0.36245134472846985
592,"Machen Sie sich eine Notiz, ab wann Sie das Arzneimittel außerhalb des Kühlschranks aufbewahren.",If you feel a decreased when the medicinal product is taken outside the refrigerator.,Make a note of when you start storing the product out of the refrigerator.,Make a note when the medicinal product is taken outside the refrigerator.,0.3076923076923077,smt,3,3_smt,0.14223921298980713|0.19931697845458984|0.4619738459587097|0.26183846592903137|0.21947261691093445
593,"Wenn Sie noch weitere Fragen zur Anwendung dieses Arzneimittels haben, fragen Sie Ihren Arzt oder Apotheker.","If you have any further questions on how yet this medicine, ask your doctor or pharmacist.","If you have any further questions on the use of this product, ask your doctor or pharmacist as well.","If you have any further questions on how yet this medicine, ask your doctor or pharmacist.",0.0,smt,3,3_smt,0.03000170737504959|0.032745007425546646|0.05331770330667496|0.05692780762910843|0.07288544625043869
594,Außerdem kann in geringem Ausmaß ebenfalls Gemcitabin in die RNS eingebaut werden.,"Furthermore, in a small extent also gemcitabine is incorporated into splashing.","Likewise, a small amount of gemcitabine may also be incorporated into RNA.","Furthermore, to a small extent gemcitabine can incorporated into RNA.",0.3333333333333333,smt,3,3_smt,0.07497913390398026|0.1365848332643509|0.14820602536201477|0.1877031773328781|0.14802253246307373
595,"Wurde Insulinglulisin 2 Minuten vor der Mahlzeit gege- ben, wurde eine bessere postprandiale Kontrolle als mit humanem Normalinsulin, das 2 Minuten vor der Mahlzeit gegeben wurde, erreicht.",When 2 minutes before the meal given was better postprandial control than regular human insulin given 2 minutes before the meal has been administered.,"17 regular human insulin given 30 minutes before the meal. When given 2 minutes prior to meal, insulin glulisine provided better postprandial control than regular human insulin given 2 minutes before the meal.","If insulin glulisine is administered 2 minutes before a meal, a better postprandial control was achieved than with regular human insulin administered 2 minutes before meal.",0.5714285714285714,smt,3,3_smt,0.13757096230983734|0.2305714339017868|0.3550707995891571|0.29090818762779236|0.19269779324531555
596,"Kinder Fentanyl-ratiopharm sollte bei Kindern unter 12 Jahren nicht angewendet werden, da nur begrenzte Erfahrungen mit der Anwendung bei Kindern vorliegen.",Children Fentanyl-ratiopharm should not be used in children under 12 years of age because of the limited experience with the use in children.,Children Fentanyl-ratiopharm should not be administered to children under 12 years of age because there is limited experience of use in children.,Children. Fentanyl patch should not be used in children under 12 years of age because of the limited experience with the use in children.,0.1153846153846153,smt,3,3_smt,0.0019206884317100048|0.009525731205940247|0.04694943502545357|0.04062892124056816|0.05021835118532181
597,Ihr Mixtard 40 NovoLet ist für eine sehr genaue und sichere Funktionsweise entwickelt worden.,Your Mixtard 40 NovoLet is designed to work accurately and safely.,Your Mixtard 40 NovoLet is designed to work accurately and safely.,Your Mixtard 40 NovoLet is designed to work accurately and safely.,0.0,smt,3,3_smt,-0.026180969551205635|-0.026451969519257545|0.01222570613026619|0.008612524718046188|0.03318674489855766
598,Hierauf folgen eine weitere Injektion vier Wochen später und anschließend Injektionen im Abstand von jeweils drei Monaten (12 Wochen).,"Hierauf is given followed by an additional injection 4 weeks later, then injections with an interval of three months (12 weeks).","This is followed by a further injection four weeks later, and then an injection every three months (12 weeks).",This is followed by an additional injection 4 weeks later and then further injections in intervals of three months (12 weeks).,0.2916666666666667,smt,3,3_smt,0.03656521439552307|0.05544344335794449|0.062043994665145874|0.1191149577498436|0.09290424734354019
599,"Um die Resorption von Tenofovir zu optimieren, wird empfohlen, Truvada zu einer Mahlzeit einzunehmen.","In order to optimize the absorption of tenofovir, it is recommended that Truvada be taken with food.","In order to optimise the absorption of tenofovir, it is recommended that Truvada should be taken with food.","In order to optimize the absorption of tenofovir, it is recommended that Truvada be taken with food.",0.0,smt,3,3_smt,-0.02318549156188965|-0.02799425832927227|0.010575851425528526|0.0038329283706843853|0.03449852019548416
600,Klinisch signifikante inhibitorische oder induktive Wirkungen von Azacitidin auf Cytochrom-P450-Enzyme sind unwahrscheinlich (siehe Abschnitt 5.2).,Clinically significant inhibitory or an inductive effects of azacitidine on cytochrome P450 enzymes are unlikely (see section 5.2).,Clinically significant inhibitory or inductive effects of azacitidine on cytochrome P450 enzymes are unlikely (see section 5.2).,Clinically significant inhibitory or an inductive effects of azacitidine on cytochrome P450 enzymes are unlikely (see section 5.2).,0.0,smt,4,4_smt,-0.04001510888338089|-0.028042806312441826|0.02550443634390831|-0.007096283603459597|0.023075466975569725
601,SUSTIVA Lösung zum Einnehmen weist im mg/mg-Vergleich eine geringere Bioverfügbarkeit auf als die Hartkapsel.,SUSTIVA oral solution in mg is less bioavailable than a lower bioavailability compared to the capsule.,SUSTIVA oral solution is less bioavailable than the hard capsule on a mg per mg basis.,SUSTIVA oral solution is less bioavailable on a mg per mg basis compared to the capsule.,0.3529411764705882,smt,4,4_smt,0.07634823769330978|0.10661022365093231|0.23969878256320953|0.1686520129442215|0.13378657400608063
602,"Anzeichen können Fieber, Müdigkeitsgefühl, Husten, grippeähnliche 36 Beschwerden, Durchfall, Zahnpr obleme und Brennen beim Wasserlassen umfassen.","Signs may include fever, feeling tired, cough, flu-like symptoms, diarrhoea, Signs may include fever, feeling tired, dental problems and burning when urinating.","Signs may include fever, feeling tired, cough, flu-like symptoms, diarrhoea, dental problems and burning when urinating.","Signs may include fever, feeling tired, cough, flu-like symptoms, diarrhoea, fever, feeling tired, dental problems and burning when urinating.",0.1111111111111111,smt,4,4_smt,0.007895432412624359|0.026888184249401093|0.17454077303409576|0.054305993020534515|0.06333621591329575
603,20 Nach der Remission sollte die antidepressive medikamentöse Behandlung über mindestens sechs Monate fortgesetzt werden.,"After remission addition, appropriate medical treatment should be continued for at least six months.",Antidepressive medicinal products should continue for at least six months following remission.,"After remission, appropriate antidepressive medical treatment should be continued for at least six months.",0.125,smt,4,4_smt,0.043807752430438995|0.06490672379732132|0.09459672123193741|0.1286400705575943|0.09881308674812317
604,Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile (siehe Abschnitt 4.4 und 4.8).,Hypersensitivity to the active substance or to any of the excipients (see section 4.4 and 4.8).,Hypersensitivity to the active substance or to any of the excipients (see section 4.4 and 4.8).,Hypersensitivity to the active substance or to any of the excipients (see section 4.4 and 4.8).,0.0,smt,4,4_smt,-0.05069440230727196|-0.05627818405628204|0.010330477729439735|-0.02932235412299633|0.011523643508553505
605,"(Prodrug ist die inaktive Vorstufe eines Medikaments, das erst im Körper in die aktive und wirksame Form umgewandelt wird.) Tenofovir ist ein Nukleotid-Reverse-Transkriptase-Hemmer.","% reduction, the inactive solution of the said tube, in the body of the previous injections.) Tenofovir is a Nukleotid-Reverse-Transkriptase-Hemmer.","Truvada, taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level.",%(Prodrug is the inactive precursor of a medicine that was first converted into the active and effective form in the body). Tenofovir is a nucleotide reverse transcriptase inhibitor.,0.696969696969697,smt,4,4_smt,0.3230229318141937|0.405165433883667|0.3820198178291321|0.4493428170681|0.39961403608322144
606,"Wenn Sie Auto fahren oder eine Maschine bedienen, besprechen Sie dies bitte mit Ihrem Arzt. Er wird Ihre Krankheitssituation und Ihr Ansprechen auf das Medikament berücksichtigen und Sie beraten, ob Sie diese Tätigkeiten einstellen sollten.","If you dial a car should not drive or operate machinery, please discuss this with your doctor. It is your disease and your tolerance of the response to the medicine into account and should advise you whether you can take these activities.","If you drive or operate machinery, discuss this with your doctor to get their recommendation about discontinuing these activities based upon the condition of your disease and your tolerance of the medication.","If you drive a car or operate machinery, please discuss this with your doctor. They will take your disease situation and your response to the medicine into account and should advise you whether you can take part in these activities.",0.3023255813953488,smt,4,4_smt,0.15515729784965515|0.23007604479789734|0.31217432022094727|0.25993427634239197|0.22590608894824982
607,5 Anämie Die Behandlung mit Rosiglitazon ist mit einer dosisabhängigen Abnahme der Hämoglobinwerte verbunden.,5 Anaemia Rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels.,Anaemia Rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels.,5 Anaemia Rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels.,0.0,smt,4,4_smt,-0.008806126192212105|0.0023051518946886063|0.01872679591178894|0.04867684096097946|0.04840695112943649
608,Behandlung von Morbus Paget des Knochens.,Treatment of Paget's disease of the bone.,Treatment of Paget’ s disease of the bone.,Treatment of Paget's disease of the bone.,0.0,smt,4,4_smt,-0.03290831670165062|-0.03477352112531662|0.01610863208770752|0.008547615259885788|0.03169050067663193
609,"Wenn Paxene als Teil einer Kombinationstherapie mit Cisplatin verabreicht wird, wird empfohlen Paxene vor der Gabe von Cisplatin zu verabreichen.","If Paxene is given as part of combination therapy with cisplatin, it is recommended that Paxene be administered prior to the administration of cisplatin.","When administered as part of a combination regimen with cisplatin, it is recommended that Paxene is given before cisplatin.","When administered as part of a combination regimen with cisplatin, it is recommended that Paxene is given before cisplatin.",0.5714285714285714,smt,4,4_smt,-0.015337437391281128|-0.01407863013446331|0.04629402607679367|0.0179524514824152|0.04328607767820358
610,Die verminderte Gabapentin-Resorption bei höheren Dosen kann auch zu einer eingeschränkten Resorption zum Zeitpunkt der Überdosierung führen und dadurch auch die Toxizität verringern.,"The decreased Gabapentin-Resorption at higher doses may also lead to impaired absorption at the time of overdose, and therefore slows down further reduce toxicity.","Reduced absorption of gabapentin at higher doses may limit drug absorption at the time of overdosing and, hence, minimize toxicity from overdoses.","The decreased gabapentin absorption at higher doses may also lead to impaired absorption at the time of overdose, and therefore reduces toxicity.",0.25,smt,4,4_smt,0.1438884437084198|0.22686561942100525|0.1876121610403061|0.27062827348709106|0.21046854555606842
611,Pharmakotherapeutische Gruppe (ATC Code):,Pharmacotherapeutic group (ATC Code):,Pharmaco-therapeutic group (ATC Code):,Pharmacotherapeutic group (ATC Code):,0.0,smt,4,4_smt,-0.051921650767326355|-0.057850249111652374|0.009759347885847092|-0.03226780891418457|0.005008925683796406
612,Jeder Beutel enthält 250 mg Creme.,Each sachet contains 250 mg cream.,Each containing 250 mg of cream.,Each sachet contains 250 mg cream.,0.0,smt,4,4_smt,-0.03928150236606598|-0.04271871596574783|0.011861378327012062|-0.013727646321058273|0.018749844282865524
613,Ihr Arzt kann Ihnen außer Humalog BASAL auch noch ein rasch wirkendes Insulin verschreiben.,Your doctor may tell you to use Humalog BASAL and / or rapidly prescribe a fast-acting insulin.,Your doctor may tell you to use Humalog BASAL as well as a fast-acting insulin.,Your doctor may tell you to use Humalog BASAL and / or prescribe a fast-acting insulin.,0.0588235294117647,smt,4,4_smt,0.082828089594841|0.12444134056568146|0.08491633832454681|0.15629656612873077|0.13408252596855164
614,"Schwangerschaft und Stillzeit Sagen Sie Ihrem Arzt, wenn Sie schwanger sind oder vermuten, schwanger zu sein.","Pregnancy and breast-feeding Tell your doctor if you are pregnant, or suspect that you might be pregnant.",Pregnancy and breast-feeding Tell your doctor if you are or think you may be pregnant.,"Pregnancy and breast-feeding: Tell your doctor if you are pregnant, or suspect that you might be pregnant.",0.05,smt,4,4_smt,-0.017735930159687996|-0.018168384209275246|0.022575007751584053|0.006800213363021612|0.02940654382109642
615,Die Unbedenklichkeit und Wirksamkeit des Arzneimittels bei Kindern konnte bisher nicht ausreichend nachgewiesen werden (siehe Abschnitt 5.1).,The safety and effectiveness of the medicine in children has not been adequately demonstrated (see section 5.1).,Safety and efficacy in children have not been adequately demonstrated (see section 5.1).,The safety and effectiveness of the medicine in children has not been adequately demonstrated (see section 5.1).,0.0,smt,4,4_smt,-0.02719496190547943|-0.02984335832297802|0.012236098758876324|0.0035338690504431725|0.028363287448883057
616,Dies gilt besonders nach einer Helicobacter-Eradikationstherapie.,This is especially important if you take a Helicobacter-Eradikationstherapie.,This is particularly true after Helicobacter eradication therapy.,This is especially important if you take a helicobacter eradication therapy.,0.25,smt,4,4_smt,0.07583513110876083|0.11746695637702942|0.17732544243335724|0.15901906788349152|0.13922372460365295
617,In einer Studie zur prä- und postnatalen Entwicklung an Ratten trat ein verringertes Überleben von Jungtieren zwischen der Geburt und Tag 21 nach der Geburt in Dosierungen ab 60 mg/kg/Tag (dem 5-Fachen der erwarteten klinischen Exposition beim Menschen) auf.,"In a pre- and postnatal development study in rats, decreased survival has occurred in pups between birth and day 21 after birth at doses of 60 mg / kg / day ( 5 times the expected human clinical exposure, respectively).","In the rat pre- and postnatal development study, a decrease in pup survival occurred between birth and postnatal day 21 at doses of 60 mg/ kg/ day or higher (5 times the expected human clinical exposure).","In the rat pre- and postnatal development study, a decrease in pup survival occurred between birth and postnatal day 21 at doses of 60 mg/ kg/ day or higher (5 times the expected human clinical exposure).",0.3809523809523809,smt,4,4_smt,0.003668986726552248|0.020033523440361023|0.04492972046136856|0.06695330142974854|0.06380598247051239
618,18 Gabe von i.th. Morphin neben stabilen Dosen von i.th. Ziconotid wird besser vertragen (es wurde über Pruritus berichtet).,Administration of IT morphine to stable doses of IT ziconotide is better tolerated (pruritis has been reported).,The addition of IT morphine to stable doses of IT ziconotide is better tolerated (pruritis has been reported).,Administration of IT morphine in stable doses of IT ziconotide is better tolerated (pruritis has been reported).,0.05,smt,4,4_smt,0.03625161945819855|0.08769716322422028|0.08419185131788254|0.12881068885326385|0.09253226965665817
619,"Die Rimonabant-Exposition im Steady State ist 3,3fach höher als die nach der ersten Gabe.","The Rimonabant-Exposition at steady state is 3,3fach higher than after the first dose.",Steady state rimonabant exposures are 3.3-fold higher than those observed after the first dose.,The rimonabant exposure at steady state is 3.3 times higher than after the first dose.,0.3125,smt,4,4_smt,0.14710469543933868|0.2159491777420044|0.18180735409259796|0.27628040313720703|0.22896574437618256
620,"Sie dürfen Humalog Pen nicht anwenden, wenn die Lösung verfärbt ist oder feste Bestandteile enthält.","Do not use Humalog Pen, if the solution is coloured or it has solid pieces in it.","Do not use Humalog Pen, if the solution is coloured or it has solid pieces in it.","Do not use Humalog pen, if the solution is discoloured or it has solid pieces in it.",0.0526315789473684,smt,4,4_smt,-0.026684986427426338|-0.02461336739361286|0.01219521276652813|0.008325260132551193|0.030686862766742706
621,Ein mit Polyethylen ausgekleideter Papierbeutel mit 1 kg oder 3 kg Inhalt.,One and ausgekleideter Papierbeutel with 1 kg or 3 kg.,One polyethylene lined paper bag containing 1 or 3 kg.,A polyethylene-lined paper sachet with 1 kg or 3 kg content.,0.4166666666666667,smt,4,4_smt,0.3273213505744934|0.4451361298561096|0.2901976406574249|0.44862040877342224|0.38314998149871826
622,Eine erhöhte Inzidenz thrombovaskulärer Ereignisse (siehe Abschnitt 4.4 und Abschnitt 4.8 - Allgemein) wurde bei Patienten unter der Behandlung mit Erythropoetinen beobachtet.,An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.,11 An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.,An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.,0.0,smt,4,4_smt,-0.021067380905151367|-0.02017226628959179|0.017051270231604576|0.009839903563261032|0.035405002534389496
623,Ausmaß und Dauer der aPTT-Normalisierung nach Anwendung von KOGENATE Bayer sind ähnlich wie nach Gabe eines aus Plasma isolierten Faktor VIII.,the extent and the duration of aPTT-Normalisierung after administration of KOGENATE Bayer are similar to those seen after administration of plasma factor VIII.,The degree and duration of aPTT normalisation observed after administration of KOGENATE Bayer is similar to that achieved with plasma-derived factor VIII.,The extent and the duration of a PTT normalisation after administration of KOGENATE Bayer are similar to those seen after administration of plasma factor VIII.,0.1153846153846153,smt,4,4_smt,0.09121055901050568|0.1376248002052307|0.09894824028015137|0.2058986872434616|0.16665494441986084
624,"- Wenn Sie weitere Fragen haben, wenden Sie sich bitte an Ihren Arzt oder Apotheker.","- If you have any further questions, ask your doctor or pharmacist.",Read all of this leaflet carefully before you start taking this medicine. − Keep this leaflet.,"- If you have any further questions, ask your doctor or pharmacist.",0.0,smt,4,4_smt,0.15909481048583984|0.2225145399570465|0.08831696212291718|0.2261032909154892|0.2092529684305191
625,"Die maximalen Nevirapin-Konzentrationen im Plasma (2 ± 0,4 µg/ml; 7,5 µM) wurden innerhalb von vier Stunden nach einmaliger Anwendung einer 200 mg-Dosis erreicht.",Peak plasma nevirapine concentrations (2 ± 0.4 µg / ml (7.5 µM) were reached within four hours following a single 200 mg dose.,Peak plasma nevirapine concentrations of 2 ± 0.4 µg/ ml (7.5 µM) were attained by 4 hours following a single 200 mg dose.,Peak plasma nevirapine concentrations (2 ± 0.4 µg / ml (7.5 µM) were reached within four hours following a single 200 mg dose.,0.0,smt,4,4_smt,0.007772971410304308|0.01381735410541296|0.035332173109054565|0.05456671491265297|0.05862373113632202
626,"Dosis, Dosierungsbereich und Behandlungsintervalle Zur Behandlung von Blutungen und zur Prophylaxe von Blutungen bei invasiven und chirurgischen Eingriffen wird eine Dosis von 90 µg(Dosierungsbereich von 80 bis 120 µg) pro kg Körpergewicht alle 2 Stunden (1,5-2,5 Stunden) empfohlen.","Dose, dose range and dose interval The recommended dose range for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 90 µg (range 80 - 120 µg) per kg body weight every 2 hours (1.5 - 2.5 hours).","Dose, dose range and dose interval The recommended dose for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 90 µg (range 80 - 120 µg) per kg body weight at intervals of two hours (1.5 - 2.5 hours).","Dose, dose range and dose interval: The recommended dose range for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgical or invasive procedures is 90 µg (dose range 80 - 120 µg) per kg body weight every 2 hours (1.5 - 2.5 hours).",0.0545454545454545,smt,4,4_smt,-0.02067943662405014|-0.020918989554047585|0.028190096840262413|0.011821573600172997|0.03974367678165436
627,Chronische Myeloische Leukämie:,193 Chronic Myelogenous Leukaemia:,Chronic Myelogenous Leukaemia:,193 Chronic Myelogenous Leukaemia:,0.0,smt,4,4_smt,-0.03976436331868172|-0.0393168181180954|0.010711287148296833|-0.009392846375703812|0.018084879964590073
628,Als neue sekundäre Endpunkte wurden der prozentuale Anteil der klinischen Heilungen bis zum 7.,The secondary endpoints were the percentage of clinical preventing up to 7.,New secondary end points were defined as percentage clinically cured on day 7 relapse and mortality rates.,New secondary end points were defined as percentage clinically cured on day 7 relapse and mortality rates.,0.7777777777777778,smt,4,4_smt,0.12494520097970963|0.21737757325172424|0.3146989643573761|0.3050459325313568|0.21853403747081757
629,Praxis bei der Anwendung von Lopid wurde der folgende Wortlaut als geeignetster harmonisierter Text für den Abschnitt 4.3 Gegenanzeigen betrachtet:,"Medical practice with the use of Lopid, the following was considered to be the most suitable harmonised text for Section 4.3 Contraindications was considered:","After an assessment of the documentation provided by the MAH and an evaluation of the current EU- wide clinical practices relating to the use of Lopid, the following was considered to be the most suitable harmonised Section 4.3 Contraindications:","Medical practice with the use of Lopid, the following was considered to be the most suitable harmonised text for Section 4.3 Contraindications was considered:",0.0,smt,4,4_smt,0.18139240145683289|0.2663232684135437|0.21454809606075287|0.2904680073261261|0.26414045691490173
630,"Sie müssen so lange mit den Raptiva- Injektionen fortfahren, wie Sie von Ihrem Arzt dazu angewiesen werden.","You must tell for as long as the continue were similar between the injections, you will be instructed to the advice of your doctor.",You should continue to inject Raptiva as long as instructed to do so by your doctor.,You must continue with the raptiva injections for as long as your doctor advises.,1.0,smt,4,4_smt,0.294786274433136|0.3251538574695587|0.6093730926513672|0.40414756536483765|0.350667804479599
631,"In dieser Studie wurde festgestellt, wie viele Patienten eine AIDS-bedingte Erkrankung entwickelten oder nach einjähriger Behandlung verstarben.","In this study, found how many patients had AIDS-bedingte developed disease or died after one year of treatment.",This study looked at how many patients developed an illness associated with AIDS or died after a year’ s treatment.,This study found out how many patients had developed disease due to AIDs or died after one year of treatment.,0.3333333333333333,smt,4,4_smt,0.10651403665542603|0.18083631992340088|0.21454738080501556|0.2307073473930359|0.17777110636234283
632,"Privigen wird hauptsächlich bei drei Patientengruppen angewendet: • Patienten, bei denen die Gefahr einer Infektion besteht, weil sie nicht genügend Antikörper (Proteine, die natürlich im Blut vorkommen und dem Körper helfen, Infektionen und andere Erkrankungen zu bekämpfen) haben.",Privigen is used in three groups of patients: • Patients who are at risk of infection because they do not have sufficient antibodies (proteins naturally found in the blood that help the body to fight infections and other illnesses).,Privigen is used in three main groups of patients: • Patients who are at risk of infection because they do not have sufficient antibodies (proteins naturally found in the blood that help the body to fight infections and other diseases).,Privigen is used in three groups of patients: • Patients who are at risk of infection because they do not have sufficient antibodies (proteins naturally found in the blood that help the body to fight infections and other illnesses).,0.0,smt,4,4_smt,-0.02769511193037033|-0.03071325458586216|0.012402273714542389|-0.007265142630785704|0.02606126293540001
633,zwei Wochen nachdem Sie die Einnahme der MAO-Hemmer beendet haben.,two weeks after you have stopped taking MAO inhibitors.,"If your doctor has prescribed Remeron for a patient under 18 and you want to discuss this, please go back to your doctor.",two weeks after you have stopped taking MAO inhibitors.,0.0,smt,4,4_smt,0.13872438669204712|0.1873646378517151|0.17197267711162567|0.2519740164279938|0.18553145229816437
634,Trotz dieser Veränderungen am Molekül behält Darbepoetin alfa eine sehr enge Spezifität für den Erythropoetinrezeptor bei.,"in vivo activity. Despite these molecular changes, darbepoetin alfa retains a very narrow specificity for the erythropoietin receptor.","345 in vivo activity. Despite these molecular changes, darbepoetin alfa retains a very narrow specificity for the erythropoietin receptor.","Despite these molecular changes, darbepoetin alfa retains a very small specificity for the erythropoietin receptor.",0.2941176470588235,smt,4,4_smt,-0.022204332053661346|-0.018044834956526756|0.01876494660973549|0.0224729273468256|0.040326520800590515
635,Name und Anschrift des/der Hersteller(s) des (der) Wirkstoffs (Wirkstoffe) biologischen Ursprungs Boehringer Ingelheim Vetmedica Inc.,"Name and address of the manufacturer (s) of the biological active substance (s) Boehringer Ingelheim Vetmedica Inc., org. sl.",Name and address of the manufacturer(s) of the biological active substance(s) Boehringer Ingelheim Vetmedica Inc.,"Name and address of the manufacturer (s) of the biological active substance (s) Boehringer Ingelheim Vetmedica Inc., org. sl.",0.0,smt,4,4_smt,0.0532362200319767|0.07133563607931137|0.042788952589035034|0.12445861846208572|0.10848230123519897
636,Wie wird Cystadane angewendet?,How is Cystadane used?,How is Cystadane used?,How is Cystadane used?,0.0,smt,4,4_smt,-0.06473366916179657|-0.06445296853780746|0.008315680548548698|-0.041486166417598724|-0.004448357969522476
637,"Weitere Symptome, die häufiger in der Paroxetin- als in der Placebogruppe auftraten, waren verminderter Appetit, Tremor, Schwitzen, Hyperkinese, Agitiertheit, emotionale Labilität (einschließlich Weinen und Stimmungsschwankungen).","Other symptoms were reported more frequently in the Paroxetin- than in the placebo group, were decreased appetite, tremor, sweating, hyperkenesia, agitation, depression, emotional lability (including, crying, and mood liability).","Additional events that were more often seen in the paroxetine compared to placebo group were: decreased appetite, tremor, sweating, hyperkinesia, agitation, emotional lability (including crying and mood fluctuations).","Other symptoms, that were reported more frequently in the Paroxetin group than in the placebo group, were decreased appetite, tremor, sweating, hyperkenesia, agitation, depression, emotional lability (including, crying, and mood liability).",0.0909090909090909,smt,4,4_smt,0.02891724929213524|0.04748542606830597|0.06689737737178802|0.08340103924274445|0.09230684489011765
638,Augenerkrankungen Häufigkeit nicht bekannt:,Eye disorders Frequency not known:,Ear disorderc Tympanic membrane disorder Skin and subcutaneous tissue disorders Common:,Eye disorders Frequency not known:,0.0,smt,4,4_smt,0.06894230097532272|0.12338443845510483|0.06745202839374542|0.18896484375|0.11570753157138824
639,"Die Patienten müssen über zu erwartende Nebenwirkungen wie Kopfschmerzen, Übelkeit, Erbrechen und Fieber und über frühe Anzeichen einer Neurotoxizität informiert werden.","Patients must be informed of the expected side effects such as headache, nausea, vomiting and fever and informed of the early signs of neurotoxicity.","Patients should be informed about the expected adverse reactions of headache, nausea, vomiting and fever, and about the early signs and symptoms of neurotoxicity.","Patients must be informed of the expected side effects such as headache, nausea, vomiting and fever and informed of the early signs of neurotoxicity.",0.0,smt,4,4_smt,-0.014691585674881935|-0.006894394755363464|0.014499238692224026|0.01880091056227684|0.04413595795631409
640,"Außerdem ist es wichtig, dass Sie die Spritze in einem durchstichsicheren Behältnis entsorgen.","In addition, it is important that you dispose of the syringe in a puncture-proof container.",It is also important that you dispose of the syringe in a puncture-proof container.,"In addition, it is important that you dispose of the syringe in a puncture-proof container.",0.0,smt,4,4_smt,-0.027120107784867287|-0.0256220530718565|0.010374803096055984|0.004979833494871855|0.03419168293476105
641,"Die Spritze passt auf die Flasche und besitzt eine Skala nach kg Körpergewicht, welche der Erhaltungsdosis (d.h.",The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i. e.,The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (ie.,The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i. e.,0.0,smt,4,4_smt,-0.013888876885175705|-0.012972092255949974|0.031605858355760574|0.022058362141251564|0.047146204859018326
642,"Unter der Annahme einer 100%igen Resorption ergibt sich daraus eine Dosis von 0,5 mg/kg für ein 10 kg schweres Kleinkind.",Under the adoption of the absorption of a 100% increase in relaxation and another dose of 0.5 mg / kg for 10 kg of severe Kleinkind.,"This exposure would result in a final dose of 0.5 mg/ kg in a 10 kg infant, assuming 100% absorption.",Under the assumption of a 100% absorption gives the result of a 0.5 mg / kg dose for 10 kg baby.,0.6086956521739131,smt,4,4_smt,0.28333282470703125|0.35711702704429626|0.42862430214881897|0.43708282709121704|0.3436557352542877
643,Prüfen Sie das Verfalldatum auf dem Etikett der Durchstechflasche (EXP:).,Check the expiry date on the vial label (EXP:).,Check the expiry date on the vial label (EXP).,Check the expiry date on the vial label (EXP:).,0.0,smt,4,4_smt,-0.025554129853844643|-0.02247646637260914|0.014376469887793064|7.461244240403175e-05|0.03319990634918213
644,"Dosierung bei eingeschränkter Nierenfunktion, Dialysepatienten und älteren Patienten:","Dosage in case of reduced renal function, dialysis patients and elderly patients:","Dosage regimen in renal impairment, in dialysis patients and elderly:","Dosage in case of reduced renal function, dialysis patients and elderly patients:",0.0,smt,4,4_smt,-0.008731376379728317|0.0038878265768289566|0.013749036937952042|0.04081486538052559|0.05172497034072876
645,rechtfertigt eine klinische Überwachung auf Sedierung und kognitive Effekte.,the potential benefit justifies the potential clinical monitoring on sedation and cognitive effects.,clinical monitoring for sedation and cognitive effects.,the potential benefit justifies the potential clinical monitoring on sedation and cognitive effects.,0.0,smt,4,4_smt,0.058201100677251816|0.08430474996566772|0.13840694725513458|0.1617221087217331|0.12138184159994125
646,"Wenn Blut in die Spritze gelangt ist, verwerfen Sie die Spritze samt Suspension und bereiten Sie das Arzneimittel erneut zu.","If blood enters the syringe, discard the syringe pointing suspension and prepare the medicine again.","If any blood is drawn into the syringe, the syringe and the dose should be discarded and fresh drug prepared.","If blood enters the syringe, discard the syringe along with suspension and prepare the medicine again.",0.1111111111111111,smt,4,4_smt,0.07999241352081299|0.13345257937908173|0.118401899933815|0.2141810953617096|0.16766361892223358
647,Die Unschädlichheit und Wirksamkeit des Impfstoffes bei männlichen Zuchttieren ist noch nicht belegt.,The Unschädlichheit and efficacy of the vaccine in male breeding animals has not been established yet.,The safety and the efficacy of the vaccine has not been established in breeding males.,The safety and efficacy of the vaccine in male breeding animals has not been established yet.,0.0588235294117647,smt,4,4_smt,0.032745666801929474|0.07592514902353287|0.027178579941391945|0.12490936368703842|0.10194680839776993
648,Der induzierende Effekt kann bis zu 2 Wochen nach Therapieabbruch von Johanniskraut anhalten.,The inducing effect may persist for up to 2 weeks after discontinuation of therapy with St John's wort.,The inducing effect may persist up to 2 weeks after cessation of treatment with St. John’ s wort.,The inducing effect may persist for up to 2 weeks after discontinuation of therapy with St John's wort.,0.0,smt,4,4_smt,-0.011638637632131577|-0.006240297108888626|0.01515293586999178|0.039401620626449585|0.048483483493328094
649,"Der Vernebler wandelt die Ventavis-Lösung in einen feinen Nebel um, der über den Mund eingeatmet wird.","The nebuliser thermally bonded to the Ventavis-Lösung transmitted by the said upside down, the mouth is present.",The nebuliser turns Ventavis solution into a mist which you breathe in through your mouth.,The nebuliser turns Ventavis solution into a mist which you breathe in through your mouth.,0.9375,smt,4,4_smt,0.6540673971176147|0.6938952803611755|0.6808999180793762|0.7079217433929443|0.6590757369995117
650,Verkehrstüchtigkeit und das Bedienen von Maschinen Es wurden keine Studien hinsichtlich der Wirkung von INTELENCE auf die Verkehrstüchtigkeit und das Bedienen von Maschinen durchgeführt.,Driving and using machines No studies regarding the effect of INTELENCE on the ability to drive and use machines have been performed.,Driving and using machines No studies on the effects of INTELENCE on the ability to drive and use machines have been performed.,Driving and using machines. No studies regarding the effect of INTELENCE on the ability to drive and use machines have been performed.,0.0416666666666666,smt,4,4_smt,-0.03772418946027756|-0.036530330777168274|0.01546104159206152|-0.003964924719184637|0.026750775054097176
651,"Die Leberfunktion ist vor der Verabreichung von Caelyx mit üblichen klinischen Labortests, wie z.B. Bestimmung der ALT/AST (GPT/GOT), alkalischen Phosphatase und Bilirubin, zu ermitteln.","Liver function before the administration of Caelyx comes into contact with the anticipated clinical laboratory tests, such as the determination of serum ALT / AST (ALT / ASAT), alkaline phosphatase, and bilirubin.","6 the normal range. Prior to Caelyx administration, evaluate hepatic function using conventional clinical laboratory tests such as ALT/ AST, alkaline phosphatase, and bilirubin.","Liver function should be checked before the administration of Caelyx in usual clinical laboratory tests, such as the determination of serum ALT / AST (ALT / ASAT), alkaline phosphatase, and bilirubin.",0.1891891891891892,smt,4,4_smt,0.08727551251649857|0.13193248212337494|0.09315423667430878|0.16181756556034088|0.15212376415729523
652,"Es hat sich gezeigt, dass eine Exposition gegenüber Chinolonen in Konzentrationen unterhalb der Hemmkonzentration die Mutationsrate bei E. coli, Staphylokokken, Pneumokokken und Mycobacterium spp. sowie eine Selektion auf Resistenz per se deutlich erhöht (3).","It has been shown that exposure to quinolones at concentrations below the inhibitory concentration of the Mutationsrate in E. coli, staphylococci, pneumococcal and Mycobacterium spp., and an resistance per se of markedly increased (3).","It has been shown that exposure to quinolones at subinhibitory concentrations significantly increase the mutation rate in E. coli, staphylococci, pneumococci and Mycobacterium spp., as well as selecting for resistance per se (3).","It has been shown that exposure to quinolones at concentrations below the inhibitory concentration of the mutation rate increases the resistance per se in E. coli, staphylococci, pneumococcal and Mycobacterium spp. (3).",0.2105263157894736,smt,4,4_smt,0.15490354597568512|0.22267238795757294|0.16497544944286346|0.25644123554229736|0.2155209630727768
653,"Wie bei Medetomidin wurde bei etwa 40 bis 50% der Tiere eine „gute“ oder„ ausgezeichnete“ Analgesie erzielt, was den Einsatz bei nicht-invasiven, leicht bis mäßig schmerzhaften Eingriffen stützt.","As medetomidine was seen in about 40% to 50% of the animals ""good 'or"" excellent' analgesia, which is consistent with mildly to moderately painful procedures.","As for medetomidine, ‘ good’ or ‘ excellent’ analgesia was reached in about 40 to 50% of the animals, supporting its use in non-invasive mildly to moderately painful procedures.","As for medetomidine, 'good' or' excellent' analgesia was reached in about 40 to 50% of the animals, supporting its use in non-invasive mildly to moderately painful procedures.",0.4285714285714285,smt,4,4_smt,0.12485974282026291|0.1723674088716507|0.183248832821846|0.22179247438907623|0.16968491673469543
654,"Wenn Effentora dennoch angewendet wird, sollte ein Antidot für das Kind unmittelbar bereitgehalten werden.","If nevertheless, Effentora should be given as an antidote to immediately bereitgehalten for the child.","If Effentora is administered, an antidote for the child should be readily available.","If, nevertheless, Effentora should be administered, an antidote should be kept immediately at hand for the child.",0.3809523809523809,smt,4,4_smt,0.16189433634281158|0.22123876214027405|0.29010123014450073|0.3150065243244171|0.22556839883327484
655,In klinisch relevanten Konzentrationen beträgt die Plasmaproteinbindung von Dasatinib ungefähr 96% basierend auf in-vitro-Experimenten.,"MPA at clinically relevant concentrations, plasma protein binding is approximately 96% of dasatinib based on in-vitro-Experimenten.","At clinically relevant concentrations, binding of dasatinib to plasma proteins is approximately 96% on the basis of in vitro experiments.",In clinical relevant concentrations of pasma protein binding are approximately 96% of dasatinib based on in-vitro experiments.,0.4210526315789473,smt,4,4_smt,0.14503520727157593|0.22653187811374664|0.24982845783233643|0.2732231318950653|0.2277732789516449
656,"• Es ist möglich, dass psychiatrische Reaktionen nach der ersten Einnahme von Ciprofloxacin Bayer auftreten.",• It is possible that psychiatric reactions the first time you take Ciprofloxacin Bayer.,378 • You may experience psychiatric reactions the first time you take Ciprofloxacin Bayer.,• It is possible that psychiatric reactions may occur after the first time you take Ciprofloxacin Bayer.,0.1666666666666666,smt,4,4_smt,0.09757093340158463|0.1415402591228485|0.1156512126326561|0.1898571401834488|0.1456504464149475
657,"In dieser Studie reduzierte die tägliche Gabe von Alendronat das Auftreten von mindestens einer neuen Wirbelfraktur um 47% (Alendronat 7,9% gegenüber Plazebo 15,0%).","In this study of 2,027 patients who had at least one fracture by 47% (alendronate 7.9% versus placebo 15.0%).",In this study alendronate daily reduced the incidence of ≥ 1 new vertebral fracture by 47% (alendronate 7.9% vs. placebo 15.0%).,"In this study, the daily administration of Alendronat reduced the occurrence of at least one vertabrae fracture by 47% (alendronate 7.9% versus placebo 15.0%).",0.3225806451612903,smt,4,4_smt,0.14316293597221375|0.22020088136196136|0.18795080482959747|0.26170918345451355|0.20535580813884735
658,Johanniskraut (CYP450-Induktor; p-GP-Induktor):,St John's wort (CYP450 inducer; P-gp inducer):,St John’ s Wort (CYP450 inducer; P-gp inducer):,St John's wort (CYP450 inducer; P-gp inducer):,0.0,smt,4,4_smt,0.006766873877495527|0.023509617894887924|0.018650615587830544|0.07612880319356918|0.07062109559774399
659,Der Verschluss der Durchstechflasche enthält ein Latexderivat.,The vial stopper contains a derivative of latex).,The vial stopper contains a derivative of latex.,The vial stopper contains a derivative of latex.,0.1111111111111111,smt,4,4_smt,-0.007361235562711954|0.0019151046872138977|0.008870622143149376|0.05949696898460388|0.057346515357494354
660,Durchstechflasche zu 30 ml aus farblosem Glas Typ I mit Butylelastomer-Stopfen und einem Aluminiumsiegel mit Kunststoffknopf aus Polypropylen.,vial of 30 ml colourless type I glass vials closed with a butyl elastomer closure and aluminium overseal with Kunststoffknopf with child resistant closure of polypropylene.,Colourless type I 30 ml glass vial sealed with butyl elastomeric stopper and aluminium seal with polypropylene plastic button.,Colourless type I 30 ml glass vial sealed with butyl elastomeric stopper and aluminium seal with polypropylene plastic button.,0.8,smt,4,4_smt,0.17238369584083557|0.26291218400001526|0.253107488155365|0.3214682936668396|0.22836165130138397
661,Patienten mit mittelgradiger oder schwerer Leberfunktionsstörung (Child-Pugh-Klasse B oder C).,Patients with moderate or severe hepatic impairment (Child-Pugh Class B or C).,Patients with moderate or severe (Child-Pugh B or C) hepatic impairment.,Patients with moderate or severe hepatic impairment (Child-Pugh Class B or C).,0.0,smt,4,4_smt,-0.024629177525639534|-0.012396641075611115|0.01533846277743578|0.01428336463868618|0.028105448931455612
662,"Wenn sich nach Abziehen des Pflasters Rückstände auf der Haut befinden, können diese mit reichlich Seife und Wasser entfernt werden.","If traces of the transdermal patch remain on the skin, these can be cleaned off using copious amounts of soap and water.","14 If traces of the transdermal patch remain on the skin after its removal, these can be cleaned off using copious amounts of soap and water.","If traces of the transdermal patch remain on the skin, these can be cleaned off using copious amounts of soap and water.",0.0,smt,4,4_smt,-0.027065129950642586|-0.023148464038968086|0.013898470439016819|0.007208355236798525|0.03958163410425186
663,Das PSUR Einreichschema für Oprymea Tabletten soll dem PSUR Einreichschema des Referenz - Arzneimittels folgen.,The PSUR submission schedule for Oprymea tablets should follow PSURs submission schedule for the reference medicinal product. -,The PSUR submission schedule for Oprymea tablets should follow PSURs submission schedule for the reference medicinal product.,The PSUR submission schedule for Oprymea tablets should follow PSURs submission schedule for the reference medicinal product.,0.0555555555555555,smt,4,4_smt,-0.00453837588429451|-2.1304935216903687e-05|0.025900904089212418|0.04129479452967644|0.05163630098104477
664,"201 denen diese Fähigkeiten von besonderer Bedeutung sind (z. B. beim Autofahren oder beim Bedienen von Maschinen), ein Risiko darstellen.",201 which may constitute a risk in situations where these abilities are of special importance (e. g. driving a car or operating machinery).,This may constitute a risk in situations where these abilities are of special importance (e. g. driving a car or operating machinery).,201 in situations where these abilities are of special importance (e. g. driving a car or operating machinery).,0.238095238095238,smt,4,4_smt,-0.023428063839673996|-0.028813233599066734|0.016702920198440552|0.004164224024862051|0.03575942665338516
665,"Es ist in Durchstechflaschen, Patronen oder Einweg-Fertigpens (OptiSet und SoloStar) erhältlich.","It is supplied in vials, cartridges or in prefilled Einweg-Fertigpens (OptiSet and SoloStar).","It is supplied in vials, cartridges, or pre-filled disposable pens (OptiSet and SoloStar).","It is supplied in vials, cartridges or in prefilled single-use pens (OptiSet and SoloStar).",0.1111111111111111,smt,4,4_smt,0.026067009195685387|0.06601503491401672|0.08632176369428635|0.09412864595651627|0.08461403101682663
666,"Ein komplettes Blutbild ist in den ersten 2 Monaten alle zwei Wochen durchzuführen, danach monatlich oder wie klinisch indiziert.","A complete blood counts shall be performed in the first 2 months, every two weeks, then monthly, or as clinically indicated.","Complete blood counts should be performed every two weeks for the first 2 months and then monthly thereafter, or as clinically indicated.","A complete blood counts shall be performed in the first 2 months, every two weeks, then monthly, or as clinically indicated.",0.0,smt,4,4_smt,0.02707827277481556|0.04189847409725189|0.04916270822286606|0.0948057547211647|0.08454637229442596
667,"93,9; 100,0) bzw. durch HPV-18 100,0% (95% KI:","93.9, 100.0) and 100.0% (95% CI:","93.9, 100.0) and 100.0% (95% CI:","93.9, 100.0) and HPV-18 100.0% (95% CI:",0.0769230769230769,smt,4,4_smt,-0.018079763278365135|-0.025115257129073143|0.01394510455429554|-0.0019910833798348904|0.032425303012132645
668,Regelmäßige Blutuntersuchungen Avaglim kann zur Abnahme der Zahl bestimmter Blutzellen führen.,Regular blood tests Avaglim can lead to decreases in the number of certain blood cells.,You will have regular blood tests Avaglim can cause reductions in some types of blood cells.,Regular blood tests Avaglim can lead to decreases in the number of certain blood cells.,0.0,smt,4,4_smt,0.01690642721951008|0.0380503386259079|0.05592092126607895|0.08531241863965988|0.07739650458097458
669,Weitere Daten zur gastrointestinalen Sicherheit In zwei 12-wöchigen doppelblinden Endoskopiestudien war die kumulative Häufigkeit gastroduodenaler Ulzerationen unter Etoricoxib 120 mg einmal täglich signifikant geringer als bei Patienten unter Naproxen 500 mg zweimal täglich oder Ibuprofen 800 mg dreimal täglich.,"Other data on the safety In two 12-week, double-blind, Endoskopiestudien was the cumulative incidence of gastroduodenal ulceration with etoricoxib 120 mg once daily significantly less than that observed in patients receiving naproxen 500 mg twice daily or ibuprofen 800 mg three times daily.","Additional Gastrointestinal Safety Data In two 12-week double-blind endoscopy studies, the cumulative incidence of gastroduodenal ulceration was significantly lower in patients treated with etoricoxib 120 mg once daily than in patients treated with either naproxen 500 mg twice daily or ibuprofen 800 mg three times daily.","Additional Gastrointestinal Safety Data In two 12-week double-blind endoscopy studies, the cumulative incidence of gastroduodenal ulceration was significantly lower in patients treated with etoricoxib 120 mg once daily than in patients treated with either naproxen 500 mg twice daily or ibuprofen 800 mg three times daily.",0.375,smt,4,4_smt,0.07288411259651184|0.11312516033649445|0.12822523713111877|0.15299175679683685|0.129682719707489
670,"In die Phase 3-Studie (Studie 008) wurden Frauen aufgenommen, ohne dass vorher bestimmt wurde, ob eine HPV-Infektion vorliegt, d.h. unabhängig der bestehenden Zytologie und des serologischen HPV-Status bzw. des HPV-DNA-Status.","In the double blind study (Study 008) were women without recurrence was previously whether the presence of HPV infection, i. e., irrespective of the existing Zytologie and serological responses HPV-Status and HPV-DNA-Status.","The phase III trial (study 008) enrolled women without pre-screening for the presence of HPV infection, i. e. regardless of baseline cytology and HPV serological and DNA status.","In the double blind study (Study 008) women were taken without previously determining whether the presence of an HPV infection, i. e., irrespective of the existing cytology and serological HPV status and HPV-DNA status.",0.275,smt,4,4_smt,0.28554028272628784|0.3883669972419739|0.3688890337944031|0.41354548931121826|0.3535621464252472
671,"Daher sollte sorgfältig abgewogen werden, ob M-M-RVAXPRO an stillende Mütter verabreicht wird.","Therefore, considering whether M-M-RVAXPRO can be given to nursing mothers.","It is not known whether measles or mumps vaccine virus is secreted in human milk; therefore, caution should be exercised when M-M-RVAXPRO is administered to a breast-feeding woman.","Therefore, it should be carefully considered whether M-M-RVAXPRO can be given to nursing mothers.",0.3125,smt,4,4_smt,0.3084814250469208|0.4120092988014221|0.2891627252101898|0.47147268056869507|0.36574098467826843
672,RotaTeq DARF NUR IN DEN MUND VERABREICHT WERDEN.,RotaTeq MUST ONLY FOR USE IN THE DIAGNOSIS OF MUND INFLAMMATION,RotaTeq IS FOR OR AL USE ONLY.,RotaTeq CAN ONLY BE ADMINISTERED ORALLY,1.0,smt,4,4_smt,0.10180587321519852|0.14964301884174347|0.23449860513210297|0.18525022268295288|0.15683545172214508
673,"Alle Ärzte, die Tysabri verordnen, müssen mit der ‚ Arztinformation und Managementleitlinien’ vertraut sein.",All physicians who prescribe Tysabri must be familiar with the Physician Information and Management.,All physicians who intend to prescribe TYSABRI must ensure they are familiar with the Physician Information and Management Guidelines.,All physicians who prescribe Tysabri must be familiar with the Physician Information and Management.,0.0,smt,4,4_smt,0.0735761746764183|0.10077989846467972|0.06267719715833664|0.13461005687713623|0.12006080150604248
674,"30% lösliches (schnell wirkendes) Insulinaspart und 70% (langsam wirkende) Insulinaspart-Protamin-Kristalle, • NovoMix 50:","30% soluble insulin aspart (rapid acting insulin aspart) and 70% (and insulin aspart crystallised with protamine), • NovoMix 50:","30% soluble insulin aspart (rapid acting) and 70% protamine-crystallised insulin aspart (long acting), • NovoMix 50:","30% soluble insulin aspart (rapid acting insulin aspart) and 70% (slow working), and insulin aspart crystallised with protamine,• NovoMix 50:",0.1666666666666666,smt,4,4_smt,0.04050108790397644|0.07841118425130844|0.10733335465192795|0.11681386828422546|0.10961328446865082
675,247 Deutschland Bristol-Myers Squibb GmbH & CO.,247 Deutschland Bristol-Myers Squibb GmbH & CO.,216 Deutschland Bristol-Myers Squibb GmbH & CO.,247 Deutschland Bristol-Myers Squibb GmbH & CO.,0.0,smt,4,4_smt,-0.006720962002873421|-0.02242259494960308|0.012014814652502537|0.025555936619639397|0.03508411720395088
676,"Sprimeo wird zur Behandlung der essenziellen Hypertonie (Bluthochdruck) angewendet. „Essenziell” bedeutet, dass sich keine spezifische Ursache für den Bluthochdruck feststellen lässt.","Sprimeo is used to treat essential hypertension (high blood pressure). ""Essential 'means that no specific cause for the hypertension can be found.",Sprimeo is used to treat essential hypertension (high blood pressure). ‘ Essential ’ means that no specific cause for the hypertension can be found.,"Sprimeo is used to treat essential hypertension (high blood pressure). ""Essential 'means that no specific cause for the hypertension can be found.",0.0,smt,4,4_smt,-0.01094113104045391|-0.007824834436178207|0.02199527621269226|0.020730117335915565|0.04561658203601837
677,"Da Dexrazoxan mutationsauslösende Wirkungen besitzt, wird Männern, die mit Dexrazoxan behandelt werden, geraten, während und bis zu 3 Monate nach der Behandlung keine Kinder zu zeugen.","As dexrazoxane possesses mutagenic activity, Men being treated with dexrazoxane, is advised, months during and up to 3 months after treatment.","As dexrazoxane possesses mutagenic activity, men being treated with dexrazoxane are advised not to father a child during and up to three months after treatment.","As dexrazoxane possesses mutagenic activity, men being treated with dexrazoxane are advised not to have children during and up to 3 months after treatment.",0.2307692307692307,smt,4,4_smt,0.13534249365329742|0.236964613199234|0.23979932069778442|0.26448386907577515|0.20525352656841278
678,Wie wirkt Prandin?,How does Prandin work?,How does Prandin work?,How does Prandin work?,0.0,smt,4,4_smt,-0.06771720200777054|-0.07532341778278351|0.008486984297633171|-0.04697773605585098|-0.009894203394651413
679,Bei Patienten mit asymptomatischer ausgeprägter Leukozyturie (> 100 Zellen/Gesichtsfeld) wurden Fälle von interstitieller Nephritis mit medullärer Kalzifizierung und kortikaler Atrophie beobachtet.,Cases of interstitial nephritis with Calcinosis (MRHD) in each of the atrophy were observed in patients with asymptomatic marked Leukozyturie ( 100 / 20).,Cases of interstitial nephritis with medullary calcification and cortical atrophy have been observed in patients with asymptomatic severe leucocyturia (> 100 cells/ high power field).,Cases of interstitial nephritis with medullary calcification and cortical atrophy have been observed in patients with asymptomatic severe leucocyturia (> 100 cells/ field of vision).,0.5517241379310345,smt,4,4_smt,0.09855629503726959|0.17882223427295685|0.22548353672027588|0.2267255336046219|0.18140192329883575
680,Pädiatrische Patienten: Nebenwirkungen bei Kindern waren generell mit denen Erwachsener vergleichbar.,Paediatric patients: undesirable effects in children were generally similar to those of adult patients.,140 Paediatric patients: undesirable effects in children were generally similar to those of adult patients.,Paediatric patients: undesirable effects in children were generally similar to those of adult patients.,0.0,smt,4,4_smt,-0.04147210717201233|-0.045292600989341736|0.013753375969827175|-0.016308873891830444|0.013812068849802017
681,Dieses Arzneimittel ist nur zum einmaligen Gebrauch bestimmt.,This medicinal product is for single use only.,This product is for single use only.,This medicinal product is for single use only.,0.0,smt,4,4_smt,-0.03413344919681549|-0.040020473301410675|0.009651156142354012|-0.01731528714299202|0.016727499663829803
682,Eine Verbesserung des Werts nach der Behandlung um 20% wurde als Maß für einen für die Patienten relevanten Nutzen genommen.,"Improvement in paliperidone, after treatment by 20% was taken as a measure of the number of patients reaching a relevant benefit.",An improvement of 20% in the score after treatment was taken as a measure of a benefit that would be relevant for patients.,An improvement of 20% in the score after treatment was taken as a measure of a benefit that would be relevant for patients.,0.6,smt,4,4_smt,0.08382190018892288|0.13881036639213562|0.2023039013147354|0.19373683631420135|0.16376008093357086
683,Angesichts des erhöhten Risikos für venöse Thromboembolien bei Patienten mit multiplem Myelom werden kombinierte orale Kontrazeptiva nicht empfohlen (siehe Abschnitt 4.5).,"In light of the increased risk of venous thromboembolism in patients with multiple myeloma, combined oral contraceptive pills are not recommended (see section 4.5).","Because of the increased risk of venous thromboembolism in patients with multiple myeloma, combined oral contraceptive pills are not recommended (see section 4.5).","In light of the increased risk of venous thromboembolism in patients with multiple myeloma, combined oral contraceptive pills are not recommended (see section 4.5).",0.0,smt,4,4_smt,-0.03141845017671585|-0.029285436496138573|0.010982331819832325|-0.0003540758043527603|0.02699531428515911
684,"Das atrophogene Potenzial von (Name (Phantasiebezeichnung) bei Menschen wurde im Vergleich zu mittel- und hochpotenten topischen Steroiden (Betametason-17-valerat 0,1% Creme, Triamcinolonacetonid 0,1% Creme) und Cremegrundlage an sechzehn gesunden Freiwilligen über 4 Wochen untersucht.","The atrophogenic potential of Invented Name in humans has been studied in comparison with and highly potent topical steroids (betamethasone-17-valerate 0.1% cream, 0.1% cream) and vehicle in sixteen healthy volunteers over 4 weeks.","The atrophogenic potential of < Invented Name > in humans was tested in comparison to medium and highly potent topical steroids (betamethasone-17-valerate 0.1% cream, triamcinolone acetonide 0.1% cream) and vehicle in sixteen healthy volunteers treated for 4 weeks.","The atrophogenic potential of Invented Name in humans has been studied in comparison with and highly potent topical steroids (betamethasone-17-valerate 0.1% cream, 0.1% cream) and vehicle in sixteen healthy volunteers over 4 weeks.",0.0,smt,4,4_smt,0.0915946215391159|0.15207944810390472|0.11709524691104889|0.184440016746521|0.159052312374115
685,In klinischen Prüfungen wurden die Tabletten bis zu einer Behandlungsdauer von 14 Tagen untersucht.,"In clinical trials, the tablets has been studied for up to a treatment duration of 14 days.",In clinical trials the tablets have been studied for up to 14 days treatment.,"In clinical trials, the tablets have been studied for up to a treatment duration of 14 days.",0.0526315789473684,smt,4,4_smt,-0.0029106810688972473|-0.002018135040998459|0.03787332773208618|0.04461010918021202|0.05046207457780838
686,Karzinogenese-Studien wurden mit Dasatinib nicht durchgeführt.,Karzinogenese-Studien have not been conducted with dasatinib.,No carcinogenesis studies were conducted with dasatinib.,Carcinogenic studies have not been conducted with dasatinib.,0.2222222222222222,smt,4,4_smt,0.02984771504998207|0.06364095211029053|0.18557429313659668|0.09719835966825485|0.0836535096168518
687,Überdosierung von Benzodiazepin oder Benzodiazepin-ähnlichen Wirkstoffen manifestiert sich gewöhnlich durch zentralnervöse Dämpfung unterschiedlichen Grades von Benommenheit bis zum Koma.,overdose of benzodiazepine or benzodiazepine or benzodiazepine-like agents is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma.,Overdose of benzodiazepine or benzodiazepine-like agents is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma.,overdose of benzodiazepine or benzodiazepine-like agents is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma.,0.0909090909090909,smt,4,4_smt,0.007409988436847925|0.02692738175392151|0.023299243301153183|0.0625520721077919|0.05732601135969162
688,Bei der Kombination von Emtricitabin und Tenofovir wurde in vitro eine synergistische antivirale Wirkung beschrieben.,In the combination of emtricitabine and tenofovir has also been observed in vitro synergistic antiviral activity.,Synergistic antiviral activity was observed with the combination of emtricitabine and tenofovir in vitro.,"In the combination of emtricitabine and tenofovir, an in vitro synergistic antiviral effect was described.",0.3529411764705882,smt,4,4_smt,0.0016114679165184498|0.036047786474227905|0.11981173604726791|0.06537184864282608|0.07039479166269302
689,"Die Empfehlung, den Gelbfieber-Impfstoff subkutan oder intramuskulär zu verabreichen, beruhte auf dem Versorgungsstandard zur Zeit der Entwicklung von STAMARIL Anfang der 1980er Jahre.","The recommendation for the YF vaccine administered subcutaneously or intramuscularly, was based on the Versorgungsstandard the time of development of STAMARIL at the beginning of the mid-1980s.",The recommendation to administer the yellow fever vaccine subcutaneously or intramuscularly was based on the standard of care at the time of the development of STAMARIL in the early 1980s.,"The recommendation for the YF vaccine administered subcutaneously or intramuscularly, was based on the supply standard the time of development of STAMARIL at the beginning of the mid-1980s.",0.0666666666666666,smt,4,4_smt,0.07425672560930252|0.11109932512044907|0.130141481757164|0.16060613095760345|0.15062281489372253
690,"Die durchschnittliche maximale Plasmakonzentration (Cmax) und die Fläche unter der Konzentrations-Zeit-Kurve (AUC0-∞) sind im Allgemeinen im gesamten Dosisbereich von 0,3– 90 μ g/kg bei Gesunden und Krebspatienten dosisproportional.",The mean maximum plasma concentration (Cmax) and area under the area under the curve (AUC0- ∞) are generally the entire over the dose range of 0.3 to 90 μ g / kg in healthy subjects and cancer patients are proportional to the dose.,Mean maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC0-∞) are generally dose-proportional over the dose range of 0.3– 90 μ g/ kg in healthy subjects and in cancer patients.,The mean maximum plasma concentration (Cmax) and area under the area under the concentration/time curve (AUC0- ∞) are generally proportional to the dose in the entire dose range of 0.3 to 90 μ g / kg in healthy subjects and cancer patients.,0.1632653061224489,smt,4,4_smt,0.09503719955682755|0.14823372662067413|0.17338073253631592|0.2026892900466919|0.1576227992773056
691,Wie wird Nexavar angewendet?,How is Nexavar used?,How is Nexavar used?,How is Nexavar used?,0.0,smt,4,4_smt,-0.07065349072217941|-0.0704505518078804|0.008214322850108147|-0.0499919056892395|-0.012194568291306496
692,Informationen über den Verschreibungsstatus dieses Arzneimittels finden Sie auf dem Etikett/der Umverpackung.,Information on the prescription status of this product may be found on the label / outer package.,Information on the prescription status of this product may be found on the label/ outer package.,Information on the prescription status of this product may be found on the label / outer package.,0.0,smt,4,4_smt,-0.048022039234638214|-0.05105266720056534|0.010072826407849789|-0.02823271043598652|0.012727211229503155
693,"Die Dosis liegt für alle Gruppen von Patienten (Kinder, Erwachsene und ältere Patienten) bei 0,15 mg pro Kilogramm Körpergewicht.","The dose for all groups of patients (children, adults and elderly patients) in a dose of 0.15 mg per kilogram body weight.","The dose is 0.15 mg per kilogram body weight for all types of patients (children, adults and elderly patients).","The dose for all groups of patients (children, adults and elderly patients) is 0.15 mg per kilogram of body weight.",0.1666666666666666,smt,4,4_smt,-0.00751415453851223|-0.013045201078057289|0.018282122910022736|0.02110842987895012|0.03852098807692528
694,"Der pH-Wert wird, sofern erforderlich, mit Natriumhydroxid und/oder Salzsäure eingestellt.",The pH may have been adjusted with sodium hydroxide and / or hydrochloric acid.,6 The pH may have been adjusted with sodium hydroxide and/ or hydrochloric acid.,The pH is adjusted as necessary with sodium hydroxide and / or hydrochloric acid.,0.2666666666666666,smt,4,4_smt,-0.03012065589427948|-0.029412804171442986|0.011083699762821198|-0.0004448341205716133|0.023227041587233543
695,Diese Wirkung trat nach zwei Wochen ein und wird durch Langzeitbehandlung aufrechterhalten.,"This effect occurred after two weeks, with long-term treatment.",This effect is observed after 2 weeks is maintained with long-term treatment.,This effect occurred after two weeks and persists with long-term treatment.,0.1666666666666666,smt,4,4_smt,0.025823235511779785|0.04387781023979187|0.07268056273460388|0.11675616353750229|0.09267127513885498
696,"Erblindung, Endophthalmitis, Hypopyon, Vorderkammerblutung, Keratopathie, Irisadhäsion, Ablagerungen auf der Kornea, Ödeme der Kornea, Striae der Kornea, Schmerzen an der Injektionsstelle, Reizungen an der Injektionsstelle, abnormales Gefühl im Auge, Reizungen des Augenlids.","Blindness, endophthalmitis, Hypopyon, Vorderkammerblutung, keratopathy, Irisadhäsion, deposits on the eye surface, oedema of mass spectrometry, 2-desmethyldiscodermolide, injection site pain, injection site irritation, abnormal sensation in the eye, irritation of the eyelid.","Blindness, endophthalmitis, hypopyon, hyphaema, keratopathy, iris adhesion, corneal deposits, corneal oedema, corneal striae, injection site pain, injection site irritation, abnormal sensation in eye, eyelid irritation.","Blindness, endophthalmitis, hypopyon, anterior chamber haemorrhage, keratopathy, iris adhesion, deposits on the eye surface, oedema of the cornea, striae of the cornea, injection site pain, injection site irritation, abnormal sensation in the eye, irritation of the eyelid.",0.22,smt,4,4_smt,0.10164003074169159|0.17787690460681915|0.13366438448429108|0.20079083740711212|0.17992433905601501
697,"Nach oraler Applikation von 14C-markiertem TMZ betrug die mittlere fäkale Exkretion von 14C über 7 Tage 0,8% der verabreichten Dosis, was auf eine vollständige Resorption hinweist.","After oral administration of 14C-labelled TMZ, the mean faecal excretion of 14C per day for 7 days to 0.8% of the administered dose, indicating full absorption.","After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8% indicationg complete absorption.","After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days was 0.8%, indicating complete absorption.",0.4347826086956521,smt,4,4_smt,0.07189033180475235|0.12595589458942413|0.1317606270313263|0.16689860820770264|0.14212171733379364
698,"Wenn Sie Raptiva verabreichen, lesen Sie bitte aufmerksam die folgenden Anweisungen und folgen Sie Ihnen Schritt für Schritt: • Waschen Sie sich die Hände.","If you administer Raptiva, be sure to read the following instructions carefully and follow them step by step. You tell you to Step 3: • Wash your hands.","If you administer Raptiva, please read the following instructions carefully and follow then step by step: • Wash your hands.","If you administer Raptiva, be sure to read the following instructions carefully and follow them step by step. • Wash your hands.",0.28,smt,4,4_smt,0.03539081662893295|0.043850451707839966|0.11272680759429932|0.07393046468496323|0.0774807259440422
699,"Zuerst brechen Sie die Spitze der Ampulle mit der Natriumchlorid-Lösung ab (a., b.).","PhotoBarr is a two-step process: the stop of the ampoule containing the sodium chloride solution (a.), b.).","First, break the top off the ampoule with the sodium chloride solution (a., b.).","First break off the top of the ampoule containing the sodium chloride solution (a.), b.).",0.3181818181818182,smt,4,4_smt,0.2120770364999771|0.24019956588745117|0.18435941636562347|0.31533098220825195|0.26077648997306824
700,"Dosisbegrenzende Nebenwirkungen sind eine Abnahme der Thrombozyten-, Leukozyten- und Granulozytenzahl (siehe Abschnitt 4.2).","Dose-limiting adverse reactions are a reduction in platelet, leucocyte and granulocyte counts (see section 4.2).","Dose-limiting adverse reactions are reductions in thrombocyte, leucocyte and granulocyte counts (see section 4.2).","Dose-limiting adverse reactions are a reduction in platelet, leucocyte and granulocyte counts (see section 4.2).",0.0,smt,4,4_smt,-0.015329515561461449|0.014480063691735268|0.015771906822919846|0.029230771586298943|0.04932084679603577
701,"Es wird zusammen mit Methotrexat (einem entzündungshemmenden Arzneimittel) bei Patienten angewendet, die auf Methotrexat allein nicht ausreichend angesprochen haben.",It is used with methotrexate (an anti-inflammatory medicine) used in patients who are not adequately responded to methotrexate alone.,It is used in combination with methotrexate (a medicine used to reduce inflammation) in patients who have not responded adequately to methotrexate alone.,It is used with methotrexate (an anti-inflammatory medicine) in patients who have not adequately responded to methotrexate alone.,0.0952380952380952,smt,4,4_smt,0.016916709020733833|0.023745786398649216|0.05190548300743103|0.06533343344926834|0.06387067586183548
702,Es tritt kein Insulin aus der Nadel.,There is no insulin comes out of the needle.,Insulin does not come out of the needle.,No insulin comes out of the needle.,0.25,smt,4,4_smt,0.03130251541733742|0.03932870924472809|0.05995474010705948|0.12219246476888657|0.1020626649260521
703,Sildenafil wirkt peripher auf Erektionen.,Sildenafil works by erections handrims.,Sildenafil has a peripheral site of action on erections.,Sildenafil has a peripheral effect on erections.,0.75,smt,4,4_smt,0.21263378858566284|0.3411768078804016|0.31130513548851013|0.4148879647254944|0.3155919313430786
704,"20 Millionen I.E./m2 täglich, 5mal in der Woche, über einen Zeitraum von 4 Wochen intravenös verabreicht.","20 million IU / m2 daily, 5 times a week, injected over a period of 4 weeks.","20 million IU/m2, intravenously, given daily for 5 days a week for a 4 week period.","20 million IU/m2 daily, 5 times a week, injected over a period of 4 weeks.",0.0,smt,4,4_smt,0.004845364484935999|0.010144349187612534|0.017673365771770477|0.04566456377506256|0.058613479137420654
705,"Wie alle Arzneimittel kann Levemir Nebenwirkungen haben, die aber nicht bei jedem auftreten müssen.","Like all medicines, Levemir may cause side effects, although not every body gets them.","Like all medicines, Levemir can cause side effects, although not everybody gets them.","Like all medicines, Levemir may cause side effects, although not every body gets them.",0.0,smt,4,4_smt,-0.04019111394882202|-0.04419349133968353|0.010288486257195473|-0.015072885900735855|0.01705462671816349
706,"41 Symptome Die Symptome einer Fentanyl-Überdosierung sind eine Verstärkung seiner pharmakologischen Wirkungen, z. B. Lethargie, Koma, Atemdepression mit Cheyne-Stokes-Atmung und/oder Cyanose.","41 Symptoms The symptoms of fentanyl overdose are an extension of its pharmacological actions, e. g. lethargy, coma, respiratory depression with Cheyne-Stokes respiration and / or cyanosis.","Symptoms The symptoms of fentanyl overdose are an extension of its pharmacological actions, e. g. lethargy, coma, respiratory depression with Cheyne-Stokes respiration and/ or cyanosis.","41 Symptoms: The symptoms of fentanyl overdose are an extension of its pharmacological actions, e. g. lethargy, coma, respiratory depression with Cheyne-Stokes respiration and/or cyanosis.",0.03125,smt,4,4_smt,0.001211498398333788|0.007414208725094795|0.01685185544192791|0.045703303068876266|0.05475848913192749
707,Jeder ml Infusionslösung enthält 10 mg Lacosamid.,Each ml of solution for infusion contains 10 mg lacosamide.,Each ml of solution contains 10 mg lacosamide.,Each ml of solution for infusion contains 10 mg lacosamide.,0.0,smt,4,4_smt,-0.019415097311139107|-0.02839178778231144|0.011221014894545078|0.006921450141817331|0.02453865110874176
708,Nur zur kutanen Anwendung (Anwendung auf der Haut) Zu Beginn Panretin Gel zweimal pro Tag auftragen und zwar einmal am Morgen und einmal am Abend.,For cutaneous use (on the skin) When you first start Panretin gel twice a day to empty and once in the morning and once in the evening.,"For cutaneous use (on the skin) only Apply Panretin twice a day to start with, once in the morning and once in the evening.","For cutaneous use (on the skin): When you first start Panretin, apply the gel twice a day, once in the morning and once in the evening.",0.21875,smt,4,4_smt,0.0517716221511364|0.07989269495010376|0.13950008153915405|0.13010284304618835|0.11244113743305206
709,"Darüber hinaus wurde vom Vogt-Koyanagi-Harada Syndrom (eine autoimmune Entzündungserkrankung, die Augen, Haut und die Membrane von Ohr, Gehirn und Rückenmark angreift) berichtet.","Furthermore, the Vogt-Koyanagi-Harada syndrome (eyes, skin, skin and the membranes of the ears, brain and spinal cord) has been reported.","Additionally, Vogt-Koyanagi-Harada syndrome (an autoimmune inflammatory disorder affecting the eyes, skin and the membranes of the ears, brain and spinal cord) has been reported.","Furthermore, the Vogt-Koyanagi-Harada syndrome (eyes, skin, skin and the membranes of the ears, brain and spinal cord) has been reported.",0.0,smt,4,4_smt,0.07141019403934479|0.10962267965078354|0.11727233231067657|0.16100329160690308|0.13686563074588776
710,2/3 gesundheitsschädlich sind.,2 / 3 are harmful.,See the Package Leaflet for the full list of these medicines.,2/3 are harmful.,0.0,smt,4,4_smt,0.44732216000556946|0.4986925423145294|0.16801339387893677|0.5486249327659607|0.48569774627685547
711,"Daher ist die Wahrscheinlichkeit von Arzneimittelwechselwirkungen mit antiretroviralen Proteasehemmern und anderen Arzneimitteln, die über die wichtigsten Cytochrom-P450-Enzyme abgebaut werden, gering.","Therefore, there is little potential for interactions with antiretroviral protease inhibitors and other medicinal products metabolised by major cytochrome P450 enzymes.","Therefore, there is little potential for interactions with antiretroviral PIs and other medicinal products metabolised by major P450 enzymes.","Therefore, there is little potential for interactions with antiretroviral protease inhibitors and other medicinal products metabolised by major cytochrome P450 enzymes.",0.0,smt,4,4_smt,0.013978332281112671|0.0457700714468956|0.02340530976653099|0.07186456024646759|0.07530184835195541
712,"Beachten Sie, dass die gewünschte Wirkung nicht erzielt wird, wenn Sie die Einnahme von Prandin abbrechen.",Note that is having the desired effect is not if you stop taking Prandin.,Be aware that the desired effect is not achieved if you stop taking Prandin.,Note that is having the desired effect is not achieved if you stop taking Prandin.,0.0625,smt,4,4_smt,0.10667288303375244|0.16303525865077972|0.28295329213142395|0.21737736463546753|0.1799488216638565
713,"Bei allen mit oralem Olanzapin oder Placebo behandelten Patienten, bei denen es zu einem zerebrovaskulären Ereignis kam, bestanden bereits vor der Behandlung Risikofaktoren.","In all patients treated with oral olanzapine or placebo, patients who experienced a cerebrovascular event, risk factors have been identified, already before treatment.",All oral olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors.,"In all patients treated with oral olanzapine or placebo who experienced a cerebrovascular event, risk factors were already identified before treatment.",0.2608695652173913,smt,4,4_smt,0.18514740467071533|0.2625748813152313|0.2848285138607025|0.33787721395492554|0.24343529343605042
714,Diese Reaktionen sind gewöhnlich vorübergehend und klingen normalerweise im Verlauf der Behandlung ab.,Most reactions are transitory and usually resolve normally during the course of treatment.,These reactions are usually transitory and normally they disappear during continued treatment.,Most reactions are transitory and usually resolve during the course of treatment.,0.0769230769230769,smt,4,4_smt,-0.02057359740138054|-0.02175813354551792|0.01977844536304474|0.016919175162911415|0.031150050461292267
715,Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden.,For reconstitution of only the unattached water for injections and the unattached Rekonstitutionsset.,For reconstitution only the water for injections and the reconstitution device provided in the pack should be used.,For reconstitution only of the enclosed water for injections and the reconstitution set.,0.2857142857142857,smt,4,4_smt,0.3131564259529114|0.40772825479507446|0.3732519745826721|0.46617257595062256|0.3747703433036804
716,25 Packung mit einer Durchstechflasche zu 4 ml.,25 Pack of 1 vial containing 4 ml.,Pack of 1 vial containing 4 ml.,25 Pack with 1 vial containing 4 ml.,0.1111111111111111,smt,4,4_smt,-0.03415397182106972|-0.03501074016094208|0.012187506072223186|-0.003143018577247858|0.025439657270908356
717,Siehe unten stehende Tabelle für empfohlene Dosis entsprechend dem Körpergewicht in 10 kg-Schritten.,See Table below the recommended dose according to body weight Sample body weights at 10 kg increments.,See table below for recommended doses for body weights at 10 kg increments.,See the table below for the recommended dose according to body weight at 10 kg increments.,0.2941176470588235,smt,4,4_smt,0.0690111294388771|0.09864143282175064|0.13699008524417877|0.1692132204771042|0.1362629383802414
718,Neulasta ist nahezu „natriumfrei“.,"Neulasta is essentially ""sodium-free.""",Neulasta is essentially sodium-free.,"Neulasta is essentially ""sodium-free.""",0.0,smt,4,4_smt,-0.04233548790216446|-0.04221789538860321|0.013907498680055141|-0.009693032130599022|0.01560305617749691
719,"Patienten mit starken Schluckbeschwerden können die Tablette ausnahmsweise in mindestens 100 ml Wasser, Orangen- oder Traubensaft zerstoßen und diese Suspension trinken.","Patients with severe difficulty swallowing the tablet exceptionally may be diluted in at least 100 ml of water, Orangen- break or crush or Traubensaft and drink the suspension.","In exceptional cases, patients who have particular difficulty swallowing can crush the tablet in at least 100 ml of water, orange juice or grape juice, and drink the resulting suspension.","Patients with severe difficulty swallowing, may dilute the tablet in at least 100 ml of water, orange juice or grape juice and drink the suspension.",0.3214285714285714,smt,4,4_smt,0.20004241168498993|0.28558120131492615|0.2955254316329956|0.33832743763923645|0.27154117822647095
720,Bei Patienten mit eingeschränkter Leberfunktion liegen pharmakokinetische Daten für die Anwendung von Agenerase Kapseln ohne Boosterung durch Ritonavir vor.,"In patients with impaired liver function, pharmacokinetic data are available on the use of Agenerase capsules without boost by ritonavir.","For subjects with hepatic impairment, pharmacokinetic data are available for the use of Agenerase capsules without the boosting effect of ritonavir.","In patients with impaired liver function, pharmacokinetic data is available on the use of Agenerase capsules without boost by ritonavir.",0.0454545454545454,smt,4,4_smt,0.005523793864995241|0.02510969713330269|0.059532154351472855|0.06524623930454254|0.0645802915096283
721,Diese Zunahme wird als nicht klinisch relevant angesehen.,This increase is not considered to be clinically relevant.,This increase is not considered clinically relevant.,This increase is not considered to be clinically relevant.,0.0,smt,4,4_smt,-0.018935520201921463|-0.024980193004012108|0.012979216873645782|0.019128451123833656|0.03165293484926224
722,91 Insulatard anzuwenden?. Sie können sie mit sich führen und bei Raumtemperatur (nicht über 25°C) bis zu 6 Wochen lang aufbewahren.,91 to use Insulatard 4. You can carry them with you and keep them at room temperature (not above 25 ° C) for up to 6 weeks.,You can carry them with you and keep them at room temperature (not above 25°C) for up to 6 weeks.,91 How to use Insulatard? You can carry them with you and keep them at room temperature (not above 25 ° C) for up to 6 weeks.,0.0967741935483871,smt,4,4_smt,0.02039240673184395|0.03831314295530319|0.07766689360141754|0.06208674609661102|0.07364065200090408
723,"Karamellfarben, filmbeschichtet, kapselförmig, bikonvex und auf einer Seite mit der Prägung “GX CG5” versehen.","Karamellfarben, capsule shaped, biconvex and engraved ""GX CG5"" on one face.","Butterscotch coloured, film-coated, capsule shaped, biconvex and engraved “GX CG5” on one face.","Caramel coloured, film-coated, capsule shaped, biconvex and engraved ""GX CG5"" on one face.",0.2105263157894736,smt,4,4_smt,0.028225481510162354|0.060065947473049164|0.06915327161550522|0.10007240623235703|0.09135603904724121
724,CYMBALTA kann unabhängig von den Mahlzeiten eingenommen werden.,CYMBALTA may be taken with or without a meal.,Taking CYMBALTA with food and drink CYMBALTA may be taken with or without food.,CYMBALTA may be taken with or without a meal.,0.0,smt,4,4_smt,0.005359102506190538|0.0071664126589894295|0.05497966334223747|0.05431229621171951|0.06543073803186417
725,"1,0%); Ösophagitis/Dysphagie/ Odynophagie (G3/4:",1.0%); Esophagitis / dysphagia / odynophagia (G3 / 4:,1.0%); Oesophagitis/ dysphagia/ odynop hagia (G3/ 4:,1.0%); Esophagitis / dysphagia / odynophagia (G3 / 4:,0.0,smt,4,4_smt,-0.01352948509156704|0.0026989514008164406|0.017476562410593033|0.01923823170363903|0.04226754605770111
726,Haltbarkeit nach Anbruch:,Shelf-life after first opening the container:,Shelf-life after first opening:,Shelf-life after first opening the container:,0.0,smt,4,4_smt,-0.043011534959077835|-0.03919491916894913|0.010417670011520386|0.019431767985224724|0.034063175320625305
727,Die mit Panretin Gel beobachteten unerwünschten Ereignisse sind ähnlich wie die mit anderen topischen Retinoiden beobachteten.,The total amount of Panretin gel seen with similar to those observed with other retinoids.,The adverse events seen with Panretin gel are similar to those seen with other topical retinoids.,The total amount of Panretin gel seen with similar to those observed with other retinoids.,0.0,smt,4,4_smt,0.13850712776184082|0.1900261640548706|0.1422191560268402|0.26555460691452026|0.2051055133342743
728,"Wie alle Arzneimittel kann KOGENATE Bayer 2000 I.E. Nebenwirkungen haben, die aber nicht bei jedem auftreten müssen.","Like all medicines, KOGENATE Bayer 2000 IU can cause side effects, although not every body gets them.","Like all medicines, KOGENATE Bayer 2000 IU can cause side effects, although not everybody gets them.","As with all medicines, KOGENATE Bayer 2000 IU can cause side effects, although not every body gets them.",0.0952380952380952,smt,4,4_smt,-0.03396566957235336|-0.03387495130300522|0.01128467358648777|-0.008066093549132347|0.023057181388139725
729,Nehmen Sie Olanzapin Teva immer genau nach Anweisung des Arztes ein.,Do not take Olanzapine Teva exactly as your doctor has told you.,Always take Olanzapine Teva exactly as your doctor has told you.,Take Olanzapine Teva exactly as your doctor has told you.,0.1818181818181818,smt,4,4_smt,-0.008560790680348873|-0.018190721049904823|0.17664432525634766|0.01775587908923626|0.03436056151986122
730,"RotaTeq kann Frühgeborenen verabreicht werden, wenn die Schwangerschaft mindestens 25 Wochen gedauert hat.",RotaTeq may be given to infants if the pregnancy is at least 25 weeks gedauert.,RotaTeq may be given to infants who were born early provided that the pregnancy had lasted at least 25 weeks.,RotaTeq may be given to infants if the pregnancy lasted at least 25 weeks.,0.1333333333333333,smt,4,4_smt,0.05494010075926781|0.08837880939245224|0.11707477271556854|0.14298847317695618|0.10077688843011856
731,"Eine HIV-Infektion gilt nicht als Kontraindikation für eine Diphtherie-, Tetanus-, Pertussis und HBV- Impfung.","HIV infection is not considered as a contra-indication for diphtheria, tetanus, pertussis and HBV vaccination.","3 HIV infection is not considered as a contra-indication for diphtheria, tetanus, pertussis and HBV vaccination.","HIV infection is not considered a contra-indication for diphtheria, tetanus, pertussis and HBV vaccination.",0.0588235294117647,smt,4,4_smt,-0.03783385455608368|-0.03332625329494476|0.011843831278383732|-0.016649363562464714|0.021199865266680717
732,Ariclaim kann unabhängig von der Nahrungsaufnahme eingenommen werden.,Ariclaim can be taken with or without food.,Ariclaim can be taken with or without food.,Ariclaim can be taken with or without food.,0.0,smt,4,4_smt,-0.035230603069067|-0.03595844656229019|0.009330062195658684|0.0005851578898727894|0.02260918915271759
733,Die Metabolite werden überwiegend über den Urin ausgeschieden (51% der Dosis) und in geringeren Mengen über die Faezes.,The metabolites are mainly excreted in the urine (51% of the dose) and a relief in the faeces.,"Metabolites are excreted mainly in the urine (51% of the dose), and to a lesser extent in the faeces.",The metabolites are mainly excreted in the urine (51% of the dose) and in smaller amounts in the faeces.,0.1304347826086956,smt,4,4_smt,0.02036832831799984|0.03592038154602051|0.10764814168214798|0.08348041027784348|0.08332978188991547
734,Es liegen keine Daten für die Verwendung von MIRCERA bei Schwangeren vor.,There are no data on the use of MIRCERA in pregnant women.,There are no data from the use of MIRCERA in pregnant women.,There is no data on the use of MIRCERA in pregnant women.,0.0769230769230769,smt,4,4_smt,-0.04059901833534241|-0.04382485896348953|0.011900132521986961|-0.013882366940379143|0.01770533248782158
735,Prophylaxe der Refluxösophagitis:,Prophylaxis of reflux oesophagitis:,Prophylaxis of reflux oesophagitis:,Prophylaxis of reflux oesophagitis:,0.0,smt,4,4_smt,-0.08210761100053787|-0.07810837775468826|0.00853506475687027|-0.05223214998841286|-0.013423973694443703
736,"Wenn nach einer Exposition Hautausschlag oder andere Symptome auftreten, ist unverzüglich ein Arzt zu Rate zu ziehen und dieser Warnhinweis vorzulegen.","If a rash or other symptoms occur, seek medical advice immediately and show this warning.","If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning.","If a rash or other symptoms occur, seek medical advice immediately and show this warning.",0.0,smt,4,4_smt,0.01966281794011593|0.028638789430260658|0.06238575279712677|0.08162388205528259|0.07858771085739136
737,"2/3 Agenerase darf nicht bei Patienten angewendet werden, die möglicherweise überempfindlich (allergisch) gegen Amprenavir oder einen der sonstigen Bestandteile sind.",2 / 3 Agenerase must not be used in people who may be hypersensitive (allergic) to amprenavir or any of the other ingredients.,Agenerase should not be used in people who may be hypersensitive (allergic) to amprenavir or any of the other ingredients.,2 / 3 Agenerase must not be used in people who may be hypersensitive (allergic) to amprenavir or any of the other ingredients.,0.0,smt,4,4_smt,-0.004483398981392384|0.003659714013338089|0.01785917393863201|0.022396011278033257|0.04225066676735878
738,"Bei Patienten, die Olanzapin zur Behandlung einer manischen Episode erhalten haben, sollte die Behandlung zur Vorbeugung eines Rezidivs mit derselben Dosis fortgesetzt werden.",In patients receiving olanzapine for the treatment of manic episode should be initiated at the treatment for the prevention of Rezidivs the same dose for another 4 weeks.,"For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose.","In patients receiving olanzapine for the treatment of a manic episode, treatment for the prevention of Rezidivs should be continued with the same dose.",0.4615384615384615,smt,4,4_smt,0.22066669166088104|0.30280801653862|0.38106757402420044|0.38017144799232483|0.29553985595703125
739,Die gesamte Menge des rekonstituierten Impfstoffs wird aus dem Fläschchen in dieselbe Spritze aufgezogen und das gesamte Volumen verimpft.,Withdraw the entire content of the reconstituted vaccine from the vial into the same syringe and inject the entire volume.,Withdraw the entire content of the reconstituted vaccine from the vial into the same syringe and inject the entire volume.,Withdraw the entire content of the reconstituted vaccine from the vial into the same syringe and inject the entire volume.,0.0,smt,4,4_smt,-0.05191875994205475|-0.05048456788063049|0.011374560184776783|-0.013110082596540451|0.01672479510307312
740,"Bei Patientinnen, die den Kriterien des DSM-IV für eine prämenstruelle dysphorische Störung (PMDD) entsprachen, wurden zwei Placebo-kontrollierte Studien durchgeführt.","In patients undergoing DSM-IV criteria for implantable dysphorische Disruptive (PMDD), two randomised, double- blind, placebo-controlled trials have been conducted.",Two placebo-controlled studies were conducted in patients meeting Pre-Menstrual Dysphoric Disorder (PMDD) diagnostic criteria according to DSM-IV.,Two placebo-controlled trials have been conducted in patients who corresponded to the DSM-IV criteria for premenstrual dysphoric disorder (PMDD).,0.7272727272727273,smt,4,4_smt,0.159124493598938|0.24806860089302063|0.19479109346866608|0.31453055143356323|0.26109442114830017
741,"Achten Sie unbedingt darauf, direktes, durch das Fenster einstrahlendes Sonnenlicht oder direktes Licht von Haushaltsgegenständen wie einer Leselampe zu vermeiden.","Care should be taken to avoid filters, through the einstrahlendes exposure to sunlight light from perethylated (B such as a Leselampe.",Remember to avoid direct sunlight coming through the window or direct light from household appliances such as reading lamps.,Remember to avoid direct sunlight coming through the window or direct light from household appliances such as reading lamps.,0.8,smt,4,4_smt,0.5320743322372437|0.6359159350395203|0.56634521484375|0.6553205251693726|0.6011063456535339
742,"Aus mikrobiologischer Sicht sollte die gebrauchsfertige Zubereitung sofort verwendet werden.Wenn die gebrauchsfertige Zubereitung nicht sofort verwendet wird, ist der Anwender für die Dauer der Aufbewahrung und die Aufbewahrungsbedingungen vor der Anwendung verantwortlich.","From a microbiological point of view, the product should be used immediately werden.Wenn not used immediately, in-use storage times and conditions prior to use are the in-use storage times and conditions prior to use are the responsibility of the user.","From a microbiological point of view, the product must be used immediately.","From a microbiological point of view, the ready-to-use product should be used immediately. If not used immediately, storage times and conditions prior to use are the responsibility of the user.",0.4117647058823529,smt,4,4_smt,0.43262767791748047|0.5579003691673279|0.5806229114532471|0.5599799156188965|0.5136786103248596
743,Wenden Sie sich an Ihren Arzt.,Contact your doctor right away.,Check with your doctor.,Contact your doctor right away.,0.0,smt,4,4_smt,0.04087534919381142|0.035058289766311646|0.02816780097782612|0.08098121732473373|0.08721315115690231
744,Vor dem Eintropfen von LUMIGAN sollten Kontaktlinsen daher heraus- genommen und frühestens 15 Minuten nach der Anwendung der Tropfen wieder eingesetzt werden.,Before Wait LUMIGAN should wear contact lenses Method and wait 15 minutes after instillation of the dose.,Contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration.,"Before putting LUMIGAN drops in your eyes, contact lenses should be taken out and wait 15 minutes after dose before putting them back in.",0.6153846153846154,smt,4,4_smt,0.24959243834018707|0.3622994124889374|0.3576778769493103|0.42788422107696533|0.32550495862960815
745,Was ist Ceplene und wofür wird es angewendet?,What Ceplene is and what it is used for 2.,What Ceplene is and what it is used for 2.,What Ceplene is and what it is used for 2.,0.0,smt,4,4_smt,-0.04225306957960129|-0.048536404967308044|0.013017874211072922|-0.015524886548519135|0.013539456762373447
746,"Sollte die Lösung nicht klar sein oder Partikel enthalten, darf sie nicht verwendet werden.","If the solution is not clear or contains particles, it should not be used.",Do not use if the solution contains particles or is not clear.,"If the solution is not clear or contains particles, it should not be used.",0.0,smt,4,4_smt,-0.020021026954054832|-0.02285950817167759|0.014373368583619595|0.00991540402173996|0.028439488261938095
747,90 Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen Anforderungen zu entsorgen.,90 Any unused product or waste material or Waste materials should be disposed of in accordance with national requirements.,Any unused product or waste material should be disposed of in accordance with local requirements.,90 Any unused product or waste material should be disposed of in accordance with national requirements.,0.1764705882352941,smt,4,4_smt,0.0036484976299107075|0.027262510731816292|0.14106693863868713|0.06267700344324112|0.06641656160354614
748,"Tierexperimentelle sowie In-vitro-Untersuchungen mit Mikrosomen aus der menschlichen Leber wiesen nach, dass Ritonavir in erster Linie einem oxidativen Stoffwechsel unterliegt.","Animal and in vitro with the liver after that ritonavir primarily in the urine, undergoes oxidative metabolism.",Animal studies as well as in vitro experiments with human hepatic microsomes indicated that ritonavir primarily underwent oxidative metabolism.,Animal and in vitro testing with human liver microprobes prove that ritonavir primarily undergoes oxidative metabolism.,0.4705882352941176,smt,4,4_smt,0.45197048783302307|0.5425634384155273|0.49745973944664|0.5772078633308411|0.5157109498977661
749,Die Wirksamkeit von NeoRecormon kann durch eine Aluminiumüberladung infolge der Therapie der chronischen Niereninsuffizienz abgeschwächt werden.,The efficacy of NeoRecormon may be due to the Aluminiumüberladung due to the treatment of chronic renal failure.,Severe aluminium overload due to treatment of renal failure may compromise the effectiveness of NeoRecormon.,The efficacy of NeoRecormon may be weakened due to the overload of aluminium due to the treatment of chronic renal failure.,0.1818181818181818,smt,4,4_smt,0.07345160096883774|0.13191771507263184|0.21105599403381348|0.20462284982204437|0.13462844491004944
750,Es gibt kein spezifisches Antidot für Olanzapin.,There is no specific antidote for olanzapine.,Management of overdose There is no specific antidote for olanzapine.,There is no specific antidote for olanzapine.,0.0,smt,4,4_smt,-0.0011942710261791945|0.009348167106509209|0.019700396806001663|0.044020652770996094|0.05391714721918106
751,Bei Kindern wurde eine Halbwertszeit von ungefähr 6 Stunden berichtet.,"In paediatric patients, a half-life of approximately 6 hours.",A half-life of approximately 6 hours has been reported in children.,"In paediatric patients, a half-life of approximately 6 hours.",0.0,smt,4,4_smt,0.04790440946817398|0.09388770908117294|0.08236608654260635|0.15504451096057892|0.11683303862810135
752,Insuman Basal gibt es in Durchstechflaschen mit 10 ml Suspension (400 I.E.).,Insuman Basal is supplied in vials containing 10 ml suspension (400 IU).,Insuman Basal is supplied in vials containing 10 ml suspension (400 IU).,Insuman Basal is supplied in vials containing 10 ml suspension (400 IU).,0.0,smt,4,4_smt,-0.04847666248679161|-0.05363522469997406|0.009540551342070103|-0.029229089617729187|0.006562249734997749
753,Cervarix wird gemäß offiziellen Empfehlungen angewendet.,Cervarix is given according to official recommendations.,Cervarix is given according to official recommendations.,Cervarix is given according to official recommendations.,0.0,smt,4,4_smt,-0.02894548512995243|-0.03493472933769226|0.00967404805123806|-0.007684685755521059|0.022554568946361542
754,"Cystinose ist eine Stoffwechselkrankheit, die als, nephropathische Cystinose“ bezeichnet wird. Sie ist gekennzeichnet durch eine abnormale Anhäufung der Aminosäure Cystin in verschiedenen Organen, wie z.B. Nieren, Augen, Muskeln, Bauchspeicheldrüse und Gehirn.","Cystinose is a metabolic disease, ""called, nephropathische Cystinose. You are characterised by abnormal build-up of the amino acid astaxanthin in various organs, such as the kidneys, eyes, muscles, pancreas, and brain.","Cystinosis is a metabolic disease called ‘ nephropathic cystinosis’ which is characterized by an abnormal accumulation of the amino acid cystine in various organs of the body such as the kidney, eye, muscle, pancreas, and brain.","Cystinose is a metabolic disease called nephropathic cystinose. It characterised by abnormal build-up of the amino acid astaxanthin in various organs, such as the kidneys, eyes, muscles, pancreas, and brain.",0.1621621621621621,smt,4,4_smt,0.05450262874364853|0.09696588665246964|0.07260460406541824|0.1204344630241394|0.12187514454126358
755,Die zusätzliche Anwendung weiterer Arzneimittel neben Liprolog Mix25 Pen muss mit dem Arzt ab- gestimmt werden.,The Liprolog Mix25 should be ab- gestimmt.,The physician should be consulted when using other medications in addition to Liprolog Mix25.,The Liprolog Mix25 should be coordinated.,0.2857142857142857,smt,4,4_smt,0.3019397258758545|0.405006468296051|0.3911324739456177|0.4666121006011963|0.37354710698127747
756,"Während dieser Eingriffe müssen alle Vorsichtsmaßnahmen eingehalten werden, um die direkte Beleuchtung des Patienten durch unabgeschirmte OP-Lampen zu verhindern.","During this procedures, all precautions should be taken before commencement of treatment in order to avoid direct of patients unabgeschirmte OP-Lampen.",All precautions must be taken to avoid direct illumination of the patient with surgical lamps during these procedures.,All precautions should be taken to protect the patient from direct light from surgical lamps during these procedures.,0.8947368421052632,smt,4,4_smt,0.370248407125473|0.4795460104942322|0.4287661910057068|0.51264888048172|0.4362819492816925
757,"< Glaxo Wellcome S.A., Avda.","Glaxo Wellcome S. A., Avda.","< Glaxo Wellcome S.A., Avda.","Glaxo Wellcome S. A., Avda.",0.0,smt,4,4_smt,0.005483618471771479|-0.003753654658794403|0.014909437857568264|0.03751472756266594|0.052005834877491
758,Die Anwendung von Nonafact kann in seltenen Fällen auch zu einem Anstieg der Körpertemperatur führen.,The use of Nonafact can result in very rare cases an increase in body temperature.,The use of Nonafact may also produce an increase in body temperature in rare cases.,The use of Nonafact can result in increased body temperature in very rare cases.,0.4,smt,4,4_smt,-8.807890117168427e-05|0.0045531559735536575|0.045180898159742355|0.042538031935691833|0.05383322387933731
759,Juli 2003 und am 29. Juli 2008 verlängert.,The marketing authorisation was renewed on 15 July 2003 and on 29 July 2008.,The marketing authorisation was renewed on 29 July 2003 and on 29 July 2008.,The marketing authorisation was renewed on 15 July 2003 and on 29 July 2008.,0.0,smt,4,4_smt,-0.027958756312727928|-0.023987891152501106|0.022162992507219315|0.008378729224205017|0.02677871845662594
760,Eine chronische GVHD wurde nur als Todesursache berichtet: 1 Patient starb 13 Monate nach der Transplantation.,One Chronic GVHD has only been reported as a cause of death: one patient died 13 months after the transplant.,Chronic GVHD was reported only if it is the cause of death: one patient died 13 months post-transplant.,One Chronic GVHD has only been reported as a cause of death: one patient died 13 months after the transplant.,0.0,smt,4,4_smt,0.02491661161184311|0.04611313343048096|0.09225726127624512|0.09647737443447113|0.08048911392688751
761,Nach wiederholter täglicher Einnahme über 8 Tage beträgt die Reduktion etwa 85%.,After repeated daily administration for 8 days of treatment is approximately 85%.,After eight days of repeated administration the reduction is about 85%.,After repeated daily administration for 8 days the reduction is approximately 85%.,0.1428571428571428,smt,4,4_smt,0.06729571521282196|0.09364108741283417|0.18783418834209442|0.18194496631622314|0.12901897728443146
762,Ihr Arzt oder Radiologe wird dies mit Ihnen besprechen.,Your doctor or Radiologe will discuss this with you.,Your doctor or radiologist will consider this with you.,Your doctor or radiologist will discuss this with you.,0.1,smt,4,4_smt,0.030390195548534393|0.02903056889772415|0.04035766422748566|0.06037677079439163|0.07588841766119003
763,In den placebokontrollierten klinischen Studien führte die Behandlung mit Abatacept im Vergleich zur Behandlung mit Placebo nicht zu einer erhöhten Bildung von Autoantikörpern wie antinukleären und Anti-dsDNA-Antikörpern (siehe Abschnitt 4.8).,"In the placebo-controlled clinical trials, treatment with abatacept compared to treatment with placebo increased the formation of autoimmune antibodies, such as indole and Anti-dsDNA-Antikörpern (see section 4.8).","In the placebo-controlled clinical trials, abatacept treatment did not lead to increased autoantibody formation, such as antinuclear and anti- dsDNA antibodies, relative to placebo treatment (see section 4.8).","In the placebo-controlled clinical trials, treatment with abatacept compared to treatment with placebo increased the formation of autoimmune antibodies, such as indole and Anti-dsDNA-Antikörpern (see section 4.8).",0.0,smt,4,4_smt,0.05888422578573227|0.09134507924318314|0.09861908853054047|0.1261470764875412|0.11860572546720505
764,"Nehmen Sie keinesfalls eine doppelte Dosis ein, um eine vergessene Einnahme nachzuholen.",Do not take a double dose to make up for a forgotten dose.,Do not take a double dose to make up for forgotten individual doses.,Do not take a double dose to make up for a forgotten dose.,0.0,smt,4,4_smt,0.03364291787147522|0.04331696033477783|0.013889670372009277|0.09827939420938492|0.0884043499827385
765,"Jalra ist ein Arzneimittel, das den Wirkstoff Vildagliptin enthält.",Jalra is a medicine containing the active substance vildagliptin.,Jalra is a medicine containing the active substance vildagliptin.,Jalra is a medicine containing the active substance vildagliptin.,0.0,smt,4,4_smt,-0.06227488070726395|-0.0705556869506836|0.008682294748723507|-0.04242800176143646|6.142817437648773e-05
766,Der Inhaber der Genehmigung für das Inverkehrbringen ist INO Therapeutics AB.,The MAH marketing authorisation holder is INO Therapeutics AB.,The marketing authorisation holder is INO Therapeutics AB.,The MAH marketing authorisation holder is INO Therapeutics AB.,0.0,smt,4,4_smt,-0.005317963659763336|-0.008488642051815987|0.01700395904481411|0.04235507920384407|0.059872500598430634
767,Auch unter Thyrogen kann es zu falsch-negativen Ergebnissen kommen.,"Also, Thyrogen can cause falsch-negativen may occur.",False negative results may occur with Thyrogen.,"Also, Thyrogen can cause false negative results.",0.3333333333333333,smt,4,4_smt,0.3648713231086731|0.4731470048427582|0.43563252687454224|0.5048558712005615|0.41792887449264526
768,"Laborwerte bei HCV/HIV co-infizierten Patienten Obwohl durch hämatologische Toxizität Neutropenie, Thrombozytopenie und Anämie häufiger bei HCV/HIV co-infizierten Patienten auftraten, konnte die Mehrheit durch Dosisanpassungen bewältigt werden und es bedurfte nur selten eines vorzeitigen Behandlungsabbruchs (siehe Abschnitt 4.4).","Laboratory values for HCV / HIV co-infected patients: Although haematological toxicities of neutropenia, thrombocytopenia and anaemia occurred more frequently in HCV / HIV co-infected patients, the majority could be managed by dose modification and the majority could be managed by dose modification and rarely required premature discontinuation of treatment (see section 4.4).","Laboratory values for HCV/HIV co-infected patients: Although haematological toxicities of neutropenia, thrombocytopenia and aaemia occurred more frequently in HCV/HIV co-infected patients, the majority could be managed by dose modification and rarely required premature discontinuation of treatment (see section 4.4).","Laboratory values for HCV/HIV co-infected patients: Although haematological toxicities of neutropenia, thrombocytopenia and anaemia occurred more frequently in HCV / HIV co-infected patients, the majority could be managed by dose modification and rarely required premature discontinuation of treatment (see section 4.4).",0.1836734693877551,smt,4,4_smt,0.01069008931517601|0.04206155985593796|0.11103811115026474|0.07299717515707016|0.07569587975740433
769,Was ist IntronA und wofür wird es angewendet?,What IntronA is and what it is used for 2.,What IntronA is and what it is used for 2.,What is IntronA and what it is used for?,0.3,smt,4,4_smt,-0.03730155900120735|-0.04216230660676956|0.013949288055300713|-0.006510155741125345|0.018742337822914124
770,Selten kann es zu Schmerzen und lokaler Hyperthermie (Anstieg der Seite 2/3 ©EMEA 2008 Körpertemperatur) kommen.,Rare Pain and local hyperthermia as it should (increase in Page 2 / 3 © EMEA 2008 rise in body temperature) can occur.,Pain and local hyperthermia (increase in body temperature) can occur in rare cases.,Rarely it leads to pain and local hyperthermia as it should (increase in Page 2 / 3 © EMEA 2008 rise in body temperature).,0.2222222222222222,smt,4,4_smt,0.36380431056022644|0.4850406050682068|0.3283338248729706|0.5182064771652222|0.43285632133483887
771,"Die Kombination von Emtricitabin und Tenofovirdisoproxilfumarat zeigte positive Ergebnisse im In-vitro-Maus-Lymphom-Test, mit vergleichbaren Resultaten wie unter Tenofovirdisoproxilfumarat allein.","The combination of emtricitabine and tenofovir disoproxil fumarate was positive in the in vivo mouse bone marrow micronucleus, with comparable results to tenofovir disoproxil fumarate alone.","The combination of emtricitabine and tenofovir disoproxil fumarate was positive in the in vitro mouse lymphoma assay, with comparable results to those obtained for tenofovir disoproxil fumarate alone.","The combination of emtricitabine and tenofovir disoproxil fumarate was positive in the in vivo mouse bone marrow micronucleus, with comparable results to tenofovir disoproxil fumarate alone.",0.0,smt,4,4_smt,0.027618400752544403|0.047622084617614746|0.04210648313164711|0.09831985831260681|0.08453750610351562
772,Die vorgelegten Daten scheinen auf eine Wirkung von Veraliprid in der Behandlung vasomotorischer Symptome im Zusammenhang mit der Menopause hinzuweisen.,The data presented appear to be stressed to the effect of veralipride in the treatment of vasomotor symptoms associated with the menopause.,The CHMP concluded that the data submitted showed only limited effect of veralipride in the treatment of vasomotor symptoms associated with the menopause.,The data presented appears to suggest an effect of veralipride in the treatment of vasomotor symptoms associated with the menopause.,0.238095238095238,smt,4,4_smt,0.05672703683376312|0.09277912974357605|0.18306265771389008|0.14724479615688324|0.11992142349481583
773,3 Anwendung bei Kindern:,2 Use in children:,Use in children:,3 Use in children:,0.2,smt,4,4_smt,-0.03962881490588188|-0.041126079857349396|0.013548498041927814|-0.018749672919511795|0.01714928448200226
774,Psychiatrische Erkrankungen Gelegentlich:,Psychiatric disorders Uncommon:,Psychiatric disorders:,Psychiatric disorders Uncommon:,0.0,smt,4,4_smt,-0.009669244289398193|0.003598146140575409|0.014689989387989044|0.03921175003051758|0.053173527121543884
775,ge Klinische Studien bei Kindern mit chronischer Hepatitis C:,ho Clinical trials in paediatric patients with chronic hepatitis C:,Clinical trials in paediatric patients with chronic hepatitis C:,Clinical trials in paediatric patients with chronic hepatitis C:,0.1,smt,4,4_smt,-0.04041936248540878|-0.04162891209125519|0.023373834788799286|-0.008140599355101585|0.019492965191602707
776,"Erkrankungen des Immunsystems Gelegentlich – Urtikaria, Exanthem Sehr selten - Anaphylaktische Reaktionen Symptome generalisierter Überempfindlichkeit, einschließlich generalisierter Hautausschlag, Jucken, Schwitzen, gastrointestinale Störungen, angioneurotisches Ödem, Atembeschwerden, Herzklopfen, niedriger Blutdruck und Ohnmacht/Bewusstlosigkeit.","Immune system disorders Uncommon - Urticaria, rash Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation, reduction in blood pressure and fainting / loss of consciousness.","40 Immune system disorders Uncommon - Urticaria, rash Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation, reduction in blood pressure and fainting/ loss of consciousness.","Immune system disorders Uncommon - Urticaria, rash Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, heart palpitation, reduction in blood pressure and fainting / loss of consciousness.",0.0196078431372549,smt,4,4_smt,-0.029260721057653427|-0.022446533665060997|0.014644300565123558|-0.005175631958991289|0.031494613736867905
777,Weitere Informationen über HBVAXPRO:,2 / 3 Other information about HBVAXPRO:,Other information about HBVAXPRO:,2 / 3 Other information about HBVAXPRO:,0.0,smt,4,4_smt,0.028753113001585007|0.04722430557012558|0.07141042500734329|0.07202503830194473|0.08324233442544937
778,Allgemein sensible Spezies:,General at species:,6 Commonly Susceptible Species:,General sensible species:,0.25,smt,4,4_smt,0.24954168498516083|0.3780924379825592|0.34615465998649597|0.4146384298801422|0.33622488379478455
779,Sildenafil wird durch CYP3A4 metabolisiert.,This effect may be due to an induction of CYP3A4.,Sildenafil is metabolised by CYP3A4.,Sildenafil may be metabolised by CYP3A4.,1.0,smt,4,4_smt,0.15296150743961334|0.2461661547422409|0.11664687842130661|0.3258088231086731|0.23942051827907562
780,"Rebif wird zu einer Klasse von Arzneimitteln gezählt, die man Interferone nennt.","Rebif is counted class of medicines, called interferons.",Rebif belongs to a class of medicines known as interferons.,Rebif is counted as a class of medicines called interferons.,0.2727272727272727,smt,4,4_smt,0.02275494858622551|0.03783809393644333|0.1232934445142746|0.06936147063970566|0.07234175503253937
781,"Populationspharmakokinetische Analysen zeigten, dass die Pharmakokinetik von Rimonabant bei gesunden Nichtrauchern vergleichbar ist mit der bei Patienten, die rauchen.",Population PK studies showed that the pharmacokinetics of rimonabant in healthy non-smokers were similar to those in people who smoke.,pharmacokinetic analysis indicated that rimonabant pharmacokinetics are similar between healthy non-smoking subjects and patients who smoke.,Population PK studies showed that the pharmacokinetics of rimonabant in healthy non-smokers were similar to those in people who smoke.,0.0,smt,4,4_smt,0.06019781529903412|0.09912259131669998|0.046824321150779724|0.12644238770008087|0.1181054562330246
782,"Die Dosierung und Länge der Behandlung ist von der Krankheit abhängig, gegen die sie eingesetzt wird.","The dose and the treatment is depending on the disease, and makes antibodies against them.",The dose and length of treatment depends on the condition for which it is being used.,"The dose and the treatment is depending on the disease, and makes antibodies against them.",0.0,smt,4,4_smt,0.23830579221248627|0.3344601094722748|0.2324502319097519|0.3862597346305847|0.31368809938430786
783,Halten Sie die Spritze waagerecht.,Hold the syringe horizontally.,Keep the syringe horizontal.,Hold the syringe horizontally.,0.0,smt,4,4_smt,0.0013864007778465748|-0.0024849530309438705|0.01507851853966713|0.06304435431957245|0.06744416803121567
784,"Herceptin darf nicht bei Patientinnen angewendet werden, die möglicherweise überempfindlich (allergisch) gegen Trastuzumab oder einen der sonstigen Bestandteile sind.",Herceptin should not be used in people who may be hypersensitive (allergic) to trastuzumab or any of the other ingredients.,Herceptin should not be used in people who are hypersensitive (allergic) to trastuzumab or to any of the other ingredients.,Herceptin should not be used in people who may be hypersensitive (allergic) to trastuzumab or any of the other ingredients.,0.0,smt,4,4_smt,-0.036035843193531036|-0.03747720271348953|0.010723005048930645|-0.013204382732510567|0.019556179642677307
785,In reproduktionstoxikologischen Prüfungen am Tier führte die Anwendung von Xeloda zu Embryoletalität und Teratogenität.,Repeated dosing in reproduction toxicological trials and in the use of Xeloda resulted in embryolethality and teratogenicity.,"In reproductive toxicity studies in animals, Xeloda administration caused embryolethality and teratogenicity.",The use of Xeloda in reproduction toxicological trials resulted in embryolethality and teratogenicity.,0.3571428571428571,smt,4,4_smt,0.042432431131601334|0.10099635273218155|0.10744298994541168|0.13567616045475006|0.11570881307125092
786,"Jede Präparatstärke ist in Packungen mit 10, 20 und 100 Tabletten erhältlich.","Each Präparatstärke is available in packs of 10, 20 and 100 tablets.","Each strength of the product is available in packs of 10, 20 and 100 tablets.","Each product strength is available in packs of 10, 20 and 100 tablets.",0.1333333333333333,smt,4,4_smt,-0.007201055064797401|-0.018647490069270134|0.04323124513030052|0.012009324505925179|0.035628460347652435
787,Episoden von Schlafwandeln müssen daher vollständig untersucht und geeignete Maßnahmen in Betracht gezogen werden.,"If an episode of somnambulism must be fully evaluated and, therefore, appropriate supportive measures should be considered.","Therefore, episodes of sleepwalking should be fully evaluated and appropriate interventions considered.","Episodes of somnambulism must, therefore, be fully evaluated and appropriate supportive measures should be considered.",0.3333333333333333,smt,4,4_smt,0.13692425191402435|0.20651301741600037|0.28371432423591614|0.2942121922969818|0.21444030106067657
788,"Jeglicher Wechsel der Wirkstärke, der Marke (Her- steller), des Insulintyps (normal, NPH, zinkverzögert usw.), der Art des Insulins (tierisches Insulin) und/oder der Herstellungsmethode kann eine Veränderung des Insulinbedarfs nach sich ziehen.","Jeglicher changing potency, (Her- steller), type, (normal, zinkverzögert NPH, etc.), the nature of the insulin (insulin) and / or supervision can cause a change in dosage.","Changes in strength, brand (manufacturer), type (regular, NPH, lente, etc.), species (animal) and/ or method of manufacturing may result in a change in dosage.","Any change of the potency, brand (producer), type, (normal, zinc delayed, NPH, etc.), the nature of the insulin (animal insulin) and/or method of production can cause a change the need for insulin.",0.3673469387755102,smt,4,4_smt,0.27715620398521423|0.3890937566757202|0.223258838057518|0.39501893520355225|0.34766635298728943
789,(Im Vergleich zu Indinavir 400 mg QID allein) Sulphamethoxazol AUC und Cmin:,(Relative to Indinavir 400 mg QID alone) sulphamethoxazole AUC and Cmin:,(Relative to Indinavir 400 mg QID alone) Sulphamethoxazole AUC and Cmin:,(Relative to Indinavir 400 mg QID alone) sulphamethoxazole AUC and Cmin:,0.0,smt,4,4_smt,-0.030698690563440323|-0.03129642456769943|0.012483425438404083|-0.015513788908720016|0.014832966029644012
790,"Wenn Sie die Einnahme von Lamictal plötzlich beenden, kann Ihre Epilepsie erneut auftreten oder sich verschlimmern.",If you stop taking Lamictal suddenly your epilepsy may occur again or get worse.,"If you suddenly stop taking Lamictal, your epilepsy may come back or get worse.",If you stop taking Lamictal suddenly your epilepsy may occur again or get worse.,0.0,smt,4,4_smt,0.03665682300925255|0.05381838232278824|0.020946970209479332|0.10255784541368484|0.08295966684818268
791,"Es sollte aber beachtet werden, dass die Inzidenz von Schläfrigkeit erhöht ist, wenn die Tagesdosis 1,5 mg (Salzform) überschreitet (siehe Abschnitt 4.8).","However, it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg / day (see section 4.8).","34 However, it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg/ day (see section 4.8).","However, it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg / day (see section 4.8).",0.0,smt,4,4_smt,-0.021512433886528015|-0.026729898527264595|0.012981599196791649|0.00320082763209939|0.02904748171567917
792,"TAXOTERE ist in Kombination mit Doxorubicin und Cyclophosphamid für die adjuvante Therapie von Patientinnen mit operablem, nodal positivem Brustkrebs angezeigt.",TAXOTERE is indicated in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive breast cancer.,TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer.,TAXOTERE is indicated in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive breast cancer.,0.0,smt,4,4_smt,-0.022238966077566147|-0.021785499528050423|0.017305495217442513|0.0042646038345992565|0.03100186586380005
793,"Stärkere Bewusstseinsstörungen und Koma, einschließlich Fälle von Enzephalopathie, wurden bei einigen, meist älteren Patienten bei höheren Dosierungen beobachtet.","161 More significant obtundation and coma, including cases of encephalopathy, have been observed in some patients, usually elderly, treated at higher doses.","More significant obtundation and coma, including cases of encephalopathy, have been observed in some patients, usually elderly, treated at higher doses.","More significant obtundation and coma, including cases of encephalopathy, have been observed in some patients, usually elderly, treated at higher doses.",0.0384615384615384,smt,4,4_smt,-0.017705384641885757|-0.01629108004271984|0.016104551032185555|0.018263723701238632|0.03644174337387085
794,Acticam sollte nicht zusammen mit anderen nicht-steroidalen Antiphlogistika oder Glukokortikoiden verabreicht werden.,Acticam must not be administered in conjunction with other NSAIDs or corticosteroids.,Acticam must not be administered in conjunction with other NSAIDS or glucocorticosteroids.,Acticam must not be administered in conjunction with other NSAIDs or corticosteroids.,0.0,smt,4,4_smt,-0.02358645759522915|-0.01638837717473507|0.01175131555646658|0.012864533811807632|0.03140988573431969
795,"Umgekehrt kann Fosamprenavir mit Ritonavir in ähnlicher Weise die Pharmakokinetik von anderen Arzneimitteln, die über diesen Weg verstoffwechselt werden, beeinflussen.","Conversely, fosamprenavir with ritonavir on the pharmacokinetics of other medicinal products metabolised by this route share this metabolic pathway.",Similarly administration of fosamprenavir with ritonavir may modify the pharmacokinetics of other active substances that share this metabolic pathway.,"Conversely, fosamprenavir with ritonavir can similarly affect the pharmacokinetics of other medicinal products metabolised in this way.",0.4210526315789473,smt,4,4_smt,0.1230364665389061|0.19957876205444336|0.23685531318187714|0.23936451971530914|0.1896711140871048
796,Dies verbessert die Herzleistung.,This relieves.,The result is an improvement in heart function.,This relieves cardiac output.,0.4,smt,4,4_smt,0.22061361372470856|0.320097953081131|0.36469656229019165|0.4041074216365814|0.3385363817214966
797,"Jede Schachtel enthält 3, 4, 10 oder 20 Durchstechflaschen, aber es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht.","Each carton contains 3, 4, 10 or 20 vials, but not all pack sizes may be marketed.","Each box contains 3, 4, 10 or 20 vials, but not all pack sizes may be marketed.","Each carton contains 3, 4, 10 or 20 vials, but not all pack sizes may be marketed.",0.0,smt,4,4_smt,-0.027985829859972|-0.030145978555083275|0.011315364390611649|-0.007861565798521042|0.02140052057802677
798,58 Salzsäure oder Natriumhydroxid (zur pH-Wert-Einstellung) Wasser für Injektionszwecke.,58 of hydrochloric acid or sodium hydroxide (for pH adjustment) Water for injections.,Solvent Sodium chloride Hydrochloric acid or sodium hydroxide (for pH adjustment) Water for injections.,58 Hydrochloric acid or sodium hydroxide (for pH adjustment) Water for injections.,0.0666666666666666,smt,4,4_smt,0.0054776608012616634|0.019328240305185318|0.03571639582514763|0.06067618727684021|0.06115701049566269
799,Bei einer Downregulation wird mit der Anwendung von GONAL-f üblicherweise etwa 2 Wochen nach Beginn der Agonist-Verabreichung begonnen.,"In a commonly used protocol, GONAL-f is approximately 2 weeks after the start of Agonist-Verabreichung 3 of the treatment cycle.","In a commonly used protocol, GONAL-f is started approximately 2 weeks after the start of agonist treatment, both being continued until adequate follicular development is achieved.","In a downregulation, GONAL-f is started approximately  2 weeks after the start of Agonist administration.",0.5882352941176471,smt,4,4_smt,0.19456960260868073|0.29329290986061096|0.29310935735702515|0.36431455612182617|0.2830907106399536
800,"Die klinische Relevanz dieses altersbezogenen Unterschiedes ist gering, da die Risiko/Nutzen-Bewertung in der Zielpopulation günstig ist.",The clinical relevance of these polynucleotide is low because of the risk / Nutzen-Bewertung in the target population is favourable.,"The clinical relevance of this age-related difference is remote, as the risk/ benefit assessment determined in the target population is favourable.",The clinical relevance of this age-specific difference is low as the risk/benefit assessment is favourable in the target population.,0.4090909090909091,smt,5,5_smt,0.16246335208415985|0.2406958043575287|0.24451875686645508|0.3138095736503601|0.2584008574485779
801,Die Pharmakokinetik war proportional zur Dosis und blieb über die gesamte Zeit hinweg unverändert.,Pharmacokinetics were proportional to dose and was maintained over time to unchanged.,Pharmacokinetics were dose proportional and did not change over time.,The pharmacokinetic was proportional to dose and was maintained unchanged over time.,0.3846153846153846,smt,5,5_smt,0.06068985164165497|0.11393927782773972|0.18898740410804749|0.1527043879032135|0.1250481903553009
802,"Patienten mit chronischer Hepatitis B oder C, die mit einer antiretroviralen Kombinationstherapie behandelt werden, haben ein erhöhtes Risiko für schwere und möglicherweise letale Nebenwirkungen der Leber.",Patients with chronic hepatitis B or C and treated with combination antiretroviral combination therapy are at an increased risk for severe and potentially fatal hepatic adverse events.,14 disorders. Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.,"Patients with chronic hepatitis B or C, who are treated with an antiretroviral combination therapy, are at an increased risk for severe and potentially fatal hepatic adverse events.",0.1612903225806451,smt,5,5_smt,-0.017658893018960953|-0.002414969727396965|0.02561976946890354|0.026573818176984787|0.04257577657699585
803,Tacrolimus kann visuelle und neurologische Störungen hervorrufen.,Tacrolimus may cause AML and neurological disorders.,Tacrolimus may cause visual and neurological disturbances.,Tacrolimus may cause AML and neurological disorders.,0.0,smt,5,5_smt,-0.0008699640166014433|0.021519657224416733|0.024547338485717773|0.04625842347741127|0.05334454029798508
804,Nicht über 30 oC lagern.,Do not store above 30 ° C).,Store below 30oC.,Do not store above 30 ° C.,0.125,smt,5,5_smt,0.04583745822310448|0.0664738118648529|0.014074056409299374|0.12476759403944016|0.10104319453239441
805,"geschwollene Füße) auftreten, suchen Sie bitte sofort einen Arzt auf. Infektionen können rascher voranschreiten und schwerwiegender verlaufen.","swelling of the feet) may occur, seek medical attention immediately. Infections may progress more rapidly and be more severe.",Infections may progress more rapidly and be more severe.,"swelling of the feet may occur, seek medical attention immediately. Infections may progress more rapidly and be more severe.",0.0454545454545454,smt,5,5_smt,0.10866700857877731|0.16760358214378357|0.0959349051117897|0.2199089229106903|0.18128500878810883
806,Flasche vor dem ersten Gebrauch gründlich schütteln und die Pumpe füllen.,Shake the bottle well before the first use and thoroughly recap the pump.,Shake the bottle thoroughly before first administration and prime the pump.,Shake the bottle well before the first use and thoroughly fill the pump.,0.0714285714285714,smt,5,5_smt,-0.009455516934394836|0.0030437521636486053|0.03133940324187279|0.04637546092271805|0.05860258638858795
807,"Arzneimittel einnehmen, die Ihr Immunsystem unterdrücken (Ihr Immunsystem schützt Sie vor Infektionen und einigen Krankheiten).",are taking medicines that suppress your immune system (your body's immune system protects you against infection and some cancerous cells.,taking medicine that suppresses your immune system (your immune system protects you against infection and some diseases).,taking medicines that suppress your immune system (your body's immune system protects you against infection and some cancerous cells.,0.0454545454545454,smt,5,5_smt,0.02348203957080841|0.04818054288625717|0.05238056182861328|0.0843987837433815|0.08103864639997482
808,Was ist Clopidogrel Winthrop?,What is Clopidogrel Winthrop?,What is Clopidogrel Winthrop?,What is Clopidogrel Winthrop?,0.0,smt,5,5_smt,-0.0561782531440258|-0.06183373183012009|0.008616289123892784|-0.02876133657991886|-0.0033538993448019028
809,Sie dürfen die Tablette nicht kauen und nicht im Mund zergehen lassen.,Do not chew the tablet allowed to dissolve in the mouth.,Do not chew the tablet or allow it to dissolve in your mouth.,Do not chew the tablet or allow to dissolve in the mouth.,0.1538461538461538,smt,5,5_smt,0.054270774126052856|0.08148514479398727|0.23448117077350616|0.14522330462932587|0.10024184733629227
810,"Um Hautreaktionen zu begrenzen, ist es wichtig, dass das Pflaster wie angewiesen verwendet wird.","To minimise skin reactions, it is important that the patch such as instructed.",It is important to use the patch as instructed to limit skin reactions.,"To minimise skin reactions, it is important that the patch is used as instructed.",0.125,smt,5,5_smt,0.05054285004734993|0.08135800808668137|0.11586370319128036|0.12489048391580582|0.11550639569759369
811,- Eine Tube REGRANEX soll nur bei einem Patienten angewendet werden.,- One tube of REGRANEX should only be used in a patient.,- A tube of REGRANEX should be used on a single patient only.,- One tube of REGRANEX should only be used by a patient.,0.0769230769230769,smt,5,5_smt,-0.028269434347748756|-0.03718964755535126|0.014954262413084507|-0.005859375465661287|0.02364063821732998
812,"Bei Patienten, die Warfarin oder ähnliche Substanzen erhalten, sollte nach Beginn einer Febuxostatbehandlung die Überwachung der gerinnungshemmenden Wirkung in Betracht gezogen werden.","In patients receiving warfarin or similar agents, after the start of a febuxostat treatment for monitoring of anticoagulant effect may be considered.","After initiation of febuxostat therapy, monitoring of anticoagulant activity should be considered in patients receiving warfarin or similar agents.","In patients receiving warfarin or similar agents, after the start of a febuxostat treatment for monitoring of anticoagulant effect may be considered.",0.0,smt,5,5_smt,0.07792384922504425|0.11811265349388123|0.2032165378332138|0.16798272728919983|0.14179423451423645
813,Diese Veränderungen könnten mit einem Anstieg des Herzzeitvolumens bei unveränderter Herzfrequenz und mit einer Zunahme des renalen Blutflusses einher gehen.,"These changes may be associated with an increase in the intact heart rate and associated with an increase of 30,000 -70,000 g renal blood flow.","These changes may be accompanied by an increase in cardiac output at unchanged heart frequency, as well as an increase in renal blood flow.",These changes may be associated with an increase cardiac output and at unchanced heart frequency and with an increase in renal blood flow.,0.4583333333333333,smt,5,5_smt,0.09326601028442383|0.15035787224769592|0.16437089443206787|0.2188468873500824|0.1690351516008377
814,Weitere Informationen über Azarga:,2 / 3 Other information about Azarga:,Other information about Azarga:,Other information about Azarga:,0.6,smt,5,5_smt,0.01845390535891056|0.03635796159505844|0.055762868374586105|0.05866561830043793|0.06660263985395432
815,Die Rate der Inzidenz kardiovaskulärer Todesfälle und Myokardinfarkte unterschied sich nicht signifikant zwischen den Behandlungsgruppen.,The rate of incidence of cardiovascular death and myocardial infarction was not significantly different between treatment groups.,The rates of cardiovascular death and myocardial infarction were not significantly different between the treatment groups.,The rate of incidence of cardiovascular death and myocardial infarction was not significantly different between treatment groups.,0.0,smt,5,5_smt,-0.018601099029183388|-0.01859663613140583|0.01316746324300766|0.024517545476555824|0.036842554807662964
816,Welchen Nutzen hat PritorPlus in diesen Studien gezeigt?,What benefit has PritorPlus shown during the studies?,What benefit has PritorPlus shown during the studies?,What benefit has PritorPlus shown during the studies?,0.0,smt,5,5_smt,-0.06323042511940002|-0.06933329254388809|0.009229863993823528|-0.040416114032268524|-0.005176041275262833
817,"Kontaktieren Sie Ihren Arzt, wenn Ihre ermittelte Dosis Effentora nicht Ihre Durchbruchschmerzen lindert.",Check with your doctor if your how dose of Effentora will relieve your breakthrough pain.,Contact your doctor if your right dose of Effentora does not relieve your breakthrough pain.,Check with your doctor if your dose of Effentora dpes relieve your breakthrough pain.,0.1333333333333333,smt,5,5_smt,0.018385641276836395|0.037495359778404236|0.09461919218301773|0.0778401717543602|0.07555413991212845
818,"Bei Ratten wurde eine Anisozytose und Poikilozytose, bei gleichzeitig negativem Coombs-Test, beobachtet; nicht jedoch bei Mäusen und Hunden.","In rats Coombs-negative anisocytosis and poikilocytosis were observed with a higher, but not in mice and dogs.","Coombs-negative anisocytosis and poikilocytosis were observed in rats, but not in mice or dogs.","In rats, anisocytosis and poikilocytosis were observed in the concomitant administration of Coombs-negative, but not in mice and dogs.",0.3181818181818182,smt,5,5_smt,0.06340968608856201|0.14334724843502045|0.20330694317817688|0.17224253714084625|0.128652423620224
819,Die blutdrucksenkende Wirkung von Irbesartan und Thiaziddiuretika ist additiv.,The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive.,37 The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive.,The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive.,0.0,smt,5,5_smt,-0.020014923065900803|-0.017776774242520332|0.011259101331233978|0.03355265036225319|0.04373932629823685
820,Nach Rekonstitution enthält die Lösung 50 IE Follitropin beta pro ml.,"After reconstitution, the solution contains 50 IU of follitropin beta per ml.","After reconstitution, the solution contains 50 IU of follitropin beta per ml.","After reconstitution, the solution contains 50 IU of follitropin beta per ml.",0.0,smt,5,5_smt,-0.033653054386377335|-0.041150882840156555|0.009226647205650806|-0.0027970527298748493|0.022945115342736244
821,"Suchen Sie beim Auftreten eines der folgenden Krankheitszeichen oder Symptome unverzüglich einen Arzt auf: Anhaltendes Fieber, Halsentzündung, Bluterguss, Blutung oder Blässe.","Contact the child has any signs or symptoms such as if the child such as persistent fever, sore throat, bruising, bleeding or paleness.","Seek medical advice immediately if you have any signs or symptoms such as persistent fever, sore throat, bruising, bleeding or paleness.","Contact the doctor immediately if any signs or symptoms appear such as persistent fever, sore throat, bruising, bleeding or paleness.",0.2916666666666667,smt,5,5_smt,0.04980234056711197|0.08364308625459671|0.24548979103565216|0.13037660717964172|0.11814124882221222
822,Sie enthält ausserdem Mannitol (Ph.Eur.) und Natriumcitrat.,It contains 1-amino-mono- mannitol and sodium citrate.,It also contains mannitol and sodium citrate.,It contains mannitol (Ph. Eur.) and sodium citrate.,0.5384615384615384,smt,5,5_smt,0.04615236818790436|0.07399769872426987|0.19824139773845673|0.11750184744596481|0.08883630484342575
823,"Sprechen Sie umgehend mit Ihrem Arzt, wenn eine der folgenden Nebenwirkungen auftritt:",Talk to your doctor as soon as possible if any of the following side effects occur:,"Check with your doctor immediately if any of the following side effects occur: chest pain; changes in the way your heart beats; breathing problems (including shortness of breath), confusion; feeling depressed, wanting to harm yourself, hallucinations, numbness or tingling feeling; dizziness, convulsion (""fit""); trouble sleeping, thinking or concentrating; difficulty remaining alert, severe stomach pain or cramps;",Talk to your doctor as soon as possible if any of the following side effects occur:,0.0,smt,5,5_smt,0.09931428730487823|0.11676876991987228|0.07032263278961182|0.18130210041999817|0.14414362609386444
824,"Wenn Sie eine größere Menge von CellCept eingenommen haben, als Sie sollten:",If you take more CellCept than you should:,If you take more CellCept than you should:,"If you take more CellCept than you should, you should:",0.25,smt,5,5_smt,-0.0413372628390789|-0.04982879012823105|0.009134791791439056|-0.022027242928743362|0.009850786998867989
825,Jede Kapsel Advagraf 5 mg enthält 5 mg Tacrolimus.,Each capsule Advagraf 5 mg vial contains 5 mg of tacrolimus.,Each capsule of Advagraf 5 mg contains 5 mg of tacrolimus.,Each capsule Advagraf 5 mg vial contains 5 mg of tacrolimus.,0.0,smt,5,5_smt,0.005530753638595343|0.004877915605902672|0.02415257692337036|0.0416739322245121|0.04679735004901886
826,"Daher darf Xeloda nicht zusammen mit Sorivudin oder dessen chemischen Verwandten, wie z.B.","Therefore, Xeloda should not be administered concurrently with sorivudine or its chemically related analogues, e. g.","Therefore, Xeloda must not be administered concomitantly with sorivudine or its chemically related analogues, such as brivudine (see section 4.3).","Therefore, Xeloda should not be administered concurrently with sorivudine or its chemically related analogues, e. g.",0.0,smt,5,5_smt,0.031098458915948868|0.051255181431770325|0.022949857637286186|0.08196499198675156|0.08180267363786697
827,Weiße gefriergetrocknete Substanz Beschreibung des Lösungsmittels:,White lyophilised substance Description:,Appearance of the powder: white lyophilised pellet.,White lyophilised substance Description of solution:,0.2857142857142857,smt,5,5_smt,0.13610240817070007|0.22426220774650574|0.06617508828639984|0.27827975153923035|0.18984153866767883
828,Die gesamte Plasma-Clearance von Telmisartan beträgt nach oraler Gabe > 1.500 ml/min.,"Total plasma clearance of telmisartan after oral administration is 1,500 ml / min.",Total plasma clearance of telmisartan after oral administration is > 1500 ml/ min.,"Total plasma clearance of telmisartan is 1,500 ml / min after oral administration.",0.0714285714285714,smt,5,5_smt,-0.047987740486860275|-0.0500418096780777|0.010808681137859821|-0.02112685702741146|0.010402795858681202
829,GONAL-f muss über einen bestimmten Zeitraum täglich zusammen mit Lutropin alfa injiziert werden.,GONAL-f should be injected over a course of daily lutropin alfa.,83 oocyte will be liberated after the administration of human chorionic gonadotrophin (hCG). GONAL-f should be given as a course of daily injections simultaneously with lutropin alfa.,GONAL-f should be injected daily over a certain period with lutropin alfa.,0.3076923076923077,smt,5,5_smt,0.18884135782718658|0.2723162770271301|0.15946127474308014|0.3262312114238739|0.249607652425766
830,"Impfungen Wenn Sie Privigen erhalten haben, kann die Wirksamkeit bestimmter Impfungen beeinträchtigt sein.","Vaccinations If you are receiving Privigen, may reduce the efficacy of certain vaccinations may be affected.","22 Vaccinations After receiving Privigen, the efficacy of certain vaccinations may be impaired.","Vaccinations If you are receiving Privigen, the efficacy of certain vaccinations may be affected.",0.125,smt,5,5_smt,0.08691896498203278|0.12854191660881042|0.20681045949459076|0.18336336314678192|0.14222003519535065
831,Ziagen ist auch als Tablette erhältlich.,Ziagen is also available as tablets.,Ziagen is also available as a tablet formulation.,Ziagen is also available as tablets.,0.0,smt,5,5_smt,-0.019938381388783455|-0.01954607479274273|0.015824494883418083|0.0026388978585600853|0.03287024423480034
832,"Außerdem erhalten Sie vor und während der Behandlung mit Abseamed Eisenpräparate, welche die Wirksamkeit von Abseamed steigern.",You will also take iron supplements before and during treatment with Abseamed Eisenpräparate to increase the effectiveness of Abseamed.,You will also take iron supplements before and during Abseamed treatment to increase the effectiveness of Abseamed.,You will also take iron supplements before and during treatment with Abseamed to increase the effectiveness of Abseamed.,0.0526315789473684,smt,5,5_smt,0.008201396092772484|0.03280032426118851|0.04343517869710922|0.06280342489480972|0.07570291310548782
833,Das Pulver befindet sich in 3 ml Durchstechflaschen (Glas Typ I) mit Brombutyl-Gummistopfen und Aluminiumversiegelung und abtrennbarer Plastikkappe.,The powder is presented in 3 ml vials (Type I glass) with stopper (bromobutyl rubber) and aluminium flip-off cap.,"The powder is presented in 3 ml vials (Type I glass), with stopper (bromobutyl rubber) and aluminium flip-off cap.",The powder is presented in 3 ml vials (Type I glass) with stopper (bromobutyl rubber) and aluminium flip-off cap.,0.0,smt,5,5_smt,-0.02990386076271534|-0.03377433121204376|0.010855849832296371|-0.002570553682744503|0.02491883561015129
834,Bei der Kombination beider Präparate empfiehlt sich daher besondere Vorsicht.,"In the two products is recommended, therefore, caution should be exercised.",Therefore special care is recommended when combining these two compounds.,With the combination of both products special caution is recommended.,0.9090909090909092,smt,5,5_smt,0.30025067925453186|0.3658685088157654|0.5330907106399536|0.46382299065589905|0.39828425645828247
835,"Wenn Sie eine größere Menge von Imprida eingenommen haben, als Sie sollten Konsultieren Sie unverzüglich Ihren Arzt, wenn Sie zu viele Imprida-Tabletten eingenommen haben oder wenn jemand anderes Ihre Tabletten eingenommen hat.","If you take more Imprida than you should consult your doctor immediately if you have taken too many Imprida-Tabletten, or if someone else has taken your tablets.","If you take more Imprida than you should If you have taken too many tablets of Imprida, or if someone else has taken your tablets, consult a doctor immediately.","If you take more Imprida than you should: Consult your doctor immediately if you have taken too many Imprida-Tabletten, or if someone else has taken your tablets.",0.0333333333333333,smt,5,5_smt,0.02858683094382286|0.03884684294462204|0.14328128099441528|0.063452810049057|0.07049094885587692
836,Die TYSABRI Durchstechflasche ist vor dem Verdünnen und der Anwendung auf Partikel zu prüfen.,"The TYSABRI vial should be given before dilution, and discolouration prior to administration.",Inspect the TYSABRI vial for particles prior to dilution and administration.,The TYSABRI vial should be checked before dilution and use on particles.,0.4615384615384615,smt,5,5_smt,0.1484179049730301|0.22037355601787567|0.37644484639167786|0.268608421087265|0.2169158011674881
837,Es ist als Kapseln (gelb:,It is available as capsules (yellow:,It is available as capsules (yellow:,It is available as capsules (yellow:,0.0,smt,5,5_smt,-0.05325257033109665|-0.06280141323804855|0.010925645008683205|-0.03344736620783806|0.001464618369936943
838,Generalisierte Angststörung Die Wirksamkeit von Paroxetin bei der Behandlung der generalisierten Angststörung bei Erwachsenen wurde in einigen Kurzzeit- und Langzeitstudien untersucht.,Generalised Anxiety Disorder The efficacy of paroxetine in the treatment of generalised anxiety disorder in adults was investigated in some short-term and long-term studies.,Generalised Anxiety Disorder The efficacy of paroxetine in the treatment of GAD in adults was investigated in some short-term and long-term studies.,Generalised Anxiety Disorder: The efficacy of paroxetine in the treatment of generalised anxiety disorder in adults was investigated in some short-term and long-term studies.,0.0384615384615384,smt,5,5_smt,-0.02482510171830654|-0.02046012692153454|0.013919130899012089|0.0092779491096735|0.03368633985519409
839,"Dafiro ist in Packungen mit 7, 14, 28, 30, 56, 90, 98 oder 280 Tabletten und in Mehrfachpackungen mit 280 (4x70) Tabletten erhältlich.","Dafiro is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets.","Dafiro is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets.","Dafiro is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets.",0.0,smt,5,5_smt,-0.040479548275470734|-0.05273594707250595|0.010697571560740471|-0.0302854236215353|0.007543512620031834
840,Indinavir (CYP3A4-Hemmer und Substrat):,Indinavir (CYP3A4 inhibitor and substrate):,Indinavir (CYP3A4 inhibitor and substrate):,Indinavir (CYP3A4 inhibitor and substrate):,0.0,smt,5,5_smt,-0.07021242380142212|-0.07367457449436188|0.008478794246912003|-0.04673013091087341|-0.006402688100934029
841,"Die Anwendung von Humira ohne Methotrexat führte zu einer gesteigerten Bildung von Antikörpern, einer erhöhten Clearance und einer verminderten Wirksamkeit von Adalimumab (siehe Abschnitt 5.1).","Administration of Humira without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).","Administration of Humira without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).","Administration of Humira without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).",0.0,smt,5,5_smt,-0.040931206196546555|-0.035274751484394073|0.011532367207109928|-0.010761557146906853|0.017926104366779327
842,Becaplermin ist ein rekombinanter humaner thrombozytärer Wachstumsfaktor-BB (rhPDGF-BB).,Becaplermin is a recombinant thrombozytärer; 32 (human).,Becaplermin is a recombinant human Platelet Derived Growth Factor-BB (rhPDGF-BB).,Becaplermin is a recombinant thrombozytärer; 32 (human).,0.0,smt,5,5_smt,0.3451530933380127|0.4831187427043915|0.2791711986064911|0.5087172389030457|0.4369024932384491
843,Stillzeit Während der Stillzeit darf CYSTAGON nicht eingenommen werden.,Breast-feeding Breast-feeding Do not take CYSTAGON.,Breast-feeding CYSTAGON must not be used during breast-feeding.,Breast-feeding: Do not take CYSTAGON while breast-feeding.,0.3333333333333333,smt,5,5_smt,0.09164098650217056|0.15316937863826752|0.21765033900737762|0.20240426063537598|0.15718136727809906
844,Ivermectin gehört zu der Endektozid-Klasse der makrozyklischen Laktone.,Ivermectin belongs to a class of Endektozid-Klasse cavity.,Ivermectin is a member of the macrocyclic lactone class of endectocides.,Ivermectin belongs to a class of endectocide class cavity.,0.2,smt,5,5_smt,0.16065539419651031|0.23640112578868866|0.21460027992725372|0.3202998638153076|0.21303124725818634
845,"Wird Gemcitabin Patienten mit Lebermetastasen oder Hepatitis, Alkoholismus oder Leberzirrhose in der Vorgeschichte gegeben, kann es zu einer Verschlechterung der bestehenden Leberinsuffizienz kommen.","When gemcitabine is given in patients with liver metastases or hepatitis C, alcoholism, or a history of cirrhosis of the liver, which may lead to worsening of existing hepatic insufficiency may occur.","21 Hepatic insufficiency Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism or liver cirrhosis may lead to exacerbation of the underlying hepatic insufficiency.","When gemcitabine is given in patients with liver metastases or hepatitis C, alcoholism, or a history of cirrhosis of the liver, it may lead to worsening of existing hepatic insufficiency.",0.088235294117647,smt,5,5_smt,0.03117867186665535|0.060981497168540955|0.10073093324899673|0.09767748415470123|0.09730102121829987
846,"Patienten mit der seltenen, hereditären Fructose- / Galactose- Intoleranz, einer Glucose-Galactose-Malabsorption oder einer Sucrase-Isomaltase-Insuffizienz sollten dieses Arzneimittel nicht anwenden.","Patients with rare hereditary problems of dyeing consists of water / galactose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.","Therefore, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.","Patients with rare hereditary fructose / galactose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.",0.3,smt,5,5_smt,0.06845545023679733|0.12632904946804047|0.059108030050992966|0.1694895625114441|0.1222119852900505
847,"Sie sollten sich erst dann an das Steuer eines Fahrzeugs setzen bzw. Werkzeuge oder Maschinen bedienen, wenn Sie wieder klar sehen.","You should not drive a vehicle or drive or use any tools or machines, until your sight is clear again.",Do not drive or use machinery until the symptoms have cleared.,"You should not drive a vehicle or drive or use any tools or machines, until your sight is clear again.",0.0,smt,5,5_smt,0.05413825809955597|0.10853603482246399|0.07958067208528519|0.15502963960170746|0.11397189646959305
848,"In keiner der Verträglichkeitsstudien, die während der Entwicklung von Equilis StrepE durchgeführt wurden, konnte eine Purpura haemorrhagica beobachtet werden.",None of the safety of the performed during the development of Equilis StrepE were purpura haemorrhagica was observed.,Purpura haemorrhagica has not been observed in any of the safety studies performed during development of Equilis StrepE.,Purpura haemorrhagica has not been observed in any of the safety studies performed during development of Equilis StrepE.,0.631578947368421,smt,5,5_smt,0.1931982934474945|0.2820515036582947|0.3944656550884247|0.34973686933517456|0.2816959619522095
849,Erhöhungen der Herzfrequenz können insbesondere bei höherer Dosierung auftreten.,", increases in heart rate may be more common with the higher doses may occur.","Increases in heart rate can occur, particularly with higher doses.",Increases in heart rate may be more common with the higher doses.,0.2307692307692307,smt,5,5_smt,0.13790592551231384|0.18934454023838043|0.17660647630691528|0.2685618996620178|0.20023858547210693
850,"Bexaroten, der in Targretin enthaltene Wirkstoff, ist ein Mittel gegen Krebs.","Bexarotene, the active ingredient in Targretin, is contained.","The active substance in Targretin, bexarotene, is an anticancer agent.","Bexarotene, the active ingredient in Targretin, is a cancer fighting agent.",0.2857142857142857,smt,5,5_smt,0.0022224788554012775|0.012642862275242805|0.09995771199464798|0.05735497921705246|0.06815403699874878
851,Klinische Erfahrungen Therapieerfolge werden in diesem Abschnitt als vollständige oder partielle Remission definiert.,Clinical experience Therapieerfolge in this section as a complete or partial response.,Clinical Experience Succesful outcome in this section is defined as complete or partial response.,Clinical experience. Therapeutic success in this section is defined as a complete or partial remission.,0.3529411764705882,smt,5,5_smt,0.1264471858739853|0.1982964128255844|0.222523495554924|0.2693990170955658|0.1969793140888214
852,"Ein kausaler Zusammenhang lässt sich nicht herstellen, da diese Fälle üblicherweise mit dem Gebrauch anderer Arzneimittel und Risikofaktoren für eine Fehlgeburt verbunden sind (siehe Abschnitt 4.6).","A causal relationship has been definite conclusion can be made, as these cases are usually associated with the use of other medicinal products and risk factors for miscarriage (see section 4.6).","It is not possible to establish a causal relationship, since cases typically involve other drug use or risk factors for spontaneous abortion (see section 4.6).","A causal relationship cannot be made, as these cases are usually associated with the use of other medicinal products and risk factors for miscarriage (see section 4.6).",0.1612903225806451,smt,5,5_smt,0.1026327908039093|0.15633898973464966|0.15559075772762299|0.1919553428888321|0.1639016717672348
853,• In Abschnitt 4.8 wurde die folgende Beschreibung der beobachteten Nebenwirkungen hinzugefügt:,"• In section 4.8, the following adverse reaction has been added to the description of observed side effects:",• The following description of the observed side-effects has been added in Section 4.8:,"• In section 4.8, the following adverse reaction has been added to the description of observed side effects:",0.0,smt,5,5_smt,-0.013573860749602318|-0.008748885244131088|0.043626636266708374|0.03099876455962658|0.04452052712440491
854,In klinischen Studien wurde Desloratadin in der Sirup-Formulierung einer pädiatrischen Population verabreicht.,"In clinical trials, desloratadine was Sirup-Formulierung in a paediatric population.","In clinical trials, desloratadine in the syrup formulation was administered to a paediatric population.","In clinical trials, desloratadine was administered to a paediatric population in the syrup formulation.",0.375,smt,5,5_smt,0.2123449295759201|0.2760658264160156|0.3103208541870117|0.33859163522720337|0.27036815881729126
855,"25 Eine anamnestische Immunantwort wurde bei Geimpften nachgewiesen, die vor der Impfung seropositiv für die entsprechenden HPV-Typen waren.",25 an anamnestic response was seen in individuals who have been demonstrated before vaccination were seropositive.,Evidence of an anamnestic response was seen in vaccinated individuals who were seropositive to relevant HPV type(s) prior to vaccination.,25 An anamnestic immune response was seen in individuals who were seropositive for the corresponding HPV type before vaccination.,0.4,smt,5,5_smt,0.14713291823863983|0.2895694375038147|0.32639846205711365|0.33627447485923767|0.2441173642873764
856,"Patienten, die zuvor mit einem TNF-Inhibitor behandelt wurden, könnten ein erhöhtes Neutropenierisiko haben.",patients who had been previously treated with a laryngoscope that could have an increased Neutropenierisiko.,There may be an increased risk of neutropenia in patients who have previously been treated with a TNF antagonist.,Patients who had been previously treated with a TNF inhibitor could have an increased risk of neutropenia.,0.2777777777777778,smt,5,5_smt,0.1706843078136444|0.2948586046695709|0.285394549369812|0.36276185512542725|0.26487118005752563
857,"Die Pen-Kappe muss nach jeder Injektion wieder auf den Pen gesetzt werden, um den Inhalt vor Licht zu schützen.",The pen cap should be replaced on the pen must be used in order to protect from light after each injection.,The pen cap must be put back on the pen after each injection in order to protect from light.,The pen cap should be replaced on the pen must in order to protect from light after each injection.,0.1,smt,5,5_smt,0.08773085474967957|0.163066104054451|0.21160784363746643|0.2471415400505066|0.17866195738315582
858,"Einstellung des pH-Wertes der Liposomen • 1,9 ml Myocet-Liposomen entnehmen.",pH-adjustment • Withdraw 1.9 ml of Myocet liposomes.,Adjust Ph of liposomes • Withdraw 1.9 ml of Myocet liposomes.,pH-adjustment of the lipsomes • Withdraw 1.9 ml of Myocet liposomes.,0.25,smt,5,5_smt,0.018801959231495857|0.030751336365938187|0.0623655840754509|0.09264227002859116|0.07748598605394363
859,Die intravenöse Anwendung einer 3-g- Tagesdosis Ertapenem über 8 Tage bei erwachsenen Probanden führte zu keinen signifikanten toxischen Wirkungen.,"The intravenous administration of the 3-g- daily dose of ertapenem for 8 days in adult volunteers, no toxicologically significant effects.",Intravenous administration of ertapenem at a 3 g daily dose for 8 days to healthy adult volunteers did not result in significant toxicity.,The intravenous administration of the 3 g daily dose of ertapenem for 8 days in adult volunteers led to no toxicologically significant effects.,0.1666666666666666,smt,5,5_smt,0.05110020935535431|0.08798298239707947|0.13501372933387756|0.13935469090938568|0.10968068987131119
860,Ein Risiko für das gestillte Kind kann nicht ausgeschlossen werden.,The risk to the suckling child cannot be excluded.,A risk to the suckling child cannot be excluded.,The risk to the suckling child cannot be excluded.,0.0,smt,5,5_smt,-0.023318201303482056|-0.028896445408463478|0.012099610641598701|0.018101178109645844|0.03252856060862541
861,Es liegen limitierte Daten für Patienten mit schwerer Leberfunktionseinschränkung vor.,There are limited data in patients with severe hepatic impairment.,There are limited data in patients with severe hepatic impairment.,There are limited data in patients with severe hepatic impairment.,0.0,smt,5,5_smt,-0.05205035209655762|-0.05323173850774765|0.009626775979995728|-0.019348489120602608|0.01079979445785284
862,"Sie sollten daher angemessene Vorsichtsmaßnahmen treffen, um dies zu verhindern.","Therefore, you should therefore continue to use appropriate precautions to prevent this.",There is an effective vaccine available to protect those at risk from becoming infected with hepatitis B virus.,You should therefore continue to use appropriate precautions to prevent this.,0.1666666666666666,smt,5,5_smt,0.1865498274564743|0.26073578000068665|0.15484805405139923|0.34904396533966064|0.25549134612083435
863,Der Fibrinogenspiegel normalisiert sich innerhalb von 2 Tagen wieder.,The target resolves within 2 days.,The fibrinogen level normalises within 2 days.,The target resolves within 2 days.,0.0,smt,5,5_smt,0.08974973857402802|0.1075773760676384|0.13620005548000336|0.2184617817401886|0.14291894435882568
864,"Kombination mit anderen Eisenchelattherapien, da die Sicherheit solcher Kombinationen nicht belegt ist (siehe Abschnitt 4.5).","Combination with other iron chelator treatment, because the safety of such combinations has not been established (see section 4.5).",Combination with other iron chelator therapies as the safety of such combinations has not been established (see section 4.5).,"Combination with other iron chelator treatment, because the safety of such combinations has not been established (see section 4.5).",0.0,smt,5,5_smt,-0.0058842673897743225|0.0023977700620889664|0.027638209983706474|0.041213348507881165|0.050042182207107544
865,Bei der Mehrzahl der Patienten (8/10) wurden Perikarderguss und Perikarditis als asymptomatisch und für die echokardiografische Beurteilung kaum relevant oder unerheblich angesehen.,"The majority of patients (8 / 10), pericardial effusion and asymptomatic pericarditis and echokardiografische little relevance of considered or negligible.","In the majority of patients (8/ 10), the pericardial effusion and pericarditis were deemed to be asymptomatic and of little or no clinical significance on echocardiographic assessment.","In the majority of patients (8 / 10), pericardial effusion and pericarditis were considered asymptomatic and of little relevance or negligible for echocardiograph evaluation.",0.3928571428571428,smt,5,5_smt,0.28578099608421326|0.4110035300254822|0.2708616554737091|0.4275253415107727|0.3497561812400818
866,Wenn Sie irgendeines dieser Symptome bemerken: → Informieren Sie Ihren Arzt.,If you notice any of these symptoms: → Talk to your doctor.,If you notice any of these symptoms: → Tell your doctor.,If you notice any of these symptoms: → Talk to your doctor.,0.0,smt,5,5_smt,-0.00934804230928421|-0.019976576790213585|0.01116817444562912|0.006038838531821966|0.03529098629951477
867,"Diese Konzentration entspricht 83,3 Mikrogramm Protein/ml (die spezifische In-vivo-Bioaktivität entspricht etwa 10 000 IE FSH/mg Protein).",This concentration is equivalent to 83.3 microgram / ml (the specific In-vivo-Bioaktivität to approximately 10 000 IU FSH / mg protein).,This strength corresponds to 83.3 microgram of protein / ml (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).,This concentration is equivalent to 83.3 microgram / ml (the specific in vivo bioactivity is approximately 10 000 IU FSH / mg protein).,0.1538461538461538,smt,5,5_smt,0.08013718575239182|0.12642569839954376|0.15404990315437317|0.15447653830051422|0.12674346566200256
868,"Konventionelle Studien zur Sicherheitspharmakologie wurden unter Lichtausschluss an Mäusen, Ratten und Hunden durchgeführt.","Conventional studies of safety pharmacology, patients treated with Lichtausschluss in mice, rats and dogs.","Standard safety pharmacology experiments were performed under light protection in the mouse, rat and dog.","Conventional studies of safety pharmacology were carried out in the dark on mice, rats and dogs.",0.3888888888888889,smt,5,5_smt,0.17768429219722748|0.2819819748401642|0.3181929886341095|0.3226606547832489|0.2593356668949127
869,Die Bestimmung der Werte sollte danach in nicht geringeren Abständen als in monatlichen Intervallen erfolgen.,The analysis of the levels should then not less than should be administered at monthly intervals.,Every attempt should be made to maintain triglyceride levels below 4.52 mmol/ l in order to reduce the risk of clinical sequelae.,The analysis of the levels should then be administered at no less than monthly intervals.,0.1875,smt,5,5_smt,0.42758238315582275|0.49986976385116577|0.4691580533981323|0.5815617442131042|0.48392996191978455
870,"Da bei einigen Patienten eine Dosisanpassung erforderlich sein kann, wird bei der Erhaltungstherapie eine klinische Überwachung empfohlen.","Since some patients a dose adjustment may be necessary in maintenance therapy, but clinical monitoring is recommended.","Therefore, clinical monitoring is recommended, as maintenance therapy may need to be adjusted in some patients.","Since a dose adjustment may be necessary some patients, clinical monitoring is recommended during maintenance therapy.",0.3333333333333333,smt,5,5_smt,0.05170377716422081|0.05429835617542267|0.1730036586523056|0.12022203952074051|0.11766299605369568
871,"Weiße runde, konvexe Tablette, mit der Prägung „DF” auf einer Seite und„ 7.5” auf der anderen Seite.","White, round, convex tablet debossed with ""DF"" on one side and ""7.5"" on the other side.","White round, convex tablet, debossed with “DF” on one side and“ 7.5” on the reverse.","White, round, convex tablet debossed with ""DF"" on one side and ""7.5"" on the other side.",0.0,smt,5,5_smt,0.005307768937200308|0.007811529561877251|0.015226275660097599|0.048622142523527145|0.05357077717781067
872,"Die Lösung befindet sich in Typ I Klarglasflaschen, die mit Butyl- oder Halobutylstopfen verschlos- sen und mit Aluminiumkappen gesichert sind.","The solution in type I Klarglasflaschen, these verschlos- and plunger heads and secured with aluminium seals Halobutylstopfen.","7 The solution is contained in type I flint glass vials, sealed with butyl or halobutyl stoppers and secured with aluminium seals.","The solution is in type I clear glass bottles, that close with butyl and halobutyl plunger heads and secured with aluminium seals.",0.4166666666666667,smt,5,5_smt,0.4284064471721649|0.5369568467140198|0.4598880410194397|0.5632026195526123|0.45548397302627563
873,"17 Verdünntes Filgrastim kann an Glas und Plastikmaterialien adsorbiert werden, wenn es nicht wie in Abschnitt 6.6 beschrieben verdünnt wird.",17 Diluted filgrastim may be adsorbed to glass and plastic materials except if it does not appear as mentioned in section 6.6.,"Diluted filgrastim may be adsorbed to glass and plastic materials except diluted, as mentioned in section 6.6.","17 Diluted filgrastim may be adsorbed to glass and plastic materials, if it does not diluted as mentioned in section 6.6.",0.0869565217391304,smt,5,5_smt,0.015518318861722946|0.03945120424032211|0.04833579808473587|0.08078869432210922|0.07850140333175659
874,"Viraler Impfstoff, ATC-Code:","Pharmacotherapeutic group: viral vaccines, ATC code:",Pharmacotherapeutic group:,"Pharmacotherapeutic group: viral vaccines, ATC code:",0.0,smt,5,5_smt,0.0675550177693367|0.09160522371530533|0.03763704374432564|0.1640866994857788|0.14185743033885956
875,Actos 15 mg Tabletten können mit oder ohne Mahlzeit eingenommen werden.,Actos 15 mg tablets can be taken with or without food.,Actos 15mg tablets can be taken with or without food.,Actos 15 mg tablets can be taken with or without food.,0.0,smt,5,5_smt,-0.034910254180431366|-0.037960633635520935|0.00926982145756483|-0.007549057248979807|0.016279740259051323
876,"Insuman Basal wird in Patronen, fest verbunden mit Patronenhaltern, angeboten; sie bilden den auswechselbaren Teil des Insulinpens OptiClik.","Insuman Basal comes in a cartridge sealed in a plastic container, which is the disposable part of OptiClik, an insulin pen.","It comes in a cartridge sealed in a plastic container, which is the disposable part of OptiClik, an insulin pen.","Insuman Basal comes in a cartridge sealed in a plastic container, which is the disposable part of the OptiClik insulin pen.",0.1304347826086956,smt,5,5_smt,0.015684448182582855|0.02059592306613922|0.030777662992477417|0.06462899595499039|0.07532692700624466
877,"Insuman Comb 25 ist in Patronen gefüllt, die fest verbunden mit Fertigpens, OptiSet, sind.","Insuman Comb 25 comes in cartridges sealed in disposable pen injectors, OptiSet.","Insuman Comb 25 comes in cartridges sealed in disposable pen injectors, OptiSet.","Insuman Comb 25 comes in cartridges sealed in disposable pen injectors, OptiSet.",0.0,smt,5,5_smt,-0.002884991466999054|0.009757300838828087|0.01845262385904789|0.059911757707595825|0.056473508477211
878,"Karvezide sollte bei Einnahme mit anderen Arzneimitteln, die sich auf den Kaliumgehalt im Blut auswirken, mit Vorsicht eingesetzt werden.","Karvezide should be used with caution in patients taking other medicines, blood potassium levels that have an effect on.",Care must be taken when using Karvezide with other medicines that have an effect on blood potassium levels.,"Karvezide should be used with caution in patients taking other medicines, blood potassium levels that have an effect on.",0.0,smt,5,5_smt,0.06918148696422577|0.10301361232995987|0.16213184595108032|0.15381447970867157|0.12431252002716064
879,"Die Wirkungen von Darifenacin auf den Metabolismus von CYP2D6-Substraten sind vor allem für CYP2D6-Substrate klinisch relevant, deren Dosierung individuell titriert wird.",The effects of darifenacin on the metabolism of CYP2D6 substrates are individually titrated mainly for CYP2D6 substrates not considered to be at risk.,The effects of darifenacin on the metabolism of CYP2D6 substrates are mainly clinically relevant for CYP2D6 substrates which are individually dose titrated.,"The effects of darifenacin on the metabolism of CYP2D6 substrates are clinically relevat mainly for CYP2D6 substrates, which are induvidually titrated.",0.3478260869565217,smt,5,5_smt,0.010728463530540466|0.04177476465702057|0.07328382134437561|0.07888399809598923|0.06953328102827072
880,Sie dürfen das Arzneimittel nach dem auf dem Umkarton angegebenen Verfallsdatum nicht mehr anwenden.,Do not use after the expiry date which is stated on the carton.,Do not use YENTREVE after the expiry date which is stated on the carton.,Do not use after the expiry date which is stated on the carton.,0.0,smt,5,5_smt,-0.023657076060771942|-0.018509944900870323|0.010588128119707108|0.005604009609669447|0.032220833003520966
881,Mischen Sie kein anderes Insulin in Ihrer Humalog Mix50 Patrone.,Do not mix any other insulin in a Humalog Mix50 cartridge.,Do not mix any other insulin in a Humalog Mix50 cartridge.,Do not mix any other insulin in a Humalog Mix50 cartridge.,0.0,smt,5,5_smt,-0.008866970427334309|-0.015560822561383247|0.009673363529145718|0.02818983979523182|0.03791572153568268
882,Sie sollten auf die mögliche Schädigungsgefahr und auf Vorsichtsmaßnahmen zur Minimierung orthostatischer Symptome hingewiesen werden.,You should be advised of the potential Schädigungsgefahr and measures of precaution to minimize orthostatic symptoms.,They should be informed about the potential risk for injuries and measures of precaution to minimise orthostatic symptoms.,You should be advised of the potential damage risk and measures of precaution to minimize orthostatic symptoms.,0.1111111111111111,smt,5,5_smt,0.04656240716576576|0.07664210349321365|0.07469397783279419|0.11568397283554077|0.10364969819784164
883,"Natrium Gemzar® 200 mg enthält 3,5 mg (< 1 mmol) Natrium pro Durchstechflasche.",sodium Gemzar 200 mg contains 3.5 mg ( 1 mmol) sodium per vial.,Sodium Gemzar 200 mg contains 3.5 mg (< 1 mmol) sodium per vial.,sodium Gemzar® 200 mg contains 3.5 mg ( 1 mmol) sodium per vial.,0.0625,smt,5,5_smt,-0.029721057042479515|-0.032139308750629425|0.012918728403747082|-0.01110810786485672|0.01904749870300293
884,"Auch wenn die Liste der möglichen Nebenwirkungen besorgniserregend aussehen mag, ist es möglich, dass keine davon bei Ihnen auftritt.","Although the list of possible side effects look like other concern, it is possible that there are no samples occurs.","Although the list of possible side effects can seem worrying, it ’ s possible that you may not have any of them.","Although the list of possible side effects may look worrying, it is possible that none will occur with you.",0.4285714285714285,smt,5,5_smt,0.24169138073921204|0.34858813881874084|0.2404787838459015|0.3931015431880951|0.31870076060295105
885,"In vier Studien wurden bei insgesamt 146 gesunden Freiwilligen, die Filgrastim Hexal oder Neupogen erhielten, die Konzentrationen von Neutrophilen im Blut untersucht.","Four studies were carried out in a total of 146 healthy volunteers who received Filgrastim Hexal or Neupogen, the levels of neutrophils in the blood.",Four studies looked at the levels of neutrophils in the blood in a total of 146 healthy volunteers who received Filgrastim Hexal or Neupogen.,The levels of neutrophils in the blood were studied in four studies with a total of 146 healthy volunteers who received Filgrastim Hexal or Neupogen.,0.2307692307692307,smt,5,5_smt,0.03360884636640549|0.05115655064582825|0.12047091871500015|0.10242901742458344|0.08826223760843277
886,"Sie sollten Ihrem Arzt berichten, wenn Sie neue oder ungewöhnliche Symptome und Begebenheiten beobachten.",You should tell your doctor if you report a new or unusual symptoms and Begebenheiten.,You should report any new and exceptional symptoms and circumstances whenever you see your doctor.,You should tell your doctor if you observe new or unusual symptoms and incidences.,0.2,smt,5,5_smt,0.07291977107524872|0.12230777740478516|0.07130111753940582|0.16128545999526978|0.13731640577316284
887,"Herzinsuffizienz Die übliche Anfangsdosis von < Cozaar > bei Patienten mit Herzinsuffizienz beträgt 12,5 mg einmal täglich.",Heart failure The usual starting dose of Cozaar is 12.5 mg once a day in patients with heart failure.,Heart Failure The usual initial dose of Cozaar in patients with heart failure is 12.5 mg once daily.,Heart failure: The usual starting dose of Cozaar is 12.5 mg once a day in patients with heart failure.,0.0476190476190476,smt,5,5_smt,-0.025642963126301765|-0.02656613476574421|0.013154390268027782|0.010830728337168694|0.02831079810857773
888,Wie bei allen Proteinprodukten zur intravenösen Anwendung besteht die Möglichkeit allergischer Reaktionen.,"As with any intravenous protein product, the possibility of allergic reactions.","As with any intravenous protein product, allergic reactions are possible.","As with any intravenous protein product, there is a possibility of allergic reactions.",0.2,smt,5,5_smt,-0.008580783382058144|-0.007336238399147987|0.08104913681745529|0.02918304316699505|0.05068717896938324
889,"- Wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder Sie Nebenwirkungen bemerken, die nicht in dieser Gebrauchsinformation angegeben sind, informieren Sie bitte Ihren Arzt oder Apotheker.","- If any of the side effects get serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist.","If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.","- If any of the side effects get serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist.",0.0,smt,5,5_smt,-0.03555826097726822|-0.03957093507051468|0.012651469558477402|-0.021151097491383553|0.020722202956676483
890,ge Erwachsene entwickelten auch Kinder und Jugendliche andere psychiatrische Nebenwirkungen (z.B.,"reported more frequently compared to adult patients, children and adolescents also experienced other psychiatric adverse events (e. g.",follow-up after treatment.,"Compared to adult patients, children and adolescents also experienced other psychiatric adverse events (e. g.",0.1666666666666666,smt,5,5_smt,0.34491273760795593|0.4368668496608734|0.2825198769569397|0.46164724230766296|0.4237891733646393
891,Lucentis wird als Einzelinjektion in das Auge gespritzt.,Lucentis is given by a single injection into the eye.,Lucentis is administered as a single injection into your eye.,Lucentis is given by a single injection into the eye.,0.0,smt,5,5_smt,-0.011925054714083672|-0.018182015046477318|0.013430578634142876|0.031094154343008995|0.04540162906050682
892,Tierstudien geben keine Hinweise auf direkte schädigende Wirkungen bezüglich Fruchtbarkeit oder Schwangerschaft.,Animal studies do not indicate direct harmful effects with respect to fertility or pregnancy.,21 Animal studies did not indicate direct harmful effects with respect to fertility or pregnancy.,Animal studies do not indicate direct harmful effects with respect to fertility or pregnancy.,0.0,smt,5,5_smt,-0.04269083961844444|-0.037477679550647736|0.01179972942918539|-0.010433055460453033|0.019044391810894012
893,Im Vergleich mit gesunden Probanden waren bei Patienten mit leichter Leberfunktionsstörung (Child-Pugh A) die mittlere AUC und Cmax um 17% bzw.,"When compared to healthy subjects in patients with mild hepatic impairment (Child Pugh A), the mean AUC and Cmax of 17% and 108% respectively.","In patients with mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased 17% and 22% respectively, compared to healthy control subjects.","When compared to healthy subjects, patients with mild hepatic impairment (Child Pugh A), the mean AUC and Cmax of 17% and 108% respectively.",0.0333333333333333,smt,5,5_smt,0.04408414289355278|0.07509300112724304|0.0607549212872982|0.12254243344068527|0.09681160748004913
894,Sie dürfen Liprolog Mix50 Pen nach dem auf dem Etikett und dem Umkarton angegebenen Verfalldatum nicht mehr anwenden.,Do not use Liprolog Mix50 Pen after the expiry date which is stated on the label and the carton.,Do not use Liprolog Mix50 Pen after the expiry date which is stated on the label and the carton.,Do not use Liprolog Mix50 Pen after the expiry date which is stated on the label and the carton.,0.0,smt,5,5_smt,-0.037505291402339935|-0.0373404398560524|0.009740767069160938|-0.009877488017082214|0.020914100110530853
895,Eine Gesamttagesdosis von über 100 mg/kg ist aufgrund einer potenziell erhöhten Gefahr von Nebenwirkungen nicht empfehlenswert.,The total daily dose greater than 100 mg / kg is not recommended due to potentially increased risk of adverse reactions.,Doses above 100 mg/ kg per day are not recommended because of an potentially increased risk of side effects.,A total daily dose greater than 100 mg/kg is not recommended due to potentially increased risk of adverse reactions.,0.0454545454545454,smt,5,5_smt,-0.010294942185282707|-0.006018487736582756|0.01570827141404152|0.028856495395302773|0.03904472291469574
896,Der Inhaber der Genehmigung für das Inverkehrbringen reichte am 12. September 2007 schriftliche Antworten auf die Fragenliste ein.,The MAH marketing authorisation submitted written responses to the List of Questions on 12 September 2007.,The Marketing Authorisation Holder submitted written responses to the List of Questions on 12 September 2007.,The MAH marketing authorisation submitted written responses to the List of Questions on 12 September 2007.,0.0,smt,5,5_smt,0.0196005180478096|0.0422656312584877|0.04564061388373375|0.08831264823675156|0.08854915201663971
897,Am 9. Juli 2003 erteilte die Europäische Kommission dem Unternehmen Pierre Fabre Médicament eine Genehmigung für das Inverkehrbringen von Busilvex in der gesamten Europäischen Union.,"The European Commission granted Pierre Fabre Médicament Marketing Authorisation for Busilvex in the European Union, for Suprelorin on 9 July 2003.",The European Commission granted a marketing authorisation valid throughout the EU for Busilvex to Pierre Fabre Médicament on 9 July 2003.,The European Commission granted Pierre Fabre Médicament Marketing Authorisation for Busilvex in the European Union for Suprelorin on 9 July 2003.,0.0454545454545454,smt,5,5_smt,0.025407293811440468|0.05158763378858566|0.10660096257925034|0.08564779907464981|0.08732886612415314
898,Jedoch wurden keine inakzeptablen Risiken in dieser Patientengruppe beobachtet.,"However, there have been no observed unacceptable risks in this population of patients.","However, no unacceptable risks appear to be present in this patient group.","However, no unacceptable risks were observed in this population of patients.",0.3846153846153846,smt,5,5_smt,0.009076936170458794|0.01812134124338627|0.03179386630654335|0.0593554750084877|0.05870134383440018
899,Laboruntersuchungen In kontrollierten klinischen Studien waren klinisch relevante Veränderungen von Standardlaborparametern selten mit der Verabreichung von Rasilez assoziiert.,"Laboratory findings In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommonly associated with the administration of Rasilez.","Laboratory findings In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommonly associated with the administration of Rasilez.",Laboratory findings In controlled clinical trials. Clinically relevant changes in standard laboratory parameters were rarely associated with the administration of Rasilez.,0.0869565217391304,smt,5,5_smt,-0.04738643765449524|-0.046564772725105286|0.012026769109070301|-0.013606736436486244|0.016690745949745178
900,2 Anleitung zur Zubereitung des Produkts vor Anwendung siehe Abschnitt 6.6.,"2 For instructions on reconstitution of the product before administration, see section 6.6.","For instructions on reconstitution of the product before administration, see section 6.6.","2 For instructions on reconstitution of the product before administration, see section 6.6.",0.0,smt,5,5_smt,-0.046217579394578934|-0.050271593034267426|0.011815007776021957|-0.022410916164517403|0.012374158948659897
901,In der PROWESS- Studie wurde Xigris bei 1 690 Patienten mit einem Placebo (Scheinbehandlung) verglichen.,In the PROWESS- Xigris in study 1 690 patients was compared with placebo (a dummy treatment).,"In the PROWESS study, Xigris was compared to placebo (dummy treatment) in 1,690 patients.","In the PROWESS study, Xigris 1,690 was compared with placebo (a dummy treatment) in patients.",0.3684210526315789,smt,5,5_smt,0.1203518807888031|0.15356113016605377|0.19073429703712463|0.22150662541389465|0.19714371860027313
902,Das Arzneimittel darf nicht im Abwasser oder Haushaltsabfall entsorgt werden.,This medicinal product should be disposed of in accordance with local requirements.,• Medicines should not be disposed of via wastewater or household waste.,This medicinal product should be disposed of in accordance with local requirements.,0.0,smt,5,5_smt,0.08076158910989761|0.11316061019897461|0.07526363432407379|0.17256249487400055|0.1416657418012619
903,Tasonermin hat sich im klassischen Tumor-Nekrose-Faktor-Test als aktiv erwiesen. Es führte nach lokaler bzw. systemischer Injektion zur hämorrhagischen Nekrose von Tumorknötchen in syngenetischen und xenogenetischen (humanen) Tumortestsystemen in der Maus.,Tasonermin has profound effects in the classic Tumor-Nekrose-Faktor-Test malfunctioning. It resulted in local or systemic injection haemorrhagic necrosis of tumour in the classic assay and Tasonermin has been shown in mice.,"Tasonermin has been shown to be active in the classic assay for tumour necrosis factor, producing haemorrhagic necrosis of tumour nodules in murine syngeneic and human xenogeneic tumour systems after local or systemic injection.",Tasonermin has shown to be positive in the classic assay for tumor necrosis factor. It resulted in haemorrhagic necrosis of tumour nodules in syngeneic and xenogeneic (human) tumor testing systems in the mouse following local or systemic injection.,0.5714285714285714,smt,5,5_smt,0.3222779631614685|0.44210055470466614|0.33449581265449524|0.4606066048145294|0.39182326197624207
904,26 Kontrolle. Insbesondere bei Patienten mit dekompensierter Herzinsuffizienz oder nach Nierentransplantation besteht das Risiko einer Einschränkung der Nierenfunktion.,"26. In particular, in patients with congestive heart failure or after renal transplant is a risk of impairment of renal function.","There is a risk of impairment of renal function, particularly in patients with congestive heart failure or after a renal transplant.",26. There is a higher risk of impairment of renal function in patients with congestive heart failure or after renal transplant.,0.3043478260869565,smt,5,5_smt,-0.01245611347258091|-0.0015459489077329636|0.08907999843358994|0.04150867462158203|0.0455782487988472
905,"Wenn Sie einen MAO-Hemmer eingenommen haben, müssen Sie nach Beendigung der Einnahme noch mindestens 14 Tage warten, bevor Sie ARICLAIM einnehmen.","If you have any MAOI than you were told to, after you have stopped taking wait at least 14 days before you can take ARICLAIM.",90 after you have stopped taking an MAOI before you can take ARICLAIM.,"If you have taken a MAOI, you must wait at least 14 days after taking it before you can take ARICLAIM.",0.5217391304347826,smt,5,5_smt,0.12682247161865234|0.17949765920639038|0.3979285657405853|0.21295274794101715|0.17149129509925842
906,"Bei Anwendung von Simulect mit anderen Arzneimitteln Bitte informieren Sie Ihren Arzt, eine Krankenschwester oder Ihren Apotheker, wenn Sie andere Arzneimittel einnehmen/anwenden bzw. vor kurzem eingenommen/angewendet haben, auch wenn es sich um nicht verschreibungspflichtige Arzneimittel handelt.","37 Using other medicines Please tell your doctor, nurse or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.","31 Using other medicines Please tell your doctor, nurse or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription.","37 Using Simulect with other medicines. Please tell your doctor, nurse or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.",0.09375,smt,5,5_smt,-0.005839118268340826|-0.0014835894107818604|0.019404631108045578|0.015438929200172424|0.04372752457857132
907,Die Unterdrückung der Magensäuresekretion kann zu einer niedrigeren Exposition von Nilotinib führen.,The suppression of gastric acid secretion may lead to lower exposure to nilotinib.,Suppression of gastric acid secretion might result in lower exposure to nilotinib.,The suppression of gastric acid secretion may lead to lower exposure of nilotinib.,0.0714285714285714,smt,5,5_smt,-0.01734623871743679|-0.002832287922501564|0.011498687788844109|0.031063305214047432|0.04470834881067276
908,Alopezie; Hauttoxizität (G3/4:,Alopecia; Hauttoxizität (G3 / 4:,Alopecia; Skin toxicity (G3/ 4:,Alopecia; skin toxicity (G3 / 4:,0.2222222222222222,smt,5,5_smt,-0.014934929087758064|-0.00824427604675293|0.02094736509025097|0.008794207125902176|0.035694561898708344
909,"Bei sehr kleinen Kindern, kann die Injektion in den Oberschenkel vorgenommen werden.","In very young children, the injection may be done in the thigh.","In very small children, the injection may be given into the thigh muscle.","In very young children, the injection may be done in the thigh.",0.0,smt,5,5_smt,-0.014658104628324509|-0.01458660140633583|0.017513815313577652|0.03135451674461365|0.04364142566919327
910,Das Verteilungsvolumen ist nicht dosisabhängig.,The volume of distribution is not dose-dependent.,The volume of distribution is not dose dependent.,The volume of distribution is not dose-dependent.,0.0,smt,5,5_smt,-0.0319179892539978|-0.03724822402000427|0.009910058230161667|0.011941302567720413|0.024362556636333466
911,"Wenn Sie etwas nicht verstehen, bitten Sie Ihren Arzt oder das medizinische Fachpersonal um weitere Erklärungen.","If there is anything you do not understand, please ask your doctor or health care professional for an additional explanations.","If there is anything you do not understand, ask the doctor or nurse to explain.","If there is anything you do not understand, please ask your doctor or health care professional for an additional explanations.",0.0,smt,5,5_smt,0.021461382508277893|0.028044305741786957|0.03667440265417099|0.05077512189745903|0.06691562384366989
912,ProQuad darf nach dem auf der Faltschachtel nach „Verwendbar bis“ angegebenen Verfalldatum nicht mehr angewendet werden.,"Do not use ProQuad after the expiry date which is stated on the carton after ""EXP.""",Do not use ProQuad after the expiry date which is stated on the outer carton after EXP.,"Do not use ProQuad after the expiry date which is stated on the carton after ""EXP.""",0.0,smt,5,5_smt,-0.002909041242673993|0.022612329572439194|0.019344152882695198|0.052673038095235825|0.05661192536354065
913,"Da Otitis media nicht nur durch die Pneumokokken-Serotypen des Impfstoffes, sondern auch durch viele andere Erreger verursacht wird, ist der zu erwartende Schutz gegen alle Otitis media-Erkrankungen gering.","As otitis media is not the vaccine but also caused by many other pathogens, is expected to protection against all otitis media is low.","As otitis media is caused by many organisms other than pneumococcal serotypes represented in the vaccine, protection against all otitis media is expected to be low.","As otitis media is not only caused by the pneumococci serotype vaccine but also caused by many other pathogens, it's expected protection against all otitis media is low.",0.2580645161290322,smt,5,5_smt,0.2283739298582077|0.3293295204639435|0.22398141026496887|0.3723195791244507|0.2903957962989807
914,Ibraxion enthält Mineralöl.,Ibraxion contains mineral oil.,Ibraxion contains mineral oil.,Ibraxion contains mineral oil.,0.0,smt,5,5_smt,-0.06744000315666199|-0.06608651578426361|0.008497419767081738|-0.043963249772787094|-0.001949535682797432
915,Sie dürfen das Arzneimittel nach dem auf dem Etikett und dem Umkarton angegebenen Verfalldatum nicht mehr anwenden.,Do not use after the expiry date which is stated on the label and the carton.,Do not use after the expiry date stated on the label and carton.,Do not use after the expiry date which is stated on the label and the carton.,0.0,smt,5,5_smt,-0.039574749767780304|-0.038532815873622894|0.009240308776497841|-0.013852814212441444|0.020788289606571198
916,Trazec bei älteren Patienten Trazec kann von Patienten über 65 Jahre eingenommen werden.,"Trazec in elderly patients, Trazec can be taken by patients over 65 years of age.",Trazec and older people Trazec can be used by people over 65 years of age.,Trazec in elderly patients. Trazec can be taken by patients over 65 years of age.,0.0588235294117647,smt,5,5_smt,0.04970572516322136|0.0747331827878952|0.07540672272443771|0.13083885610103607|0.1003463938832283
917,Besondere Vorsichtsmaßnahmen für den Anwender Personen mit bekannter Überempfindlichkeit gegenüber Chinolonen sollten jeglichen Kontakt mit dem Produkt vermeiden.,Special precautions to be taken by the person People with a known hypersensitivity to quinolones should avoid any contact with the product.,Special precautions to be taken by the person administering the veterinary medicinal product to animals People with a known hypersensitivity to quinolones should avoid any contact with the product.,Special precautions to be taken by the user: People with a known hypersensitivity to quinolones should avoid any contact with the product.,0.0833333333333333,smt,5,5_smt,0.014886362478137016|0.026977505534887314|0.03820841386914253|0.0680127963423729|0.07216184586286545
918,"VERBOT DES VERKAUFS, DER ABGABE UND/ODER DER ANWENDUNG Nicht zutreffend.","PROHIBITION OF SALE, SUPPLY AND / OR USE.",Not applicable.,"PROHIBITION OF SALE, SUPPLY AND / OR USE.",0.0,smt,5,5_smt,0.22945651412010193|0.24162207543849945|0.10504410415887833|0.26977863907814026|0.2574770748615265
919,Die vollständige Auflistung der im Zusammenhang mit Faslodex berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen.,For a full list of the side-effects reported with Faslodex (allergic) to ribavirin or any of the other ingredients.,"For the full list of all side effects reported with Faslodex, see the Package Leaflet.",For a full list of the side-effects reported with Faslodex to is available on the package leaflet.,0.5,smt,5,5_smt,0.2165200263261795|0.29269659519195557|0.5420150756835938|0.3496372103691101|0.27207881212234497
920,Wichtige Informationen über bestimmte sonstige Bestandteile von Avamys Avamys enthält Benzalkoniumchlorid.,Important information about some of the ingredients of Avamys Avamys contains benzalkonium chloride.,Important information about some of the ingredients of Avamys Avamys contains benzalkonium chloride.,Important information about some of the ingredients of Avamys. Avamys contains benzalkonium chloride.,0.0666666666666666,smt,5,5_smt,-0.027828343212604523|-0.02427154965698719|0.011950653977692127|0.0004901634529232979|0.02472250908613205
921,Trinken Sie sofort den gesamten Inhalt des Dosierbechers.,Immediately drink the whole content of the glass Dosierbechers.,Swallow the entire contents of the dosing cup immediately.,Immediately drink the whole content of the glass Dosierbechers.,0.0,smt,5,5_smt,0.11169485002756119|0.17504209280014038|0.07953312993049622|0.2478434443473816|0.17092542350292206
922,"Karvezide 150 mg/12,5 mg Tabletten stehen in Blisterpackungen zu 14, 28, 56 oder 98 Stück zur Verfügung.","Karvezide 150 mg / 12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.","Karvezide 150 mg/ 12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.","Karvezide 150 mg / 12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.",0.0,smt,5,5_smt,-0.036080073565244675|-0.04620436578989029|0.011736932210624218|-0.022957852110266685|0.00955190695822239
923,"Die Therapie mit Visudyne kann, wenn nötig, alle drei Monate wiederholt werden.","Treatment with Visudyne may, if necessary, be repeated every three months.","If necessary, Visudyne therapy can be repeated every 3 months.","Treatment with Visudyne may, if necessary, be repeated every three months.",0.0,smt,5,5_smt,-0.01558181457221508|-0.01564633660018444|0.012602749280631542|0.02023281715810299|0.0411149263381958
924,Für eine andere Dauer und andere Bedingungen der Aufbewahrung nach Anbruch trägt der Anwender die Verantwortung.,For a different duration and other in-use storage times and conditions prior to use are the responsibility.,Other in-use storage times and conditions are the responsibility of the user.,For a different duration and other conditions for storage after first use are the responsibility of the user.,0.4210526315789473,smt,5,5_smt,0.20889167487621307|0.3413988947868347|0.40141674876213074|0.37870579957962036|0.3231388032436371
925,Anfälle sowie bei Anfällen in Zusammenhang mit dem Lennox-Gastaut-Syndrom.,seizures and seizures associated with Lennox-Gastaut syndrome.,seizures and the seizures associated with Lennox-Gastaut syndrome.,seizures and seizures associated with Lennox-Gastaut syndrome.,0.0,smt,5,5_smt,-0.025814780965447426|-0.021168263629078865|0.021151939406991005|0.027234064415097237|0.03930459916591644
926,sichelähnliche Form annehmen).,sichelähnliche outwards).,of the red blood cells).,sickle-like shape).,0.5,smt,5,5_smt,0.4824446439743042|0.5601475834846497|0.6055519580841064|0.6042379140853882|0.5529596209526062
927,"Eine Beschränkung hinsichtlich der Nahrungsaufnahme ist notwendig, da festgestellt wurde, dass sich der Verzehr von Nahrungsmittel auf das pharmakokinetische Profil auswirkt.","One limitations regarding food intake is necessary, because it has been established that the consumption of food on the pharmacokinetic profile of perindopril.","A restriction regarding food intake is necessary, since effects of food consumption on the pharmacokinetic profile has been observed.","One limitation regarding food intake is necessary, because it has been established that the consumption of food has an effect on the pharmacokinetic profile.",0.2307692307692307,smt,5,5_smt,0.1314622312784195|0.21695074439048767|0.12457957863807678|0.2780235707759857|0.23797981441020966
928,"Nespo i n Zusammenhang gebracht wurden, ist folgende:",Nespo is a fluid related to the following:,"placebo-controlled studies of Nespo with a total of 2112 patients (Nespo 1200, placebo 912).",Nespo is related to the following:,0.2857142857142857,smt,5,5_smt,0.2124052494764328|0.2976086139678955|0.2696564495563507|0.4100404679775238|0.3453049957752228
929,"(Die Fachinformation zu Ribavirin ist ebenfalls zu beachten, wenn IntronA in Kombination mit Ribavirin bei Patienten mit chronischer Hepatitis C angewendet werden soll).",(Also see ribavirin SPC if IntronA is to be administered in combination with ribavirin in patients with chronic hepatitis C)., 240 (Also see ribavirin SPC if IntronA is to be administered in combination with ribavirin in patients with chronic hepatitis C).,(Also see ribavirin SPC if IntronA is to be administered in combination with ribavirin in patients with chronic hepatitis C).,0.0,smt,5,5_smt,-0.0043819136917591095|0.0025171861052513123|0.04035155847668648|0.039040643721818924|0.04325076937675476
930,"Häufig: Dyspnoe, Rhinitis Gelegentlich:","Common: dyspnoea, rhinitis Uncommon:","Respiratory, thoracic and mediastinal disorders:","Common: dyspnoea, rhinitis Uncommon:",0.0,smt,5,5_smt,0.23339267075061798|0.38276487588882446|0.1121465414762497|0.4091678559780121|0.32568249106407166
931,"Der Wirkstoff in Valdoxan, Agomelatin, ist ein Antidepressivum.","The active substance in Valdoxan, agomelatine, is an antidepressant.",This is believed to help relieve the symptoms of depression.,"The active substance in Valdoxan, agomelatine, is an antidepressant.",0.0,smt,5,5_smt,0.14180926978588104|0.19158835709095|0.08589436858892441|0.24477936327457428|0.20910167694091797
932,"Nach 48 Wochen sank das relative Risiko auf 1,27 (95 %-Konfidenzintervall:",After 48 weeks the relative risk decreased to 1.27 (95% CI:,"At 48-weeks the relative risk decreased to 1.27 (95% CI=0.76, 2.12).",After 48 weeks the relative risk decreased to 1.27 (95% CI:,0.0,smt,5,5_smt,0.04992225766181946|0.06576095521450043|0.044739432632923126|0.13551069796085358|0.11134861409664154
933,Enbrel 25 mg ist als weißes Pulver und Lösungsmittel zur Herstellung einer Injektionslösung erhältlich.,Enbrel 25 mg is supplied as a white powder and solvent for solution for injection.,Enbrel 25 mg is supplied as a white powder and solvent for solution for injection.,Enbrel 25 mg is available as a white powder and solvent for solution for injection.,0.0625,smt,5,5_smt,-0.04771199822425842|-0.05529022216796875|0.009809459559619427|-0.025702327489852905|0.011496203951537609
934,"Falls Sie Informationen über das Arzneimittel gewünscht werden, setzen Sie sich bitte mit dem örtlichen Vertreter des Pharmazeutischen Unternehmers in Verbindung.","If you have information about this medicine, please contact the local representative of the Marketing Authorisation Holder.","If you want more information about this medicine, please contact the local representative of the Marketing Authorisation Holder.","If you would like more information about this medicine, please contact the local representative of the Marketing Authorisation Holder.",0.1428571428571428,smt,5,5_smt,-0.008764050900936127|-0.018146587535738945|0.04694858193397522|0.016917655244469643|0.03963068127632141
935,"Efient darf nicht bei Patienten angewendet werden, die möglicherweise überempfindlich (allergisch) gegen Prasugrel oder einen der sonstigen Bestandteile sind.",Efient should not be used in people who may be hypersensitive (allergic) to prasugrel or any of the other ingredients.,Efient should not be used in people who may be hypersensitive (allergic) to prasugrel or any of the other ingredients.,Efient should not be used in people who may be hypersensitive (allergic) to prasugrel or any of the other ingredients.,0.0,smt,5,5_smt,-0.038583360612392426|-0.04258362948894501|0.011575939133763313|-0.018563074991106987|0.015881340950727463
936,"Basierend auf den Daten anderer CYP3A4-Inhibitoren ist zu erwarten, dass die Midazolam-Plasmakonzentration nach oraler Anwendung von Midazolam signifikant erhöht ist.","Based on data for other CYP3A4 inhibitors, it is expected that the Midazolam-Plasmakonzentration significantly increased after oral administration of midazolam.","Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally.","Based on data for other CYP3A4 inhibitors, it is expected that the Midazolam-plasma concentration is significantly increased after oral administration of midazolam.",0.125,smt,5,5_smt,0.03334672749042511|0.06131675839424133|0.08340483903884888|0.09199806302785873|0.08279849588871002
937,"Sie wird in einer Aluminiumtube mit einem Plastikverschluss angeboten, die 5, 10 oder 15 Gramm Salbe enthält, oder in einem Aluminiumbeutel, der 0,5 g Salbe enthält.","It is supplied in a Aluminiumtube with a Plastikverschluss of 5, 10 or 15 grams ointment contains, or aluminium foil sachet of 0.5 g ointment.","It is supplied in an aluminium tube with a plastic cap, containing either 5, 10 or 15 grams of ointment, or in an aluminium foil sachet containing 0.5 g of ointment.","It is supplied in a aluminium tube with a plastic cap containing 5, 10 or 15 grams ointment, or in an aluminium foil sachet of 0.5 g ointment.",0.2580645161290322,smt,5,5_smt,0.13607320189476013|0.21546553075313568|0.1633799970149994|0.23345568776130676|0.20196181535720825
938,Welche Nebenwirkungen sind möglich? 5. Wie ist Helicobacter Test INFAI aufzubewahren? 6.,Possible side effects 5 How to store Helicobacter Test INFAI 4.,Possible side effects 5 How to store Helicobacter Test INFAI 6.,Possible side effects 5 How to store Helicobacter Test INFAI 6.,0.0833333333333333,smt,5,5_smt,-0.005689810495823622|0.010137587785720825|0.03832509368658066|0.047971487045288086|0.05404861271381378
939,"Die Kompatibilität von rekonstituiertem ECALTA mit intravenösen Substanzen, Additiva oder anderen Arzneimitteln außer mit 9 mg / ml (0,9%) Natriumchlorid-Infusionslösung oder 50 mg / ml (5%) Glucose-Infusionslösung ist nicht nachgewiesen.","Compatibility of reconstituted ECALTA with intravenous substances, additives, ATCC No. HB 9212 or other medicinal products except diluted with sodium chloride 9 mg / ml (0.9%) sodium chloride for infusion or 50 mg / ml (5%) glucose solution for infusion has not been established.","The compatibility of reconstituted ECALTA with intravenous substances, additives, or medicines other than 9 mg/ ml (0.9%) sodium chloride for infusion or 50 mg/ ml (5%) glucose for infusion has not been established.","The compatibility of reconstituted ECALTA with intravenous substances, additives, or medicines other than 9 mg/ ml (0.9%) sodium chloride for infusion or 50 mg/ ml (5%) glucose for infusion has not been established.",0.3409090909090909,smt,5,5_smt,0.04154800623655319|0.06542454659938812|0.09425554424524307|0.0908488854765892|0.09345227479934692
940,Den vollständigen Wortlaut des EPAR für Orfadin finden Sie hier.,The full EPAR for AVAMYS for Orfadin can be found here.,The full EPAR for Orfadin can be found here.,The full EPAR for AVAMYS for Orfadin can be found here.,0.0,smt,5,5_smt,0.008098574355244637|0.01599927246570587|0.11959036439657211|0.05350407585501671|0.05824878811836243
941,"Dies wurde in einer pharmakokinetischen Studie mit nichtrauchenden und rauchenden gesunden Probanden, die eine Einzeldosis von 150 mg Erlotinib oral erhielten, bestätigt.","This has been confirmed in a pharmacokinetic study nichtrauchenden reduced and healthy subjects, a single dose of 150 mg of erlotinib oral therapy.",This was confirmed in a pharmacokinetic study in non-smoking and currently cigarette smoking healthy subjects receiving a single oral dose of 150 mg erlotinib.,"This has been confirmed in a pharmacokinetic study with non-smoking, healthy subjects receiving a single oral dose of 150 mg of erlotinib.",0.25,smt,5,5_smt,0.1530008763074875|0.23636214435100555|0.20925170183181763|0.29251304268836975|0.22966855764389038
942,Unterstützung durch Wachstumsfaktoren wurde selten (< 5%) und Unterstützung durch Transfusionen wurde bei ca. 15% der Patientinnen benötigt (siehe Abschnitt 4.2).,"provision of growth factors, has been rarely ( 5%), and the provision of transfusions was needed in approximately 15% of patients, respectively (see section 4.2).",Growth factor support was required infrequently (< 5%) and transfusion support was required in approximately 15% of patients (see section 4.2).,"Support by growth factors has been rarely (<5%), and the support of transfusions was needed in approximately 15% of patients (see section 4.2).",0.21875,smt,5,5_smt,0.07220043987035751|0.09361694753170013|0.10940621048212051|0.14642205834388733|0.11744417995214462
943,Diese Krankheiten werden als „Immunmangelsyndrome“ bezeichnet und mit Hilfe einer so genannten„ Substitutionstherapie“ (Ersatztherapie) behandelt. • Patienten mit bestimmten Immunstörungen.,"These diseases are considered ""PID"" and the treatment is called ""replacement therapy (replacement therapy). • Patients with certain immune disorders.",These types of conditions are called ‘ immunodeficiency syndromes’ and their treatment is called ‘ replacement therapy ’. • Patients with certain immune disorders.,"These diseases are considered ""PID"" and the treatment is called ""substitution therapy (replacement therapy). • Patients with certain immune disorders.",0.037037037037037,smt,5,5_smt,0.04044369235634804|0.0578484907746315|0.0986991748213768|0.10554637759923935|0.10099027305841446
944,"rz Gleiche wie für r-HuEPO, aber Ihr Arzt wird Ih nen sagen, wie viel und wann Sie Nespo anwenden sollen.",er the same as with r-HuEPO but your doctor will divinylbenzeac should tell you how much and when you should take Nespo.,Your doctor may decide to change the way that your injection is given (either under the skin or into a vein).,The same as with r-HuEPO but your doctor will will tell you how much and when you should take Nespo.,0.1428571428571428,smt,5,5_smt,0.43802058696746826|0.5194820761680603|0.34475627541542053|0.5302115678787231|0.48665356636047363
945,"In Studien, in denen die Zeitdauer gemessen wurde, die der Proband in den verschiedenen Stadien des Schlafes verbrachte, erhielt Zerene ebenfalls die Schlafmuster aufrecht.","In trials investigating the measured the subject in the different stages of daytime verbrachte Zerene, was also preserved sleep patterns.",Zerene also preserved sleep patterns in the studies that measured the time spent in different stages of sleep.,"In trials investigating the different stages of sleep the subject went through, Zerene also preserved sleep patterns.",0.4210526315789473,smt,5,5_smt,0.36206936836242676|0.46445950865745544|0.4175957441329956|0.5484846830368042|0.4551575481891632
946,23 Die beim Menschen gemessene Pharmakokinetik war proportional zur verabreichten Dosis.,The pharmacokinetics of gadobutrol in humans are dose proportional.,The pharmacokinetics of gadobutrol in humans are dose proportional.,The pharmacokinetics of gadobutrol in humans are dose proportional.,0.0,smt,5,5_smt,-0.0154785867780447|-0.013235889375209808|0.011597974225878716|0.03821743279695511|0.04195213317871094
947,"Pfirsichfarbene, bikonvexe, oval geformte Tablette mit Prägung, auf der einen Seite ein Herz und auf der anderen Seite die Zahl 2875.","Peach, biconvex, oval-shaped, with a heart debossed on one side of the heart on one side and the number 2875 engraved on the other side.","Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2875 engraved on the other side.","Peach, biconvex, oval-shaped, with a heart debossed on one side of the heart on one side and the number 2875 engraved on the other side.",0.0,smt,5,5_smt,0.0011553303338587284|0.003455422818660736|0.05943819135427475|0.05257437750697136|0.05427008867263794
948,Atorvastatin wird durch das Cytochrom P 450 Isoenzym 3A4 metabolisiert.,Atorvastatin is metabolised by the cytochrome P450 isoenzyme 3A4.,Atorvastatin is metabolized by cytochrome P450 3A4.,Atorvastatin is metabolised by the cytochrome P450 isoenzyme 3A4.,0.0,smt,5,5_smt,0.007875720039010048|0.03752534091472626|0.0148853100836277|0.06454196572303772|0.0707770362496376
949,In einer Standard-Versuchsreihe von in-vitro und in-vivo-Tests zur Genotoxizität erwies sich Emedastin-Difumarat als nicht genotoxisch.,In a Standard-Versuchsreihe and the neurostimulation intensity categories of genotoxicity was found to be Emedastin-Difumarat not to be genotoxic.,Emedastine difumarate was not genotoxic in a standard battery of in vitro and in vivo genotoxicity assays.,"In a standard test series of in-vitro and in-vivo test on genotoxicity, the Emedastin-Difumarat was found not to be genotoxic.",0.6363636363636364,smt,5,5_smt,0.45593541860580444|0.5557599067687988|0.5638965368270874|0.5548891425132751|0.47007688879966736
950,"Pharmakotherapeutische Gruppe: Zytostatikum (Antimetabolit), ATC-Code:","Pharmacotherapeutic group: cytostatic (antimetabolite), ATC code:","Pharmacotherapeutic group: cytostatic (antimetabolite), ATC code:","Pharmacotherapeutic group: cytostatic (antimetabolite), ATC code:",0.0,smt,5,5_smt,-0.06918454170227051|-0.06878334283828735|0.009058474563062191|-0.05117896944284439|-0.003662360832095146
951,"Es liegen keine Erfahrungen zur Verabreichung von Pritor bei Patienten vor, die kürzlich eine Nierentransplantation erhielten.",There is no experience regarding the administration of Pritor in patients with recent kidney transplantation.,There is no experience regarding the administration of Pritor in patients with recent kidney transplantation.,There is no experience regarding the administration of Pritor in patients with recent kidney transplantation.,0.0,smt,5,5_smt,-0.05082917958498001|-0.05435175448656082|0.00963940005749464|-0.026315560564398766|0.011345716193318367
952,"Die tägliche Aufnahme von Fett, Kohlenhydraten und Eiweiß sollte auf drei Hauptmahlzeiten verteilt werden.","The daily dietary intake of fat, carbohydrate intake and protein should be divided in three main meals.","The daily intake of fat, carbohydrate and protein should be distributed over three main meals.","The daily dietary intake of fat, carbohydrates and protein should be divided in three main meals.",0.1111111111111111,smt,5,5_smt,-0.011699921451508999|-0.0013173241168260574|0.01313058566302061|0.04369063302874565|0.049303799867630005
953,"später Da Ritonavir zusammen mit einer Mahlzeit, Didanosin dagegen nüchtern eingenommen werden soll, sollten zwischen den Einnahmen der beiden Arzneimittel zweieinhalb Stunden liegen.","Since ritonavir later, when administered with a meal, didanosine, however, should be separated by recommended to prevent pain.","As ritonavir is recommended to be taken with food and didanosine should be taken on an empty stomach, dosing should be separated by 2.5 h.","Since ritonavir should be administered with a meal and didanosine should be taken on an empty stomach, dosing should be separated by two and a half hours.",0.5862068965517241,smt,5,5_smt,0.2528124451637268|0.34643372893333435|0.3496524691581726|0.39174580574035645|0.3279873728752136
954,"Bei den Patienten, die unter einer Monotherapie mit Indinavir 800 mg alle 8h einen Wiederanstieg der Viruslast aufwiesen, wurden Substitutionen an nur drei dieser Stellen bei der Mehrheit der Patienten beobachtet:","Among patients receiving immunosuppressive monotherapy with indinavir 800 mg every 8h a viral load rebound, substitutions were conducted in only three of these sites were observed in the majority of patients:","Among patients experiencing viral RNA rebound during indinavir monotherapy at 800 mg q8h, substitutions at only three of these sites were observed in the majority of patients:","Patients receiving immunosuppressive monotherapy with indinavir 800 mg every 8h who exhibited an increase in the viral load, substitutions were observed at only three of these sites in the majority of patients:",0.3529411764705882,smt,5,5_smt,0.11907138675451279|0.19298343360424042|0.19889657199382782|0.2456694394350052|0.19704893231391907
955,rz In aus gesunder menschlicher Haut isolierten Langerhans-Zellen reduzierte Tacrolimus in vitro die stimulierende Aktivität gegenüber T-Zellen.,er In selected from the healthy cospinning tacrolimus reduced in vitro is activity towards T cells.,"14 In vitro, in Langerhans cells isolated from normal human skin, tacrolimus reduced the stimulatory activity towards T cells.","In vitro, tacrolimus reduced the stimulatory activity towards T cells in Langerhans cells isolated from normal human skin.",0.7,smt,5,5_smt,0.41128969192504883|0.5208284258842468|0.45759421586990356|0.567101776599884|0.501146674156189
956,Die maximale Konzentration im Plasma Cmax von 48 ng/ml wird durchschnittlich 112 Minuten nach der Infusion gemessen.,The maximum concentration in plasma Cmax of 48 ng / ml is measured by an average of 112 minutes after infusion.,A maximum plasma concentration Cmax of 48 ng/ ml is measured on average 112 minutes after the infusion.,The maximum concentration in plasma Cmax of 48 ng/ml is measured by an average of 112 minutes after infusion.,0.0,smt,5,5_smt,-0.010594280436635017|-0.013050135225057602|0.047233425080776215|0.027764352038502693|0.037818923592567444
957,Was ist CEPROTIN?,What is CEPROTIN?,What is CEPROTIN?,What is CEPROTIN?,0.0,smt,5,5_smt,-0.07662167400121689|-0.08477670699357986|0.008359967730939388|-0.06291459500789642|-0.020005570724606514
958,Ihr Actraphane 30 NovoLet ist für eine sehr genaue und sichere Funktionsweise entwickelt worden.,Your Actraphane 30 NovoLet is designed to work accurately and safely.,Your Actraphane 30 NovoLet is designed to work accurately and safely.,Your Actraphane 30 NovoLet is designed to work accurately and safely.,0.0,smt,5,5_smt,-0.027212727814912796|-0.027598140761256218|0.012685357592999935|0.011313682422041893|0.0346626341342926
959,"Die Flasche sehr behutsam schwenken, bis die Flüssigkeit klar und frei von nicht gelöstem Pulver oder Partikeln ist.",Keep the bottle very gently draw swirl until the solution is clear and does not dissolved powder or particulate matter.,Swirl very gently until the liquid looks clear and without undissolved powder or particles.,Very gently swirl the bottle until the solution is clear and does not contain dissolved powder or particulate matter.,0.25,smt,5,5_smt,0.155894473195076|0.22745098173618317|0.22886048257350922|0.307485967874527|0.2290126383304596
960,250 mg) und als Pulver zur Herstellung einer Infusionslösung (Tropfinfusion in eine Vene) erhältlich.,250 mg) and as a powder for solution for infusion (drip into a vein).,250 mg) and as a powder to be made up into a solution for infusion (drip into a vein).,250 mg) and as a powder for solution for infusion (drip into a vein).,0.0,smt,5,5_smt,-0.0050628092139959335|-0.012755662202835083|0.020860204473137856|0.025416994467377663|0.04667745530605316
961,"Das bedeutet, die Tablette wird unter die Zunge gelegt, wo sie sich rasch auflöst und der Wirkstoff Fentanyl über die Mundschleimhaut aufgenommen wird.","This means that the tablet on the tongue, where they will quickly dissolve and fentanyl through the oral mucosa.",This means that the tablet should be placed under the tongue where it dissolves rapidly in order to allow fentanyl to be absorbed across the lining of the mouth.,"This means that the tablets are placed under the tongue, where they will quickly dissolve and the active ingredient, fentanyl, is absorbed through the oral mucosa.",0.3666666666666666,smt,5,5_smt,0.23278316855430603|0.31658467650413513|0.3007572293281555|0.3656737506389618|0.3016010522842407
962,"Patienten mit dieser Krankheit fehlt ein Enzym namens Clucocerebrosidase, was zur Ansammlung eines Glycosphingolipids, des so genannten Glucosylceramids, in verschiedenen Teilen des Körpers wie z. B.","Patients with this disease is missing or an enzyme called Clucocerebrosidase, accumulation of Glycosphingolipids, Glucosylceramids in different parts of the body, such as","Patients with this disease lack an enzyme called glucocerebrosidase, resulting in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones.","Patients with this disease are missing an enzyme called glucocerebrosidase that leads to the accumulation of glycosphingolipids, known as glucosylceramides, in different parts of the body, such as",0.3548387096774194,smt,5,5_smt,0.19928891956806183|0.29039013385772705|0.2507535219192505|0.3202647566795349|0.24901480972766876
963,Vermeiden Sie längeres oder heftiges Schwenken.,Avoid Avoid prolonged or vigorous agitation.,Do not use prolonged or vigorous agitation.,Avoid prolonged or vigorous agitation.,0.1666666666666666,smt,5,5_smt,0.06598541140556335|0.1428399384021759|0.06507270783185959|0.188567653298378|0.139537051320076
964,Wie ist Xeloda einzunehmen? 4.,How to take Xeloda 4.,How to take Xeloda 4.,How to take Xeloda 4.,0.0,smt,5,5_smt,-0.04651713743805885|-0.05649494379758835|0.011273507960140705|-0.02641444467008114|0.008121692575514317
965,"Diese Wechselwirkung wurde ebenfalls festgestellt, wenn Cholestagel eine Stunde nach dem oralen Kontrazeptivum eingenommen wurde.",This interaction has also been observed when Cholestagel was administered one hour after the oral contraceptive pill.,This interaction was also observed when Cholestagel was administered one hour after the oral contraceptive pill.,This interaction has also been observed when Cholestagel was administered one hour after the oral contraceptive pill.,0.0,smt,5,5_smt,-0.023069676011800766|-0.015667492523789406|0.012197895906865597|0.011379159986972809|0.03253079950809479
966,wobei die Impfstoffe an unterschiedlichen Stellen injiziert werden.,the vaccines sites should be injected.,"injection sites, during the same session.",The vaccines should be injected at different sites.,0.3333333333333333,smt,5,5_smt,0.2922969460487366|0.35059258341789246|0.37194734811782837|0.4546464681625366|0.3921862840652466
967,"Sollte sich das Sichtfenster nicht gelb gefärbt haben, so kontaktieren Sie bitte Ihren Arzt, Ihr Krankenpflegepersonal oder Ihren Apotheker.","If the inspection window is not yellow, you must contact your doctor, nurse or pharmacist.","If the inspection window is not yellow, you must contact your doctor, nurse or pharmacist.","If the inspection window is not yellow, you must contact your doctor, nurse or pharmacist.",0.0,smt,5,5_smt,-0.027656029909849167|-0.03730960935354233|0.011122102849185467|-0.006538736168295145|0.027440372854471207
968,"Die Durchstechflasche bis zum Zeitpunkt der Anwendung im Umkarton aufbewahren, um den Inhalt vor Licht zu schützen.",Keep the vial until time of use in the outer carton in order to protect it from light.,Keep the vial in the outer carton until time of use in order to protect from light.,Keep the vial until in the outer carton until use in order to protect it from light.,0.1666666666666666,smt,5,5_smt,-0.031272150576114655|-0.027633478865027428|0.0116023700684309|0.013273153454065323|0.030665293335914612
969,"Jedoch besteht potentiell die Möglichkeit einer Wechselwirkung mit Arzneimitteln, die stark an Erythrozyten binden, z.B.","However, there are potentially is potential for an interaction with drugs that are highly bound to red blood cells e. g.","However, there is potential for an interaction with drugs that are highly bound to red blood cells e. g. cyclosporin, tacrolimus.","However, there is potential for an interaction with drugs that are highly bound to red blood cells e. g.",0.0952380952380952,smt,5,5_smt,0.15782606601715088|0.2249458283185959|0.09893213212490082|0.30203619599342346|0.2403302937746048
970,In einer pharmakokinetischen Mehrfachdosis-Studie mit der Tablettenformulierung an gesunden Erwachsenen zeigten 4 Personen eine eingeschränkte Metabolisierung von Desloratadin.,"In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine.","24 In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine.","In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine.",0.0,smt,5,5_smt,-0.009890248998999596|-0.0018344689160585403|0.015404801815748215|0.03416170924901962|0.04839738458395004
971,Zwei Studien beschäftigten sich mit der Wirksamkeit von Tredaptive bei der Veränderung des Blutfettspiegels.,Two studies looked at the efficacy of Tredaptive in changes in modifying blood fat levels.,Two studies looked at the effectiveness of Tredaptive in modifying blood fat levels.,Two studies looked at the efficacy of Tredaptive in modifying fat levels in blood.,0.2,smt,5,5_smt,-0.022510293871164322|-0.023399194702506065|0.07637923955917358|0.0185831431299448|0.040503278374671936
972,Eine Ribavirin-Monotherapie darf nicht angewendet werden.,One Ribavirin must not be used.,Ribavirin monotherapy must not be used.,Ribavirin monotherapy must not be used.,0.2857142857142857,smt,5,5_smt,0.06797219812870026|0.11972248554229736|0.05377355217933655|0.1665686070919037|0.11584725230932236
973,Nach Gabe von 14C-Rivastigmin erfolgt die renale Elimination rasch und fast vollständig (> 90%) innerhalb von 24 Stunden.,After administration of 14C-Rivastigmin renal elimination is rapidly and almost completely ( 90%) within 24 hours.,"Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete (> 90%) within 24 hours.",After administration of 14C-Rivastigmin renal elimination occurs rapidly and almost completely ( 90%) within 24 hours.,0.0526315789473684,smt,5,5_smt,0.07287979871034622|0.1295018494129181|0.0745067372918129|0.16996575891971588|0.13008378446102142
974,Ratiograstim enthält keine Konservierungsmittel.,Ratiograstim does not contain any preservative.,32 Ratiograstim does not contain any preservative.,Ratiograstim does not contain any preservative.,0.0,smt,5,5_smt,-0.04594013839960098|-0.05142410844564438|0.009855619631707668|-0.018937988206744194|0.010692969895899296
975,"DEXDOMITOR enthält den Wirkstoff Dexmedetomidin, der zu einer Gruppe von Arzneimitteln mit psycholeptischer (sedativer, d. h. beruhigender bzw. dämpfender) Wirkung gehört.","DEXDOMITOR contains the active substance dexmedetomidine, which belongs to a group of medicines with psycholeptischer at least 20 (i. e. a and providing sedative effect.","DEXDOMITOR contains the active substance dexmedetomidine, which belongs to a class of medicines having a psycholeptic (sedative) action.","DEXDOMITOR contains the active substance dexmedetomidine, which belongs to a group of medicines with psycholeptic effects (sedative i. e. calming or rather depressant effect).",0.3571428571428571,smt,5,5_smt,0.13734070956707|0.19891420006752014|0.202511265873909|0.23219579458236694|0.20130006968975067
976,Sie dürfen die nuklearmedizinische Abteilung nach einer Kontrollmessung der Strahlendosis verlassen (im Allgemeinen innerhalb von 6 Stunden nach der Injektion von QUADRAMET).,Do not leave the nuclear medicine department to leave the cell after a Kontrollmessung of radiation (generally) within 6 hours after the injection of QUADRAMET.,You will be authorised to leave the nuclear medicine department after a dosimetric follow-up (generally within 6 hours following QUADRAMET injection).,Do not leave the nuclear medicine department to leave the cell after a control measurement of radiation (generally) within 6 hours after the injection of QUADRAMET.,0.0689655172413793,smt,5,5_smt,0.1538287252187729|0.21639737486839294|0.27537310123443604|0.28509438037872314|0.23291806876659393
977,"Hydrochlorothiazid, das in diesem Arzneimittel enthalten ist, könnte bei einem Doping- Test zu einem positiven Analyseergebnis führen.",Anti-doping test: hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an Doping- test for a number of muscarinic receptor.,"As with any anti-hypertensive agent, excessive blood pressure decrease in patients with ischemic cardiopathy or ischemic cardiovascular disease could result in a myocardial infarction or stroke.",Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in a doping- test.,0.5882352941176471,smt,5,5_smt,0.34485357999801636|0.45417818427085876|0.34539681673049927|0.5030782222747803|0.4406763017177582
978,"Wurde Tenecteplase im mittleren oder späten Embryonalstadium gegeben, traten bei den Muttertieren am Tag nach der ersten Dosis vaginale Blutungen auf.",When tenecteplase in the late Embryonalstadium occurred in mothers on the day after the first dose vaginal bleeding.,When tenecteplase was given during the mid- or late-embryonal period maternal animals showed vaginal bleeding on the day after the first dose.,When tenecteplase was given during the mid- or late-embryonal period maternal animals showed vaginal bleeding on the day after the first dose.,0.5217391304347826,smt,5,5_smt,0.12241298705339432|0.22416530549526215|0.3208473026752472|0.2903048098087311|0.21905598044395447
979,Die Fluorochinolone entfalten ihre antibakterielle Wirkung sowohl gegen replizierende als auch gegen ruhende Mikroorganismen.,The The fluoroquinolones exert their antibacterial effects against both replicating and against a phytotherapic against magnesium stearate.,The fluoroquinolones exert their antibacterial effect against both replicating and non-replicating micro-organisms.,The fluoroquinolones exert their antibacterial effects against both replicating and non-replicating micro-organisms.,0.5384615384615384,smt,5,5_smt,0.33918488025665283|0.44406604766845703|0.42882588505744934|0.476863831281662|0.4181547164916992
980,Die Behandlung sollte in regelmäßigen monatlichen Abständen bis mindestens einen Monat nach dem letzten Auftreten von Stechmücken fortgesetzt werden.,Treatment should be continued at monthly intervals until 1 month after the last exposure.,The treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.,Treatment should be continued at monthly intervals until 1 month after the last exposure.,0.0,smt,5,5_smt,0.014009440317749977|0.026538070291280746|0.031064972281455994|0.09170860797166824|0.07440092414617538
981,Was ist Pradaxa und wofür wird es angewendet?,What is Pradaxa is and what it is used for 2.,What Pradaxa is and what it is used for 2.,What is Pradaxa is and what it is used for?,0.1818181818181818,smt,5,5_smt,-0.017074601724743843|-0.02086317352950573|0.04791085794568062|0.022869667038321495|0.03556106984615326
982,"1,5 mg Tablette:",1.5 mg tablet:,For the 1.5 mg tablet:,1.5 mg tablet:,0.0,smt,5,5_smt,-0.014512831345200539|-0.01806851290166378|0.01906130649149418|0.006879062857478857|0.03172384575009346
983,"Dies bedeutet, dass er im Körper zu Aprepitant umgewandelt wird.",This means that it is converted to aprepitant in your body.,This means that it is converted to aprepitant in the body.,This means that it is converted to aprepitant in your body.,0.0,smt,5,5_smt,-0.01587551273405552|-0.02062525413930416|0.021241798996925354|0.028951259329915047|0.0381016880273819
984,1 Durchstechflasche mit 2 ml humanem Thrombin (800 – 1200 IE/ml).,1 vial containing 2 ml of human thrombin (800 - 1200 IU / ml).,1 vial containing 2 ml of human thrombin (800 – 1200 IU/ ml).,1 vial containing 2 ml of human thrombin (800 - 1200 IU / ml).,0.0,smt,5,5_smt,-0.043680742383003235|-0.049901269376277924|0.011078615672886372|-0.022928910329937935|0.01173478364944458
985,Sowohl in klinischen Studien als auch in Anwendungsbeobachtungen wurde gelegentlich über Überempfindlichkeitsreaktionen berichtet.,Both in clinical trials and post-marketing experience there have been reports of hypersensitivity reactions are uncommon.,5 Manifestations of hypersensitivity have been reported uncommonly in both clinical and post-marketing settings.,Both in clinical trials and post-marketing experience eports of hypersensitivity reactions were common.,0.4285714285714285,smt,5,5_smt,0.14343757927417755|0.26148703694343567|0.21453817188739777|0.3171256482601166|0.2309131771326065
986,"Die Einfuhr, der Verkauf, die Lieferung und/oder die Verwendung von Nobilis IB 4-91 sind in bestimmten Mitgliedstaaten im Rahmen innerstaatlicher tierärztlicher Maßnahmen in ihrem gesamten Hoheitsgebiet oder in Teilen davon untersagt oder können untersagt werden.","The import, sale, supply and / or use of Nobilis IB 4-91 in certain Member States in the innerstaatlicher veterinary measures the whole or part of their territory national or national animal health policy.","The import, sale, supply and/ or use of Nobilis IB 4-91 is/ or may be prohibited in certain Member States on the whole or part of its territory pursuant to national animal health policy.","The import, sale, supply and / or use of Nobilis IB 4-91 is prohibited of can be prohibited in certain Member States in line with the veterinary measures in their whole territories or in parts of it.",0.475,smt,5,5_smt,0.18002860248088837|0.29413697123527527|0.23488321900367737|0.3104623556137085|0.2707332372665405
987,"Zu Beginn der Behandlung verursacht IntronA gewöhnlich grippeähnliche Krankheitszeichen mit Fieber, Ermüdung, Kopfschmerzen, Muskelschmerzen, Gelenkschmerzen und Schüttelfrost.","At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills / rigors.","At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills/rigors.","At the beginning of treatment with IntronA, you may experience a flu-like reaction with fever, fatigue, headache, muscle ache, joint pain and chills.",0.1034482758620689,smt,5,5_smt,-0.032215747982263565|-0.030282916501164436|0.01190055813640356|-0.010014567524194717|0.025448080152273178
988,zu • Berühren Sie nicht die Injektionsnadel.,If you take too much insulin • Do not touch the tip of the needle.,Important not e • Do not touch the needle or allow it to touch any surface before the injection. • It is normal to see a small air bubble in this syringe.,• Do not touch the tip of the needle.,0.6,smt,5,5_smt,0.13997961580753326|0.17473016679286957|0.15610265731811523|0.23604801297187805|0.2006043940782547
989,"Die Dosis kann von Ihrem Arzt allmählich und, falls erforderlich, bei Depression bis auf eine maximale Dosis von 375 mg täglich erhöht werden.","The dose may be adjusted by your doctor gradually and, if needed, depression, up to a maximum dose of 375 mg daily.","The dose can be raised by your doctor gradually, and if needed, even up to a maximum dose of 375 mg daily for depression.","The dose may be adjusted by your doctor gradually and, if needed, up to a maximum dose of 375 mg daily in the case of depression.",0.1724137931034483,smt,5,5_smt,0.05974198877811432|0.06741572916507721|0.0738535076379776|0.13789556920528412|0.10403091460466385
990,Bitte beachten Sie bei einer antiviralen Begleittherapie für eine Hepatitis B oder C die relevanten Produktinformationen zu diesen Arzneimitteln.,"Please with concomitant antiviral therapy for hepatitis B or C, the relevant product information for these medicinal products.","In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.",Please be aware of relevant product information on medicinal products for concomitant antiviral therapy for hepatitis B or C.,0.3,smt,5,5_smt,0.054098013788461685|0.09242889285087585|0.15356029570102692|0.12656418979167938|0.10711926221847534
991,Erwachsene und ältere Menschen (> 65 Jahre) sollten anfänglich 3 mal täglich 1 oder 2 Tabletten zu den Mahlzeiten einnehmen.,Adults and elderly ( 65 years) The recommended starting dose of Renagel for three times daily to take 1 or 2 tablets taken with food.,The recommended starting dose of Renagel for adults and the elderly (> 65 years) is one or two tablets with each meal 3 times a day.,Adults and elderly ( 65 years) The recommended starting dose of Renagel is to take 1 or 2 tablets three times daily with food.,0.1153846153846153,smt,5,5_smt,0.04854054003953934|0.06383159011602402|0.13142269849777222|0.1120157390832901|0.09153551608324051
992,Nicht verwendete Tierarzneimittel oder davon stammende Abfallmaterialien sind entsprechend den örtlichen Vorschriften zu entsorgen.,Any unused product of waste material to be disposed of in accordance with local requirements.,Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.,Any unused product of waste material to be disposed of in accordance with local requirements.,0.0,smt,5,5_smt,0.05525114759802818|0.08444181084632874|0.0960860475897789|0.1382112056016922|0.12375537306070328
993,Juni 2005 ein befürwortendes Gutachten.,June 2005 gave a positive opinion.,The list of product names concerned is given in Annex I.,June 2005 gave a positive opinion.,0.0,smt,5,5_smt,0.27780717611312866|0.3872639536857605|0.1646859049797058|0.43697506189346313|0.3624784052371979
994,Über die Auswirkungen einer gleichzeitigen Verabreichung von Volibris mit CYP3A4- und 2C19-Induktoren liegen keine Erkenntnisse vor.,There are no data on the effect of concomitant administration of Volibris with inhibitors of CYP3A4 and 2C19-Induktoren.,The impact of the co-administration of Volibris with inducers of CYP3A4 and 2C19 is unknown.,There are no data on the effect of concomitant administration of Volibris with inhibitors of CYP3A4 and 2C19-Induktoren.,0.0,smt,5,5_smt,0.08753424137830734|0.16462932527065277|0.0564524307847023|0.1929059475660324|0.15054945647716522
995,Eine Tablette Vimpat 50 mg enthält 50 mg Lacosamid.,One tablet of Vimpat 50 mg contains 50 mg lacosamide.,One tablet of Vimpat 50 mg contains 50 mg lacosamide.,One tablet of Vimpat 50 mg contains 50 mg lacosamide.,0.0,smt,5,5_smt,-0.0429256372153759|-0.049947939813137054|0.008906260132789612|-0.020049193874001503|0.00827278383076191
996,Nach Anbruch kann ein Pen bis zu 4 Wochen aufbewahrt werden.,"Once in-use, vials may be kept for up the pen for up to 4 weeks.","Once in-use, pens may be kept for up to 4 weeks.","Once use, a pen can be stored for up to 4 weeks.",0.5714285714285714,smt,5,5_smt,0.0451686754822731|0.08643096685409546|0.12316076457500458|0.13979533314704895|0.12409022450447083
997,"In zwei kleineren, randomisierten, Plazebo-kontrollierten Prüfungen fand sich keine signifikante Besserung der anhand der EORTC-QLQ-C30-Skalen bzw, der CLAS bewerteten Parameter der Lebensqualität.","Two smaller, randomised, placebo-controlled trials, there was no significant improvement in the EORTC-QLQ-C30-Skalen, the assessment of the CLAS quality of life measures.","Two other smaller, randomized, placebo-controlled trials failed to show a significant improvement in quality of life parameters on the EORTC-QLQ-C30 scale or CLAS, respectively.","Two smaller, randomised, placebo-controlled trials, there was no significant improvement in CLAS assessed parameters of life quality with the help of the EORC-QLQ-C30 scale.",0.3214285714285714,smt,5,5_smt,0.15733163058757782|0.23957785964012146|0.2139691263437271|0.2912505567073822|0.24668733775615692
998,"Für Kinder und Erwachsene, die keine Kapseln schlucken können, steht Agenerase Lösung zum Einnehmen zur Verfügung.","For children and adults, who are unable to swallow capsules, Agenerase oral solution is available.",An oral solution of Agenerase is available for children or adults unable to swallow capsules.,"For children and adults, who are unable to swallow capsules, Agenerase oral solution is available.",0.0,smt,5,5_smt,-0.006324475631117821|-0.001344071701169014|0.019800424575805664|0.03421754762530327|0.043596118688583374
999,"Häufig gibt es andere Arzneimittel, die Sie stattdessen einnehmen können.",Common There are other medicines that you can take instead.,"Often, there are other medicines you can take instead.",There are other common medicines that you can take instead.,0.0909090909090909,smt,5,5_smt,0.01755952462553978|0.00448102131485939|0.044697973877191544|0.04834211245179176|0.057517558336257935
